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Summary 
 
 
Background 
Growing attention has been dedicated by researchers and practitioners to early identification and intervention on young 
individuals considered as at ultra-high-risk (UHR) of a first psychosis episode. Cognitive behavioural therapy (CBT) has 
shown to be the first-line treatment strategy. However, there is a small number of trials on its efficacy. UHR groups who 
do not make transition frequently report poor functioning and secondary symptoms, such as depression and anxiety. 
Existing trials focused on psychosis prevention as a dichotomous outcome without sufficiently targeting additional 
outcomes. Despite it has been linked with frank psychosis, worry has not been considered as outcome.  
Objectives 
Primary objective of the current study was (a) to assess whether a CBT modular protocol was able to reduce or delay risk 
of transition to psychosis in a group of UHR help-seeking individuals after 6 months (post-treatment) and 14-months 
(follow-up) compared with treatment as usual as a control condition. Secondary objectives were (b) to compare the CBT 
intervention with the control condition on secondary outcomes, including depression, anxiety, worry and global 
functioning.  
Methods 
Participants were included if they were 16-35-year old and met criteria for At-Risk-Mental State (ARMS) at the 
Comprehensive Assessment of At-Risk-Mental States (CAARMS). Fifty-eight individuals recruited from mental health 
services (mean age= 25.51, SD= 6, 67.20% males) were randomly assigned to CBT or control condition. The CBT 
modular protocol consisted of 30 weekly sessions with multiple components including engagement and goal setting, 
psychoeducation on psychotic experiences, (meta)cognitive restructuring, intervention on depression, worry, social 
anxiety and skills. Kaplan-Meier survival statistics were used to analyse the primary outcome. Participants lost to follow-
up were coded conservatively as non-converters. In the group that did not make transition, secondary outcomes were 
analysed by ANCOVA.  
Results 
Overall, 7 participants (12.10%) at post-treatment and 11 (19%) at 14-month follow-up cumulatively made the conversion 
to psychosis. In the CBT group, the number of individuals who made cumulative conversion to psychosis (n= 4, 10.30%) 
at 14-month follow-up was lower than in the control group (n= 8, 27.60%), despite this difference was at a borderline 
significance level (Log rank test χ2(1)= 3.66, p= 0.05). In the CBT group, a higher number of participants achieved 
remission than in the control group on secondary outcomes at post-treatment (75% vs 38.10% for both depression and 
anxiety) [χ²(1)= 6.25, p< 0.05] and also at follow-up. However, a significantly greater effect of CBT than control condition 
on depression, anxiety, worry and functioning was not found when these outcomes were considered as continuous.  
Conclusions 
CBT seems to be an option of intervention able to reduce drop out among UHR individuals and to some extent also 
prevent the risk of a first episode with some benefits on secondary outcomes such as anxiety and depression when levels 
on these outcomes are clinically significant. Further research is required to examine additional strategies targeting worry 
and functioning. Clinical implications, limitations and future directions are discussed.  
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Riassunto 
 
 
Premessa 
L’identificazione precoce di giovani considerati a alto rischio di un primo episodio di psicosi è un tema che sta ricevendo 
attenzione crescente da parte di ricercatori e clinici. La terapia cognitivo comportamentale (TCC) si è dimostrata il 
trattamento di prima linea. Tuttavia, ad oggi esiste un numero ridotto di studi sulla sua efficacia. I soggetti a alto rischio 
tendono frequentemente a riportare ridotto funzionamento e sintomi secondari, come ansia e depressione. Gli studi 
esistenti si sono focalizzati prevalentemente sulla prevenzione del rischio di psicosi senza indagare sufficientemente 
ulteriori indici di esito. Inoltre, il rimuginio non è stato considerato come misura di esito, nonostante sia associato ai 
disturbi psicotici conclamati.  
Obiettivi 
L’obiettivo primario del presente studio è stato (a) valutare se un protocollo di TCC modulare fosse in grado di ridurre o 
ritardare il rischio di sviluppo di psicosi in un gruppo di soggetti afferenti ai servizi di salute mentale dopo sei mesi (post-
trattamento) e 14 mesi (follow-up) a confronto con treatment as usual come controllo. Gli obiettivi secondari sono stati 
(b) confrontare la TCC con il controllo su misure di esito secondarie, come la depressione, l’ansia, il rimuginio, il 
funzionamento globale. 
Metodi 
I partecipanti sono stati inclusi se avevano età compresa tra 16 e 35 anni e soddisfacevano i criteri per uno stato mentale 
a rischio alla Comprehensive Assessment of At-Risk-Mental States (CAARMS). Cinquantotto soggetti reclutati da servizi 
di salute mentale (età media= 25.51, DS= 6, 67.20% maschi) sono stati randomizzati a TCC o gruppo di controllo. Il 
protocollo modulare di TCC includeva 30 sedute settimanali con componenti multiple, ovvero ingaggio, definizione degli 
obiettivi, psicoeducazione sulle esperienze psicotiche, ristrutturazione (meta)cognitiva, interventi sulla depressione, 
rimuginio, ansia e abilità sociali. Sono state calcolate le statistiche di sopravvivenza Kaplan-Meier per analizzare 
l’obiettivo primario. Nel gruppo che non ha sviluppato psicosi, le misure di esito secondarie sono state analizzate con 
ANCOVA. 
Risultati 
Complessivamente, 7 partecipanti (12.10%) e 11 (19%) hanno sviluppato psicosi al post-trattamento e follow-up 
rispettivamente. Nel gruppo TCC, il numero di soggetti che ha sviluppato psicosi a follow-up in modo cumulativo è stato 
inferiore (n= 4, 10.30%) a quello del gruppo di controllo (n= 8, 27.60%), sebbene questa differenza sia risultata per un 
livello di significatività borderline (Log rank test χ2(1)= 3.66, p= 0.05). Nel gruppo TCC, un numero più alto di soggetti 
ha raggiunto la remissione rispetto al gruppo di controllo sulle misure secondarie (75% vs 38.10% sia per depressione 
che ansia) [χ²(1)= 6.25, p< 0.05]. Tuttavia, non si è rilevato un effetto significativamente più elevato della TCC su 
depressione, ansia, rimuginio e funzionamento quando questi indici sono stati considerati come variabili continue.  
Conclusioni 
La TCC sembra essere una forma di intervento in grado di ridurre il drop out nei soggetti a alto rischio di psicosi ed in 
una certa misura prevenire il rischio di un primo episodio con benefici anche su misure di esito secondarie, quali ansia e 
depressione quando i loro livelli sono considerati come variabili continue. Si richiedono ulteriori ricerche che indaghino 
strategie aggiuntive per il rimuginio e il funzionamento. Si discutono le implicazioni dei risultati, i limiti e le prospettive 
future. 
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Introduction 
 
 
 
 
 
 
Despite its low incidence of 0.03 per 100 persons every year (Kirkbride et al., 2012), psychosis 
represents the third most costly brain vulnerability with direct and indirect healthcare economic costs 
of about 93 billion in the European countries (Mangalore & Knapp, 2007; Olesen, Gustavsson, 
Svensson, Wittchen, & Jönsson, 2012). Once thought to be inevitably progressive, psychosis can have 
very heterogeneous outcomes (Harrison et al., 2001). During the last two decades, a wide 
international movement of researchers and practitioners has sought to apply principles of practice 
based on early detection and treatment that are well established for other branches of medicine, such 
as cancer and cardiovascular diseases (Marshall & Rathbone, 2011). Increasing efforts have been put 
into developing early detection and prevention strategies before the development of a first episode of 
psychosis. 
In patients with first psychotic episode only 20% will completely recover from a single episode and 
70-80% will have a relapsing and chronic course with lifelong vulnerability and social impairment 
(Alvarez-Jiménez et al., 2011). Clinical observations have suggested that a relevant part of first-
episode psychosis patients (about 70%) report having suffered from mental problems including 
attenuated or intermittent psychotic symptoms and increasing psychosocial impairment for an 
average 5-year period prior to the onset of psychosis (Schultze-Lutter, Ruhrmann, Berning, Maier, & 
Klosterkötter, 2010).  
Initially, the early psychosis movement focused on timely recognition and phase-specific treatment 
of first-psychosis episode. However, it was recognized that for most patients a prolonged period of 
attenuated symptoms and impaired functioning precedes the first episode. Much of the disability 
associated with psychosis develops much longer before the onset of frank symptoms and is difficult 
to reverse, even if the first psychotic episode is successfully treated. This pre-onset period has been 
named as prodromal phase (Hafner et al., 2003; Yung, 2003; Yung & McGorry, 1996).   
About half of individuals diagnosed with psychotic disorders have sought mental health care prior to 
onset of psychosis (Rietdijk et al., 2011). Screening for psychosis among help-seeking populations 
with psychiatric symptoms in mental health, or even in primary care settings, is very important given 
that psychosis can be underestimated if individuals receive professional help for symptoms other than 
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psychotic symptoms (van der Gaag, Nieman, & van den Berg, 2013). Several studies reported a high 
rate of individuals meeting criteria for a psychotic disorder, who had not been detected by clinicians, 
suggesting that practitioners are not often aware of psychotic manifestations in individuals who seek 
help for other kinds of mental problems (Boonstra et al., 2011; Marshall et al., 2005).  
In the last subsequent decade, growing interest has been dedicated to the development of early 
identification and intervention strategies for young people who experience the prodromal states of 
psychosis. Two main approaches were developed when identifying individuals in a CHR state (Fusar-
Poli et al., 2013): the ultra-high-risk criteria (UHR) that focus on detecting an imminent risk of 
psychosis (Yung et al., 1996) and the basic symptom criteria that focus on the detection of the earliest 
possible specific symptoms (Schultze-Lutter, 2009). As many as 4–8% of adolescents and young 
adults seeking mental health care may meet CHR criteria (Ising et al., 2012; Rietdijk et al., 2014). 
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Chapter 1: The at-risk-mental state (ARMS) 
 
 
 
 
 
 
1.1.Psychotic-like experiences are normal 
Population-based studies have shown that the dichotomous disease model of psychotic disorders can 
be integrated into a model of psychosis as an extended phenotype across clinical and non-clinical 
expressions, where at one end of the continuum lies schizophrenia, in the middle are non-psychotic 
mental disorders with psychotic-like experiences (PLEs), and at the other extreme lie PLEs in healthy, 
non-help-seeking individuals (Kaymaz et al. 2012; van Os & Linscott, 2012). Schizophrenia only 
represents the poorest outcome segment of this much wider spectrum of psychotic manifestations, 
which have a lifetime prevalence of 3.50% (van Os, Hanssen, Bijl, & Vollebergh, 2001).  
Psychotic features are not uncommon in the general population, and psychotic symptoms are 
experienced not only by patients with full psychotic disorders but also by patients with non-psychotic 
disorders and part of the general population (van Os et al., 2001). Having one of psychotic symptoms 
was reported in about 25% (n= 5877) of the American population (Kendler, Gallagher, Abelson, & 
Kessler, 1996), 17.50% (n= 7076) of the Dutch population (van Os et al., 2001), and in 17.50% (n= 
2548) of the German population (Spauwen, Krabbendam, Lieb, Wittchen, & van Os, 2003). In an 
English-Italian cohort study (Ohayon, 2000), where hypnagogic and hypnopompic hallucinations 
were considered, the percentage increased to about 40% (n= 13057). The incidence of subthreshold 
psychotic characteristics tends to be about 100 times as high as in the population as the incidence of 
a psychotic disorder (Hanssen, Bak, Bijl, Vollerbergh, & van Os, 2005). In a population-based survey 
(n= 7076), about 18% of participants reported one or more psychotic symptoms, while 0.40% had a 
schizophrenic psychotic disorder and 1.10% an affective psychotic disorder (Hanssen et al., 2005). 
After three years, the group with one or more symptoms was symptom-free in 84% of the cases; 
psychotic symptoms were enduring among 8%, while another 8% had a transition into psychosis 
(Hanssen et al., 2005).  
PLEs include a variety of types (Kelleher & Cannon, 2011). One group consists of sensory 
experiences which are not shared by other present people and refer to hearing sounds (such as voices, 
noises), unexplained visual experiences (such as visions, seeing ghosts), unusual bodily experiences 
(such as feeling touched) or smell that nobody else seems to smell (van der Gaag, Nieman, & van den 
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Berg, 2013). Other kinds include distorted self-experiences, which regard a distorted sense of self. 
Most of these feelings include one or more of the following (Nelson, Thompson, & Yung, 2012; 
Yung et al., 2009):  
 a diminished sense of basic self, such as sense of inner void, lack of identity, being different 
from others; 
 a decreased ability to be affected by people, situations and events; 
 different kinds of depersonalization experiences, such as decreased or temporally delayed 
sense of “mineness” to experience, a pervasive sense of distance between the self and 
experience; 
 different feelings of derealisation, such as an impression that the external environment has 
somehow transformed, is unreal or strange or experiencing the world as if seen through fog; 
 intense reflectivity: the tendency to take oneself or parts of oneself or elements of the external 
environment as objects of intense reflection (such experience can include also thinking about 
one’s own experiences); 
 perplexity: difficulty automatically grasping the meaning of the everyday events. 
 
 
1.2.The staging model of psychosis and the clinical high risk status (CHR) 
McGorry and colleagues (2006) criticized diagnostic systems highlighting that they include 
categories, such as schizophrenia and depression, that are too broad and poorly informative for 
prognosis and treatment decision-making (McGorry et al., 2006). The authors believed that DSM-
IV-TR (American Psychiatric Association, 2000) or ICD-10 (World Health Organization, 1993) 
consist of artificial constructions based on cross-sectional symptom sets confused with course of 
illness variables (McGorry et al., 2007). Clinical features that occur early in the course are not 
distinguished from those that become apparent as a disorder persists (McGorry et al., 2006). Different 
from conventional diagnostic practice, clinical staging models, originally developed for medical 
conditions such as autoimmune or cardiovascular diseases, aim to define the extent of progression of 
disease at a specific time point, and consequently conceptualize conditions along the continuum of 
the illness course (Hasselbach, 1993). Such models are able to differentiate early and milder clinical 
phenomena from those that accompany illness progression and chronicity (McGorry et al., 2007). 
They make practitioners more capable of selecting treatments specific to earlier stages, and assume 
that such interventions will be both more effective and less harmful than treatments delivered later in 
the course (McGorry et al., 2007).  
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McGorry and colleagues (2006) developed a clinical staging theoretical model of psychosis and mood 
disorders, within which biological markers can be progressively introduced to build a 
clinicopathological model. The staging model of psychosis is presented in Table 1.1. 
  
 
 
Table 1.1. Staging model of psychosis (McGorry et al., 2006). 
Clinical 
stage 
Definition 
Target populations 
for recruitment 
Potential interventions 
Indicative biological and 
endophenotypic markers 
0 
Increased risk of psychotic or 
severe mood disorder. No 
symptoms currently 
1st degree teenage 
relatives of probands 
Improved mental health literacy, 
family education, drug education, 
brief cognitive skills training 
Trait marker candidates and 
endophenotypes, e.g. Smooth 
Pursuit Eye Movements, P 50, 
Niacin sensitivity, Binocular 
rivalry, Prepulse inhibition, 
Mismatch negativity, Olfactory 
deficits, etc. 
1a 
Mild or non-specific symptoms, 
including neurocognitive deficits 
of psychosis or severe mood 
disorder. Mild functional change 
or decline 
Screening of teenage 
populations, referral 
by primary care 
physicians, referral by 
school counsellors 
Formal mental health literacy, 
family psychoeducation, formal 
CBT, active substance abuse 
reduction 
Trait and state candidates where 
feasible according to sample size 
1b 
Ultra-high-risk: moderate but 
subthreshold symptoms, with 
moderate neurocognitive changes 
and functional decline to caseness 
(GAF<70) 
Referral by 
educational agencies, 
primary care 
physicians, emergency 
departments, welfare 
agencies 
Family psychoeducation, formal 
CBT, active substance abuse 
reduction, atypical antipsychotics 
agents for episode, antidepressant 
agents or mood stabilizers 
Niacin sensitivity, folate status, 
MRI and MRS changes, HPA axis 
dysregulation 
2 
First episode of psychotic or 
severe mood disorder 
Full threshold disorder with 
moderate-severe symptoms, 
neurocognitive deficits and 
functional decline (GAF 30-50) 
Referral for primary 
care physicians, 
emergency 
departments, welfare 
agencies, specialist 
care agencies, drug 
and alcohol services 
Family psychoeducation, formal 
CBT, active substance abuse 
reduction, atypical antipsychotics 
agents for episode, antidepressant 
agents or mood stabilizers, 
vocational rehabilitation 
Continue with markers of illness 
state, trait and progression 
3a 
Incomplete remission from FEP  
Could be linked or fast-tracked to 
stage 4 
Primary and specialist 
care services 
As for “2” with additional 
emphasis on medical and 
psychosocial strategies to achieve 
full remission 
Continue with markers of illness 
state, trait and progression 
3b 
Recurrence of relapse of 
psychotic or mood disorder which 
stabilizes with treatment at a level 
of GAF, residual symptoms, or 
neurocognition below he best 
level achieved following 
remission from first episode 
Specialist care 
services 
As for “3a” with emphasis on 
long-term stabilization 
Continue with markers of illness 
state, trait and progression 
3c 
Multiple relapses, provided 
worsening in clinical extent and 
impact of illness is objectively 
present 
Specialist care 
services 
As for “3b” with emphasis on 
long-term stabilization 
Continue with markers of illness 
state, trait and progression 
4 
Severe, persistent or unremitting 
illness as judged on symptoms, 
neurocognition and disability 
criteria 
Note: could fast track to this stage 
at first presentation through 
specific clinical and functional 
criteria (from stage 2) or 
alternatively by failure to respond 
to treatment (from stage 3a) 
Specialist care 
services 
As for “3c” but with emphasis on 
clozapine, other tertiary 
treatments, social participation 
despite ongoing disability 
Continue with markers of illness 
state, trait and progression 
Note. CBT= cognitive behavioural therapy, FEP = first episode psychosis, GAF= Global Assessment of Functioning, HPA= Hypothalamic-pituitary 
axis, MRI= magnetic resonance imaging, MRS= magnetic resonance spectroscopy.  
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1.3.The Ultra-High Risk of psychosis criteria (UHR) 
The ultra-high-risk of psychosis criteria (UHR) define a condition identifying three subgroups of 
CHR individuals:  
(a) those reporting attenuated psychotic symptoms (APS); 
(b) those having brief limited intermittent psychotic episodes (BLIPs) below DSM-IV’s duration 
criteria for a brief psychotic episode; 
(c) those individuals who have genetic vulnerability, consisting of familial risk or presence of a 
schizotypal personality disorder combined with recent decline in functioning during the last years 
(McGorry et al., 2009).  
An age range of 15–30 years was also included in the identification approach, as this age group has 
been found to have the highest risk for psychosis (McGorry et al., 2009). APS can include at least 
any of ideas of reference, odd beliefs or magical thinking, such as ideas of grandiosity, paranoid 
ideation and unusual perceptual experiences, thinking and speech (McGorry et al., 2009). BLIPs can 
include presence of at least any of hallucinations, delusions, and formal thought disorders (McGorry 
et al., 2009). Presence of a genetic risk factor can consist of family history of psychosis in first-degree 
relatives, schizotypal personality disorder in combination with a recent significant decline in 
psychosocial functioning. UHR criteria are met if at least one of BLIPs, APS or genetic risk factors 
are met.  
As suggested by Debbané and colleagues (2015), APS were modelled both on “psychotic-like 
experiences” defined by Chapman and Chapman (1980) as delusional and hallucinatory phenomena 
in that some insight is still maintained, and on the five positive DSM-III-R prodromal symptoms of 
schizophrenia (American Psychiatric Association, 1987) that are phenomenologically equal to the 
positive symptoms in the definitions of the clinical manifestation of schizotypy in the ICD-10 
category of schizotypal personality disorder (World Health Organization, 1994).  
As many as 4–8% of adolescents and young adults seeking mental health care may meet UHR criteria 
(Ising et al., 2012; Rietdijk et al., 2014). Individuals with APS consistently account for the majority 
of the UHR population (Debbané et al., 2015). The temporal relationship between CHR subgroups 
and early psychosis across time windows and phase-specific interventions is provided in Figure 1.1. 
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Figure 1.1. CHR groups across time windows and phase-specific interventions (source: Fusar-Poli et al., 2012). 
 
 
 
1.4.The Basic Symptoms criteria (BS) 
A similar early detection strategy complementary to the UHR approach was created in Germany: the 
basic symptoms criteria (BS; Klosterkotter et al., 2001). BS were conceptualized as subtle, 
subjectively experienced subclinical disturbances in drive, affect, thinking, speech, (body) 
perception, motor action, central vegetative functions, and stress tolerance (Gross, 1989; Huber & 
Gross, 1989). They can occur and have been reported in every stage of the psychosis illness, such as 
in the prodromal phase to the first episode, in prodromes to relapse, in residual states, and even during 
psychotic episodes per se (Gross, 1989).  
BS are different from what is considered to be one’s ‘‘normal’’ mental self. Being subjective, they 
remain predominately private and apparent only to the affected person (Gross, 1989). They are rarely 
observable to others, although the patient’s self-initiated coping strategies (including avoidance 
behaviours and social withdrawal) in response to his/her BS may be recognizable to others. Being 
self-experiences, BS differ from negative symptoms as they are currently understood and appear as 
functional deficits observable to others (Parnas et al., 2005). BS are also distinct from frank psychotic 
symptoms that are experienced by the patient as real, normal thinking, and feeling. In contrast, BS 
are spontaneously and immediately recognized by the affected person as disturbances of his/her own 
mental processes. Insight that something is wrong with one’s thinking is present, yet some 
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experiences might be so new and strange that they remain nearly inexplicable. The rare, highly 
introspective person may be able to articulate what is happening, but any detailed description of these 
experiences usually requires help in the form of guided questioning (Schultze-Lutter et al., 2007). 
The ability to experience BS with insight and to cope with them often attenuates with progressive 
illness and emerging psychotic symptoms but is restored upon remission (Gross, 1989). Thus, an 
evaluation of BS is often hindered by acute and/or prominent psychotic symptoms. 
BS were considered as the earliest subjectively experienced symptoms of psychosis and the most 
immediate symptomatic expression of its neurobiological correlates — thus the term ‘‘basic’’ (Huber 
& Gross, 1989). According this model, early symptoms would occur in three developmental forms: 
‘‘uncharacteristic’’ BS affecting drive, volition, and affect, concentration and memory (level 1); 
‘‘characteristic’’, qualitatively peculiar BS, especially of thinking, speech (body) perception, and 
motor action (level 2); and psychotic symptoms per se (level 3) (Gross, 1989). Upon onset at level 1, 
BS would gradually increase in number and severity and, in most cases, ultimately develop into 
psychotic symptoms. Temporary improvements, however, are possible. In some cases, level 1 and/or 
level 2 BS will remit completely and spontaneously before reaching the threshold for psychotic 
symptoms. These symptomatic phases without conversion to a frank psychotic episode can reproduce 
true prodromal stages and are called ‘‘outpost syndromes’’ because they precede the subsequent 
prodrome. The emergence of level 2 or characteristic BS and their conversion to level 3 psychotic 
symptoms can be triggered by everyday stressful situations and demands that overstrain an already 
pathologically vulnerable information processing capacity (Gross, 1989). Given favourable 
environmental and individual conditions, such as a supportive social network, effective social and 
problem solving skills or coping successfully with pressure such as passing difficult exams, BS can 
be compensated for at any state almost completely as long as their number and/or severity do not 
overextend personal resources and coping strategies (Gross, 1989).  
A list of cognitive and perceptual BS associated with psychosis is presented in Table 1.2. 
 
 
 
 
 
 
 
 
 
16 
 
 
Table 1.2. Cognitive and perceptual basic symptoms associated with psychosis (Klosterkotter et al., 2001). 
Thought interference 
An intrusion of completely insignificant thoughts hindering concentration/thinking (‘‘I can’t help thinking about other things, which is very 
distracting’’) 
Thought perseveration 
An obsessive like repetition of insignificant thoughts or mental images (‘‘I always have to mull over what I just said. I can’t stop thinking about 
what I might have said wrong or what I could have added although I really don’t think that anything was wrong with what I said”) 
Thought pressure 
A self-reported ‘‘chaos’’ of unrelated thoughts (‘‘If I am stressed out my mind gets chaotic and I have great problems thinking straight. Too many 
thoughts come up at once’’) 
Thought blockages either with or without intrusion of a new thought  
A sudden loss of the thread or train of thoughts (‘‘Sometimes my thoughts just stop, are suddenly gone, like being cut off’’) 
Disturbance of receptive language 
Paralysis in the immediate comprehension of simple words/sentences, either read or heard, that can result in giving up reading or avoiding 
conversations (‘‘I often can’t get the meaning of common words when I am reading’’) 
Disturbance of expressive speech 
Problems in producing appropriate words, sometimes also experienced as a reduction in active vocabulary (‘‘Sometimes I think it must appear as if 
English were really my second language, like I don’t know English very well because I have difficulties expressing myself. I forget the words’’) 
Disturbances of abstract thinking 
An unusual basic symptom seen when asking the patient to explain sayings or idioms (‘‘Sometimes I get puzzled if a certain object or event only 
stands as a metaphor for some more general, abstract or philosophical meaning’’) 
Inability to divide attention  
Difficulty dividing attention between simultaneous nondemanding tasks that each draw primarily upon a different sense that would not usually 
require a switching of attention (‘‘Doing two things at once has become impossible even with the simplest things. I always have to concentrate on 
one thing at a time, like if I prepare a sandwich, I cannot do anything else, like watch a film’’) 
Captivation of attention by details of the visual field that catches and holds the look  
(‘‘Sometimes an object really seems to stand out from the rest of what I see. My eyes then fix on it. It’s like being spellbound, even though I don’t 
want to look at it at all’’) 
Decreased ability to discriminate between perception and ideas, true memories and fantasies  
(‘‘I thought about my grandparents. Then a weird thing happened: I couldn’t remember if knew my grandparents properly, if they were real or if 
they were just in my imagination. Did I know them, or had I made them up?’’) 
Unstable ideas of reference with insight  
(‘‘When I was listening to the radio the idea that the lyrics had some special meaning for me suddenly popped up into my head. Off course I knew 
straight away that it was just my imagination, a kind of weird thing. I did not have to think twice about it to know that’’) 
Derealization 
A decreased emotional and gestalt connection with the environment (‘‘Sometimes, I feel disconnected from the world around me, like I’m under a 
glass cover’’) 
Visual or acoustic perceptual disturbances with insight 
Unlike hallucinations or schizotypal perceptual distortions, basic symptom perceptual observations are not regarded as real but are immediately 
recognized as a sensory or subjective problem. The knowledge that the misperception, eg, a wrong colouring, distorted shape or changed sound 
quality/intensity, has no counterpart in the real world is immediate and unquestioned (‘‘People suddenly seemed changed and had different hair 
colours’’) 
 
 
1.5. Prognostic accuracy 
Available studies in the literature reported a wide variety of transition rates of UHR criteria. The first 
published study (Yung et al., 1998) using UHR criteria found a transition rate of 40% to threshold 
psychotic disorder within one year. Another early study examining psychosis conversion in 
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individuals meeting CHR criteria reported a 45% two-year conversion rate (Yung et al., 2004). These 
findings were subsequently replicated by several international groups (Riecher-Rossler et al., 2007; 
Mason et al., 2004; Miller et al., 2002). Using a combination of studies, Ruhrman and colleagues 
(Ruhrmann, Schultze-Lutter, & Klosterkötter, 2003) reported an average one-year transition rate of 
36.70% in CHR individuals who did not receive antipsychotic medications. The North America 
Prodrome Longitudinal Study (NAPLS; Addington et al., 2007) consisted of cohorts of 291 
individuals recruited from eight North American centres. The UHR criteria predicted a group for 
early transition to psychosis with a large RR of 405. However, a limitation of the study was that 
treatments were not controlled and varied across centres.  
Investigations of the accuracy of BS in predicting the onset of psychosis within 12 months after 
baseline assessments revealed that presenting with at least two of nine cognitive disturbances cluster 
of BS resulted in a transition rate to psychosis of 23.90% within twelve months, an additional 22.40% 
within the second year and a further 14.90% within the third year (Lencz et al., 2003). Thus, the 
twelve-month transition rate of the cognitive disturbances cluster of BS is comparable with that 
observed among individuals classified as CHR for APS (twelve-month transition rate of 26.50% for 
APS alone) (Lencz et al., 2003). 
In conclusion, both approaches (BS and UHR) as well as the instruments specifically developed for 
their assessment, have shown the ability to detect a considerably increased CHR for psychosis with 
pooled 1–3-year conversion rates to psychosis ranging from 15% to 29% for UHR (Fusar-Poli et al., 
2012; Kempton et al., 2015) and from 14% to 50% for BS criteria, and sufficient prognostic accuracy 
of their assessment, in particular in ruling out psychosis risk (Fusar-Poli et al., 2015). Indeed, there is 
evidence that about 23% of patients with CHR who disengage from CHR services (drop-outs) will 
later develop psychosis (Green et al., 2011). However, these figures are not stable but were shown to 
vary not only with the follow-up time but also with characteristics of the group in which CHR state 
is assessed, for example, with age composition or referral source (Fusar-Poli et al., 2015; 
Schimmelmann et al., 2015).  
A meta-analysis (Fusar-Poli et al., 2012) provided a summary Kaplan-Meyer estimate of psychosis 
risk in CHR samples (mainly by UHR criteria), and indicated that most transitions occurred within 
the first 2 years. There was a consistent transition risk, independent of the psychometric instruments 
used, of 18% after 6 months of follow-up, 22% after 1 year, 29% after 2 years, and 36% after 3 years 
(Fusar-Poli et al., 2012). Transition risks from the meta-analysis of Fusar-Poli and colleagues (2012) 
are provided in Figure 1.2. 
The sensitivity and specificity of CHR assessments have recently been estimated at meta-analytical 
level. The prognostic sensitivity for psychosis prediction at 38 months was 96% (95% CI: 92%-98%), 
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while the prognostic specificity for psychosis prediction at 38 months was 47% (95% CI: 38%-57%) 
(Fusar-Poli et al., 2015). These values indicate that CHR assessments have an outstanding ability to 
rule out psychosis risk and an only modest ability to rule in subsequent psychosis (Fusar-Poli et al., 
2015).  
Recent studies and meta-analyses (Kempton et al., 2015; Schultze-Lutter et al., 2015; Wiltink et al., 
2015) found considerably lower transition risks as compared to earlier research on CHR status. 
Subsequent studies consistently found lower two-year conversion rates ranging from 15 to 30% 
(Demjaha et al., 2012; DeVylder et al., 2014; Katsura et al., 2014; Lee et al., 2014; Liu et al., 2011; 
Nelson et al., 2013; Riecher-Rossler et al., 2009; Ruhrmann et al., 2010; Woods et al., 2009; Ziermans 
et al., 2011). It was suggested that this risk dilution was partially caused by increasing attention paid 
to early symptoms by clinicians and early intervention but also by an increase of false positive related 
to higher awareness of the UHR phase. In addition, it was hypothesized that risk dilution was caused 
by changes in referral pathways and inclusion of younger age groups and, consequently, in changes 
of the populations (ie, pre-test risk of psychosis) from which CHR patients are selected (Cornblatt et 
al., 2015). Thus, recruitment strategies might have an important role in the accuracy of predicting 
psychosis onset using CHR criteria. The individual risk of developing psychosis after being tested for 
CHR criteria depends upon the underlying risk of the disease of the population from which the person 
is selected (pre-test risk of psychosis), and thus on recruitment strategies. Yet, the impact of 
recruitment strategies on pre-test risk of psychosis is unknown (Fusar-Poli et al., 2015).  
In a recent meta-analytic study, Fusar-Poli and colleagues (2015) included 11 studies for a total of 
2519 individuals. Findings indicated that pre-test risk for psychosis in help-seeking individuals was 
15%. A thorough examination of the studies highlighted that recruitment strategies were 
heterogeneous and opportunistic (Fusar-Poli et al., 2015). Heterogeneity was largely accounted for 
by intensive outreach campaigns primarily targeting the general public along with higher proportions 
of self-referrals, which diluted pre-test risk for psychosis in patients undergoing CHR assessment. 
The average 15% risk of pre-test risk of psychosis in these help-seeking samples is significantly 
higher than the comparable 0.1% risk of psychosis in the general population over the same period 
(Fusar-Poli et al., 2015). Since recruitment strategies can significantly increase psychosis risk in help-
seeking individuals even before they undergo CHR assessment (pre-test risk of psychosis), it is not 
only the criteria themselves that determine the post-test risk of transition to psychosis but also the 
process of preselection of samples, such as the defined populations of origin of these samples, which 
creates substantial enrichment in risk (Fusar-Poli et al., 2015). 
Recently, some researchers claimed the potential value of symptom-based risk prediction to clinical 
practice. The majority of published studies examining symptoms and risk prediction likewise have 
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reported that items reflecting disordered thought content unusual ideas (Katsura et al., 2014; Nelson 
et al., 2013; Salokangas et al., 2013; Wilcox et al., 2014), suspiciousness (Riecher-Rossler et al., 
2009; Salokangas et al., 2013), bizarre thoughts (Ruhrmann et al., 2010), odd beliefs/magical thinking 
and  problems distinguishing fantasy and reality (Mason et al., 2004), unstable ideas of reference 
(Klosterkotter et al., 2001), derealization (Klosterkotter et al., 2001) are more severe in converters 
than nonconverters.  
In the NAPLS Study, Perkins and colleagues (2015) developed a classifier that included those items 
of the Scale of Psychosis-Risk Symptoms (McGlashan, Walsh, & Woods, 2010), that best 
distinguished individuals who converted to psychosis from nonconverters in the dataset of obtained 
cases. Results demonstrated that the severity of unusual thought content, referential thinking and 
suspiciousness are key high-risk symptoms in the prediction of transition to psychosis (Perkins et al., 
2015). With two exceptions (Klosterkotter et al., 2001; Mason et al., 2004), most other studies have 
likewise failed to find perceptual disturbances as predictive (DeVylder et al., 2014; Katsura et al., 
2014; Nelson et al., 2013; Riecher-Rossler et al., 2009; Ruhrmann et al., 2010; Salokangas et al., 
2013; Thompson et al., 2013; Velthorst et al., 2009; Wilcox et al., 2014). 
 
 
 
Figure 1.2. Transition risk from subclinical symptoms to full psychosis as a function of time windows (Fusar-Poli et al., 2012). 
 
 
1.6. Should CHR be inserted in the DSM5? Strength and weakness  
In the recent DSM5 (American Psychiatric Association, 2013), the diagnostic category of attenuated 
psychosis syndrome (APS) has been identified and relegated to the research appendix because of lack 
of consensus among researchers on the validity of this category as a syndrome and for the 
20 
 
inconclusiveness of data supporting its diagnostic reliability (Addington, Penn, Woods, Addington, 
& Perkins, 2008; Fusar-Poli et al., 2015). 
During the preparation of DSM5, the Psychotic Disorders Work Group proposed the creation of a 
new diagnostic category to serve as a placeholder for the ARMS concept (Fusar-Poli, Carpenter, 
Woods, & McGlashan, 2014). The proposal was firstly termed Psychosis Risk Syndrome (PRS) and 
was then criticized as a premature and confusing category. Subsequent field research showed that 
individuals at risk already needed treatment for their current psychiatric symptoms and not only the 
potential preventive effect of early intervention on a “risk syndrome” (Phillips, 2013). Thus, the new 
category proposal was reconsidered as a mental disorder per se. It was renamed attenuated psychosis 
syndrome (APS), according to the term assigned to one subgroup of patients identified by the high-
risk mental state research criteria (Yung & Nelson, 2011). Although other sets of high-risk criteria 
existed, most at-risk patients identified in specialized research centres presented APS as their main 
medical complaint. The syndrome differed from full-blown psychosis due to the subthreshold 
(attenuated) intensity or frequency of presented symptoms (Fusar-Poli et al., 2014).  
On one side of the debate, opponents of the APS category argued that this diagnosis could undesirably 
stigmatize and generate unnecessary treatment to young people whose majority would never 
transition to psychosis (Mittal, Dean, Mittal, & Saks, 2015). Identifying APS as an official diagnostic 
category could also determine inappropriate allocation of the already scarce resources destined to 
mental health (Regier, Kuhl, Kupfer, & McNulty, 2010). Potential inadequate prescription of 
antipsychotic medication, with their harmful effects of weight gain and increased cardiovascular risk, 
could cause a profound impact on the life of identified population. Moreover, stigmatizing effects 
could be unpredictable on the individually and socially perceived sense of autonomy and 
responsibility of diagnosed patients (Yung, Nelson, Thompson, & Wood, 2010). Researchers in the 
field recognized the possibility of stigma, discrimination and inappropriate prescription of 
antipsychotics as one element of the risk-benefit analysis of APS inclusion in DSM5, given that 
current evidence does not support antipsychotics as more effective than other more benign treatments 
(Yung et al., 2012). 
On the other hand, supporters of the APS inclusion in the DSM5 believed that it could increase access 
to adequate treatments for people having this condition (Corcoran, First, & Cornblatt, 2010). 
Moreover, associated symptoms could be treated, including anxiety, depression, social withdrawal, 
and work/academic impairment, even for those individuals who would never develop psychosis 
(Corcoran et al., 2010). Also, clinical recognition of APS could hypothetically reduce the rates of 
misdiagnoses, improving the process of differential diagnosis, promoting better case management 
and providing proper reimbursement (Corcoran et al., 2010). 
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Some advocates of APS inclusion also argued that this move could enhance the exchange and 
acquisition of new knowledge in the field of high-risk mental states (Carpenter & van Os, 2011; 
Sadler, 2013). APS inclusion would also bring psychiatry in line with other fields of medicine that 
identify risk factors for the purposes of instituting preventative interventions (Corcoran et al., 2010). 
Consistent with the necessity of identifying ARMS as a category in the DSM5, a large recent meta-
analysis performed by Fusar-Poli and colleagues (2015) indicated that individuals at CHR had 
impaired functioning and quality of life compared with healthy controls, and that no significant 
difference emerged between the CHR groups and groups of patients with full-blown psychosis. 
Among the groups at CHR, those individuals who had conversion to psychosis showed poorer 
functioning than those who did not have the transition at baseline prior entering treatments (Fusar-
Poli et al., 2015).  
 
 
1.7.Time matters: the Duration of Untreated Psychosis (DUP) 
Duration of Untreated Psychosis (DUP) is generally determined as the time from the onset of 
psychotic symptoms to the initiation of treatment or first clinical presentation, when a diagnosis of 
first episode psychosis may be given (Norman & Malla, 2001). Ising and colleagues (2011) found 
1.4% of the help-seeking population presenting with a nonpsychotic disorder to actually have a 
psychotic disorder. An UHR syndrome was diagnosed in 4.0% of the help-seeking population. The 
high rate of the interviewed participants that met the criteria for a psychotic disorder, but that had not 
been detected by clinicians, suggested that mental health professionals are often unaware of the 
presence of psychotic symptoms in patients who seek treatment for other mental disorders, as it has 
also been demonstrated by other authors (Boonstra et al., 2011; Nieman et al., 2009). 
A systematic review including 24 studies evidenced a median DUP of 6-21 weeks (Anderson, Fuhrer, 
& Malla, 2010). Other recent data (Addington et al., 2016) suggested that in community settings 
length of DUP may be greater than in academic settings (median DUP= 74 weeks; 68% of participants 
had DUP of greater than six months). Patients with a longer DUP have more symptoms at first 
presentation, and longer DUP may be associated with a reduced response to antipsychotic 
medications as measured by severity of global psychopathology, positive and negative symptoms, 
demoralization, depression, and functional outcomes (Perkins et al., 2005). Neuroimaging studies 
have also indicated that prolonged untreated illness is associated with more pronounced structural 
brain abnormalities, whereas this is less prominent earlier in the course of the disorder (Lieberman et 
al., 2005). 
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In conclusion, treatment delay can be viewed as a complex behavioural phenomenon moderated by a 
variety of factors, including illness-related predictors (e.g., mode of onset of psychosis, age at onset, 
premorbid functioning), patient-related issues (e.g., marital status, premorbid substance use), family-
related factors such as family coping, health system-level variables like health insurance status, and 
environmental factors such as abuse and neglect during childhood/adolescence, and even 
neighbourhood disorder.  
Some studies aimed to examine predictors of longer DUP (Compton & Broussard, 2011). Evidence 
showed that single marital status, greater negative symptoms, a gradual onset of psychosis, 
childhood/adolescence maltreatment, living in poverty, poor family functioning, not having health 
insurance, the family’s report of financial problems were significant predictors of longer DUP 
(Bonstra et al., 2009; Broussard et al., 2013; Compton et al., 2008, 2011; Haar et al., 2016; 
O’Donoghue et al., 2016; Pek et al., 2006).  
Regarding cannabis use, most of the studies examining DUP among cannabis users and non-users 
reported a shorter DUP in users (Burns, 2012); other data suggested a relationship between substance 
use and a longer DUP (Broussard et al., 2013). Some recent evidence showed variations in DUP 
between age of onset of psychosis, highlighting that the DUP among individuals with adolescent-
onset psychosis was approximately twice than the length of DUP among individuals with adult-onset 
(Dominguez et al., 2013). Additionally, DUP among cases with onset of psychosis in adolescence 
appeared largely different as a function of ethnic group: White adolescents had a median DUP of 454 
days, Black 103 days and Asian 28.5 days (Dominguez et al., 2013). 
A recent systematic review of 33 observational studies (Penttilä, Jääskeläinen, Hirvonen, Isohanni, 
& Miettunen, 2014) investigated the relation between DUP and long-term outcomes. Findings 
indicated a significant association between longer DUP and poorer general symptom outcomes, more 
severe positive and negative symptoms and failure to achieve remission, as well as decreased social 
functioning. In addition, there was no significant correlation between DUP and quality of life or 
hospitalization (Penttilä et al., 2014). The correlation between DUP and poor outcomes appeared 
stronger in longer follow-up periods (Penttilä et al., 2014). However, the relatively high withdrawal 
rate in the primary studies and variation in the methods of defining DUP and increased the risk of 
selection and information bias for this systematic review.  
 
 
1.8. Beyond psychosis risk, towards a broad model of psychopathology staging 
The goal of prospectively identify the prodromal phase is a challenge complicated by the nonspecific 
nature of prodromal symptoms (McGorry et al., 2009). It is necessary to consider that psychosis is 
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just one possible outcome of the CHR state: remission, transition to a non-psychotic disorder and 
persistence of the high-risk state account for most of outcomes at follow-up. One possible explanation 
is that a relevant part of individuals referred to services for CHR individuals are experiencing transient 
psychotic experiences (Nelson & Yung, 2009). While they fulfil CHR criteria, these experiences may 
not underlie impending psychotic illness (Nelson & Yung, 2009). Psychotic experiences often occur 
in the general population, but they persist in only a small proportion of the people who report them 
(Lin et al., 2011), and an even smaller proportion develop a psychotic disorder (van Os, Linscott, 
Myin-Germeys, Delespaul, & Krabbendam, 2009). Rather, psychotic experiences may be related to 
other forms of psychopathology, such as depression, anxiety and OCD (Wigman et al., 2011; Wigman 
et al., 2012), which are common in individuals with CHR (Fusar-Poli, Nelson, Valmaggia, Yung, & 
McGuire, 2014; Salokangas et al., 2012; Yung et al., 2007; Velthorst et al., 2009; Woods et al., 2009). 
Preliminary research with small samples found high rates of mood disorders at 6-month (Lam, Hung, 
& Chen, 2005) and 12-month follow-up assessments (Simon & Umbricht, 2010). Anxiety disorders 
are also common. In a large sample, Addington and colleagues (2011) reported that, of the individuals 
who did not make transition to psychosis, 29% had a mood disorder and 38% had an anxiety disorder 
after 1 year. These rates dropped to 15% and 32%, respectively, by 2-year follow-up (Addington et 
al., 2011). Substance use disorders were also prevalent, but their number was reduced after 2 years.  
It is also possible that at-risk individuals who have not transitioned to psychosis continue to 
experience attenuated psychotic symptoms and meet at-risk criteria (McGorry et al., 2002). Rates of 
attenuated psychotic symptoms at 1-year follow-up vary from 23% to 42% (Haroun, Dunn, Haroun, 
& Cadenhead, 2006; Simon & Umbricht, 2010). At 2 year-follow-up, attenuated symptoms have been 
evident in 35-40% (Addington et al., 2011; McGorry et al., 2002) of at-risk samples and in 25% and 
50% at 3 years (Velthorst et al., 2011; Lemos-Goràldez et al., 2009). Continued attenuated symptoms 
could represent an extended prodrome with transition to psychosis yet to occur. Alternatively, young 
people with attenuated symptoms may not be prodromal, but their ongoing symptoms may be 
distressing and disabling and may be comorbid with threshold or subthreshold mood or anxiety 
disorder. Lin and colleagues (2015) evaluated a large cohort of 226 young individuals at follow-up 
that had been identified as UHR individuals in the 2-14 years previously at the Personal Assessment 
and Crisis Evaluation (PACE) clinic. Results indicated that the presence of attenuated psychotic 
symptoms was significantly associated with mood disorder and with any nonpsychotic disorder over 
the follow-up period, but not with anxiety and substance use disorders (Lin et al., 2015). The 
proportion of participants still APS at follow-up that were at or above the threshold for UHR was 
28.3% for the entire cohort, those without mood disorder at baseline, 32.8% developed one. Of those 
with an anxiety disorder at baseline (39.9%), 40.7% experienced persistent or recurrent anxiety. Of 
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those without anxiety disorder at baseline, 29.5% developed one. Substance use disorders were 
present at baseline for 21.9% (of the 192 with available baseline substance use diagnoses). Of them, 
over half (52.4%) showed persistent or recurrent substance use disorder over follow-up. Of those 
without substance use disorder at baseline, 22.0% developed a substance use disorder. Mood 
disorders were the most common diagnosis during follow-up. Major depressive disorder was 
especially common. This was followed by high rates of anxiety disorders, cannabis dependence, and 
alcohol abuse (Lin et al., 2015). 
The CHR state seems to predict much broader outcomes than schizophrenia/psychotic disorders 
alone, suggesting that there is much more to be “prevented”, increasing the public health relevance 
of the strategy (Fusar-Poli, Yung, & McGorry, 2013). It is important to note that those who do not 
transition to psychosis are not healthy “false-positives”, but are help-seeking individuals suffering 
from a range of mental and social role functioning problems, and are carrying a poor prognosis for a 
range of adverse sequela (Yung et al., 2010). A recent meta-analysis (Kaymaz et al., 2012) suggested 
that although the relative risk for transition to a mental disorder is highest for (rare) psychosis 
outcomes, the absolute number of preventable cases is much higher for (more common) non-
psychotic outcomes, including anxiety and depressive disorders. Fusar-Poli, Yung and McGorry 
(2013) observed that the CHR paradigm might be extended beyond the context of subthreshold 
psychotic symptoms in the prediction of psychotic outcomes, but broadly to the context of non-
specific subthreshold mental distress predicting both psychotic and non-psychotic outcomes. The 
authors believed that a wider model should be introduced in early detection and intervention, focusing 
on a general syndrome of early mental distress requiring non-specific interventions to prevent more 
severe stages of psychopathology, that may develop in more specific, and relatively treatment-
resistant, syndromes later benefits a much narrower population (Fusar-Poli et al., 2013). A picture of 
this model is presented in Figure 1.3 (source: Fusar-Poli et al., 2013). Early intervention on mental 
distress therefore may more efficiently prevent transition to mental disorders in general. In 
comparison, only a small fraction of individuals would benefit from exclusive focus on CHR states 
and prevention of schizophrenia (Fusar-Poli et al., 2013).  
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Figure 1.3. Broad model of staging and prevention (source: Fusar-Poli et al., 2013). Psychiatric disorders develop from non-specific states of 
mental distress gradually developing into full syndromes of anxiety (syndrome 1), depression (syndrome 2) and psychosis (syndrome 3). Note: 
HR= High risk. 
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Chapter 2: Correlates of CHR states 
 
 
 
 
 
 
2.1. The role of gender  
Psychosis is a condition with heterogenous clinical expressions and outcomes, that presents 
differently in men and women. Gender differences of chronic and first-episode psychosis have long 
been recognized in the literature (Abel, Drake, & Goldstein, 2010; Køster et al., 2008). Thereby, men 
and women often require different intervention strategies regarding doses and/or types of 
medications, staging of interventions, and array of treatments offered (Smith, 2010). Men with 
psychosis tend to show a higher propensity to negative symptoms, lower social functioning, earlier 
age at onset and co-morbid substance abuse, whereas women display more affective symptoms (Usall 
et al., 2003). However, other research found inconsistent evidence about gender-related differences 
in psychosis symptom expression (Cotton et al., 2009; Morgan et al., 2008). A recent meta-analysis 
conducted by Fusar-Poli and colleagues (2015) did not evidence gender as a moderator of worse 
quality of life and functioning in UHR individuals compared with healthy controls.  
As suggested by Barajas and colleagues (2015), a variety of factors may account for this 
inconsistency, including medication status (higher doses of typical antipsychotics contributing to 
negative symptomatology), diagnostic stringency (use of stricter criteria excluding women with 
affective symptoms), age at onset (negative symptoms are more prominent in younger men than in 
younger women), and sampling bias (inadequate sample size or overrepresentation of men).  
Recent research examined the role of gender as a potential moderator of the heterogeneity in the 
clinical manifestations also of UHR states (Amminger et al., 2006). Van Os and colleagues (2009) 
formulated the continuum hypothesis, which stated that gender differences would be equally present 
over the entire psychosis continuum, including also the UHR phase. It has been also hypothesized 
that men and women are vulnerable to different “types” of psychotic disorders or that psychosis 
develops differently in men and women. In a study (Amminger et al., 2006) evaluating individuals 
with UHR for psychosis by gender, it was found that female gender was one of the independent 
significant predictors of affective psychosis, which is in accordance with the higher prevalence of 
affective disorders in women (Blazer et al., 2014). In contrast, other studies of individuals with UHR 
for psychosis did not find gender differences in the expression of symptoms (Cocchi et al., 2014). 
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Willhite and colleagues (2008) investigated gender differences in the clinical symptom presentation 
of UHR individuals. Sixty-eight UHR individuals were assessed at baseline, and twenty-seven 
returned for follow-up assessments approximately 6 and 12 months later. Findings did suggest 
differences in demographic variables, symptoms or functioning at baseline across gender (Willhite et 
al., 2008). Males were found to have significantly higher levels of negative symptoms and marginally 
lower levels of functioning when baseline and follow-up time points were considered collectively. 
Additionally, females reported higher levels of social support at baseline. Differences in negative 
symptoms were found to mediate differences in functioning between male and female patients 
(Willhite et al., 2008). 
Rietschel and colleagues (2015) investigated gender differences in clinical symptoms and functioning 
in 239 UHR individuals of which 80 were females. Men displayed more pronounced negative 
symptoms, higher rates of past substance abuse disorders and higher deficits in social functioning. 
No gender difference was found for depression, which affected almost 50% of the cohort, or age at 
onset for the fulfilment of UHR criteria.  
Barajas and colleagues (2015) provided a recent systematic review of available evidence on gender 
related differences in the clinical expression of UHR symptoms. Overall, results indicated that UHR 
men have more severe negative symptoms than women, being more difficult to detect them across 
current risk criteria for psychosis focused on positive attenuated symptoms. Inconsistent results were 
found in relation to transition to psychosis: some studies did not show gender differences and others 
indicated a greater risk for conversion to psychosis in men (Barajas et al., 2015). It might be suggested 
that differential precipitating factors exist as a function of gender, which are involved in conversion 
to psychosis and their identification should be useful in clinical practice (Barajas et al., 2015). Most 
of the studies suggested that differences between men and women in the expression of psychosis 
extended across a continuum, from the subthreshold forms of illness to the psychosis onset, mainly 
in aspects of clinical expression (such as more negative symptoms in men) and social functioning 
(such as premorbid and psychosocial functioning, worse in men). However, the small number of 
studies and their significant methodological limitations did not allow for firm conclusions. The 
limited evidence about cognitive impairment in prodromal phase per gender indicated a differential 
sex effect that varied by risk status (Barajas et al., 2015).  
Few studies with inconsistent findings investigated whether differences related to gender would be 
extended to those individuals who are in the UHR status. In addition, it is important to note that 
findings could be complicated by the fact that more women than men seek help for psychological or 
medical problems (van Os et al., 2009).  
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In a study on a general population sample, Maric, Krabbendam, Vollebergh., de Graaf and van Os 
(2003) observed that subclinical positive psychotic symptoms were more prevalent in women, while 
subclinical negative psychotic symptoms were more prevalent in men. In contrast, in a meta-analysis 
Van Os and colleagues (2009) found slightly increased odds ratios for men regarding prevalence 
rates, whereas the incidence rate was minimally higher for women. Spauwen and colleagues (2003) 
analysed a representative Dutch population sample (aged 17 to 28), with their focus being on possible 
gender differences before and after the age of 21. They found that the incidence of subclinical 
psychotic experiences was higher in men aged 17 to 21, but then became comparable with that of 
women when those men reached 22 to 28 years of age (Spauwen et al., 2003). 
In a recent study, as part of the North American Prodrome Longitudinal Study (NAPLS; Walder et 
al., 2013), no gender differences were found in conversion rates at 2.5-year follow-up (26.5% women; 
24.5% men) in UHR adolescents and young adults. Lemos-Giráldez and colleagues (2009) reported 
that the conversion rate to psychosis was 22.95% in the three-year follow-up period without statistical 
gender differences (22.5% men versus 23.8% women). In addition, in a study with UHR help-seeking 
people, Ziermans and colleagues (2011) showed that at the end of the follow-up period (2 years) 
15.6% of UHR adolescents had experienced a psychotic transition, with a higher proportion of men. 
Furthermore, Nordentoft and colleagues (2006) found that, among young adults with a diagnosis of 
schizotypal disorder, men had a fourfold greater risk for conversion to schizophrenia one year after 
enrolment when compared to women. However, the findings of this study may not be directly 
comparable to the entire UHR population, which includes a wider definition of psychosis risk. 
On the other hand, Goldstein and colleagues (2011) demonstrated that there are sex-specific patterns 
of transmission of psychosis. Among fathers with psychoses most offspring who developed psychosis 
were female (15.2% females versus 3.1% males); in contrast, among mothers with psychosis 18.8% 
of their male offspring developed psychosis compared with 9.5% of their daughters. 
Inconsistency of findings across the studies might be attributed to differences in methodological 
aspects, including the lack of consensus among the studies in the definition of CHR states as well in 
the screening tools used to detection the prodromal phase (Barajas et al., 2015).  
Consistent significant gender differences have not been found in DUP: it is shorter in women than in 
men in most of the studies (Thomas & Nandhra, 2009; Thorup et al., 2007) although in other it was 
shorter in men (Køster, Lajer, Lindhardt, & Rosenbaum, 2008). It is likely that more women seek 
help for psychological or medical problems than men. In addition, it has been hypothesized this would 
be dependent on females’ higher ability to recognize distress and emotional problems, which may 
influence a prompt self-referral after onset, and hence a shorter DUP (Galdas, Cheater, & Marshall, 
2005). Young males, in particular, are influenced by negative attitudes and beliefs about mental 
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disorders, with higher stigmatizing attitudes associated with lower use of both clinical and non-
clinical sources of support (Eisenberg, Downs, Golberstein, & Zivin, 2009). Additional detection 
strategies, especially targeted at males, should be developed, not only to improve the quality of 
research but also above all to prevent the development of more severe forms of the disease. 
 
 
2.2. CHR across age cohorts 
Some research has investigated potential age-related differences in the clinical manifestations of 
ARMS comparing groups of early adolescents, adolescents and young adults (Schultze-Lutter et al., 
2015). Transition risk in help-seeking UHR groups aged 12-18 years appeared lower than those 
observed in adult or mixed-age samples (Schultze-Lutter et al., 2015; Wells & Tiffin, 2014; Ziermans 
et al., 2011), which might indicate a lesser predictive accuracy of UHR criteria in this age group 
(Schultze-Lutter et al., 2015). Additionally, though not assessing the UHR criteria with specific 
instruments, community studies of children and adolescents found high prevalence rates of APS, 
particularly hallucinations, with a spontaneous remission in approximately 75% of cases (Rubio et 
al., 2012).  
Fusar-Poli and colleagues (2012) conducted a meta-analysis of 27 longitudinal studies (n= 2502) 
investigating predictors of psychosis transition in CHR samples. Findings from meta-regressions 
indicated that age cohort moderated conversion probability, showing a modest yet significant increase 
of transition risk with increasing age of patients at CHR (β=0.07; 95% CI: 0.05-0.09; Q=27.94; 
p<.001) (Fusar-Poli et al., 2012). 
More recently, Gerstenberg and colleagues (2016) examined the prevalence of BS and APS in 13- to 
35-year-old individuals seeking help in an early recognition program. Participants presenting APS 
criteria were compared with participants meeting only BS criteria across different characteristics. Co-
occurrence of BS and APS was compared across 13–17, 18–22 and 23–35 years age groups. 
Compared to BS, APS status was associated with younger age (18.30 ± 5.0 vs 23.20 ± 5.60 years) 
with age-related differences in the prevalence of APS (ranging from 80.30% in 13- to 17-year-olds 
to 33.3% in 23- to 35-year-olds). Within the group with APS, fewer adolescents fulfilled combined 
risk criteria of APS and BS compared to the older age groups (Gerstenberg et al., 2016). 
Other authors (Schimmelmann, Michel, Martz-Irngartinger, Linder, & Schultze-Lutter, 2015) 
investigated UHR symptoms in a large sample of individuals aged 8-40 years. Individuals with APS 
were younger than those without APS. Compared to persons aged 20-24 years, those aged 8-12 and 
13-15 years were more likely to report APS, while all other age groups (i.e., 16-17, 18-19, 25-29, 30-
40) were not. When only perceptual abnormalities were considered, odds ratios in individuals aged 
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8-12 and 13-15 increased while no effect was found in the adult groups and in the 16-17-year olds. 
Conversely, when only non-perceptive APS were considered, the model was non-significant, 
suggesting that individuals across all age groups were equally likely to report non-perceptive APS 
(Schimmelmann et al., 2015). When the UHR onset/worsening requirement was considered, the age 
effects on the prevalence of APS increased. Again, only individuals aged 8-12 and 13-15 years were 
more likely to meet the requirement, as compared to the 20-24-year-olds (Schimmelmann et al., 
2015).  
 
 
2.3. Substance use and CHR status 
Several epidemiological studies have reported associations between substance use, generally 
cannabis, and increased risk of developing frank psychotic symptoms (Kuepper et al., 2011; Moore 
et al., 2009). Alcohol was the next most frequently reported kind of substance use behaviour with 
frequency rates ranging between 17% and 44% across the studies (Auther et al., 2012; Corcoran et 
al., 2008; Dragt et al., 2012; Ruhrman et al., 2007). In relation to diagnoses of alcohol abuse, rates 
ranged from 10% of samples to 30% (Corcoran et al., 2008; Kristensen & Cadenhead, 2007; Ruhrman 
et al., 2010). Some studies evidenced that prevalence of tobacco/nicotine lifetime use ranged from 
16% to 34% (Auther et al., 2012; Kristensen K, Cadenhead, 2007). However, the available limited 
data showed that use of substances other than cannabis, alcohol and tobacco/nicotine, is very 
heterogenous in CHR populations, being present only in a CHR subgroup. The use of other substances 
was also noticeably lower compared with cannabis: the use of hallucinogens was reported as the 
highest (7% - 19%) (Auther et al., 2012; Phillips et al., 2002).  
Addington and colleagues (2014) conducted a systematic review of 10 longitudinal cohort studies 
investigating the role of substance use in conversion to psychosis. Only two studies indicated a 
significant association between cannabis and nicotine use and transition to psychosis within one year 
(Corcoran et al., 2008; Kristensen & Cadenhead, 2007). In the study conducted by Kristensen and 
Cadenhead (2007), 12% of 48 CHR individuals made the transition to psychosis, with 5 of these 
individuals meeting criteria for current cannabis abuse, thus showing a significant association 
between cannabis use and conversion to psychosis. However, because this study was also examining 
psychophysiological and neuropsychological variables, individuals with current cannabis dependence 
had been excluded from the study to avoid the risk of affecting the psychophysiological and 
neuropsychological test measures.  
In a large sample (n= 291), Cannon and colleagues (2008) highlighted a transition rate of 35% during 
a 2.5-year follow-up and reported that a history of any substance use disorder was one of five 
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predictors of conversion to psychosis. Another study (Auther et al., 2012) did not find any association 
between age of cannabis onset and age of psychosis onset. However, two studies (Dragt et al., 2010; 
Korver et al., 2010) found that a younger age of onset of cannabis use resulted in a younger age of 
psychotic symptom onset.  
One review on predictors of psychosis in UHR individuals showed that a history of substance abuse 
was one of the risk factors associated with an increased probability of developing psychosis (Fusar-
Poli et al. 2013). However, findings from subsequent research and reviews appeared inconsistent 
(Addington et al., 2014; Buchy, Perkins, Woods, Liu, & Addington, 2014; Dragt et al., 2012), despite 
a larger number of studies to date has not reported a role for substance use in later conversion to 
psychosis. 
Kraan and colleagues (2015) performed a systematic review of seven prospective studies reporting 
lifetime cannabis use in UHR individuals (n = 1171). Of these studies, five also examined current 
cannabis abuse or dependence. Lifetime cannabis use was not significantly associated with transition 
to psychosis (OR= 1.14, 95% CI: 0.856–1.524, p= 0.37). A second meta-analysis yielded an OR of 
1.75 (95% CI: 1.135–2.710, p< 0.01), indicating a significant association between current cannabis 
abuse or dependence and transition to psychosis (Kraan et al., 2015). 
 
 
2.4. The role played by stressful life events 
Some research focused on stressful life events in individuals at CHR and their role in transition to 
psychosis. Kraan and colleagues (2014) performed a series of meta-analyses investigating prevalence 
rates of childhood traumatic events and recent life events in CHR groups compared with healthy 
groups. Findings showed that the prevalence scores of childhood trauma were significantly higher in 
CHR patients (86.8%: 95% CI 77%–93%) than in healthy controls (47%-60%) (Kraan et al., 2014).  
Furthermore, it has been observed that CHR participants experience their first trauma at an earlier 
age compared to healthy controls, and that both the incidences of trauma, and the age at which trauma 
occurred were significant predictors of having a CHR status (Russo et al., 2014). On the other hand, 
Sahin and colleagues (2013) reported that not only is the frequency of childhood trauma higher among 
high-risk participants compared to healthy controls, but also that childhood trauma was related to 
baseline severity of positive symptoms. Others have found that the intensity of perceptual 
abnormalities are higher among groups that have experienced physical abuse and other trauma 
compared to those without a history of trauma (Velthorst et al., 2013) and that CHR participants who 
report experiencing childhood trauma have poorer premorbid functioning compared to controls 
(Tikka et al., 2013). Yung and colleagues (2015) recently found that childhood maltreatment, as 
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assessed by the Childhood Trauma Questionnaire (Bernstein et al., 2003), was a significant predictor 
of poor functioning in CHR groups, as well as those who eventually transition.  
Prevalence rates of trauma among CHR appeared consistent with the reported prevalence rates of 
85% in patients diagnosed with schizophrenia (Larsson et al., 2013). However, in contrast with 
hypotheses, CHR patients experienced a significantly less number of life events compared with 
healthy controls; yet, this series of meta-analyses was based only on a narrow pool of studies (Larsson 
et al., 2013).  
Other research focused on perceived discrimination among the CHR sample (n= 540) recruited in the 
of the NAPLS-2 study. CHR individuals endorsed significantly more perceived discrimination 
compared to healthy controls, and this was associated with negative schemas about the self and others 
(Saleem et al., 2014). Subsequently, a recent study investigated the role of discrimination in an 
enriched sample of 764 CHR individuals recruited in the NAPLS (Stowkowy et al., 2016). Results 
showed that the CHR group reported having experienced significantly more trauma, bullying, and 
endorsed more items on perceived discrimination relative to controls. Trauma and bullying were not 
found to contribute to the prediction of psychosis; yet, individuals who reported higher levels of 
perceived discrimination had a greater chance of conversion to psychosis (Stowkowy et al., 2016).  
 
 
2.5. Schizotypy in CHR status 
Schizotypy is a clinical comprised of three factors, which broadly correspond to the positive, negative 
and disorganized dimensions of schizophrenia, respectively (Nelson et al., 2013). The positive 
dimension is the Cognitive-perceptual factor, which includes magical thinking, unusual perceptual 
experiences, ideas of reference and paranoia (Nelson et al., 2013). Another Disorganized factor 
consists of odd behaviours and weird speech. The third one is the Interpersonal factor, which 
resembles the negative dimension of schizophrenia and includes constricted affect, social anxiety, 
lack of close personal relationships, and suspiciousness (Nelson et al., 2013).  
Debbané and colleagues (2015) conducted a review of 18 prospective studies examining the evidence 
for a link between schizotypal traits and conversion to psychosis in 4 different types of samples: 
general population, clinical risk samples according to UHR and/or BS criteria, genetic (familial) risk, 
and clinical samples at-risk for a nonpsychotic schizophrenia-spectrum disorders. Four samples 
(n=7282) were included. All studies consistently showed that schizotypal dimensions significantly 
predicted later development of either psychotic disorders or schizophrenia spectrum disorders 
(Debbané et al., 2015). More specifically, findings revealed that the positive dimension was mainly 
related to the later onset of psychosis, while the negative dimension (especially anhedonia) was rather 
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selectively associated with the emergence of nonpsychotic schizophrenic-spectrum disorders. 
Information on the disorganization dimension was missing since none of these general population 
studies had assessed this dimension (Debbané et al., 2015). 
Irrespective of whether self-report questionnaires or clinical semi-structured interviews were adopted 
in the assessment of schizotypal traits, there was some, though not consistent, indication that 
schizotypal dimensions could be involved in the transition to psychosis in individuals already 
identified at CHR prior to and independently from schizotypy assessment. 
Overall, contrary to the evidence drawn from population-based samples, CHR studies showed that 
the positive dimension of schizotypy was of poor value in terms of increasing the predictive accuracy 
of psychotic disorders in samples already considered to be prone to psychosis for UHR and/or BS 
criteria (Debbané et al., 2015). Rather, when schizotypy was differentially assessed, the interpersonal, 
negative dimension seemed to explain additional variance and to assist the detection of converters to 
psychosis (Seeber & Cadenhead, 2005). However, except for one study on CHR patients (Ruhrman 
et al., 2010), all studies had relatively short follow-up time that might not have been sufficient to 
detect onset of psychosis in patients with more pronounced schizotypy.  
Three studies investigated the development of psychosis in patients with a clinical picture of 
schizotypy, such as a schizotypal or schizoid personality disorder, involved follow-up assessments 
for 2–20 years but did not provide information on psychometric schizotypy dimensions (McGlashan, 
1984; Nordentoft et al., 2006; Wolff, 1991).  
In the study by Nordentoft and colleagues (2006) on adult in- and outpatients diagnosed with 
schizotypal personality disorder, the conversion rates to a psychotic disorder varied between 25% and 
48% (Nordentoft et al., 2006). Suspected schizotypal personality disorder in children however seldom 
led to the later development of a psychotic disorder (only 6.25%). Despite a relation between 
schizotypal personality disorder and psychosis risk is clearly indicated, future studies of this clinical 
group should therefore provide dimensional scores of schizotypy to clarify the possible patterns of 
associations between schizotypal personality disorder and emerging psychotic disorders. 
Four studies (Carter, Parnas, Cannon, Schulsinger, & Mednick, 1999; Erlenmeyer-Kimling et al., 
1993; Johnstone, Ebmeier, Miller, Owens, & Lawrie, 2005; Shah et al., 2012) on samples at genetic 
risk for psychosis included a total of 637 offsprings (first- or second-degree relatives) of patients 
diagnosed with schizophrenia, and covered follow-ups between 8 and 25 years. Like general 
population studies, schizotypy dimensions were found to be significantly related with the later onset 
of psychosis in genetic high-risk samples (Carter et al., 1999). However, no clear pattern of 
associations between schizotypal dimension and psychotic disorders emerged. Yet, substantially 
different assessment methods were employed over the 20-year span covered by these studies (1993 
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and 2012) that may have contributed to the heterogeneity of findings. The most recent study by Shah 
and colleagues (2012) underscored the pre-eminence of schizotypy amongst a variety of predictive 
risk factors from etiological (degree of relatedness to family member with schizophrenia: genetic 
risk), to environmental (cannabis use, obstetric complications, welfare), and cognitive (intelligence 
quotient, perseveration, verbal fluency) assessments. In a multivariate structural equation model, only 
baseline ratings on the Chapman scales (Chapman, Chapman, & Kwapil, 1995) (Magical Ideation, 
Perceptual Aberration, and Social Anhedonia Scales) were directly and positively related to 
conversion to psychotic disorders (Shah et al., 2012).  
Therefore, Debbané and colleagues (2015) hypothesized the interactions between dimensions of 
schizotypy, clinical expressions of schizotypy, symptomatic CHR criteria, and overt psychosis. The 
model is presented in Figure 2.1. Schizotypal traits during adolescence could represent a 
developmental link between early risk factors and later development of psychotic disorders (Debbané 
et al., 2015). Specifically, consistent with Meehl’s hypotheses (Meehl, 1962), it was assumed that a 
distribution of schizotypal characteristics in the general population from absence to clinically 
significant manifestations in terms of schizotypal personality disorder to the most extreme psychotic 
expression, with increasing severity of schizotypy being associated with higher levels of distress 
and/or functional impairment. APS might appear at as a clinical manifestation or as an exacerbation 
of the underlying schizotypy, in particular of features of the cognitive-perceptual and, though to a 
lesser degree, the disorganization dimension (Debbané et al., 2015). The occurrence of APS might be 
triggered by aberrations in information processing at neurobiological level, that are perceived and 
expressed as basic symptoms, in particular of cognitive-perceptive basic symptoms and cognitive 
disturbances (Debbané et al., 2015).  
Thus, CHR individuals with high levels on schizotypy measures might need for a tailored adaptation 
early intervention approach, including techniques which should not only address positive symptoms 
of schizotypy or APS but also aberrant information processing style of reality (Debbané et al., 2015). 
Moreover, standard care interventions might not be optimally suited to address the needs of patients 
with pronounced negative features of the interpersonal dimension not captured by CHR criteria whose 
personality traits are characterized by enduring social withdrawal and poverty of interpersonal 
relationships (Debbané & Barrantes-Vidal, 2015). However, more longitudinal research on the 
complex relationships between early and intermediate risk indicators for psychosis is needed to 
examine this assumption. 
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Figure 2.1. Model of the assumed relationship and interactions between dimensions of schizotypy, clinical 
expressions of schizotypy, symptomatic CHR criteria, and overt psychosis (source: Debbané et al., 2015) 
 
 
2.6. Emotion recognition and regulation in CHR status 
Emotion recognition is the ability to recognize other people’s feelings (Brüne, 2005). Although most 
of studies observed deficits in emotion recognition in CHR individuals when compared to healthy 
controls (Amminger et al., 2012; Comparelli et al., 2013; Kohler et al., 2014; van Rijn et al., 2011; 
Wölwer et al., 2012), mixed findings have been reported, with some studies not evidencing a deficit 
(Gee et al., 2012; Seiferth et al., 2008; Thompson et al., 2012) and others showing selective deficits 
in a sub-set of negative emotions (Amminger et al., 2011). Those studies that did not report a 
significant deficit in emotion recognition tended to have smaller samples, typically less than 20 
participants. 
Compared to healthy controls, CHR individuals had deficits in social cognition similar to those 
observed in patients at the first episode of psychosis and patients who have a more chronic course of 
schizophrenia (Green et al., 2012). Such deficiencies were reported in several domains of social 
cognition, such as theory of mind, emotion recognition, social perception and attributional style 
(Addington & Barbato, 2015). 
Several studies, using a variety of tasks, have shown that theory of mind, is impaired among CHR 
individuals (Hur et al., 2013; Thompson et al., 2012), although few studies have not observed this 
outcome (Brüne et al., 2011; Stanford et al., 2011). In most of these studies, participants were asked 
to read short stories or cartoons and perform a first or second order mental state attribution, which 
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means inferring the mental state of a character in the story, or inferring the character’s beliefs about 
another character. 
Another important aspect of theory of mind is the ability to process counterfactual information, for 
example detecting sarcasm or lies. In everyday social interactions, sarcasm and lie detection entails 
going beyond the literal meaning of a message by using social cues. Most studies examining emotion 
recognition in CHR individuals have focused on prosody and facial affect processing (Brüne, 2005). 
The only study to date examining how CHR individuals process counterfactual information reported 
impaired detection of sarcasm and lies (Green et al., 2012). 
Social perception generally refers to the awareness of cues and rules that occur in social situations. 
Three studies have examined social perception in individuals at CHR as compared to healthy controls 
(Couture et al., 2008; Thompson et al., 2012), although they investigated different aspects of social 
perception. Findings from the PREDICT study (Couture et al., 2008) showed that CHR individuals 
had biased complex social judgements compared to healthy controls and to a help-seeking control 
sample (Healey et al., 2013). Green and colleagues (2012) looked at perception of social relationships 
and demonstrated poorer performance for the CHR group compared to the control group. Thompson 
and colleagues (2012), using the Managing Emotions branch of the Mayer–Salovey–Caruso 
Emotional Intelligence Test (MSCEIT; Mayer et al., 2002), did not evidence that their CHR sample 
had impairment. Although the Managing Emotions section of the MSCEIT includes questions about 
perception of social or interpersonal situations, the MSCEIT is usually considered a measure of 
emotional intelligence, that is, the ability to understand and manage emotions and to problem-solve 
on the basis of them (Mayer et al., 1999), and therefore may not necessarily measure social perception.  
Attributional style is an individual’s tendency when inferring the cause of an event. A few studies 
have looked at attributional style in CHR individuals (An et al., 2010; DeVylder et al., 2013; 
Thompson et al., 2013). Although DeVylder and colleagues (2013) did not evidence an attributional 
bias in individuals at CHR compared to controls, An and colleagues (2010) reported a perceived 
hostility bias and Thompson and colleagues (2013) found a significantly more externalized locus of 
control for the CHR group compared to controls. However, it should be noted that most of these 
studies were under-powered due to small sample sizes. More recently, in a large multi-site cross-
sectional cohort study, the North American Prodromal Longitudinal Study-2 (NAPLS-2; Barbato et 
al., 2015), large groups of CHR individuals and healthy controls completed measures of social 
cognition, such as The Awareness of Social Inference Test (TASIT; McDonald et al., 2006), measures 
of theory of mind, facial emotion recognition, and social perception, respectively. Results indicated 
that social cognition was not associated with positive and negative symptom severity, but it was 
associated with age and intelligence quotient. Individuals at CHR demonstrated poorer performance 
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on all measures of social cognition. However, after controlling for age and intelligence quotient, the 
group differences remained significant for measures of theory of mind and social perception, but not 
for facial emotion recognition. In conclusion, theory of mind and social perception seemed to be 
impaired in individuals at CHR for psychosis.  
However, in the current literature there is still a lack of longitudinal studies investigating the role of 
emotion recognition as potential predictors of transition to psychosis. 
 
 
2.7. The role of comorbidity in CHR status 
Although the rates of transition to psychosis have declined in recent years, leading to debates on the 
validity of the UHR state and legitimacy of its treatment (Fusar-Poli et al., 2013), studies have 
highlighted the existence of a significant proportion of nonpsychotic psychiatric comorbidity in the 
UHR population, where participants fulfil the criteria for both UHR and at least one nonpsychotic 
mental disorder (Fusar-Poli et al., 2014a; Hui et al., 2013; Kwon et al., 2012; Salokangas et al., 2012; 
Woods et al., 2009). Additionally, comorbidity has been associated with lower global functioning and 
more severe psychopathology (Fusar-Poli et al., 2014a). Comorbidity rates in UHR populations are 
comparable to those in schizophrenia (Buckley et al., 2009). However, evidence that comorbidity 
might influence transition to psychosis has been equivocal (Fusar-Poli et al., 2014; Salokangas et al., 
2012).  
Lim and colleagues (2015) followed for one year 163 CHR individuals who were assessed through 
the CAARMS. Baseline comorbidity patterns showed that about 80% of participants recorded at least 
one lifetime comorbid diagnosis while about 50% had at least one current comorbid diagnosis. The 
most frequent diagnoses were depressive and anxiety disorders. Within these categories, the most 
common depressive and anxiety disorders were major depressive disorder and obsessive–compulsive 
disorder (OCD), respectively (Lim et al., 2015). Fourty-two percent of participants reported one 
lifetime comorbid diagnosis, whereas 37% reported more than one diagnosis. Thirty-two participants 
reported one current comorbid diagnosis and 17% reported more than one current comorbid diagnosis 
(Lim et al., 2015). In addition, the authors found that UHR individuals with comorbidity had more 
severe symptoms, higher distress and lower functioning with no differences in general cognition (Lim 
et al., 2015). Lower functioning was associated with current comorbidity. There were no differences 
in the comorbidity rates between those who developed psychosis (6.7%) after one year and those who 
did not.  
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2.8. Cognitive biases in CHR status 
A great body of research highlighted the role of cognitive biases as vulnerability and maintenance 
factors in schizophrenia, particularly delusions (Bell et al., 2006; Moritz & Woodward, 2007). 
Patients rarely are aware when they gather data and make decisions based on biases (Bell et al., 2006). 
In experimental research, Freeman and colleagues (2006) reported that despite adopting a marked 
data-gathering bias, patients viewed themselves as reflective decision-makers able to adequately 
weigh the pros and cons of different perspectives. Moritz and Woodward (2007) developed a 
metacognitive training for patients with schizophrenia aimed at reducing the most powerful biases 
playing a role in the symptoms.  
Growing attention has been dedicated to the recognition of cognitive biases also in ARMS conditions 
(Broome et al., 2007). Improvement of the patients’ awareness can be an important target of the 
psychological intervention with individuals at CHR (van der Gaag et al., 2013). 
 
 
2.8.1. Jumping to conclusions 
Cognitive models propose that psychotic symptoms arise from faulty appraisals of anomalous or 
ambiguous experiences, driven by emotional processes and cognitive biases (Garety et al., 2007; van 
der Gaag, 2006). A key contributing factor to the formation of these appraisals is a ‘‘data gathering’’ 
or Jumping to Conclusions (JTC) bias (van Dael et al., 2006), a tendency to use less information to 
reach a decision. This can be studied using a probabilistic reasoning task, in which a participant 
guesses which of the two jars a series of coloured beads is drawn from. Compared with healthy 
controls, patients with psychotic disorders tend to make their decision after seeing fewer beads, 
demonstrating a so-called JTC bias (Moritz & Woodward, 2005), and this bias is related to the 
intensity and conviction of delusional ideation (Fine, Gardner, Craigie, & Gold, 2007).  
Thus, it was hypothesized that JTC tendencies and misattribution of the source of self-generated 
material could increase the likelihood that subclinical psychotic experiences will develop into a 
psychotic disorder (Garety et al., 2007). It is also present in the first-degree relatives of patients with 
schizophrenia, in non-clinical delusion-prone participants, and in people with a ARMS for psychotic 
disorders tend to make their decision after seeing fewer beads, demonstrating a so-called JTC bias 
(Broome et al., 2007; Liney, Peters, & Ayton, 1998; van Dael et al., 2006), and this bias is related to 
the intensity and conviction of delusional ideation (Fine et al., 2007).  
In a study by Broome and colleagues (2007), 35 UHR individuals and 23 healthy volunteers 
participated in a modified version of the “beads” reasoning task with different levels of difficulty.  
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When task demands were high, the at-risk group made judgements on the basis of less information 
than the control group. Within both groups, JTC was directly correlated with the severity of abnormal 
beliefs and intolerance of uncertainty. In the UHR group it was also associated with impaired working 
memory, whereas in the control group poor working memory was associated with a more conservative 
response style (Broome et al., 2007). 
A self-recognition deficit such as faulty appraisal of ambiguous auditory verbal experiences, is 
thought to contribute to auditory verbal hallucinations (Allen, Aleman, & McGuire, 2007), and can 
be studied using an on-line Verbal Self-Monitoring (VSM) paradigm. The VSM task requires 
participants to make source judgments (i.e. self/other) about externally presented distorted speech 
trials. Relative to healthy controls, individuals with schizophrenia, affective psychosis or a ARMS 
(Johns, Gregg, Allen, & McGuire, 2006) tend to misidentify their own distorted speech as being non-
self in origin, particularly if they experience auditory verbal hallucinations (Johns & McGuire, 1999). 
In a prospective study, Winton-Brown and colleagues (2014) followed twenty-three individuals with 
ARMS for about a mean of 30 months administering measures of clinical symptoms and cognitive 
tasks that engage VSM and probabilistic reasoning. Findings showed a relation between JTC 
performance and PANSS delusion and hallucination item scores at follow-up, despite it appeared 
only at a trend level. This supported increasing evidence that the JTC bias relates most specifically to 
delusion. In contrast, VSM task performance did not relate to symptoms either at follow-up nor in 
terms of the respective longitudinal changes between baseline and follow-up. Neither task 
performance at baseline nor the change in performance over time was significantly related to the later 
onset of psychosis. Because the number of participants who developed psychosis was small (n = 5), 
the possibility that this was related to limited statistical power, cannot be excluded. There was a trend 
for more conservative baseline (i.e. normal) JTC scores to relate to greater functional status at follow-
up, and baseline PANSS scores also related to GAF at follow-up. However, these associations were 
not significant when considered in a multivariate regression model, which identified baseline anxiety 
ratings as a significant independent predictor: individuals who had low levels of anxiety at baseline 
were more likely to have a good functional outcome (Winton-Brown et al., 2014). In addition to the 
low power, a limitation of the study was the use of a very heterogenous follow up time point (mean 
follow up= 31 months, SD= 19).  
 
 
2.8.2. Negative expectation bias 
Subthreshold negative symptoms, such as lack of motivation starting new activities and feelings of 
emptiness, and impaired cognitive performances, such poor capacity to plan, are common among 
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people suffering from ARMS. Furthermore, when they experience initial cognitive deficits such as 
poor sustained attention and memory, they can lose faith in themselves. Grant and Beck (2009) have 
found a relation between negative symptoms defeatist beliefs. In ARMS individuals, it has been 
shown that negative performance beliefs are endorsed to a greater extent than in healthy controls. 
These beliefs were associated with negative symptoms independently from depression and positive 
symptoms (Perivoliotis, Morrison, Grant, Frech, & Beck, 2009). Beck and colleagues identified a 
series of six beliefs that are defined as follows: 
 Social aversion: “I attach very little importance to having close friends”; 
 Negative expectancies about performance: “If you cannot do something well, there is little 
point in doing it all”; 
 Low expectancies for pleasure: “It is more work than it is worth”; 
 Low expectancies for success: “I am not going to be enough”; 
 Low expectancies owing to stigma: “What do you expect? I am mentally ill”; 
 Beliefs about limited resources: “I do not have enough energy”. 
Such beliefs would perpetuate disengagement as a safety behaviour and lead to a worse outcome and 
a diminished social functioning. 
 
 
2.8.3. Metacognitive factors 
Metacognitive beliefs may guide information and attention processes, increasing affective and 
symptomatic reactions to stressful events. Cognitive self-consciousness (CSC; i.e., a preoccupation 
with one's thoughts) may increase awareness of metacognitive beliefs, potentially triggering the onset 
of psychotic symptoms. Morrison, French and Wells (2007) administered the Metacognition 
Questionnaire (MCQ; Wells & Cartwright-Hatton, 2004) to 73 patients with a psychotic disorder, 43 
UHR individuals, 188 healthy controls. Results indicated that patients with psychotic diagnoses and 
those at risk scored higher on metacognitive belief dimensions than non-patients. Patients with 
psychosis showed higher positive metacognitive beliefs than the CHR patients, indicating a greater 
range of unhelpful metacognitions overall, when compared to non-patients (Morrison et al., 2007).  
In an experimental study (Palmier-Claus, Dunn, Taylor, Morrison, & Lewis, 2012) the role of 
metacognitive beliefs as moderator of affective and symptomatic reactions to stress in UHR 
individuals was analysed. A small group of individuals with ARMS completed a self-report diary 
when prompted by an electronic wristwatch several times each day for 6 days (experience sampling). 
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Metacognitive beliefs moderated the association between affective, but not symptomatic, responses 
to social stress. CSC preceded the subsequent occurrence of hallucinations in individuals who 
reported strong beliefs about the need to control their thoughts (Palmier-Claus et al., 2012).  
 
 
2.8.4. Self-monitoring bias 
Verbal self-monitoring refers to the bottom-up cognitive process of self-monitoring. However, the 
paradigm also measures the top-down decision-making process of appraising ambiguous sensory 
stimuli (Johns et al., 2010). Both cognitive processes seem to be involved in the external attribution 
of inner speech and the generation of auditory hallucinations. 
Cognitive models of auditory hallucinations propose that they arise from a deficit or bias in source 
monitoring, whereby verbal thoughts are not recognized as self-generated and are misidentified as 
externally generated voices (Keefe et al. 1999). Patients with schizophrenia showed poor self-
monitoring on a range of cognitive and motor tasks, and this impairment seems to be more marked in 
patients who have current positive symptoms (Farrer & Franck, 2007). Self-monitoring of speech in 
patients with schizophrenia has been examined in a series of studies using a paradigm in which online 
auditory verbal feedback is manipulated while participants speak out loud (Johns et al. 2006). If 
defective self-monitoring contributes to the development of hallucinations and other positive 
symptoms, then this impairment should be present in individuals who are at high risk of developing 
psychosis, before the onset of severe symptoms. 
Two previous studies have examined self-monitoring in CHR groups, with mixed results (Vermissen 
et al., 2007a, 2007b). On a task measuring self-monitoring of actions, Versmissen et al. (2007b) found 
poor self-monitoring in a genetic high-risk group (first-degree relatives of patients with psychosis) 
and a psychometric UHR group. They also found a positive association between self-monitoring 
errors and level of delusional ideation, but no relationship between errors and severity of 
hallucinations. However, Versmissen et al. (2007a) found no evidence of impairments in the same 
UHR groups using a shortened version of the verbal self-monitoring task that has been associated 
with deficits in patients with schizophrenia. 
Impaired verbal self-monitoring is evident in people with ARMS, although the deficit seems to be 
less marked than in patients with schizophrenia (Johns et al., 2010). In an experimental study, Johns 
and colleagues (2010) tested 31 individuals with ARMS and 31 healthy volunteers. Participants read 
single adjectives aloud while the source and pitch of the online auditory verbal feedback was 
manipulated, then immediately identified the source of the speech they heard (Self/Other/Unsure). 
Response choice and reaction time were recorded. When reading aloud with distorted feedback of 
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their own voice, ARMS participants made more errors than controls (misidentifications and unsure 
responses). ARMS participants misidentified the source of their speech as “Other” when the level of 
acoustic distortion was severe, and misidentification errors were inversely related to reaction times 
(Johns et al., 2010).  
 
 
2.9. Biomarkers of CHR status 
A variety of candidate biomarkers has been recently identified, suggesting that the CHR status is 
associated with brain abnormalities at the neuroanatomical, functional, and chemical levels (Allen et 
al., 2012; Bodatscht et al., 2011; Fusar-Poli et al., 2011; Fusar-Poli, 2012, Fusar-Poli et al., 2012; 
Schmidt et al., 2013). The longitudinal investigation of individuals at high-risk for schizophrenia 
using structural magnetic resonance imaging (MRI) has provided insights into brain changes during 
the period of transition from ARMS to the psychosis state (Pantelis et al., 2005). Overall, these 
alterations seem to be similar to, but less severe than those in the full-blown disease (Fusar-Poli et 
al., 2007). More specifically, MRI studies comparing UHR individuals with a subsequent full-blown 
illness to those without a later disease transition showed reduced grey matter in prefrontal, temporal, 
cingulate, insular, and subcortical brain structures in the former group (Smieskova et al., 2010). 
Growing evidence suggested also that reduced size of the hippocampus was a potential premorbid 
marker of illness, particularly reduced left hippocampal volume identified in first-episode psychosis 
and bilaterally smaller hippocampi in patients diagnosed with schizophrenia (Velakoulis et al., 1999). 
In a small cross-sectional study combining UHR individuals (both those converting to psychosis with 
those not converting), this group had smaller volumes than a healthy comparison population (Phillips 
et al., 2002). However, subsequent analyses of the high-risk group by psychosis outcome found that 
those individuals who subsequently developed psychosis had normal hippocampal volumes, while 
those who did not develop a psychosis had reduced volume of the hippocampus (Phillips et al., 2002). 
In a larger study involving 473 participants, comprised of 89 patients with chronic schizophrenia, 162 
with first-episode psychosis, 135 UHR patients and 87 healthy controls (Velakoulis et al., 2006). In 
addition to hippocampal volumes this study included separate estimates of amygdala volumes. 
Patients with chronic schizophrenia had bilaterally smaller hippocampi but normal amygdala 
volumes, while first episode schizophrenia patients had smaller left hippocampal volumes and normal 
amygdala volumes. The hippocampal/amygdala volumes of first-episode schizophreniform patients 
and both UHR groups did not differ from those of controls. In contrast, patients with affective 
psychoses exhibited larger amygdalae but normal hippocampal volumes. Thus, in first-episode and 
established schizophrenia patients, the hippocampi were reduced but amygdalae were normal, while 
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in affective and other psychoses the hippocampi were normal and amygdalae were enlarged. These 
findings are broadly consistent with the meta-analyses mentioned above in patients with established 
schizophrenia (Steen et al., 2006), which have identified reduced hippocampal volume as one of the 
more robust structural imaging findings in schizophrenia.  
In a voxel-based morphometry imaging study, increasing duration of illness was significantly 
associated with loss of volume in the right medial temporal, medial cerebellar and bilateral anterior 
cingulate grey matter regions (Velakoulis et al., 2002). Different from data obtained on patients with 
schizophrenia (Heckers, 2001), the UHR group as well as first-episode patients did not exhibit any 
reduction on magnetic resonance spectroscopy in hippocampal N-acetylaspartate, compared with 
controls, which is a marker of neuronal integrity (Wood et al., 2003), Therefore, these findings were 
at odds with the dominant neurodevelopmental theories of schizophrenia that, on the basis of an early 
and static neurodevelopmental disturbance, predict that patients at all stages of schizophrenia should 
exhibit the same degree of structural change (Weinberger & Marenco, 2003). However, these studies 
had the limitation of a cross-sectional design.  
A voxel-based morphometry study examined brain structural changes over the transition phase to 
illness (Pantelis et al., 2003). Twenty-one of the 75 UHR individuals who had a baseline magnetic 
resonance scan were followed up with a second scan, either immediately post-psychosis (UHR-P 
group) or after at least 12 months had elapsed for those not developing psychosis (UHR-NP group). 
Comparison between baseline and follow-up scans for the two groups indicated that in the UHR-P 
group, four regions of the left hemisphere were reduced, involving a left inferior frontal region, a left 
medial temporal region (that included the parahippocampal gyrus), a left inferior temporal region, 
and the mid-cingulate bilaterally. Both UHR-P and UHR-NP showed a reduction of grey matter 
volume in the left cerebellum (Pantelis et al., 2003). It should be noted, however, that there are a 
number of methodological limitations to this study, including small sample size in the longitudinal 
arm, the use of relatively thick slices that may hinder detection of subtle changes, the use of voxel-
based morphometry that has been criticized as not optimal for structural imaging (including 
inadequacy in dealing with registration of brains between individuals due to variation in cortical 
folding), the lack of a control group and possible medication related effects (Crum, Griffin, Hill, & 
Hawkes, 2003). Despite these limitations, this was the first study to demonstrate progressive brain 
structural changes (grey matter loss) in individuals who were developing active psychotic illness 
followed longitudinally from before illness onset. 
In a subsequent voxel-based morphometry follow-up study, Job and colleagues (Job et al., 2005) 
examined brain changes over two years in young high-risk adults compared with healthy controls. 
The CHR group exhibited significant reductions in grey matter density in temporal lobe, right frontal 
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and right parietal lobes, which were not observed in the healthy comparison group. Comparing those 
individuals with transient or isolated psychotic symptoms versus those with no such symptoms 
showed progressive changes in left temporal lobe regions, including the hippocampus (Job et al., 
2005). CHR individuals who later developed schizophrenia (3 at time of second scan, 5 developing 
schizophrenia subsequent to the second scan) showed reductions in the left inferior temporal lobe, 
left uncus and right cerebellum. Importantly, these participants were all neuroleptic-naïve, indicating 
that medication did not explain these changes. 
 
 
2.9.1. Dopamine sensitization 
Laruelle, Kegeles and Abi-Dargham (2003) suggested that frontal dopamine activation can inhibit 
dopamine sensitization in the medial brain. Sensitization regards the process by which a cellular 
receptor becomes more likely to respond to a stimulus. Thus, dopamine sensitization refers to the 
process by which the dopamine system responds fiercely to the release of dopamine. Abi-Dargham 
and colleagues (2000) proposed that D2 receptor blockade, if sustained, might allow for an extinction 
of this sensitization process with potential re-emergence upon treatment discontinuation.  
A biological substrate of the salience network may be anterior cingulate cortex and anterior insula. 
Reduced activation in these areas is shown to be related to reality distortion (Palanyappanan et al., 
2010; Palanyappan et al., 2013).  
Howes and Kapur (2009) proposed that the locus of dopamine deregulation is primary at the 
presynaptic dopaminergic control level and that this deregulation is the final common pathway to 
psychosis. The abnormal release of dopamine lead to an aberrant assignment of salience to innocuous 
stimuli. It is argued that psychotic symptoms, especially delusions and hallucinations, emerge over 
time as the individual’s own explanation for the experience of aberrant salience (Kapur, 2003). 
Psychosis, is therefore, aberrant salience driven by dopamine and filtered through the individual’s 
existing cognitive and sociocultural schemas (Howes & Kapur, 2009).  
Salience is like a highlighter in the perceptual field that makes certain stimuli emerge in the centre in 
the perceptual field and are experienced as extremely important.  
 
 
2.9.2. The hypothalamic–Pituitary–Adrenal (HPA) function 
Consistent research evidence has shown the link between the activity of the Hypothalamic-Pituitary-
Adrenal (HPA) function and psychotic disorders. Elevated cortisol levels were found in patients with 
first episode and recent onset (Modelli et al., 2010), and increased activity of systemic cortisol 
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metabolism in patients with psychosis (Steen et al., 2010). In addition, higher levels of cortisol and 
more pronounced cortisol reactivity to daily stressors have been observed in relatives of patients with 
schizophrenia (Yildirim, Dogan, Semiz, & Kilicli, 2011). Recently, a study of first-episode patients 
revealed no differences from controls in cortisol, but the magnitude of the decrease in cortisol over 
12 weeks was associated with the decline in severity of positive and negative symptoms (Garner et 
al., 2011). 
Poor work has been conducted to explore the activity of the HPA function in the CHR state. As stress 
response is believed to play a role in triggering symptoms, indices of the biological response to stress 
are important during the prodromal phase. In one study assessing pituitary volume through magnetic 
resonance imaging, the CHR individuals who later converted to psychosis had a significantly larger 
baseline pituitary volume compared with those who did not (Garner et al., 2005). The authors 
concluded that the larger pituitary volume may be indicative of increased HPA activation (Garner et 
al., 2005). However, in another study conducted by the same research group on 18 CHR individuals, 
cortisol levels were not significantly associated with global psychopathology, psychotic symptoms, 
or pituitary and hippocampal volumes, but positively correlated with ratings of depression and anxiety 
(Thompson et al., 2007).  
These investigators also conducted a study in which they administered the dexamethasone 
corticotrophin releasing hormone test to a small group of 12 individuals at CHR at baseline 
(Thompson et al., 2007). Three of the 12 developed psychosis within 2 years. Due to the small sample 
size, statistical analyses were not conducted, but the authors reported that participants who did not 
develop psychosis showed a trend toward higher cortisol levels at the latter stages of the test, when 
compared to the three participants who did develop psychosis (Thompson et al., 2007). 
Other studies with larger samples have indicated that CHR individuals reported higher cortisol levels 
(Mizrahi et al., 2012; Walker et al., 2010; Weinstein, Donald, Schiffman, Walker, & Bonsall, 1999).  
Findings from a recent study showed that CHR youth who convert to a psychotic disorder had 
significantly increased cortisol levels in the year preceding onset (Walker et al., 2010). Of the 56 
included CHR young participants, 14 subsequently developed a psychotic disorder. Multiple saliva 
samples were obtained to enhance cortisol estimation reliability. As in previous studies of HPA 
activity in adolescence, an age-related increase in cortisol secretion was also observed, suggesting 
that the developmental period of peak risk for prodromal onset is also characterized by greater stress 
sensitivity.  
Another recent study assessed a group of UHR individuals and a group of patients with psychosis 
using positron emission tomography to index percent change in receptor binding between conditions 
(stress versus control) in the limbic, associative, and sensorimotor striatum (Mizrahi et al., 2012). The 
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stressor was a challenging mental arithmetic task. Compared to healthy controls, CHR and patients 
with psychosis had more pronounced dopamine response in the associative and sensorimotor striatum, 
as well as a greater cortisol response to the stressor. Further, there was a significant association 
between the increases in cortisol and DA (Mizrahi et al., 2012). 
Recently, in the context of the large multicentre NAPLS study, Walker and colleagues (2013) 
followed 256 CHR individuals and 141 healthy controls, all of whom underwent baseline assessment 
and measurement of salivary cortisol. Findings indicated that the CHR group had higher cortisol 
levels. There were modest, positive correlations of cortisol with baseline symptom severity, and 
baseline cortisol was higher among those who transitioned to psychotic level symptoms when 
compared to healthy controls and CHR participants who remitted (Walker et al., 2013). 
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Chapter 3: Assessment procedures for the detection of CHR individuals  
 
 
 
 
 
 
3.1. Screening interviews 
In a recent meta-analysis, Fusar-Poli and colleagues (2015) included 12 studies assessing help-
seeking individuals referred to CHR services and assessed through a CHR interview. Findings 
indicated an excellent overall prognostic performance in terms of the area under the curve (AUC) at 
38-month follow-up, which appeared comparable to other preventive approaches in medicine. 
However, excellent AUC values were mainly mediated by an outstanding ability of the instruments 
to rule out psychosis, then high sensitivity but only moderate overall specificity, which suggested 
some need to further improvement of prediction tools (Fusar-Poli et al., 2015). 
 
 
3.1.1. Bonn Scale for the Assessment of Basic Symptoms (BSABS) 
In the 1960s Huber and Gross developed the Bonn Scale for the Assessment of Basic Symptoms 
(BSABS; Gross, 1987) on basis of the primary symptoms of schizophrenia according to Bleuler 
(1950). Further analyses of the BS resulted subsequently in a set of predictive criteria based on nine 
cognitive disturbances, the BSABS-P (Schültze-Lutter & Klosterkötter, 2002), an instrument able to 
cover the earliest signs of psychosis. 
 
 
3.1.2. Structural Interview for Prodromal Syndromes (SIPS) 
The SIPS (McGlashan et al., 2001; Miller et al., 2002) is a structured diagnostic interview used to 
diagnose the three prodromal syndromes and may be thought of as analogous to the Structured 
Clinical Interview for DSM-IV (SCID; First et al., 1997) or other structured diagnostic interviews. 
The SIPS includes the SOPS, the Schizotypal Personality Disorder Checklist (American Psychiatric 
Association, 1994), a family history questionnaire (Andreasen et al. 1977), and a well-anchored 
version of the Global Assessment of Functioning scale (GAF; Hall 1995). The SIPS also covers 
operational definitions of the three prodromal syndromes (the Criteria of Prodromal Syndromes 
[COPS]) and an operational definition of psychosis onset (Presence of Psychotic Syndrome [POPS]). 
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As part of the SIPS, the COPS and the POPS are applied to the information from the positive 
symptoms of the SOPS, the schizotypal personality disorder Checklist, and the family history 
questionnaire to diagnose a prodromal syndrome or the presence of psychosis. The SOPS is a 19-item 
scale designed to measure the severity of prodromal symptoms and changes over time. It may be 
conceptualized as analogous to the Positive and Negative Syndrome Scale (PANSS; Kay, Flszbein, 
& Opfer, 1987), the Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1962), and other 
established severity rating scales for patients who are fully psychotic. The SOPS contains four 
subscales for Positive, Negative, Disorganization, and General Symptoms constructs. There are five 
Positive, six Negative, four Disorganization, and four General Symptoms items. The Negative, 
Disorganization, and General Symptoms rated on the SOPS are not currently part of making 
prodromal diagnoses according to the COPS but are useful in describing the severity of the diagnosis 
once established.  
 
 
3.1.3. Comprehensive Assessment of At-Risk Mental States (CAARMS) 
The Comprehensive Assessment of At-Risk Mental States (CAARMS, Yung et al. 2005) is a well-
established instrument to classify individuals at UHR for developing a psychotic disorder. The 
CAARMS is assessed in an interview that takes approximately one to 2 hours, and needs to be 
conducted by a specifically trained mental health professional, which is usually not widely available 
outside of specialized services. The CAARMS was used to determine if a patient was either psychotic 
(or had life time diagnosis of a psychotic disorder), UHR for psychotic disorder, or neither of both 
prior categories. It allows to identify 3 UHR groups: 
 Individuals with a family history of a psychotic disorder in a first-degree relative and 
non-specific symptoms for at least one month associated with a significant decrease 
in functioning; 
 Individuals with attenuated psychotic symptoms (APS), such as sub-threshold with 
respect to intensity of symptoms; 
 Individuals with Brief Limited Intermittent Psychotic Symptoms (BLIPS), symptoms 
of psychotic intensity that are infrequent with a total duration of less than seven days. 
The CAARMS is composed by seven sections: 
1) Positive symptoms (four items) 
2) Cognitive change attention/concentration (two items) 
3) Emotional disturbance (three items) 
4) Negative symptoms (three items) 
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5) Behavioural change (four items) 
6) Motor/physical change (four items) 
7) General psychopathology (eight items) 
The positive symptoms items are the main items on the basis of which individuals are included in the 
ARMS state. The four positive symptoms are: 
1.1 unusual content of thoughts 
1.2 Non-bizarre ideas 
1.3 Perceptual disturbance 
1.4 Disorganized speech 
These items are scored with anchor points on intensity (0-6 point Likert scale) and frequency/duration 
(0-6 point Likert scale). In addition, dates of start and end of symptoms are annotated as well as the 
level of distress (0-100) and relationship with drug use (0-2). It is very important to ascertain the 
combination of intensity and frequency/duration of the positive symptoms if an individual has APS, 
BLIPS, psychosis and/or above below the threshold symptoms. ARMS groups according to 
CAARMS are presented in Table 3.1. 
 
 
Table 3.1. ARMS groups identified by the CAARMS. 
  Intensity frequency 
Attenuated psychotic symptoms   
subthreshold intensity group 
Unusual thought content 3-5 3-6 
Non-bizarre ideas 3-5 3-6 
Perceptual abnormalities 3-4 3-6 
Disorganized speech 4-5 3-6 
Attenuated psychotic symptoms  
subthreshold frequency group 
Unusual thought content 6 3 
Non-bizarre ideas 6 3 
Perceptual abnormalities 5-6 3 
Disorganized speech 6 3 
Brief limited intermittent psychotic symptoms group 
Unusual thought content 6 4-6 
Non-bizarre ideas 6 4-6 
Perceptual abnormalities 5-6 4-6 
Disorganized speech 6 4-6 
Note. ARMS= At-risk mental state, CAARMS= Comprehensive Assessment of At-Risk-Mental State. 
 
 
3.1.4. Early Recognition Inventory based on IRAOS (ERIraos) 
The instrument Early Recognition Inventory based on IRAOS (ERIraos) has been developed with the 
aim to cover comprehensively a detailed assessment of APS, BLIPS and BS into one measure. Pioneer 
work by Häfner and colleagues elucidated the early course of schizophrenia in a retrospective 
assessment (ABC study IRAOS; Maurer, Hörrmann, Trendler, Schmidt, & Haefner, 2006). ERIraos 
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assesses the 10 cognitive-perceptive basic symptoms (COPER symptoms) (“Thought perseveration 
of past events”, “Disturbance of receptive speech”, “Thought interference”, “Pressing and racing 
thoughts”, “Thought block”, “Decreased ability to discriminate between ideas, perception, fantasy 
and true memories”, “Derealisation, Depersonalisation”, “Unstable ideas of reference (subject-
centrism)”, “Disturbances of optic perceptions”, “Disturbances of acoustic perceptions”) and 
additionally the item “Disturbances of olfactory, gustatory, sensible, somatic and tactile perceptions; 
Impaired bodily sensations (coenaesthesia)” that showed predictive validity for a transition to 
psychosis in the German Research Network on Schizophrenia (GRNS study; Schultze-Lutter et al., 
2010). This scale consists of 50 symptoms, including BS, APS and BLIPS. For each of the 50 
symptoms subjects are asked to refer (A) if this specific symptom was present in the past four weeks, 
(B) if it already occurred within the last 12 months, (C) if there was a deterioration during the last 12 
months, and (D) if there is a current emotional strain regarding this symptom (score range 0–200, cut-
off = 30). The absence of an increased risk of psychosis is assumed, when no BLIPS, no APS or less 
than two basic symptoms and no transgression of the cut-off score is presented. Early ARMS is 
defined by a transgression of the cut-off or the presence of at least two basic symptoms, while a late 
ARMS is defined by the presence of at least one BLIPS or APS, independent of the score achieved. 
The patients are further evaluated by the instruments Global Assessment of Functioning (GAF; 
Startup, Jackson, & Bendix, 2002) to evaluate the psychological, social and occupational functioning, 
the Personal and Social Performance Scale (PSP; Morosini et al., 2000), which focuses on socially 
useful activities, personal and social relationships, self-care and disturbing and aggressive behaviour, 
and the Schizotypal Personality Questionnaire – Brief (SPQ-B; Raine & Benishay, 1995), which is a 
brief, self-report screening instrument for schizotypal personality features. Finally, the associated 
instruments of the ERIraos “Alcohol and drug consumption”, and “Mental illness in the family” are 
applied. 
 
 
3.1.5. Schizophrenia Proneness Instrument-Adult version (SPI-A) 
Schizophrenia Proneness Instrument-Adult version (SPI-A) is composed by 34 items comprising 6 
subscales of 5 to 6 items each, based on a 7-point severity scale with maximum of occurrence within 
the last three months as the guiding criterion (“Symptom absent”= 0, “Present daily”= 6): (a) 
“affective dynamic disturbances” including impaired stress tolerance, a change in general mood and 
a decrease in general as well as positive emotional responsiveness; (b) “cognitive-attentional 
impediments” including some cognitive basic symptoms that were found to be less specific to 
individuals later developing psychosis, such as attention and short-term memory deficits as well 
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concentration problems; (c) “cognitive disturbances” comprising of the more peculiar cognitive basic 
symptoms found to be rather specific to prodromal individuals (Klosterkötter et al., 2001), such 
thought interference and blockages, indecisiveness with regard to minor choices; (d) “disturbances in 
experiencing self and surroundings”, including self-reported pressure of thoughts unrelated to each 
other and unstable ideas of reference; “body perception disturbances” comprising of coenesthetic 
phenomena, such as unusual perceptive experiences related to the body in a non-delusive way; (f) 
“perception disturbances” with hypersensitivity to optic and acoustic stimuli, micro-/macropsia, 
changes in the perception of the intensity/quality of acoustic stimuli.  
 
 
3.1.6. Schizophrenia Proneness Instrument-Child and Youth version (SPI-CY) 
The Schizophrenia Proneness Instrument, Child and Youth version (SPI-CY; Schultze-Lutter et al., 
2012) was developed to assess BS in 8- to 18-year-old individuals. The tool is designed to assess Risk 
criterion “Cognitive-perceptive basic symptoms” (COPER), including at least any of the following 
10 basic symptoms with a SPI-CY score of ≥3 (i.e., several times in a month or weekly) within the 
past 3 months: (a) decreased ability to discriminate between ideas and perception, fantasy and true 
memories (B1), (b) unstable ideas of reference (B2), (c) visual perception disturbances (B3, O1, O3), 
(d) acoustic perception disturbances (B4.2, B5), (d) derealisation (B7), (e) thought interference (D9), 
(f) thought pressure (D10), (g) disturbance of receptive speech (D11), (h) thought perseveration 
(D14), (i) thought blockages (D15). The measure evaluates also the high-risk criterion “Cognitive 
Disturbances” (COGDIS), consisting of at least 2 of the following 9 basic symptoms with a SPI-CY 
score of ≥3 (i.e., several times in a month or weekly) within the past 3 months: (a) unstable ideas of 
reference (B2), (b) disturbances of abstract thinking (D7), (c) inability to divide attention (D8), (d) 
thought interference (D9), (e) thought pressure (D10), (f) disturbance of receptive speech (D11), (g) 
disturbance of expressive speech (D12), (h) thought blockages (D15), (i) captivation of attention by 
details of the visual field (O2).  
The SPI-CY consists of 4 subscales, each including 8 to 19 items rated on a 7-point severity scale 
according to their maximum frequency during the past 3 months: 
 Adynamia: decreased drive; impaired stress tolerance; affective changes; and unspecific 
concentration, memory, and thought disturbances; 
 Perception Disturbances: disturbances in visual, acoustic, and body perception; 
derealisation; unstable ideas of reference; disturbances in apprehension of perceptions; and 
decreased ability to discriminate between ideas and perception. All but 2 are included in BS 
criteria, particularly COPER; 
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 Neuroticism: reduced desire for social contact; increased emotional responsiveness to the 
misfortunes of strangers; irritability; obsessive compulsive and phobic phenomena; 
depersonalization; and bodily sensations of circumscribed pain and of touch being 
negatively experienced; 
 Thought and Motor Disturbances: 8 thought disturbances that are part of BS criteria; 6 other 
thought and memory disturbances; 3 cognitive motor disturbances; decreased spontaneity; 
and disturbances in social skills.  
Findings from the Age, Beginning and Course Schizophrenia Study (ABC-study; Maurer et al., 2006) 
identified different ARMS-subgroups, the so-called pre-psychotic and psychotic prodromal states 
(Rausch et al., 2013).  
In conclusion, the CAARMS, ERIraos and SPI-A are aimed to comprise different subgroups 
according to prodromal states and time windows (Figure 3.1).  
 
 
 
Figure 3.1. ARMS groups, related diagnostic scales and time windows (source: Rausch et al., 2013). 
 
 
3.2. Self-report tools 
For several reasons, however, clinical interviews targeting CHR status are not considered suitable for 
contexts beyond tertiary settings. Interviews targeting CHR status are typically lengthy, and clinicians 
must receive training to become familiar with the constructs, rating scales, and diagnostic criteria 
(McGlashan et al., 2010). The development of brief, easy to-use instruments that can be implemented 
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for clinical use is a crucial step toward establishing and disseminating evidence-based care for 
individuals most vulnerable to psychosis. 
Brief self-report questionnaires have the potential to screen populations of interest and may ultimately 
aid in the detection of far more CHR individuals than would be possible through clinician- or self-
referrals to specialized programs, offering a potential solution to the challenge of sample 
ascertainment for CHR research programs.  
A key question remains whether and how the criteria for the psychosis risk syndrome can be applied 
in populations with a lower a priori probability of psychosis risk, outside the specialized clinics 
(Carpenter & van Os, 2011). As the incidence of UHR is low and the early signs and symptoms are 
non-specific, this approach is only likely to succeed if an adequate diagnostic screening instrument is 
available, with which individuals with suspected UHR symptoms can be identified for further in-
depth diagnostic interviews. The test should have a high specificity (to maximize the proportion of 
actual negatives which are correctly identified as such) and also a good sensitivity (to maximize the 
proportion of actual positives which are correctly identified as such) (Wilson & Jungner, 1968). In 
addition, the screening should be acceptable to clinicians and the population to be screened, and the 
procedure should be cost effective and feasible in routine mental health care. 
A variety of self-report screening tools have been developed to detect more efficiently for the ARMS 
(Kline et al., 2012). In several of these measures, item content focuses on symptoms associated with 
the attenuated symptom construct such as unusual perceptions and sensations, difficulty 
concentrating, affective changes, superstitious beliefs, or abnormally suspicious thoughts (e.g., 
Heinimaa et al., 2003; Loewy et al., 2005; Ord et al., 2004). 
 
 
3.2.1. Prodromal Questionnaire (PQ) 
The Prodromal Questionnaire (PQ; Loewy et al., 2005) is a 92-item self-report screening 
questionnaire that assesses the presence of APS on a two-point scale (true/false). On average, it takes 
20 minutes to complete. The items are divided into four major subscales: positive symptoms (45 
items), negative symptoms (19 items), disorganized symptoms (13 items), and general symptoms (15 
items). Positive symptoms are grouped in three subscales: (1) unusual thought content, delusional 
ideas and paranoia (22 items); (2) perceptual abnormalities and hallucinations (17 items); and (3) 
conceptual disorganization (6 items).  
As part of the Dutch Early Detection and Intervention Evaluation study (EDIE-NL; Riedijk et al., 
2010), Ising and colleagues (2012) administered the PQ in the context of a two-stage screening 
procedure in the consecutive help-seeking population for nonpsychotic disorders accessing secondary 
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mental health care services. Participants were 3533 individuals aged 18–35 years who were screened 
with the PQ. Individuals with scores above the cut-off were then assessed with the CAARMS to 
investigate possible psychosis risk status. In line with other researchers (Loewy et al., 2011), people 
were selected if they were with PQ-positive symptom scores in the top 20% of the distribution for 
further investigation using the criterion was 18 or more PQ-positive symptom items. A 16-item list 
was selected. For use as a screening instrument, a cut-off score of 6 or more symptom items was 
found to identify ‘‘caseness’’ (UHR/psychosis) best with a sensitivity of 87%, resulting in a 
specificity of 87% and PPV of 44%. Total score on the PQ-16 was significantly correlated with the 
CAARMS diagnosis. Cronbach’s alpha for the total score on the PQ-16 was 0.77. The newly 
developed PQ-16 has good concurrent validity with both the interview-based CAARMS diagnoses in 
our population and also in comparison to the original PQ. A cut-off of 6 or more symptoms on the 
PQ-16 has a high true positive rate (87%) and high specificity (87%) when differentiating 
UHR/psychosis from those with no CAARMS diagnosis. The 16-item PQ consists of 9 items out of 
the perceptual abnormalities/hallucinations subscale, 5 items including unusual thought 
content/delusional ideas/paranoia, and 2 negative symptoms. If the individual scores above the cut-
off, a semi-structured interview, like the CAARMS, is recommended to ascertain whether he/she 
fulfil the UHR criteria.  
 
 
3.2.2. Community Assessment of Psychic Experience (CAPE) 
The Community Assessment of Psychic Experience (CAPE; Konings et al., 2006) is a 42-item self-
report questionnaire that proved to be stable, reliable and valid for self-reported PLES in the general 
population. Mossaheb and colleagues (2012) investigated whether the CAPE could be used as a 
screening tool to detect individuals at an increased risk for developing psychosis in a clinical help-
seeking population. A cut-off value of 2.80 for the positive dimension identified UHR individuals in 
a clinical population with a high sensitivity (83%). 
 
 
3.2.3. PRIME Screen 
The PRIME Screen (Miller et al., 2004) is based on items from the Structured Interview for Prodromal 
Syndromes (SIPS), which was also developed by Miller et al. (2003). This screening questionnaire 
consists of 12 items covering positive symptoms and utilizes a self-rated scoring system of between 
0 (“Definitely disagree”) and 6 (“Definitely agree”). In the developmental phase of the PRIME 
Screen, Miller et al. (2004) reported that it showed a sensitivity of 0.90 and had a perfect specificity, 
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but these results were obtained using small samples (n=36) and the predictive validity was not 
examined. 
 
 
3.2.4. Basel Screening Instrument for Psychosis (BSIP) 
The Basel Screening Instrument for Psychosis (BSIP; Riecher-Rössler et al., 2008) is modelled on 
the Brief Psychiatric Rating Symptom Scale (BPRS; Overall & Gorham, 1962). It is a 46-item 
checklist used in combination with the BPRS Three symptoms of the BPRS are used for the 
assessment of APS: hallucinations, unusual thought content, and suspiciousness. Four symptoms of 
the BPRS are used for the assessment of BLIPS: hallucinations, unusual thought content, 
suspiciousness, and conceptual disorganisation.  
 
 
3.2.5. Early Detection Primary Care Checklist (PCCL) 
The research group of Paul French developed a short tool, the Early Detection Primary Care Checklist 
(PCCL; French et al., 2012). The measure was completed by primary care practitioners who referred 
positive screens for specialized psychiatric assessment (UK adolescents and young adults ages 14–
34). With regard to CAARMS CHR/psychosis diagnoses, the PCCL was found to have excellent 
sensitivity (0.96) but poor specificity (0.10). An optimized 6-item version yielded a sensitivity of 0.88 
and specificity of 0.47; an optimized 20-item version sensitivity of 0.89 and specificity of 0.60 
(French et al., 2012). 
 
 
3.3. The European Psychiatric Association guidelines on early detection 
Recently, according the European Psychiatric Association (EPA) guidelines (Schultze-Lutter et al., 
2015), the following three CHR criteria should be alternatively used in the early detection of 
psychosis when past or current psychosis and causation by a somatic condition have been excluded: 
 at least any one attenuated psychotic symptom, that meets the additional requirements of either 
SIPS or early CAARMS, such as (1) unusual thought contents or delusional ideas not held with 
full conviction, including ideas of reference not immediately rectified by cognition, (2) 
perceptual aberrations or hallucination with remaining insight, or (3) disorganized 
communication or speech that is still comprehensible and responds to structuring in the 
interview;  
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 at least any two self-experienced and self-reported cognitive basic symptoms rated irrespective 
of their appearance in the interview, such as (1) interference of completely insignificant thought 
contents, (2) blockage of thoughts not explained by lack of concentration or attention, (3) 
thought pressure by thoughts unrelated to a common topic, (4, 5) disturbances of receptive or 
expressive speech in everyday use of native language, (6) inability to divide attention between 
tasks relating to different senses and generally not requiring full attention each such as making 
a sandwich and talking to someone, (7) disturbance in the immediate recognition and 
understanding of any kind of abstract, figurative or symbolic phrases or contents, (8) subjective 
experience of self-reference that are almost immediately rectified by cognition, and (9) 
captivation of attention by insignificant details of the visual field that impairs paying attention 
to more relevant stimuli. These features should have not been evident in what the patient 
considers his/her premorbid stage, have occurred at least on a weekly basis for some time in the 
past 3 months and are not an effect of drug use; 
 at least any one transient psychotic symptom, such as delusion, hallucination, formal thought 
disorder that meet the additional requirements of either SIPS or early CAARMS. 
Additionally, the EPA guidelines state that a genetic vulnerability related to a family history of 
psychosis in at least one first-degree relative should not be used as a clinical indicator of a CHR per 
se, even if accompanied by functional decline. Rather, it should be regarded as a general risk factor 
indicating an already increased pre-CHR assessment risk for psychosis that should be carefully 
considered in CHR individuals (Schultze-Lutter et al., 2015). Patients not presenting the above CHR 
criteria but a genetic risk and other mental problems should however be encouraged to present again 
for a CHR assessment, should they note the onset of mental problems resembling CHR symptoms 
(Schultze-Lutter et al., 2015). 
In line with the general EPA guidance on prevention of mental disorders whose aims include 
reduction of the burden of mental disorders by improvement in quality of life and productivity of 
individuals, the EPA considers that a significant decline in occupational and/or social functioning 
should not be an obligate requirement in the above CHR criteria for the lack of evidence for an 
improvement of prediction by this addition. However, it should be considered as an indication of an 
imminence of risk of conversion and CHR patients with a significant functional decline should be 
considered at high need for treatment (Schultze-Lutter et al., 2015). 
The EPA considers that the above CHR criteria should only be applied in persons already distressed 
by mental problems and seeking help for them or persons seeking clarification of their current risk 
for a vulnerability for psychosis, e.g., by genetic risk. Any clinical screening of other persons seems 
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not warranted by current scientific evidence. In late adolescence, however, the CHR criteria seem to 
be as applicable as in adults. 
The EPA considers that a trained specialist (psychiatrist, clinical psychologist or equivalent mental 
health professional) with sufficient experience in CHR should carry out the assessment; if referral to 
a specialist is not possible, the responsible clinician should consult a trained specialist on the case 
(Schultze-Lutter et al., 2015).  
Moreover, the EPA guidelines also did not include the basic symptom criterion COPER because of 
its large overlap with COGDIS and, compared to COGDIS, its poorer evidence due to the reduced 
number of available studies (Kosterklötter et al., 2001) and meta-analytic data not supporting the 
assumption that it would improve prediction of psychosis in help-seeking samples.  
Furthermore, the EPA working group evidenced that a “one-fits-all” detection approach most likely 
does not account for noticeable heterogeneity of conversion rates even in CHR samples of equal 
intake criteria (Schultze-Lutter et al., 2015). Future early detection approaches should therefore define 
different CHR groups that are identified, for example, by a risk stratification approach, which might 
consider most likely level of functioning but also other potential predictors such as neurocognitive or 
neurobiological abnormalities (Schultze-Lutter et al., 2015). 
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Chapter 4: Preventing or delaying psychosis: interventions for CHR states 
 
 
 
 
 
 
4.1. Cognitive behavioural therapy (CBT) protocols  
French and Morrison (2004) developed a cognitive behavioural therapy (CBT) protocol based on 26 
weekly sessions over 6 months following the principles of the cognitive therapy manual by Aaron T. 
Beck (1976). This kind of intervention is structured, problem-oriented and time-limited; it encourages 
collaborative empiricism, uses guided discovery and homework tasks. It is based on the cognitive 
model most appropriate to the disorder that is prioritised on a problem list agreed between the 
therapist and the patient. Therefore, if a transient or an attenuated psychotic symptom is prioritised, 
the case conceptualisations (and subsequent treatment strategies) are based on Morrison’s recent 
integrative model of hallucinations and delusions (Morrison, 2001). This model emphasises the 
culturally unacceptable interpretations that people with psychosis make for events, in addition to their 
responses to such events and their beliefs about themselves, other people and control strategies. The 
central feature of the approach to the prevention of psychosis involves normalising the interpretations 
that people make, helping them to generate and evaluate alternative explanations, decatastrophising 
their fears of impending madness and helping them test out such appraisals using behavioural 
experiments and cognitive restructuring. However, if the problem prioritised was an anxiety disorder 
(such as panic, social phobia, obsessive–compulsive disorder or generalised anxiety) or depression, 
then the appropriate models are employed (e.g., Beck et al, 1979; Clark, 1986; Clark & Wells, 1995; 
Wells, 1995). The case formulation model of French and Morrison (2004) is provided in Figure 4.1.  
The purpose of the model is to facilitate the collaborative development of idiosyncratic case 
formulations, from intervention strategies ca be derived (Smethurst, French, & Morrison, 2013). In 
the manual sequence of treatment components included definition of a list of problems and goals, 
normalization interventions, practice of skills and coping through in-session role-playing exercises, 
cognitive restructuring through in- and out-session behavioural experiments, examination of 
advantages/disadvantages, generating alternative explanations and survey planning, planning of 
activities to reduce social isolation and increase pleasure emotions (French & Morrison, 2004). All 
the CBT components are delivered also in the form of homework assignment. The manual also 
included a relapse prevention module, where the therapist and the patient collaboratively develop a 
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“blueprint”. This step involves the review of all the skills that he/she has learnt during the therapeutic 
course and how will apply them in the future. The patient is encouraged to image all the obstacles 
that he/she could face in the future and discuss with therapist how to manage them. The patients is 
also invited to identify all potential trigger situations and warning signs of distress (Smethurst, 
French, & Morrison, 2013). 
Bechdolf and colleagues (2007) developed a novel Integrated Psychological Intervention (IPI) 
package for CHR youth. IPI includes individual CBT, group therapy focusing on skills training, 
cognitive remediation for concentration, attention, vigilance, and memory, and psychoeducational 
multifamily groups providing family members with information on the CHR state. McFarlane and 
colleagues (1992) adapted Family-Aided Assertive Community Treatment (FACT), historically used 
in the treatment of severe schizophrenia, for use with CHR youth. The principal psychosocial 
ingredient of FACT is psychoeducational multifamily group treatment, designed to educate families 
on biomedical aspects of psychopathology and use the family as leverage in assisting the client in 
goal setting and problem solving. 
More recently, van der Gaag and colleagues (2012) developed a CBT protocol, based on the protocol 
by French and Morrison (2004), that was enriched with psychoeducation on dopamine sensitivity and 
cognitive biases involved in early psychosis. Psychoeducation provides information on how this 
affects perception (aberrant salience for trivial stimuli) and thinking (more intrusions, more causal 
reasoning over coincidences, stronger data-gathering bias). Furthermore, exercises were added to 
experience cognitive biases; becoming aware of cognitive biases may lead to corrected secondary 
appraisals (van der Gaag et al., 2012). 
The biases addressed are the following domains: (a) data-gathering bias, mainly characterized by 
jumping to conclusions distortions; (b) selective attention to threatening stimuli; (c) confirmatory 
bias, moderating delusion formation; (d) negative expectation bias, leading to increased distress 
levels, as well as underrating of one’s capacities; (e) covariance bias, in which the chance of a causal 
relationship between independent events is overrated (van der Gaag et al., 2013). 
The use of written materials is considered as necessary for compensate attention and memory deficits. 
Activity scheduling is a relevant component of the treatment in order to develop more activities and 
to strengthen the feeling of satisfaction and joy. The involvement of family members can be very 
helpful in these patients to help transfer behaviour outside in real-life contexts, to help with homework 
and to prevent unnecessary conflicts (van der Gaag et al., 2013). 
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Figure 4.1. Case formulation model in the CBT protocol of French and Morrison (2004). 
 
 
 
4.2. Family-based psychological treatments 
Some researchers have hypothesized that early intervention on CHR groups would be strengthened 
by involving family members in treatment, as individuals at CHR are often adolescents living with 
their parents, and parental involvement may enhance the young person’s access to mental health 
services (Schlosser et al., 2010). Moreover, the evolution of APS may be affected by family contextual 
variables. For example, levels of expressed emotion (EE), such as criticism, hostility, or 
overprotectiveness, in parents were associated with the severity of APS in CHR youth over 6 months 
(Schlosser et al., 2010). Levels of parental EE may escalate in reaction to the functional deterioration 
of an offspring with emerging psychosis but may also become a stressor for the offspring (McFarlane 
& Cook, 2007; Miklowitz, 2004).  
Miklowitz and colleagues (2014) developed and evaluated a protocol of family-based psychological 
treatment. Treatment consisted of 18 1-hour sessions family sessions (12 weekly and 6 biweekly 
sessions over six months) including psychoeducation about early warning signs of psychosis, trigger 
situations, stress management techniques (including relaxation exercises), communication enhancing 
training, and problem-solving training. During communication enhancement training, participants 
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rehearsed skills for expressing positive feelings, active listening, requesting changes in another 
person’s behaviour, communication clarity, and expressing negative feelings (Miklowitz et al., 2014). 
Last sessions were dedicated to practice of problem-solving, where participants learned to break down 
larger problems (e.g., “We have to stop fighting”) into smaller ones (e.g., “We need to use lower 
tones of voice”), generate and evaluate solutions, and develop a solution implementation plan. 
Overall, the intervention was aimed to reduce EE, criticism, enhance warm, assertive communication 
between family members, promote active listening skills thus reducing irritability, anger, and 
complaints (Miklowitz et al., 2014).  
Landa and colleagues (2015) developed a group and family-based cognitive behavioural therapy 
program consisting of 15 weekly sessions, where CHR adolescents and their family members are 
provided with CBT skills individually or in small groups. The aims of the program are directed at 
enhancing family and peer support, reducing isolation feelings, normalizing PLES, facilitating 
positive thinking and decision-making skills, and reduce cognitive biases. In a recent preliminary 
uncontrolled study on a small UHR group screened by the CAARMS (n= 6), all enrolled participants 
remitted from ARMS, showed significant decreases also in depression, cognitive biases and 
improvements in functioning (Landa et al., 2016). Family members showed significant improvements 
in use of CBT skills, more effective communication with their offspring, and greater confidence in 
their ability to help (Landa et al., 2016).  
 
 
4.3. Pharmacological treatments  
Growing research focused on the use of low-dose use of antipsychotics as a potential treatment 
strategy to reduce risk of development of a first episode of psychosis (e.,g, McGorry et al., 2013). 
Preliminary data (Tsujino et al., 2013; Woods et al., 2009) examined the use of aripiprazole or 
perospirone, a combined serotonin (5-HTdopamine antagonist and 5HT1A receptor agonist). 
However, these trials were based on an uncontrolled design. Further, RCTs investigated the potential 
benefit of 5-15 mg/die of olanzapine versus placebo (McGlashan et al., 2006) or the combination of 
low-dose risperidone with CBT versus placebo + supportive therapy (McGorry et al., 2013).  
Recently, on the basis of poor evidence in favour of antipsychotics, some researchers have argued 
that there are several problems associated with using antipsychotic medication in a CHR group. The 
risks associated with using pharmacological interventions with false-positive cases are considerable, 
adherence to antipsychotic medication regimens within this group is variable (McGorry et al, 2002) 
and the ethical position has caused some debate. In particular, it has been suggested (Bentall & 
Morrison, 2002) that use of antipsychotic medication is problematic because these drugs have harmful 
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and stigmatising side-effects, their effect on the developing brain in adolescents is unknown, and 
because they target psychotic experiences, which may not be the priority for people at high risk. 
According van der Gaag and colleagues (2013), trials with anti-psychotic medications may focus on 
prescription of low doses of the second-generation antipsychotics associated with low metabolic 
impact and possibly improved adherence rates and fewer side effects. Anti-psychotic medication can 
also be offered as a second line intervention after failed or partial treatment response in CBT. The 
finding that effects wane over time for both pharmacological and psychosocial interventions might 
point to the need for more elaborate interventions or booster sessions to preserve the results (van der 
Gaag et al., 2013). 
 
 
4.4. Nutritional supplements 
Eicosapentaenoic acid increases glutathione is the brain’s principal antioxidant protective factor 
(Berger et al 2007). There is evidence that acute psychotic symptoms are associated with glutathione 
deficiency and, hence, oxidative stress. Some evidence suggested that long-chain o-3 (o-3) 
polyunsaturated fatty acids (PUFAs) could add some benefit. A recent randomized placebo-controlled 
trial (Amminger et al., 2010) found a 4.9% rate of transition to acute psychosis in UHR patients 
treated with PUFAs as compared with a psychosis transition rate of 27.5% in individuals who 
received placebo in addition to standard care, indicating that supplementation with o-3 PUFAs may 
reduce the risk of transition to psychosis. Lower levels of o-3 PUFAs correlate with more severe 
negative symptoms in UHR patients (Amminger & McGorry, 2012) and that decreased levels of fatty 
acids (that is, nervonic acid, o-3 PUFAs) may serve as biomarkers predicting the conversion to 
psychosis in UHR subjects (Amminger et al., 2011). However, the pharmacological and 
neurochemical mechanisms of o-3 PUFA action remain incompletely understood 
 
 
4.5. Efficacy of CHR interventions: what RCTs say 
Efficacy of CBT as an adjunct to routine treatments has been widely demonstrated in acute psychosis 
(Drury et al, 1996; Zimmermann, Favrod, Trieu, & Pomini, 2005) and in cases of chronic, persistent 
psychotic symptoms (Tarrier et al, 1998, 2000; Sensky et al, 2000), as well as in relapse prevention 
(Gumley et al, 2003). Growing attention has been focused on the identification of effective strategies 
for individuals at CHR (Seidman & Nordentoft, 2015). Some promising results have been produced. 
In a first study, 59 participants at CHR were randomized to six months of active treatment 
(Risperidone 1–3 mg/day plus a CBT protocol) or to a needs-based intervention (McGorry et al., 
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2002). By the end of treatment, significantly fewer individuals in the active treatment group had 
progressed to a first-episode of psychosis (9.7% vs 36%). A second, more rigorous study (McGlashan 
et al., 2006), was a randomized, double-blinded trial of 60 help-seeking prodromal patients comparing 
the efficacy of an antipsychotic (Olanzapine) vs placebo in preventing or delaying the onset of 
psychosis. Although not statistically significant, at one-year follow-up 16% of olanzapine-treated 
participants had converted to psychosis compared with 35% of placebo-treated participants 
(McGlashan et al., 2006). Olanzapine was associated with significantly greater symptomatic 
improvement in prodromal symptoms than placebo (McGlashan et al., 2006). 
Morrison and colleagues (2002, 2004) conducted the Early Detection and Intervention Evaluation 
(EDIE) trial, a single-blinded randomized trial which aimed to identify the CHR group. Participants 
were randomly allocated to a monthly monitoring condition or CBT plus monthly monitoring. 
Eligible participants were recruited from a variety of settings, including primary care teams, student 
counselling services, accident and emergency departments, specialist services (e.g. community drug 
and alcohol teams, child and adolescent psychiatry and adult psychiatry services) and voluntary sector 
agencies (such as carers’ organisations). Individuals were included if they were aged between 16 and 
35 years old and met the criteria used in Yung and colleagues (1998). Sixty individuals were included, 
of these twenty-three were assigned to monitoring condition and 37 to CBT. The randomised 
participants were monitored at monthly intervals using the Positive and Negative Symptoms Scale 
(PANSS; Kay, Flzsbein, & Opfer, 1987) for a period of 12 months following initial assessment. The 
CBT intervention was based on the manual of French and Morrison (2004). Fourty-eight participants 
had APS, 6 transient psychotic symptoms and 4 were included on the basis of a family history and 
recent deterioration. In the CBT condition, withdrawal rate was 14%. Using PANSS-defined 
transition as the dependent variable, results showed that the main effect of cognitive therapy was 
significant (OR= 0.04, 95% CI 0.01–0.71, p<0.028), suggesting that there was a 96% reduction in the 
odds of making a transition in the CBT group compared with those who received monitoring alone, 
after adjustment for age, gender, family history and baseline PANSS score. In addition, CBT 
improved positive symptoms with some benefits maintained at 3-year follow-up. However, CBT had 
not an effect on functioning and distress, assessed by the Global Assessment of Functioning (GAF; 
Startup, Jackson, & Bendix, 2002) and the General Health Questionnaire (GHQ; Goldberg & Hiller, 
1979).  
Another trial compared eicosapentoic acid (EPA) with placebo (Amminger et al., 2010) for twelve 
months. At 12 months 4.9% (2/41) of individuals in the EPA group compared to 27.5% (11/40) in the 
placebo group developed psychosis. Furthermore, there were significant group differences in positive 
and negative symptoms at 12 weeks and 12 months in favour of the treatment group.  94% completed 
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the twelve-week intervention period. Omega 3 fatty acids proved safe to administer as an alternative 
therapy and did not cause side effects other than mild gastrointestinal symptoms (Amminger et al., 
2007). Of note is the relatively high percentage of individuals accepting to participate in a trial 
involving substances that are normally found in the human body (67% consent for omega 3) compared 
with RCTs involving antipsychotics (35% in the PACE study) (Phillips et al., 2009). 
Addington and colleagues (2011) compared the efficacy of a 20-sessions CBT protocol based on the 
manual of French and Morrison (2004) with supportive therapy in 51 individuals aged between 14 
and 30 years. There were no conversions in those who received CBT and three in the supportive 
therapy group, but this was not a significant difference. All three conversions had a final diagnosis of 
schizophrenia. Two of the conversions occurred approximately 15 weeks after baseline, and the third 
occurred 10 weeks after baseline. Participants in both treatment groups made significant 
improvements in attenuated positive symptoms, anxiety and depression and neither treatment 
impacted negative symptoms nor poor functioning. Although both groups had improved at six 
months, there were no differences in positive symptoms between the groups. However, an 
examination of the change in positive symptoms over the first 5 months demonstrated that the CBT 
group had an earlier and thus faster reduction in their positive symptoms. It should be considered that 
in this trial participants in the CBT condition received an inadequate dose of CBT treatment - for 
many of the CBT cases, the intervention focused primarily on engagement and less on the strategies 
that are the core of CBT. Furthermore, the number of sessions was limited which may have accounted 
for less time spent on core CBT strategies. In addition, the study was underpowered, and the sample 
was clearly too small to detect a difference although all effects were in the predicted direction. Finally, 
the conversion rates were much lower than expected, and for a few the final conversion status is 
unknown. Approximately 40% of the sample did not complete the 18-month follow-up. Several of 
these young people left the study when they felt they had made some improvement.  
Recently, van der Gaag and colleagues (2012) conducted a randomized controlled trial, the Dutch 
Early Detection Intervention Evaluation (EDIE-NL), where CBT for individuals at CHR was 
compared as add-on with treatment as usual in a group of help-seeking people at mental health 
services. Both the experimental and the control group were treated with evidence-based active 
treatment for the axis 1 or 2 disorder from which they were suffering. The experimental group was 
given an add-on treatment that focused on subclinical psychosis (van der Gaag et al., 2012). CBT for 
UHR people had a maximum provision of 26 weekly sessions. The mean number of sessions was 10: 
16 patients had no sessions at all; 21 had 1–5 sessions; 16 had 6–11 sessions; and 45 had 12–25 
sessions. Patients were eligible for inclusion if the following criteria were met: (1) age 14–35 years; 
(2) a genetic risk or CAARMS scores in the range of the ARMS; and (3) an impairment in social 
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functioning (a score on the SOFAS of 50 or less, and/ or a reduction by 30% on the SOFAS for at 
least 1 month in the past year). Patients were excluded if they met any of the following criteria: (1) 
current or previous use of antipsychotic medication with ≥15 mg cumulative haloperidol equivalent; 
(2) severe learning impairment; (3) problems due to an organic condition; (4) insufficient competence 
in the Dutch language; and (5) history of psychosis. Two hundred and one were included and 
randomized to conditions. Each patient was treated during 6 months and followed-up during 18 
months. In the survival analyses, those who were lost to follow-up were conservatively considered as 
non-transitions. The Kaplan-Meier curves showed a significant difference between individuals 
assigned to CBT and control patients. The odds ratio was 0.522 (95% CI: 0.188–0.948). In the CBT 
condition, 5 patients at 6 months, 9 patients at 12 months, and 10 patients at 18 months cumulatively 
made the transition to psychosis. In the TAU condition, 14 patients at 6 months, 20 patients at 12 
months, and 22 patients at 18 months made the transition to psychosis. Overall, 16.3% of the patients 
developed a psychotic episode. After transition to psychosis, the DSM-IV diagnoses were 
schizophrenia, paranoid type (19); schizophrenia, disorganized type (2); psychotic disorder not 
otherwise classified (3); brief psychotic disorder (1); schizo-affective disorder (1); depression with 
psychotic features (4); and bipolar disorder (2). All patients who transitioned fulfilled the PANSS 
criteria for psychosis (14 had 1 positive symptom intensity of 4; 12 had an intensity score of 5; 5 had 
an intensity score of 6; and 1 person had missing data). With regard to at risk status at 18-month 
follow up, the CBT group had a higher remission rate of ARMS (70.4% remission of ARMS; 17.3% 
ARMS; 12.3% psychosis) than the TAU group (57.0% remission of ARMS; 19.4% ARMS; 23.7% 
psychosis. The number needed to treat for preventing transition to psychosis was 9. 
Subsequently, Ising and colleagues (2016) reported the EDIE-NL trial data obtained through 4-year 
follow-up assessments on 113 participants who consented to complete measures of the original 196.  
The number of participants assigned to the CBT group developing psychosis increased from 10 at 18-
month follow-up to 12 at 4-year follow-up, whereas it did not change in the treatment as usual 
condition (n = 22) still suggesting a clinically meaningful and statistically significant effect (incidence 
rate ratio= 12/22 = 0.55) in favour of CBT (Ising et al., 2016). In addition, significantly more 
participants remitted from their UHR status in the CBT condition (76.3%) compared with the 
treatment as usual (58.7%). Finally, conversion to psychosis was associated with more severe 
psychopathology and social functioning at 4-year follow-up (Ising et al., 2016). 
In another recent study, the detection and evaluation of psychological therapy (DEPTh) trial (Stain et 
al., 2016), 57 young individuals (mean age=16.5) suffering from a CHR state were randomly 
allocated to CBT (n=30) or non-directive reflective listening (n=27). Rate of transition to psychosis 
was 5%, rather lower than in previous trials; the 3 transitions occurred in the CBT condition (baseline, 
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2 months, 5 months respectively). The non-directive reflective listening condition was associated with 
significantly greater reduction in distress associated with psychotic symptoms as compared to CBT. 
There were no significant treatment effects on frequency and intensity of psychotic symptoms, global, 
social or role functioning (Stain et al., 2016). 
 
 
4.6. Evidence from meta-analytic studies 
Some meta-analytic studies were conducted to assess the efficacy of interventions for people at CHR. 
A first meta-analysis was conducted using the data from five randomized controlled trials (Preti & 
Cella, 2010). The pooled relative risk was 0.36, meaning that the risk of a first psychotic episode was 
reduced by 64%, and statistically significant. Heterogeneity was absent, meaning that differences 
across the primary studies could be attributed to random sample error rather than to systematic factors 
(Preti & Cella, 2010).  
The Cochrane group conducted another systematic review and meta-analysis using six studies, but 
did not pool the data (Marshall & Rathbone, 2011). The most recent meta-analysis was based on 
seven studies (Fusar-Poli et al., 2013) and reported a relative risk of 0.34 (95% CI: 23–7; p< 0.001), 
indicating the interventions were successful in reducing the risk of a first psychotic episode in a 
statistically significant way by 66%. These outcomes were associated with a number needed to treat 
of 6 indicating that 6 UHR individuals needed to receive treatment for preventing one more transition 
to psychosis compared to treatment as usual (Fusar-Poli et al., 2013). 
Van der Gaag and colleagues (2013) performed a meta-analysis of 10 randomized controlled trials 
published by 2012. In the three trials examining antipsychotic medication, a statistically significant 
pooled RR of 0.55 was found with a NNT of 7. In the five trials evaluating CBT, a pooled RR of 0.52 
was observed. Six studies included measures of social, occupational or global functioning; however, 
there was no significant difference favouring experimental conditions (van der Gaag et al., 2013).  
A main limitation of the meta-analysis was the risk of publication bias, low number of primary studies 
and that some studies were under-powered. The authors concluded that although the effects are 
encouraging, more research is needed. The focus on transition to psychosis must be broadened with 
the clinical staging idea (McGorry and Van Os, 2013). The UHR group who does not transition is 
still not functioning well and is suffering from anxiety or depression and limitations in social role 
functioning. This requires that a broader set of outcome measures must be used in a next generation 
of prevention studies in psychosis. After all, the UHR group is not only psychosis-prone, but more 
general psychopathology-prone and at risk for compromised social functioning (Yung et al., 2010). 
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Miklowitz and colleagues (2014) conducted a trial where CHR adolescents and young adults were 
randomly assigned to 18 sessions of family-focused therapy in 6 months or 3 sessions of family 
psychoeducation. One hundred and two were followed for six months. Participants assigned to the 
family focused therapy showed greater improvements in attenuated positive symptoms than those 
allocated to family psychoeducation. Negative symptoms improved independently of psychosocial 
treatments. Changes in psychosocial functioning depended on age: individuals over 19 years showed 
more role improvement in family focused therapy, whereas participants between 16 and 19 years 
showed more role improvement in family psychoeducation (Miklowitz et al., 2014). Individuals at 
high risk and their family members who participated in the family focused therapy demonstrated 
greater improvement from baseline to 6-month reassessment in constructive communication and 
decreases in conflictual behaviours during family interactions than those in family psychoeducation 
(O’Brien et al., 2014). Participants in family focused therapy showed greater increases from baseline 
to 6 months in active listening and calm communication and greater decreases in irritability and anger, 
complaints and criticism, and off-task comments compared to participants in family psychoeducation 
(O’ Brien et al., 2014). These changes occurred equally in high-risk participants and their family 
members. 
 
 
4.7. The European Psychiatry Association on early intervention guidelines  
In the context of the European Psychiatry Association (EPA) working group on early psychosis, 
Schmidt and colleagues (2015) produced a guidance paper on early intervention in CHR states 
evaluating the efficacy of interventions that aim at preventing the conversion to psychosis and/or a 
deterioration of functional outcome. In a preliminary step, the authors performed a meta-analysis of 
15 randomized controlled trials on intervention for individuals at CHR conducting a systematic 
literature search by 2014. Regarding pharmacological treatments, the working group found six 
studies, two uncontrolled studies and four RCTs. The mean therapy duration was 6.83 months (SD= 
4.31, range = 2–12), the mean follow-up period was 15.29 months (SD= 16.23, range = 2–48), and 
the drop-out rate ranged between 13.0 and 55.0%. These trials investigated the efficacy of aripiprazole 
(Woods et al., 2009) and perospirone (Tsujino et al., 2013) using an uncontrolled design, and, as 
RCTs, olanzapine versus placebo (McGlashan et al., 2006), “risperidone plus CBT” versus need-
based intervention (McGorry et al., 2002), “amisulpride plus needs based intervention” versus needs-
based intervention (Ruhrman et al., 2007), and “risperidone plus CBT” versus “placebo plus 
supportive therapy” (McGorry et al., 2013). Only one pharmacological study did not use 
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antipsychotic medication but a neuroprotective approach, and investigated the effect of PUFAs in 
CHR individuals compared to placebo through a randomized design.  
Among the psychological interventions, the authors found nine studies (Schmidt et al., 2015). Mean 
therapy duration was 6.87 months (SD= 3.7, range = 2–12), a mean follow-up period of 16.67 months 
(SD= 10.40, range = 2–36), and a drop-out rate between 15.0 and 45.0%. Five interventions used 
CBT techniques such as normalization, behavioural experiments, and cognitive restructuring to 
improve stress- and symptom-management. These compared CBT with monitoring (Morrison et al., 
2004, 2012), supportive therapy (Addington et al., 2011), supportive therapy with placebo (McGorry 
et al., 2013), and other evidence-based interventions for the disorders patients sought help (van der 
Gaag et al., 2012). One uncontrolled study evaluated cognitive remediation therapy in CHR patients 
(Hooker et al., 2014). Moreover, a multi-family psycho-educational group program was evaluated 
first in one uncontrolled study (O’Brien et al., 2007), and next in a RCT with enhanced care as control 
condition (Miklowitz et al., 2014). One of the included RCTs (Bechdolf et al., 2012) combined all of 
the aforementioned approaches with social skills training and compared this integrated psychological 
intervention with supportive therapy. 
Findings of the meta-analysis suggested that early interventions can significantly reduce conversion 
rates in adult CHR patients at short- to medium term follow-up (Schmidt et al., 2015). However, the 
effect of these interventions may only be specific for conversion rates but not for functional outcome 
because the experimental conditions did not achieve larger functional improvements than the control 
conditions. This indicates that patients have functionally benefited from control interventions to a 
similar degree. This may be due to that this particular patient group is quite heterogeneous, for 
example, with regard to their individual vulnerability, their developmental status, their level of 
functional impairments, different environmental factors, and the prevalence of comorbid mental 
health issues (Kirkbride et al., 2006).  
Another point was that this meta-analysis provides preliminary evidence that early intervention 
programs are less effective in reducing conversion to psychosis in youth compared to adult patients. 
This may be due to the lower conversion rates generally found in children and adolescents (Schultze-
Lutter et al., 2015) but needs to be interpreted cautiously due to the lack of studies consisting of youth 
samples, in particular with regard to conversion rates. However, together with the result that youth 
also achieved lower functional improvements than adults, this suggests that current intervention 
programs do not sufficiently address the special needs and developmental stage of younger CHR 
patients. 
Finally, the EPA guidance considers that the current evidence on the efficacy of psychological and 
pharmacological interventions in children and young adolescents is not sufficient to justify primarily 
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preventive interventions (Schmidt et al., 2015). The EPA considers that psychological, specifically 
CBT, as well as pharmacological interventions are able to prevent or at least postpone a first psychotic 
episode in adult CHR patients. In line with the general EPA guidance on prevention of mental 
disorders, the EPA considers that an early intervention in patients presenting with CHR should not 
only aim to prevent the first episode of an affective or non-affective psychotic disorder but also the 
development or persistence of functional impairment. The EPA guidance considers that any 
intervention in CHR should also address current individual needs and other mental disorders present 
(comorbidities), specifically depression and anxiety, according to their respective treatment 
guidelines (Schmidt et al., 2015). Where psychological interventions have proved ineffective, they 
should be complemented by low dose second-generation antipsychotics in adult CHR patients if 
severe and progressive CHR symptomatology (APS with only minimal or clearly declining insight, 
or BLIPS in higher or increasing frequency) is present and with the primary aim to achieve a degree 
of symptomatic stabilization that is required for psychological interventions to be effective. Thus, any 
long-term antipsychotic treatment with a primarily preventive purpose is not recommended (Schmidt 
et al., 2015).  
In conclusion, CBT is regarded as the first-choice intervention for the prevention of conversion to 
psychosis but it might be complemented by pharmacological interventions with low dose second-
generation antipsychotics for symptomatic stabilization, if risk symptoms limit the efficacy of CBT 
(Schmidt et al., 2015).  
 
 
4.8. “One size does not fit all”: towards modular treatments  
Along with efficacy trials, some pioneer research is starting analysing active therapeutic processes 
involved in CBT for UHR populations. In a recent Delphi study of expert opinion (Morrison & 
Barratt, 2010), the essential therapeutic components of cognitive behavioural therapy for psychosis 
produced consensus regarding the importance of goal setting (development of a problem list and goals 
of therapy in a collaborative, shared and problem-orientated fashion, which requires the development 
of a problem list and shared goal), an idiosyncratic case formulation based on the cognitive model, 
and provision of normalising information, evidential analysis and testing beliefs by modification of 
safety behaviours.  
In the context of a secondary data analysis of the Early Detection and Intervention Evaluation trial 
(EDIE-2; Morrison et al., 2012), Flach and colleagues (2015) investigated whether specific 
therapeutic active components of the cognitive model (a shared problem list, case formulation, 
homework tasks) acted as processes increasing the effect of therapy. Interestingly, receiving all 
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aspects of therapy was associated with a significant reduction of symptom severity by 20 points 
compared to those who receive only some or none of the components; however, this effect showed a 
borderline significance level (Flach et al., 2015). When each aspect of therapy is considered 
separately as a mechanism of CBT, there is no longer a significant direct effect of randomisation on 
the severity of symptoms. There was no direct effect of randomisation on outcomes, suggesting that 
allocation to therapy per se is not sufficient to produce change, rather it is the quality of the therapy 
providing gains in clinical outcomes (Flach et al., 2015). When the therapeutic components were 
analysed, agreement on problems and goals was not associated with better outcomes. The lack of an 
effect of having a problem list might be that it is a necessary, but not sufficient, condition for 
achievement of clinical improvement (Flach et al., 2015). There was instead a significant additional 
decrease in the symptom score estimated for case formulation (estimated 23 points decrease) and the 
proportion of sessions involving homework (estimated 26-point decrease). Thus, the inclusion of 
active therapeutic components in therapy seemed to improve outcomes although the estimate was 
again at a trend level of significance (Flach et al., 2015).  
In a recent paper, Thompson and colleagues (2015) reviewed the therapeutic components of 
psychosocial treatments that have demonstrated efficacy in the intervention for CHR. The authors 
noted that all the trials assessing psychosocial interventions for CHR included the following common 
therapeutic components (Thompson et al., 2015).:  
 Assessment; 
 Engagement;  
 Safety planning; 
 Individualized case formulation;  
 Cognitive behavioural strategies; 
 Psychoeducation; 
 Treating comorbidity; 
 Improving social skills;  
 Integration with other services to help meet client needs and support their goals outside of 
psychotherapy.  
It could be believed that a comprehensive treatment for CHR should include all these core aspects 
delivered in appropriate modules. Assessment with valid reliable tools is a very important first step 
in order to develop the participant’s awareness of symptoms and help him/her to self-monitor them 
over time, including a collaborative sharing of baseline data from psychometric scales and tracking 
progress during therapy (Kline & Schiffman, 2014). Engagement - as the reciprocal process in which 
rapport and trust are built with the patient - may be considered as extremely important for young 
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individuals suffering from a CHR status, particularly for those reporting increased suspicion and 
social isolation that could precedes frank psychosis (French & Morrison, 2004). Strong engagement 
may facilitate better treatment adherence and further steps of care increasing willingness to consent 
to higher levels of care when necessary (e.g., medication, hospitalization).  
Thompson and colleagues (2015) identified the most commonly used therapeutic components of 
psychoeducation delivered in the recent RCTs for UHR individuals (e.g., Bechdolf et al., 2007; Ising 
et al., 2016; Miklowitz et al., 2014; Morrison et al., 2004, 2012; van der Gaag et al., 2012). A summary 
of the components is presented in Table 4.1. In addition, during the therapy progress a central role is 
played also by a clinical case formulation (Thompson et al., 2015). Most of RCTs on psychological 
interventions for UHR individuals included this core aspect of therapy (e.g., Addington et al., 2011; 
Bechdolf et al., 2012; Morrison et al., 2004, 2012; Kim et al., 2011), which involves a thorough 
understanding of the role of thoughts and beliefs in the development and maintenance of APS, 
continuative engagement sessions until clinical formulation is established, consider unique concerns, 
experience, and strengths of the participant, and a focus on “bridging” participants' and families' goals 
with the goals of therapy.  
In the review by Thompson and colleagues (2015), development of cognitive and behavioural 
strategies has been found the central component on 10 RCTs of psychological treatments for CHR 
states. A detailed description of the core therapeutic processes involved in all the RCTs of CBT for 
UHR participants is provided in Table 4.2 as illustrated by Thompson and colleagues (2015). 
Finally, another main target of interventions is treatment of comorbid conditions, that can improve 
the outcomes as evidenced by RCTs (e.g, Bechdolf et al., 2007; Yung et al., 2011). This area of therapy 
includes assertiveness and social skills training techniques (e.g, Bechdolf et al., 2007). Interpersonal 
relationship impairments are relatively common among individuals at CHR and may be an important 
moderator of risk for future psychosis (Addington et al., 2008; Cornblatt et al., 2011), making these 
skills a potentially important target for early intervention. Among adults with schizophrenia, social 
skill deficits predict poor occupational functioning (Dickinson et al., 2007); for younger people, poor 
social skills may lead to problems making friends or dealing with bullies (Yung et al., 2011). Social 
communication skills can be delivered both in individual and group settings to improve social 
network (Thompson et al., 2015).  
In conclusion, it could be considered that CHR individuals show a variety of levels of symptom 
intensity, persistence, and distress (Thompson et al., 2015). For some, APS may be the primary target 
of therapy because of associated distress and impairment. For others, however, it may be useful to 
monitor these symptoms over time while targeting other areas of concern, such as social impairment, 
employment/education difficulties, comorbidities (Thompson et al., 2015). A modular approach to 
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treatment that is adapted from evidence-based interventions and designed to be flexible, tailored and 
sensitive to the needs of the individual may improve clinicians’ ability to effectively treat this unique 
population. 
 
 
 
Table 4.1. The most commonly used psychoeducation components in trials for CHR (Thompson et al., 2015) 
Psychoeducation components 
Psychoeducation provides information about mental health, coping, and CHR  
Family involvement provides education to relatives  
Identifying the participant's unique constellation of symptoms and teaching basic classification of symptoms (e.g., 
anxiety versus negative symptoms) to develop a context for effective communication 
Education on the CHR neurobiology and guiding through appropriate interpretation of information 
Education on environmental risk and protective factors includes discussing the role of the social climate, sleep patterns, 
and substance use  
Discussion of role of stress response and coping  
Presentation of the cognitive model (e.g., beliefs, attributions) promotes understanding of relation between thoughts, 
emotions, and behaviours 
Normalization includes understanding symptoms as extensions of normal experiences, discussing fear as an 
understandable response, presenting data regarding prevalence of psychotic-like experiences, and making efforts to 
reduce stigma 
Multiple families are brought together for psychoeducational sessions  
Handouts (i.e., mood charts, symptom lists) are provided and participants/families are asked to keep records of 
symptoms, stress levels, mood. 
Note. CHR= clinical high risk. 
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Table 4.2. Core therapeutic processes of CBT interventions in RCTs for CHR states (Thompson et al., 2015). 
CBT processes RCTs studies 
Evaluation and testing of cognitive distortions and metacognitive beliefs  
Beliefs about thought processes, such as appraisals of cognitions, are collaboratively identified and 
tested through thought and behavioural experiments 
 
Addington et al., 2011; 
Bechdolf et al., 2007, 2012; 
Kim et al., 2011; McGorry 
et al., 2013; Morrison et al., 
2004, 2012; van der Gaag et 
al., 2012; Yung et al., 2011 
 
Evaluation and testing of core beliefs 
Maladaptive beliefs about the client's self that influence the interpretation of his/her surroundings 
are collaboratively identified and tested through thought and behavioural experiments 
 
Addington et al., 2011; 
Bechdolf et al., 2007, 2012; 
Kim et al., 2011; McGorry 
et al., 2013; Morrison et al., 
2004, 2012; van der Gaag et 
al., 2012; Yung et al., 2011 
 
Generating and evaluating alternative explanations 
Adaptive alternatives to dysfunctional appraisals, assumptions, and beliefs are collaboratively 
developed 
 
Addington et al., 2011; 
Bechdolf et al., 2007, 2012; 
Kim et al., 2011; McGorry 
et al., 2013; Morrison et al., 
2004, 2012; van der Gaag et 
al., 2012; Yung et al., 2011 
 
Addressing and modifying safety behaviours  
Behavioural responses to distress that maintain symptoms are identified and modified by 
collaboratively generating healthier responses 
 
Addington et al., 2011; 
Bechdolf et al., 2007, 2012; 
Kim et al., 2011; McGorry 
et al., 2013; Morrison et al., 
2004, 2012; van der Gaag et 
al., 2012; Yung et al., 2011 
 
Note. CBT= cognitive behavioural therapy, CHR= clinical high risk, RTCs= randomised controlled trials. 
 
 
4.9. Strengths of psychological interventions 
Treating young people in the putative prodromal phase does cause some concern that they may be 
exposed to unnecessary and potentially harmful treatments. For example, there have been some 
concerns about the use of antipsychotic medication (Bentall & Morrison, 2002). Thus, psychological 
interventions might be expected to be promising in this pre-psychotic period particularly when the 
symptoms are less severe and also less specific. Antipsychotic medication is effective in reducing the 
rate of transition to psychosis by 45%, but antipsychotics are associated with high attrition rates, e.g. 
54.8% in the McGlashan et al. (2006) and McGorry et al. (2002) studies, and 37.2% in the McGorry 
et al. (2013) study. In addition, McGlashan and colleagues reported an 8.8 kg weight gain. The 
conclusion of the recent study by McGorry and colleagues (2013) was that antipsychotic medication 
should not be offered as a first-line treatment in CHR patients. After all, the data on antipsychotic 
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medication in CHR patients are based on small trials and more evidence is needed to demonstrate 
efficacy and safety. 
French and Morrison (2004) present several arguments to support why CBT may be a beneficial 
psychological intervention for this clinical high-risk group. It addresses the range of symptoms and 
concerns present in the clinical high-risk period and teaches potentially effective strategies to protect 
against the impact of environmental stressors that may contribute to the emergence of psychosis.  
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Chapter 5: The CHiRis study (Challenging High Risk of psychosis): efficacy of cognitive 
behavioural therapy for individuals at ultra-high risk for first episode of psychosis.  
A randomised controlled trial 
 
 
 
 
 
5.1. Introduction and rationale 
In the last decade, growing attention has been dedicated by researchers and practitioners to early 
identification and intervention on groups of young individuals, who could be at increased risk of a 
first episode of psychosis (Fusar-Poli et al., 2014, 2015). Some recent research has been conducted 
by RCTs to investigate the potential benefits of CBT as a treatment strategy for these conditions (van 
der Gaag et al., 2013).  
On one hand, there appears to be still a small number of trials on the efficacy of treatment options. 
One point that emerged was that the UHR group, who does not transition, reports still poor 
functioning and secondary clinical symptoms, such as depression and anxiety (van der Gaag et al., 
2013). It has been argued that a broader set of outcomes must be used in a next generation of 
prevention studies in psychosis, not only focusing on prevention of a first episode of psychosis (van 
der Gaag et al., 2013). It has been, recently, reported that few UHR trials in the literature focused on 
such additional outcomes (Stain et al., 2016). Worry is an outcome that has not been considered in 
previous trials. It refers to a covert process of repetitive negative thinking about the future (Borkovec 
& Roemer, 1995), which has been consistently studied in anxiety and depressive disorders (Borkovec 
& Roemer, 1995), but also in frank psychosis and schizophrenia, since it has been investigated as 
moderator of progression into delusional symptoms (Luzón, Harrop, & Nolan, 2009; Startup, 
Freeman, & Garety, 2007).  
More recently worry has been studied in UHR groups through observational research (e..g., 
Meneghelli et al., 2016). Hypervigilance of cognitive processes caused by repetitive worry has been 
hypothesized to be involved in the progression of psychotic symptoms among UHR groups by 
increasing awareness and potentially triggering the onset of frank psychotic symptoms. In a 
preliminary study (Palmier-Claus, Dunn, Taylor, Morrison, & Lewis, 2012), 27 UHR individuals 
completed a self-report diary when prompted by an electronic wristwatch several times each day for 
a week overall. Cognitive self-consciousness, a cognitive construct like worry, preceded the 
subsequent occurrence of hallucinations in individuals who reported strong beliefs about the need to 
control their thoughts (Palmier-Dunn et al., 2012). 
Finally, as recently highlighted by some researchers (Thompson et al., 2015), given the heterogeneity 
76 
 
of the clinical picture reported by UHR groups, modular treatments may be improve outcomes of 
UHR individuals as they can include multiple therapeutic components designed to be tailored for the 
clients, such as modules to target not only PLES but also anxiety, depression and social skills. 
 
 
5.1.1. Primary objectives 
 
Primary objectives of the current study were: 
(a) to assess whether a CBT modular protocol can reduce or delay risk of transition to psychosis 
in a group of UHR individuals after 6 months (post-treatment) and 14-months (follow-up), 
compared with treatment as usual as a control condition. The primary outcome was the 
number of participants who developed a first episode of psychosis.  
(b) to compare the CBT intervention with the control condition on the number of participants who 
reported a remission status on the ARMS and of those who had subthreshold psychotic 
symptoms (still ARMS status) at post-treatment and follow-up. 
 
 
 
5.1.2. Secondary objectives 
Secondary objectives were: 
(c) to compare the CBT intervention with the control condition on secondary outcomes, including 
depression, anxiety, worry and global functioning at post-treatment and follow-up. 
 
 
 
5.2. Method 
 
5.2.1. Eligibility criteria of participants 
Participants were help-seeking individuals recruited from secondary mental health services of 
Azienda USL Toscana Centro. They were included if were 16 to 35 years old and met criteria for 
ARMS at the Comprehensive Assessment of At Risk Mental States (CAARMS; Yung et al., 2006; 
Yung et al., 2005). Participants were not included if they had diagnosis of a neurological disorder, 
mental retardation, autism, current or history of psychosis or bipolar disorder, previous psychotic 
episodes, active suicidal intent, had undergone CBT, were on antipsychotic medications, had 
insufficient competence in the Italian language. Concomitant antidepressant medications were 
allowed only if they were kept on a stable dosage for the whole treatment duration. Concurrent 
psychological treatments also resulted in exclusion. 
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Participants were identified and contacted through advertisements on leaflets and e-mail messages to 
general medicine doctors, psychiatrists, psychologists, social workers of public and private services. 
A series of workshops for mental health professionals were organized by a group of psychologists 
extensively trained in this topic in order to provide information on identification of signs of ARMS 
and encourage referrals. Help-seeking individuals at mental health services with a suspicion of 
clinical picture of a psychotic risk were referred by mental health professionals, then were assessed 
through the CAARMS by the study staff.  
The study also used the following exit/discontinuation criteria: (a) voluntary discontinuation by the 
participant who was free to leave the study at any time, without prejudice to further treatment; (b) 
safety reasons as judged by the investigator (ie, the participant met criteria for conversion to a first 
psychotic episode or developed suicidal intent). Participants who developed a first episode of 
psychosis entered into routine mental health service treatment pathways.  
 
 
5.2.2. Baseline measures 
Baseline Axis I disorders were assessed through the Structured Clinical Interview for DSM-IV-TR 
Axis I Disorders (SCID-I; First et al., 1997; SCID-I Italian version; Mazzi et al., 2000). The module 
on psychosis was administered at post-treatment and follow-up and used as primary outcome 
measure. Comorbid personality disorders were investigated through the Structured Clinical Interview 
for DSM-IV-TR Personality Disorders (SCID-II; First et al., 1997). The SCID-II is a semi-structured 
clinical interview composed by 140 questions which assess symptoms of diagnostic criteria of 
personality disorders classified by the DSM-IV-TR. Score on each question are coded by the 
interviewer on a three-point Likert scale (“Absent symptom”= 1, “Doubt”= 2, “Present”= 3). 
Assessment of each personality disorder is conducted calculating the sum of scores. The Italian 
version of the SCID-II (Maffei et al., 1997) had good internal consistency (Cronbach’s alpha= 0.79).  
 
 
5.2.3. Primary outcomes 
Primary outcomes were the number of participants who reported a first psychotic episode at post-
treatment or follow-up, including also any of psychotic disorders or bipolar disorders according the 
DSM-IV-TR (American Psychiatric Association, 2000). Diagnosis was assigned through the SCID-I 
and confirmed by the PANSS. Development of a first psychotic episode was assessed 6 months after 
baseline (post-treatment) and 14 months after baseline (8-month follow-up from post-treatment) or at 
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the moment the therapist who was conducting treatment, informed the researchers that a transition 
had (probably) occurred.  
Primary outcomes were also the reduction of subthreshold psychotic symptoms assessed by the 
CAARMS. The Positive And Negative Syndrome Scales (PANSS; Kay et al., 1989) was used as a 
measure of psychotic symptoms. The structure of the measure is based on the bidimensional model 
of Crow (1980), which differentiates positive symptoms from negative ones, and is composed by 7 
items assessing positive, 7 assessing negative symptoms and 16 covering general psychopathological 
symptoms (Kay et al., 1989). The questionnaire is a self-report tool. High scores indicate severe 
psychotic symptoms. 
 
 
5.2.4. Secondary outcomes 
Secondary outcomes were severity of depressive symptoms, anxiety, worry, and general functioning.  
The Beck Depression Inventory-second edition (BDI-II; Beck, Steer, & Brown, 1996) was used as a 
measure of severity of depressive symptoms. The BDI-II is a self-report tool composed by 21 
statements assessing cognitive, affective, motivational and physiological characteristics of 
depression. A cut-off score of 20 was identified to define clinically significant depression. The Italian 
version (Sica, Ghisi & Lange, 2007) showed excellent internal consistency in clinical and non-clinical 
samples (Cronbach’s alpha was 0.93 and 0.92, respectively). In the current study, internal consistency 
was ex excellent (Cronbach’s alpha= 0.92). 
The Beck Anxiety Inventory (BAI; Beck & Steer, 1990) is a 21-item self-report tool designed to 
assess anxiety symptoms. Items are rated from 0 to 3 scores. The Italian version (Sica et al., 2007) 
had good internal consistency (Cronbach’s alpha= 0.80). A cut-off score of 20 was identified to define 
clinically significant anxiety. In the current study, internal consistency was ex excellent (Cronbach’s 
alpha= 0.90). 
The Penn State Worry Questionnaire (PSWQ; Meyer et al., 1990) was used as a measure of worry 
and its characteristics of intensity, frequency, persistence and uncontrollability. The PSWQ is a self-
report tool composed by 16 items on a five-point Likert scale (“Not at all typical of me”= 1, “Vey 
typical of me”= 5). High scores indicate severe worry. The Italian version (Morani, Pricci, & Sanavio, 
1999) had good internal consistency. In the current study, internal consistency was good (Cronbach’s 
alpha= 0.84). 
The Global Assessment of Functioning scale (GAF; Startup, Jackson, & Bendix, 2002) combines the 
evaluation of symptoms as well as relational, social and occupational functioning on a single axis. 
The scale runs from 1 to 100 and is divided into 10 equal parts providing defining characteristics, 
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both symptoms and functioning, for each 10-point interval. A low rating reflects worse symptoms 
and a poorer level of functioning, whereas a high rating reflects less symptoms and a better level of 
functioning. The GAF score is known to be a valid measure of global functioning in patients with 
schizophrenia (Schwartz, 2007). 
 
 
5.2.5. Feasibility and satisfaction with CBT 
Feasibility of the treatment was evaluated by calculating attrition rates for each treatment arm. 
Satisfaction with treatment was assessed through a satisfaction self-report questionnaire ad hoc 
developed to measure aspects related to satisfaction, self-efficacy in the self-management of 
symptoms after the end of the psychotherapeutic course. It is composed by 11 statements (eg, “Did 
the psychotherapeutic path improve your psychological well-being?”) rated on a five-point Likert 
scale (“Completely”= 5, “Not at all”= 0). In the current study, internal consistency was excellent 
(Cronbach’s alpha= 0.90). 
 
 
5.2.6. Design 
The study was conducted following The Standard Protocol Items: Recommendations for 
Interventional Trials (SPIRIT 2013; Chan et al., 2013) with a randomised controlled superiority 
parallel-group single-blinded design. Participants classified as at high risk were randomly assigned 
to CBT or a control condition. Control condition included 30 weekly individual supportive sessions, 
consisting of identification of needs and current problems of the participant, validating, empathetic 
listening and confrontation (i.e, paraphrasing what the participant was telling), and clarification what 
he/she was saying without the use of active CBT techniques and concepts for PLEs and any secondary 
symptoms (eg, psychoeducation on PLEs, cognitive restructuring). Supportive sessions in the control 
condition were delivered by clinical psychologists. The flowchart of participants’ progression over 
study course is presented in Figure 5.1. 
Socio-demographic and clinical characteristics were collected before randomisation. Random 
sequence was created by a computerized program. An independent researcher, not involved in the 
study assigned participants to treatment arms. Allocation was conducted through a 1:1 blocking 
procedure. Random sequence was concealed by an independent researcher, who put random numbers 
into envelopes and kept them in a remote location. Allocation concealment was ensured, as the 
researcher did not release the randomization code until the patient was recruited into the trial, which 
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occurred after all baseline measures were administered. Participants were then allocated after 
providing informed consent 
A single-blinding procedure was adopted. Assessment at baseline, 6-month post-treatment, and 14-
month follow-up with both clinical interviews and self-report measures were conducted by blind 
independent assessors. Due to difficulties related to blinding of participants in psychotherapy trials, 
in the current study a double-blinding procedure was not adopted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. CONSORT flowchart of participants through the phases of the trial. 
Screening on inclusion/exclusion criteria (n= 102) 
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Early discontinuation of treatment (n= 10) 
 
Lost at post-treatment (n= 10) 
Lost at follow-up (n= 1) 
 
Assigned to CBT (n= 28) 
Early discontinuation of treatment (n= 3) 
 
Lost at post-treatment (n= 3) 
Lost at follow-up (n= 0) 
 
Excluded from the analyses (n= 0) 
 
 
Participants who discontinued treatment 
and were included in the ITT analysis (n= 
3) 
 
Analysed (n= 28) 
Excluded from the analyses (n= 0) 
 
 
Participants who discontinued treatment 
and were included in the ITT analysis (n= 
11) 
 
Analysed (n= 28) 
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5.2.7. Diagnostic inter-rater reliability 
The CAARMS SCID-I and SCID-II were administered by two independent assessors (psychiatrists 
or psychologists), who were trained by internships in conducting the SCID-I, SCID-II and CAARMS 
(including observation of experienced trainers conducting the interviews). Assessors were blind to 
treatment allocation.  
All the diagnoses were reached by inter-rater consensus through staff meetings during the enrolment 
of the participants, in which each case was carefully reviewed for accuracy and between-rater 
discrepancy was discussed to reach consensus. Inter-rater agreement was reached for all the included 
participants except for two cases whose ARMS status was not resolved initially. Then, these 
participants were excluded by consensus of a third independent assessor.  
 
5.2.8. Treatment fidelity 
The CBT intervention was delivered by clinical psychologists with four-year training in CBT and 
extensively trained in the assessment and treatment of UHR states with three years of experience in 
the CBT treatment of ARMS. Training of therapists included reading of therapy manuals for UHR 
CBT, attending oral presentations, meetings with international experts, workshops, conferences, 
courses with international experts in this field, participating in role playing sessions on CBT for CHR 
supervised through monthly meetings of supervision. Psychologists who delivered CBT were on 
supervision by at least one expert with 30-year experience in CBT.  
Treatment fidelity was assessed by a random selection of a group of CBT sessions which were 
audiotaped (n= 10). Such sessions were subsequently rated by two other clinical psychologists trained 
in the CBT protocol who were not involved in the trial. Cohen’s kappa estimates of fidelity 
judgements were all equal or higher than 0.70, suggesting satisfactory inter-rate agreement on fidelity 
to the protocol (Cohen, 1960).  
 
5.2.9. Procedure 
The study was conducted between March 2014 and November 2016. Participants were screened and 
recruited between June 2014 and September 2015. The CBT manual was created during December 
2013 and May 2014. Data analysis was conducted in October 2016. 
Participation was voluntary and uncompensated. All participants were offered antidepressant or 
anxiolytic medication according to needs. However, no anti-psychotic medication was prescribed 
unless/until participants met criteria for the onset of a psychotic episode. Prescription and 
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management of medication was the responsibility of medical staff who was in contact with, but not 
involved in, the study and was blind to group allocation. All the individuals who were included were 
asked to provide written informed consent to participate after having received a detailed description 
of the study aims. Individuals being under 18 years old required informed consent from both parents. 
Participants’ identities remained anonymous. Participants had the possibility to withdraw their 
informed consent at any time with no consequence for their treatment 
All materials containing personal information about participants were kept accurately on electronic 
supports protected by passwords or clinical folders that contained an identification code specific for 
each participant. On each folder, the name of the participant was not included, but it was kept in 
another protected site. The research protocol has been approved by the Institutional Ethics 
Committee. The trial was conducted according to the Helsinki Declaration.  
 
 
5.2.10. Cognitive behavioural therapy (CBT) protocol 
The CBT protocol consisted of 30 individual weekly sessions each lasting about one hour. Treatment 
lasted for six months overall. The protocol was a modular treatment based on a manual of CBT for 
young individuals at UHR for psychosis (van der Gaag et al., 2013), whose efficacy has been already 
assessed in previous trials (Ising et al., 2016; Riedtijk et al., 2010).  
The goal of the intervention was to reduce distress provoked by extraordinary experiences (van der 
Gaag et al., 2013). Therapeutic components were adapted to follow recommendations by Thompson 
and colleagues (2015) who identified the following core components in RCTs of psychological 
interventions for CHR states: Assessment, Engagement, Individualized case formulation, 
Psychoeducation, Cognitive behavioural strategies, Treatment of comorbid conditions (depression, 
anxiety), Improvement of social skills. The intervention developed by van der Gaag and colleagues 
(2013) was enriched with additional components targeting depression (e.g, cognitive restructuring 
and behavioural experiments testing depressive distortions), social skills (e.g, assertiveness training), 
and worry and generalized anxiety (time for worry, cognitive restructuring of metacognitive 
distortions of worry advantages and its dangerous effects).  
The protocol was divided in different phases including specific therapeutic components: (1) 
introduction, (2) assessment, (3) engagement and goal setting, (4) normalization of PLEs, (5) 
cognitive restructuring and metacognitive intervention, (6) skills of emotions management, (7) 
intervention on depression, (8) intervention on worry, (9) intervention on social anxiety and social 
skills, (10) relapse prevention, (11) booster sessions. A detailed description of the protocol and 
therapeutic materials/worksheets is provided in the Appendix at the end of the manuscript. 
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During the Introduction phase, the therapeutic path is presented including sessions agenda and 
techniques which will be used. During the Assessment phase, collaborative functional analysis aimed 
at identified trigger situations; ABC diaries are completed by the participant and the therapist during 
the session; symptom monitoring is facilitated; automatic thoughts, intermediate and basic 
assumptions are analysed. Subsequently, in the Engagement phase, working together, the therapist 
and the participant develop a shared hierarchy of goals for the therapeutic intervention. The 
therapeutic model is based on the hypothesis that the final common pathway from ARMS to psychosis 
is largely caused by catastrophic misinterpretations of psychotic-like symptoms which are then 
exacerbated by a high level of emotional arousal (Riedijk et al., 2010). 
During the fifth phase, psychoeducation on extraordinary experiences and PLEs is provided. Young 
individuals with ARMS often are worried about their extraordinary experiences: they can fear losing 
control over their minds (Meneghelli et al., 2016). Receiving an exploratory model of extraordinary 
experiences and learning that there is an adequate treatment is a comforting message, that attenuates 
distress associated with extraordinary experiences themselves (van der Gaag et al., 2013).  
The subsequent phase, Cognitive restructuring and metacognitive intervention, aims to increase the 
awareness of the individual of the effects of cognitive distortions on emotional experience, 
physiological responses and behaviours. The intervention aims to enhances monitoring by the young 
individual of the effects of distortions and help him/her to modify them and their impact on thought, 
emotions and behaviours. The ABC (activating events, beliefs, consequences) model is provided and 
is used to help the individual to discover the connection between emotions, thoughts and behaviours. 
The aim here is learning how activating events can induce beliefs, which can cause response in terms 
of emotions, somatic signals and behaviours (van der Gaag et al., 2013). Cognitive interventions, 
such as cognitive restructuring and behavioural experiments are designed to challenge and test 
dysfunctional beliefs. Those interventions are also developed in order to help the individual stopping 
avoidance of trigger situations and safety behaviours; in addition, exposure to trigger stimuli is 
scheduled.  
The subsequent three modules, Intervention on depression, Intervention on worry, Intervention on 
social anxiety and social skills are conceived to target comorbid conditions which are often present 
among UHR individuals. Intervention on depression starts with completing mood charts, analysing 
pleasant activities for the young individual, scheduling pleasant activities that are assigned using a 
self-monitoring diary. In this diary, the individual had to indicate and schedule activities that they 
have engaged during the subsequent days, to report emotions and thoughts they had and to measure 
the intensity of these emotions. The rationale for this is to enhance greater awareness of positive 
emotions and the intensity associated to them, to enhance self-efficacy in the management of daily 
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living, thus reducing experience of anxiety and depressive symptoms. Such activities are conceived 
as behavioural experiments, aimed to challenge catastrophic beliefs about capacity to get pleasure 
from daily activities (“My days always are unemotional”, “I never feel emotions”). Different from 
the protocol of van der Gaag and colleagues (2013), a module on worry is added, introducing 
psychoeducation on worry, exploring and correcting metacognitive maladaptive assumptions about 
worry (positive and negative cognitions about worry) and CBT strategies to manage worry 
(exposures, problem solving, behavioural experiments, relaxation techniques). Intervention on social 
anxiety integrates principles of assertiveness training, targets self-esteem by role-playing and in-
session and out-session exposure. Trigger situations are identified first. Then, distorted beliefs about 
self, others and the world are analysed with restructuring strategies. Finally, to optimize flexibility of 
the intervention, the participant and the therapist can expose themselves together in the real-life 
context of the young UHR individual out of the office. Subsequently, the participant is encouraged 
to face such situations on his/her own in order to enhance generalizability of the therapeutic process. 
At the end of the therapeutic course, a relapse prevention module is dedicated to the identification of 
early warning signs of relapse.  
Between-session homework tasks are planned during all the treatment course. At the end of each 
session, the therapist asks the participant for feedback (e,g, how he/she did feel during the session, 
potential encountered difficulties, usefulness of the session content). Together, they develop key take-
home messages.  
A detailed description of the phases and CBT psychotherapeutic components used during each session 
is provided in Table 5.1. 
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Table 5.1. Description of the CBT psychotherapeutic components for each session and phase. 
Sessions Phase Psychotherapeutic components 
1 
Introduction 
and goal setting  
 Defining agenda of the session 
 Presentation of the ABC model 
 Discussion of outcomes of interviews and questionnaires completed at pre-
treatment 
 Completing diaries 
 Setting of therapeutic goals 
 Presentation of the CBT techniques 
 Discussion on rationale for homework 
 Asking the patient for feedback about the session 
 Take-home messages 
 Homework  
2 Assessment  
 Review of previous session 
 Discussion on homework 
 Defining agenda of the session 
 Completing diaries 
 Identification of trigger situations 
 Symptom monitoring 
 Exploring automatic thoughts, intermediate beliefs, basic assumptions 
 Downward arrow 
 Asking the patient for feedback about the session 
 Take-home messages 
 Homework 
3 Assessment  
 Review of previous session 
 Discussion on homework 
 Defining agenda of the session 
 Meeting with parents and family members 
 Asking the family members for feedback about the session 
 Take-home messages 
4 Engagement  
 Review of previous session 
 Discussion on homework 
 Defining agenda of the session 
 Case formulation 
 Asking the patient for feedback about the session 
 Take-home messages 
 Homework 
5-7 
Normalization 
of psychotic 
experiences 
 Review of previous session 
 Discussion on homework 
 Defining agenda of the session 
 Normalizing information and psychoeducation on psychotic-like experiences 
 Information on dopamine sensitization  
 Written materials 
 Flashcards   
 Asking the patient for feedback about the session 
 Take-home messages 
 Homework 
8-12 
Cognitive 
restructuring 
and 
metacognitive 
intervention 
 Review of previous session 
 Discussion on homework 
 Defining agenda of the session 
 Introduction of cognitive distortions 
 Written materials 
 Cognitive and metacognitive restructuring 
 Identifying alternative explanations 
 Development of more functional thoughts 
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 Attentional training 
 Flashcards  
 Asking the patient for feedback about the session 
 Take-home messages 
 Homework 
13-15 
Cognitive 
restructuring 
and 
metacognitive 
intervention 
 Review of previous session 
 Discussion on homework 
 Defining agenda of the session 
 Organizing of hierarchy 
 Exposure and behavioural experiments  
 Asking the patient for feedback about the session 
 Take-home messages 
 Homework  
16 
Skills for 
emotions 
management 
 Review of previous session  
 Discussion on homework 
 Defining agenda of the session 
 Normalizing information and psychoeducation on emotions and bodily sensations 
 Written materials on emotions 
 Asking the patient for feedback about the session 
 Homework 
17 
Skills for 
emotions 
management 
 Review of previous sessions 
 Defining agenda of session 
 Discussion on homework 
 Relaxation techniques (diaphragmatic breath, muscular progressive relaxation) 
 Written materials 
 Flashcards 
 Asking the patient for feedback about the session 
 Take-home messages  
 Homework 
18-19 
Intervention on 
depression 
 Review of previous session 
 Discussion on homework 
 Defining agenda of the session 
 Cognitive bias of depression 
 Cognitive restructuring of depression bias 
 Daily mood graph 
 Behavioural experiments 
 Behavioural activation 
 Pleasant activities 
 Flashcards  
 Asking the patient for feedback about the session 
 Take-home messages 
 Homework 
20-21 
Intervention on 
depression 
 Review of previous session 
 Discussion on homework 
 Defining agenda of the session 
 Intervention on procrastination 
 Self-instructional training 
 Asking the patient for feedback about the session 
 Take-home messages 
 Homework 
22-25 
Intervention on 
worry 
 Review of previous session 
 Discussion on homework 
 Defining agenda of the session 
 Problem solving 
 Time for worry 
 Flashcards  
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 Asking the patient for feedback about the session 
 Take-home messages 
 Homework 
26-29 
Intervention on 
social anxiety 
 Review of previous session 
 Discussion on homework 
 Defining agenda of the session 
 Psychoeducation on assertiveness and social skills 
 Completing assertiveness diaries 
 Role playing on social skills 
 Exposure on social cues and trigger situations 
 Assertiveness exercises 
 Exercises to strengthen self-esteem 
 Flashcards  
 Asking the patient for feedback about the session 
 Take-home messages 
 Homework 
30 
Relapse 
prevention 
 Overview of the psychotherapeutic course and key points 
 Asking the patient for feedback about the session 
 Relapse prevention 
31 Booster session 
 Review of the psychotherapeutic course 
 Review of case formulation 
 Review of psychoeducation on psychotic-like experiences 
 Review of cognitive and metacognitive restructuring 
 Completing ABC diaries on recent trigger situations 
 Asking the patient for feedback about the session 
 Take-home messages 
 Booster homework 
32 Booster session 
 Review of the assertiveness concept 
 Completing ABC diaries on recent trigger situations  
 Asking the patient for feedback about the session 
 Take-home messages 
 Booster homework 
 
 
 
5.2.9. Homework tasks compliance 
Compliance with homework tasks (defined as completion of homework written worksheets, reading 
psychoeducation materials, listening of relaxation audiotaped records, performing between-session 
exposures and behavioural experiments) was recorded as present at each session if a review of the 
homework tasks assigned in the previous session was added in the notes.  
 
 
5.2.10. Data analysis 
Comparisons between the CBT and the control groups on baseline sociodemographic and clinical 
characteristics were conducted through ANOVA or non-parametric statistics (chi squared, Kruskal-
Wallis, Mann-Whitney U test). 
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The primary outcome was analysed using Kaplan-Meier survival statistics. Participants lost to follow-
up were coded conservatively as non-converters. Survival curves were compared using the log-rank 
test.  
Data at post-treatment and follow-up on secondary outcomes were analysed using the intention to 
treat approach that was applied with the last observation carry-forward technique (Newell, 1992). 
Analyses on secondary outcomes were conducted on the group of participants who did not make a 
transition to psychosis during the study period. These analyses cannot be done by linear mixed-
modelling analysis because the missing values after a transition were not random: in the control 
group, a higher number of participants developed a psychosis episode as compared as the those in 
CBT group.  
Changes over time were analysed by univariate tests of ANCOVA of the data at post-treatment (6 
months) and follow up (14 months), with baseline scores as covariate of the people who were non-
transitions at that measurement moment. Eta Squared (η²) were calculated as effect sizes (Olejnik & 
Algina, 2003). Values of 0.01, 0.06, 0.14 suggest low, moderate, and large effect sizes, respectively 
(Cohen, 1988).  
Chi square linear-by-linear test was performed to assess the discrete outcomes, such as ARMS status 
(in remission, at risk, psychosis).  
Numbers needed to treat were calculated for prevention of transition and attaining remission status. 
For all the analyses, statistical significance was set at a 0.01 or 0.05 p-value. Statistical analyses were 
conducted with the Statistical Packages for the Social Sciences software (SPSS, version 21.00).  
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5.3. Results 
 
5.3.1. Baseline socio-demographic characteristics in the total study group 
A total of 58 participants were included in the study. In the total study group, mean age was 25.71 
years (SD= 6.00, range 16-35). Thirty-nine individuals (67.20%) were males. Fifty-one (87.90%) 
were born in Italy. Individuals who were born in another country were 7 participants (12.10%); in 
this subgroup, mean duration of stay in Italy was 16.71 years (SD= 8.28, range= 8-26). One 
participant was born in Eastern Europe (Romania), three in Central or Northern Europe (one in 
France, one in Switzerland, one in the Netherlands), two in Africa (one in Ethiopia, one in Iran), one 
in Southern America (Bolivia). Nineteen (32.80%) were students, 27 (46.60%) were unemployed, 12 
(20.60%) were employed. Twenty-nine (50%) had high-school license. Participants were referred 
from mental health professionals of secondary mental health services. Specifically, thirty-four 
participants (58.60%) were recruited from Struttura Operativa Semplice 5, 5 (8-60%) from Struttura 
Operativa Semplice 6, 3 (5.10%) from Struttura Operativa Semplice 2-4, 6 (10.30%) from Unità 
Funzionale di Salute Mentale Adulti (UFSMA) zona Mugello, 2 (3.40%) from Unità Funzionale 
Salute Mentale Infanzia e Adolescenza (UFSMIA) of Florence, 3 (5.10%) from Unità Funzionale 
Salute Mentale Adulti e Unità Funzionale Salute Mentale Infanzia e Adolescenza of Prato, 5 (8-60%) 
from private mental health professionals (psychiatrists and psychologists) working in Florence or 
Prato and coworking with those public secondary mental health services.  
A detailed overview of baseline socio-demographic characteristics is provided in Table 5.2. 
 
 
5.3.2. Comparison of baseline socio-demographic characteristics in CBT and control groups 
Mean age in the CBT group was not significantly different from age in the control group (F(1, 56)= 
0.13, p= 0.71). Groups were not significantly different also on gender [χ²(1)= 0.78, p= 0.78], area of 
residence in Italy [χ²(1)= 2.07, p= 0.15], birth country [Kruskal-Wallis χ²(1)= 0.15, p=0.69], marital 
status [χ²(1)= 0, p= 1], education level [Kruskal Wallis χ²(1)= 2.06, p= 0.15], employment status [χ²(1)= 
2.06, p=.07], birth country (immigrant status) [χ²(1)= 0.16, p= 0.68].  
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Table 5.2. Baseline socio-demographic characteristics of total study group and conditions groups. 
 
Total group  
(n= 58) 
CBT  
(n= 29) 
Control condition  
(n= 29) 
χ²(df) / F(df) 
 M (SD; range) 
range) 
M (SD; range) M (SD; range)  
Age (years) 25.71 (6; 16-35) 25.41 (6.12; 16-35) 26 (5.97; 16-35) 0.13(1, 56) 
 n (%) n (%) n (%)  
Gender     0.78(1) 
Males 39 (67.20) 19 (65.50) 20 (69)  
Females 19 (32.80) 10 (34.50) 9 (31)  
Area of residence in Italy    2.07(1) 
Centre 56 (96.60) 29 (100) 27 (93.10)  
South 2 (3.40) 0 2 (6.90)  
Birth country    0.15(1) 
Italy 51 (87.90) 26 (89.70) 25 (86.20)  
Eastern Europe 1 (1.70) 0 1 (3.40)  
Central or Northern Europe 3 (5.20) 0 3 (10.30)  
Africa 2 (3.40) 2 (6.90) 0  
Southern America 1 (1.70) 1 (3.40) 0  
Marital status    0(1) 
Single  54 (93.10) 27 (93.10) 27 (93.10)  
Married  4 (6.90) 2 (6.90) 2 (6.90)  
Employment status    3.23(1) 
Student  19 (32.80) 12 (41.40) 7 (24.10)  
Employed  12 (20.70) 7 (24.10) 5 (17.20)  
Unemployed  27 (46.60) 10 (34.50) 17 (58.60)  
Education level    2.06(1) 
Mid school license 20 (34.50) 7 (24.10) 13 (44.80)  
High school license 29 (50) 17 (58.60) 12 (41.40)  
Degree  9 (15.50) 5 (17.20) 4 (13.80)  
 
 
 
5.3.3. Baseline clinical characteristics 
In the total study group, 58 participants (100%) reported APS for intensity, 58 (100%) reported APS 
for frequency, 3 (5.20%) had BLIPS and 8 (13.80%) had a family history of psychosis or schizotypal 
personality disorder. Twenty (34.50%) had any of anxiety disorders, 27 (46.60%) had any of unipolar 
mood disorders. The most prevalent axis I disorders were Dysthymia (n= 18, 31%), Obsessive 
compulsive disorder (n= 12, 20.70%), Major depressive disorder (n= 8, 13.80%), and Panic disorder 
(n= 7, 12.10%). Sixty-three percent had a BDI-II score above the cut-off (20), showing clinically 
significant depression symptoms. Sixty-one had a BAI score above the cut-off (20). Twenty-seven 
(46.60%) had a comorbid personality disorder. The most prevalent personality disorders were 
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schizoid/schizotypal personality (n= 14, 24.10%) and avoidant personality (n= 6, 10.30%). Thirty-
two (55.20%) were on concomitant antidepressants, 10 (17.20%) were on anxiolytic benzodiazepines.  
The two groups were not significantly different for the number of participants having an unipolar 
mood disorder [χ²(1)= 0.62, p= 0.43], any of anxiety disorders [χ²(1)= 0.30, p= 0.58], one or more 
comorbid personality disorders [χ²(1)= 1.73, p= 0.18], current cannabis use [χ²(1)= 0.89, p= 0.34]. The 
two groups did not differ for the number of participants on antidepressants [χ²(1)= 0.27, p= 0.59] and 
anxiolytics [χ²(1)= 1.61, p= 0.20], for the number of those having BLIPs [χ²(1)= 0.34, p= 0.55], 
belonging to the CAARMS vulnerability group [χ²(1)= .058, p= 0.44]. The CBT and the control group 
did not significantly differ for intensity of subclinical positive symptoms assessed by the CAARMS 
[F(1, 56)= 0.04, p=0.84] and frequency [F(1, 56)= 0.68, p= 0.41]. An overview of baseline clinical 
characteristics is provided in Table 5.3. 
 
 
5.3.4. Differences across gender and age on subclinical psychotic symptoms 
No significant difference across gender was found on intensity and frequency of subclinical positive 
symptoms. Regarding types of subclinical symptoms, a significant difference was found only between 
males and females on disorganised speech [F(1, 56)= 6.05, p<0.05], with males having more severe 
subclinical levels than females. No difference was found for unusual content thought, non-bizarre 
ideas and perceptual abnormalities. 
Bivariate correlations between age and intensity and frequency of subclinical positive symptoms did 
not result significant [range of Pearson’s r= 0.21-0.24, p= 0.07-0.11]. Correlations between age and 
types of subclinical symptoms were not significant for unusual content of thoughts, non-bizarre ideas 
and perceptual abnormalities [range of Pearson’s r= -0.17-0.17, p= 0.18-0.19]. A moderate positive 
correlation was found between age and disorganised speech [Pearson’s r= 0.32, p<0.05], suggesting 
that older participants reported higher subclinical symptoms of disorganised speech. 
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Table 5.3. Baseline clinical characteristics. 
 
Total group  
(n= 58) 
CBT condition  
(n= 29) 
Control condition  
(n= 29) 
χ²(df) / t(df) 
 n (%) n (%) n (%)  
Any of non-psychotic Axis I disorders 45 (77.60) 21 (72.40) 24 (82.80) 0.89(1) 
Type of non-psychotic Axis I disorders     
Generalized anxiety disorder 6 (10.30) 4 (13.80) 2 (6.90)  
Dysthymia 18 (31) 11 (37.90) 7 (24.10)  
Obsessive compulsive disorder 12 (20.70) 7 (24.10) 5 (17.20)  
Panic disorder 7 (12.10) 4 (13.80) 3 (10.30)  
Agoraphobia  5 (8.60) 1 (3.40) 4 (13.80)  
Social phobia 5 (8.60) 4 (13.80) 4 (3.40)  
Major depressive disorder 8 (13.80) 4 (13.80) 4 (13.80)  
Eating disorders 2 (3.40) 0 2 (6.90)  
Specific phobias 2 (3.40) 0 2 (6.90)  
Hypocondriasis  2 (3.40) 0 2 (6.90)  
Alcol abuse 1 (1.70) 0 1 (3.40)  
Gambling 1 (1.70) 0 1 (3.40)  
Number of personality disorders    1.73(1) 
None of personality disorders 32 (55.20) 19 (65.50) 13 (44.80)  
One personality disorder 21 (36.20) 9 (31) 12 (41.40)  
More than one personality disorder 5 (8.60) 1 (3.40) 4 (13.80)  
Type of personality disorders     
Schizoid/schizotypal 14 (24.10) 5 (17.20) 9 (31)  
Avoidant 6 (10.30) 4 (13.80) 2 (6.90)  
Dependent 5 (8.60) 2 (6.90) 3 (10.30)  
Borderline 4 (6.90) 1 (3.40) 3 (10.30)  
Obsessive compulsive 3 (5.20) 1 (3.40) 2 (6.90)  
Paranoid 1 (1.70) 0 1 (3.40)  
Cannabis use 13 (22.40) 5 (17.20) 8 (27.60) 0.89(1) 
CAARMS groups     
APS intensity 58 (100) 29 (100) 29 (100) 0(1) 
APS frequency 58 (100) 29 (100) 29 (100) 0(1) 
BLIPs 3 (5.20) 2 (6.90) 1 (3.40) 0.35(1) 
Vulnerability group 8 (13.80) 3 (10.30) 5 (17.20) 0.58(1) 
Antidepressants 32 (55.20)   0.27(1) 
Sertraline  9 (15.50) 7 (24.10) 2 (6.90)  
Paroxetine 5 (8.60) 3 (10.30) 2 (6.90)  
Fluoxetine  2 (3.40) 2 (6.90) 0  
Fluvoxamine  3 (5.20) 1 (3.40) 2 (6.90)  
Citalopram  4 (6.90) 2 (6.90) 2 (6.90)  
Escitalopram  7 (12.10) 2 (6.90) 5 (17.20)  
Venlafaxine 1 (1.70) 0 1 (3.40)  
Mirtazapine 1 (1.70) 0 1 (3.40)  
Duloxetine 1 (1.70) 0 1 (3.40)  
Anxiolytic benzodiazepines 10 (17.20) 3 (10.30) 7 (24.10) 1.61(1) 
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5.3.5. Relation between comorbidity and subclinical psychotic symptoms in the total group 
In the total study group, the group with personality disorders had higher intensity of subclinical 
positive symptoms measured by the CAARMS [F(1, 56)= 10.32, p<0.01], negative symptoms measured 
by the PANSS [F(1, 56)= 17.37, p<0.001], and at a trend level higher frequency of subclinical positive 
symptoms measured by the CAARMS [F(1, 56)= 3.69, p= 0.06] but not the positive symptoms 
measured by the PANSS [F(1, 56)= 0.62, p= 0.43]. Specifically regarding subclinical symptoms, those 
with at least one of personality disorders had higher non-bizarre ideas [F(1, 56)= 9.79, p<0.01] and 
disorganized speech measured by the CAARMS [F(1, 56)= 11.51, p<0.01], and at a trend level usual 
thought content [F(1, 56)= 3.08, p= 0.08] but not perceptual abnormalities [F(1, 56)= 0.0, p= 0.98].  
The group with any of non-psychotic Axis I disorders had higher disorganised speech [F(1, 56)= 5.84, 
p< 0.05] but not the other subclinical positive symptoms measured by the CAARMS, neither intensity 
nor frequency of positive subclinical symptoms.  
The group with any of unipolar mood disorders had higher general psychopathology measured by the 
PANSS [F(1, 56)= 7.33, p<0.01], and at a trend level frequency of positive subclinical symptoms [F(1, 
56)= 3.36, p= 0.07]. The group with and that without any of anxiety disorders did not differ on any 
positive and negative symptoms measured.  
 
 
5.3.6. Rates and characteristics of drop-outs in the total study group 
In the total group, 13 participants (22.40%) left early the study before completing post-treatment 
assessments and were considered as drop-outs. Among drop-outs, the mean number of attended 
sessions was 4.92 (SD= 2.53; range= 2-11). The number of completed sessions and reasons for drop 
out are presented in Table 5.4. 
The number of females in the drop-out group was significantly higher than in the group of those who 
completed all treatment sessions and post-treatment assessments [χ²(1)= 10.11, p<0.001]. Drop-outs 
and completers were not significantly different for age [Mann Whitney U= 270, p= 0.67], having a 
non-psychotic Axis I disorder [χ²(1)= 0.04, p= 0.94], having any of anxiety disorders [χ²(1)= 0.10, p= 
0.75], any of unipolar mood disorders [χ²(1)= 0.44, p= 0.50], having a personality disorder [χ²(1)= 0.01, 
p= 0.97] or current cannabis use  [χ²(1)= 0.67, p=0.41], intensity of subclinical positive symptoms on 
the CAARMS [F(1, 56)= 0.07, p=0.79] or frequency [F(1, 56)= 0.28, p=0.59], global functioning [F(1, 56)= 
1.29, p= 0.26].  
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5.3.7. Rates and characteristics of drop-outs in the CBT group 
Three participants (10.30%) were drop outs in the CBT condition, while 10 (34.50%) were in the 
control group. The number of drop-outs in the CBT condition was significantly lower than in the 
control condition [χ²(1)= 4.85, p<0.05]. 
In the CBT group, age was not significantly different between completers and drop-outs (Mann-
Whitney U= 20, p= 0.17). A significant difference did not emerge also for gender [χ²(1)= 1.53, p= 
0.21],  having a non-psychotic Axis I disorder [χ²(1)= 2.55, p= 0.11], having any of anxiety disorders 
[χ²(1)= 0.03, p= 0.86], any of unipolar mood disorders [χ²(1)= 0.45, p= 0.50], having a personality 
disorder [χ²(1)= 0.03, p= 0.86] or current cannabis use  [χ²(1)= 0.69, p=0.40], intensity of subclinical 
positive symptoms [Mann Whitney U= 28, p= 0.42], frequency [Mann Whitney U= 37.50, p= 0.91], 
global functioning [Mann Whitney U= 37.50, p= 0.91].  
 
Table 5.4. Participants who left the study before post-treatment with completed sessions and reasons for drop out. 
  
 
 
 
 
 
Participant Assessments completed Completed sessions Reasons for stop attending sessions 
20 Baseline 4 
She said that felt better, returned to attending high school 
lessons and did not need continue treatment 
23 Baseline 4 She said that attending sessions was unhelpful 
29 Baseline 2 She said that she did not need a psychological treatment  
21 Baseline 5 
She said that did not need a psychological treatment, only 
needed medications 
25 Baseline 3 She stopped coming, then was unable be contacted 
28 Baseline 4 She stopped coming, then was unable be contacted 
26 Baseline 11 She said that did not need any treatment 
27 Baseline 2 
He said that did not need a psychological treatment, only 
needed medications 
24 Baseline 8 
He said that the distance attending the centre was too long. 
He stopped coming, then was unable to be contacted. 
58 Baseline 7 
His parents were able to bring him only sporadically, then 
they refused continuing course  
56 Baseline 6 She said that sessions were too demanding 
57 Baseline 4 She stopped coming, then was unable be contacted 
22 Baseline 4 He moved to other places 
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5.3.8. Primary outcomes  
In the CBT group, mean survival time was 445.46 days (95% CI: 407.37-483.55), in the control 
condition it was 410.24 (95% CI: 350.39-470.09). The odds ratio was 0.30 (95% CI: 0.07-1.28). 
Overall, in the total study group, 7 participants (12.10%) at post-treatment and 11 (19%) at 14-month 
follow-up cumulatively made the conversion to psychosis. In the CBT group, 1 participant (3.40%) 
at post-treatment and 3 (10.30%) at 14-month follow-up cumulatively made the conversion to 
psychosis. In the control group, 6 (20.70%) participants at post-treatment and 8 (27.60%) at 14-month 
follow-up cumulatively made the conversion to psychosis. In the survival analyses, those who were 
lost to follow-up were conservatively classified as non-converters. The Kaplan-Meier curves showed 
a difference between individuals assigned to CBT and those in the control condition (Log rank test 
χ2(1)= 3.66, p= 0.05), despite this difference was at a borderline significance level. Kaplan-Meier 
survival curves are presented in Figure 5.2. The number needed to treat (NTT) to prevent 
cumulatively transition to psychosis at 14-month follow-up was 5.88, suggesting that on average 
about 6 participants were necessary to be treated with CBT (instead of being assigned to the control 
condition) to prevent a transition event in one additional participant.  
After conversion to psychosis, the DSM-IV-TR diagnoses were brief psychotic disorder (n= 5, 
8.60%), schizoaffective disorder (n= 2, 3.40%), psychotic disorder not otherwise specified (n= 1, 
1.70%), schizophrenia, disorganised type (n= 1, 1.70%), manic episode (n= 1, 1.70%). All patients 
who transitioned at post-treatment or follow-up fulfilled the criteria on the PANSS for psychosis.  
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Figure 5.2. Cumulative survival CBT and control curves of psychosis transitions at 14-month follow-up. 
 
 
 
5.3.9. Comparison between CBT and control on subclinical psychotic symptoms at 6-month post- 
         treatment 
In the total study group, at post-treatment 55% of participants achieved recovery on ARMS status, 
while 45% still reported subthreshold psychotic symptoms. The number of participants who 
recovered from ARMS was significantly higher in the CBT (80%) than in the control group (13.30%) 
[χ²(1)= 16.83, p<0.001]. 
Subsequently, a series of ANCOVA was conducted entering group allocation as random factor, 
baseline CAARMS scores on each subclinical psychotic symptom as covariates and CAARMS scores 
on each subclinical psychotic symptom at post-treatment. Main and interaction effects of ANCOVAs 
are displayed in Table 5.5.  
An interaction effect of baseline unusual content of thoughts and group allocation was found on 
unusual content of thoughts at post-treatment [F= 7.51, η²= 0.14, p<0.01]: individuals with higher 
baseline unusual content of thoughts assigned to control group had significantly higher unusual 
content of thoughts at post-treatment [β= 0.71, t= 2.74, η²= 0.14, p< 0.01].  
An interaction effect of baseline non-bizarre ideas and group was found on non-bizarre ideas at post-
treatment [F= 4.81, η²= 0.09, p<0.05]: individuals with higher baseline non-bizarre ideas assigned to 
control group had significantly higher non-bizarre ideas at post-treatment [β= 0.68, t= 2.19, η²= 0.09, 
p< 0.05].  
A significant interaction effect between baseline perceptual abnormalities and group allocation was 
found on perceptual abnormalities at post-treatment [F= 6.40, η²= 0.12, p<0.05]: individuals with 
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higher baseline perceptual abnormalities assigned to control group, had higher perceptual 
abnormalities at post-treatment [B= 0.66, t= 2.53, η², p< 0.05]. In addition, a main effect of baseline 
perceptual abnormalities was found [F= 12.61, η²= 0.21, p<0.001]: individuals with higher baseline 
perceptual abnormalities had higher perceptual abnormalities at post-treatment.  
Finally, a main effect of baseline disorganized speech on disorganized speech at post-treatment was 
found [F= 21.36, η²= 0.31, p<0.001]. A baseline x group interaction effect did not emerge.  
 
 
Table 5.5. Between-subject tests of group and baseline CAARMS subclinical psychotic symptoms effects  
on post-treatment subclinical psychotic symptoms. 
 F p-value η² 
Group 
 0.42 0.51 0.01 
    
CAARMS Unusual content of thoughts main effect 
 4.56 <0.05 0.09 
    
Group x CAARMS Unusual content of thoughts  7.51 0.14 0.01 
Group 
 0.47 0.49 0.01 
    
CAARMS Non-bizarre ideas 
 3.12 0.08 0.06 
    
Group x * CAARMS Non-bizarre ideas  4.81 <0.05 0.09 
Group 
0.15 0.69 0.01 
   
Perceptual abnormalities 
12.61 <0.001 0.21 
   
Group x CAARMS Perceptual abnormalities 6.40 <0.05 0.12 
Group  
2.04 0.15 0.04 
   
CAARMS Disorganised speech  
21.36 <0.001 0.31 
   
Group x CAARMS Disorganised speech  0.01 0.98 0.01 
Note. CAARMS= Comprehensive Assessment of At-Risk-Mental States 
 
 
 
5.3.10. Comparison between CBT and control on subclinical psychotic symptoms at 14-month follow-
up 
In the total study group, 54.30% achieved recovery on the ARMS status, while 45.70% still reported 
subclinical psychotic symptoms at follow-up. The number of participants recovered on ARMS was 
significantly higher in the CBT group (69.60%) than in the control group (25%) [χ²= 6.31, p<0.05].  
Subsequently, a series of ANCOVAs was conducted entering group allocation as random factor, 
baseline CAARMS scores on each subclinical psychotic symptom as covariates and CAARMS scores 
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on each subclinical psychotic symptom at follow-up. Main and interaction effects are displayed in 
Table 5.6. 
A significant main effect of baseline unusual content of thoughts on unusual content of thoughts at 
follow-up was found [F= 7.65, η²= 0.15, p<0.05]: individuals with higher baseline unusual content of 
thoughts had higher scores on this subclinical psychotic symptom after 14 months irrespective of 
group allocation. 
No significant main effect or interaction between group and baseline scores were found on non-
bizarre ideas at follow-up.  
A significant main effect of baseline perceptual abnormalities was found on perceptual abnormalities 
at follow-up [F= 11.62, η²= 0.21, p<0.01]. No interaction effect emerged between baseline perceptual 
abnormalities and group allocation. 
A significant interaction effect between baseline disorganized speech and group allocation on 
disorganized speech was found [F= 7.10, η²= 0.14, p<0.05]: individuals with higher baseline 
disorganized speech allocated to CBT group had lower disorganized speech after 14 months. A main 
effect of disorganized speech also was found. 
 
 
5.6. Between-subject tests of group and baseline CAARMS subclinical psychotic symptoms effects  
on follow-up subclinical psychotic symptoms. 
 F p-value η² 
Group  0.01 0.93 0.01 
CAARMS Unusual content of thoughts main effect  7.65 <0.01 0.15 
Group x CAARMS Unusual content of thoughts  1.74 0.19 0.04 
Group   0.32 0.57 0.01 
CAARMS Non-bizarre ideas  2.68 0.10 0.06 
Group x * CAARMS Non-bizarre ideas  2.66 0.11 0.06 
Group 0.26 0.61 0.01 
Perceptual abnormalities 11.62 <0.01 0.21 
Group x CAARMS Perceptual abnormalities 1.58 0.21 0.04 
Group   0.53 0.47 0.01 
Disorganised speech  28.81 <0.001 0.41 
Group x CAARMS Disorganised speech  7.10 <0.05 0.14 
Note. CAARMS= Comprehensive Assessment of At-Risk-Mental States 
 
 
5.3.11. Secondary outcomes 
No significant difference was found between the CBT and the control groups on BDI-II scores at 
post-treatment. A significant main effect of BDI-II baseline scores emerged [F= 96.92, p<0.001], 
indicating that individuals with higher baseline scores on the BDI-II had higher post-treatment scores 
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on the BDI-II irrespective of group allocation. In addition, an interaction effect was found between 
BDI-II baseline scores and group: individuals with higher baseline scores on the BDI-II in the control 
condition had significantly higher scores on the BDI-II at post-treatment than those in the CBT group.  
No significant difference was found between the CBT and the control groups on BAI scores at post-
treatment. A significant main effect of BAI baseline scores emerged [F= 78.24, p<0.001]: individuals 
with higher baseline scores on the BAI had higher post-treatment scores on the BAI (β= 0.47, t= 4.12, 
p<0.001). In addition, an interaction effect was found between BAI baseline scores and group: 
individuals with higher baseline scores on the BAI in the control condition had significantly higher 
scores on the BAI at post-treatment than those in the CBT group (β= 0.47, t= 2.94, p<0.01).  
No significant difference was found between the CBT and the control groups on PSWQ scores at 
post-treatment. A significant main effect of PSWQ baseline scores emerged [F= 40.53, p<0.001]: 
individuals with higher baseline scores on the PSWQ had higher post-treatment scores on the PSWQ. 
In addition, an interaction effect was found between PSWQ baseline scores and group: individuals 
with higher baseline scores on the PSWQ in the control condition had significantly higher scores on 
the PSWQ at post-treatment than those in the CBT group (β= 0.82, t= 5.54, p<0.01).  
A significant main effect of baseline GAF scores was found on scores at post-treatment [β= 0.75, t= 
2.93, p<0.01]. No interaction effect between baseline scores and group was found on scores at post-
treatment.  
Baseline, post-treatment and follow-up means on secondary outcomes in all the study groups are 
presented in Table 5.7. 
 
 
5.3.12. Remission on secondary outcomes at 6-month post-treatment 
In the total study group, 57.80% had a scores lower than the cut-off (20) on the BDI-II at post-
treatment, while 42.20% had still a score equal to 20 or higher. In the CBT group, the number of 
participants who achieved remission (75%), measured by a BDI-II score lower than cut-off, was 
significantly higher than that (38.10%) in the control group [χ²(1)= 6.25, p< 0.05]. Regarding anxiety, 
in the total study group, 57.80% had a scores lower than the cut-off (20) on the BAI at post-treatment, 
while 42.20% had still a score equal to 20 or higher. In the CBT group, the number of participants 
who achieved remission (75%), measured by a BAI score lower than cut-off, was significantly higher 
than that (38.10%) in the control group [χ²(1)= 6.25, p< 0.05].  
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5.3.13. Remission on secondary outcomes at 14-month follow-up 
In the total study group, 68.90% had a BDI-II score lower than the cut-off at follow-up, while 31.10% 
had a score equal or higher than 20. The number of participants who achieved remission on depression 
symptoms in the CBT group (87%) was significantly higher than that in the control group (50%) 
[χ²(1)= 7.16, p<0.01]. Regarding anxiety, 61.40% of the total study group had a score lower than the 
cut-off at follow-up. The number of participants who achieved remission in the CBT group was 
significantly higher (79.20%) than in the control group (40%) [χ²(1)= 7.05, p<0.01].  
 
 
Table 5.7. Baseline, post-treatment and follow-up means (standard deviations) on secondary outcomes. 
 Total study group (n= 58) CBT (n= 29) Control condition (n= 29) 
 Baseline Post-treatment Follow-up Baseline Post-treatment Follow-up Baseline Post-treatment Follow-up 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
BDI-II 21.37 (10.95) 15.34 (11.01) 14.23 (11.19) 21.54 (11.54) 11.08 (8.34) 10.43 (8.28) 21.20 (10.59) 20.18 (11.83) 18.38 (12.61) 
BAI 24.20 (13.60) 18 (13.50) 17.04 (12.23) 25.59 (12.56) 13.78 (9.39) 13.13 (8.75) 22.81 (14.67) 22.75 (15.88) 21.52 (14.17) 
PSWQ 51.94 (14.31) 47.21 (10.62) 45.77 (11.84) 53.84 (13.32 45.55 (9.33) 46.47 (12.45) 49.36 (15.68) 50.25 (12.51) 43.40 (10.33) 
GAF 52.97 (9.55) 68.15 (14.24) 77.74 (12.45) 54.83 (8.01) 75.03 (11.88) 79.72 (12.18) 51.10 (10.69) 59.83 (12.43) 70.60 (11.86) 
Note. BAI= Beck Anxiety Inventory, BDI-II= Beck Depression Inventory-II, CBT= cognitive behavioural therapy, GAF= Global Assessment of 
Functioning, PSWQ= Penn State Worry Questionnaire 
 
 
 
5.3.14. Satisfaction with CBT 
About half of individuals in the CBT group responded as “much” or “completely” (42.90% and 
28.60%, respectively) on item 1, that asked whether his/her problems were understood during the 
psychotherapeutic path. The majority responded as “much” or “completely” (78.60% and 14.30%, 
respectively) on item 2 asking whether the psychotherapeutic path improved awareness of their 
problems.  
Half of individuals (14.30% and 50%, respectively) responded as “a little” or “some” on item 7, 
asking whether the path provided useful tools and skills to manage on their own the period after the 
end of psychotherapy. About half (7.10% and 42.90%, respectively) responded as “a little” or “some” 
on item 8 asking whether the goals set for the psychotherapeutic path were achieved.  
A detailed description of frequencies of responses on each item of the satisfaction questionnaire is 
provided in Table 5.8. 
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Table 5.8. Percentages of responses on each item of the satisfaction questionnaire in the CBT group. 
 Not at all A little Some Much Completely 
Item 1. Were your problems understood during the psychotherapeutic 
path? 
  28.60% 42.90% 28.60% 
Item 2. Did the psychotherapeutic path allow you to become more 
aware of your problems? 
  7.10% 78.60% 14.30% 
Item 3. Were your care needs met by the psychotherapeutic path?   42.90% 28.60% 28.60% 
Item 4. Were your treatment expectations met by the 
psychotherapeutic path? 
  42.90% 28.60% 28.60% 
Item 5. Did the psychotherapeutic path provide effective tools to deal 
with your problems? 
  28.60% 50.00% 21.40% 
Item 6. Did the psychotherapeutic path strengthen your resources?  7.10% 7.10% 78.10% 7.10% 
Item 7. Did the path provide useful tools and skills to be able to 
manage on your own the period after the end of psychotherapy? 
 14.30% 50.00% 14.30% 21.40% 
Item 8. Were the goals of the psychotherapeutic path achieved?  7.10% 42.90% 35.70% 14.30% 
Item 9. Did the psychotherapeutic path help you to manage the 
problems/symptoms which you suffered from? 
  35.70% 42.90% 21.40% 
Item 10. Did the psychotherapeutic path improve your psychological 
well-being? 
  50% 35.70% 14.30% 
Item 11. Overall, how much did you feel satisfied with the 
psychotherapeutic path? 
  28.60% 42.90% 28.60% 
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5.4. Discussion 
 
5.4.1. Summary of findings on primary objectives 
The current study investigated the efficacy of a CBT modular protocol for individuals at UHR of 
psychosis with the primary aim of prevention or postponement of a first episode of psychosis. As 
compared as previous research (Addington et al., 2011; Morrison et al., 2012; Stain et al., 2016; Yung 
et al., 2011), additional outcomes were considered to test secondary objectives, such as the effects of 
CBT on depression, anxiety, worry and functioning. Prevention of psychosis was assessed after 6 
months since baseline (post-treatment) and 14 months at follow-up.  
Fifty-eight individuals were randomised to CBT or a control condition that included supportive 
therapy as treatment as usual. Overall, in the current study mean age resulted higher than in the 
previous study by van der Gaag and colleagues (2012), where it was 22.9 years (SD= 5.60), and in 
the study by Stain and colleagues (2016), where it was 16.47 years (SD= 3.16).  
All the participants (n= 58, 100%) reported having APS at baseline, while two smaller groups had 
also BLIPS (n= 3, 5.20%) and family history of psychosis or schizotypal personality disorder (n= 8, 
13.80%). This result appeared consistent with recent data of the RCTs of Stain and colleagues (2016), 
where 46 (81%) had APS, 4 (7%) BLIPS and 19 (33%) a family history or schizotypal personality.  
Overall, the number of drop-outs (n= 13, 22.40%) was lower than in the study by Stain and colleagues 
(n= 27, 53%), but it was higher than in the study by van der Gaag and colleagues (2012), where drop-
outs were 27 (13.77%). A potential explanation for this could be that in the study of Stain and 
colleagues (2016), a much younger cohort was included; the study by van der Gaag and colleagues 
(2012) compared a generic CBT versus CBT for UHR states; thus, it could be hypothesized that just 
the use of CBT components has reduced drop-out rates as compared with the current study, where 
CBT was compared with a control condition not involving any of CBT principles.  
In the total study group, the mean number of attended sessions among drop-outs was relatively small 
(4.92, SD= 2.53; range= 2-11). This could suggest that early drop out is a more typical phenomenon 
among UHR individuals; thus, more therapeutic efforts should be focused on the initial phase of 
treatment, including building motivation and engagement, defining goals.  
Overall, female gender was associated with a higher probability of drop out. This finding was 
somewhat surprising and in contrast with previous research, given that females at CHR typically 
showed better functioning and more help-seeking behaviours than males (Barajas et al., 2015; 
Willhite et al., 2008).  
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On the other hand, other clinical variables potentially related to drop out, did not result significantly 
associated to early interruption of therapy, such as comorbid personality disorders, cannabis use, 
functioning and subclinical psychotic symptoms.  
The number of drop-outs in the CBT condition (n= 3, 10.30%) was significantly lower than in control 
condition (n= 10, 34.50%). This result could suggest that a modular CBT protocol can significantly 
reduce attrition and increase feasibility of the treatment in a population difficult to be engaged in 
therapy due to intermittent loss of symptom insight or subclinical negative symptoms which 
frequently limit attending sessions. Drop out is a relevant phenomenon in psychosis treatment (van 
der Gaag et al., 2013). Some strategies were adopted in the protocol in order to minimize early drop 
out, such as conducting all the sessions in the mental health centre, where the participant had been 
recruited or at his/her home when he/she had difficulties going out due to panic attacks or 
agoraphobia. Additional engagement strategies were conducting “real-life” exposure sessions out of 
office, in order to increase motivation, willingness of the young individuals to expose themselves and 
also help them to generalize skills learnt during in-office sessions by confronting with the modelling 
behaviour of the therapist.  
In contrast with findings in the total study group, no clinical variables were found to be significantly 
associated with drop out in the CBT group. Additional analyses were prevented in the current study 
due to the low number of drop-outs in the CBT group. Thus, further research should investigate other 
potential predictors of drop out during CBT course. 
Overall, the transition rate in the current study was 19%, which resulted higher than that observed in 
recent trials, where it was ranging from 5 to 9% (Addington et al., 2011; Morrison et al., 2012; Stain 
et al., 2016; Yung et al., 2011), and also than that reported in the EDIE-NL trial by van der Gaag and 
colleagues (2012), who found a 16% of transition rate. Some differences across the studies could 
account for this inconsistency, as in the study of Stain and colleagues (2016) follow-up length was 
12 months, while in the EDIE-NL trial it was 18 months (van der Gaag et al., 2012). In addition, the 
study of Stain and colleagues (2016) included a much younger cohort (mean age= 16.47, SD= 2.73, 
range= 16-30) and also in the study of van der Gaag and colleagues (2012) mean age was slightly 
lower (22.9, SD= 5.60). Moreover, an explanation of this finding was that in the current study 
participants were recruited through referrals from mental health professionals while in the EDIE-NL 
trial van der Gaag and colleagues (2012) used a two-step procedure screening help-seeking youth 
through the PQ, then identifying UHR individuals by the CAARMS administration. Indeed, previous 
research showed that differences in recruitment procedures are associated with different transition 
estimates with the group recruited through screening being much more prone to conversion than that 
recruited by referrals (Riedijk et al., 2012). On the other hand, current transition rate appeared 
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substantially in line with the rates reported in other trials (6-20%; Bechdolf et al., 2012; 10-21%; 
McGorry et al., 2013). Transition rate in the current study was, however, lower than that observed by 
Morrison and colleagues (2012), who reported a value of 22%.   
In the current study, survival analyses indicated that the CBT protocol was associated with a reduced 
risk of transition to psychosis although the difference between the curves was found at a borderline 
significance level. In addition, the estimated number needed to treat suggested that on average about 
6 participants should be treated with the CBT modular protocol, instead of being assigned to the 
control condition, to prevent a transition to psychosis in one additional participant. 
Overall, 55% and 54% of participants reported remission on the ARMS status at post-treatment and 
follow-up, respectively. This suggested that remission remained stable over time in both CBT and 
control groups. In the CBT group, the number of participants who achieved remission on the ARMS 
at post-treatment was significantly higher (80% vs 13.30%) and also at follow-up (69.60% vs 25%), 
suggesting that CBT was effective on subclinical psychotic symptoms and that therapeutic gains were 
maintained after 14 months.  
 
 
5.4.2. Summary of findings on secondary objectives 
Results of ANOVAs showed interaction effects of baseline subclinical symptoms and group 
allocation on subclinical psychotic symptoms at post-treatment and follow-up. Specifically, analyses 
indicated that individuals with higher unusual content of thoughts, non-bizarre ideas and perceptual 
abnormalities reported lower scores on these types of subclinical symptoms when assigned to CBT 
condition than to control condition. This could suggest that CBT could add benefit on specific types 
of subclinical symptoms for those individuals having more severe subclinical symptoms at intake.  
A higher number of individuals receiving CBT achieved remission on depression and anxiety (75% 
vs 38% for both depression and anxiety symptoms) at post-treatment and follow-up (87% vs 50% for 
depression, 79% vs 40% for anxiety). This finding was in contrast with most previous trials 
(Addington et al., 2011; Morrison et al., 2004, 2012; van der Gaag et al., 2012; Yung et al., 2011), 
which reported no significant difference between individuals assigned to CBT and those in the control 
conditions. This finding could be explained by the fact that the CBT protocol in the current study was 
a modular treatment, that included several additional techniques to target anxiety, mood, and worry 
problems. However, some differences in the control conditions between the previous trials could also 
account for this outcome. In effect, the study by van der Gaag (2012) assigned participants to 
evidenced-based psychological treatments for non-psychotic disorders + CBT for PLEs or evidenced-
based psychological treatments alone; thus, different from the current study, where participants in the 
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control condition did not receive any ingredients of CBT, in the EDIE-NL trial (van der Gaag et al., 
2012) participants also in the control conditions receive some components targeting anxiety and 
depression. 
Main effects of group were not observed on secondary outcomes. However, interaction effects 
between group and baseline scores showed that individuals with higher baseline depression, anxiety 
and worry had significantly lower scores on secondary outcomes. Therefore, these results indicated 
that CBT did not add greater benefit than a control condition on secondary outcomes when such 
symptoms are considered as a continuous outcome. Thus, CBT could target the reduction of 
depression, anxiety and worry symptoms when they are present at a clinically significant level.  
No interaction effect or main effect of group on functioning was found, suggesting that CBT did not 
produce a significantly higher improvement than control condition. This finding was consistent with 
that observed by van der Gaag and colleagues (2012), who reported no significantly greater effect of 
CBT for UHR on functioning and also quality of life.  
Finally, current findings from a satisfaction scale indicated that about 70% of participants who 
completed all CBT sessions were much or completely satisfied with the treatment path overall. 
Specifically, about 90% were much or completely satisfied with the treatment path as it allowed them 
to become more aware of their problems or symptoms. About 70% of participants were much or 
completely satisfied with CBT as it provided effective tools to manage their symptoms, as during the 
path their problems were much or completely understood, and for over 85% of participants it 
strengthened their personal resources.  
About 50% responded that CBT improved their well-being much or very, while another 50% 
responded that it did at some degree. Another point was that about 60% responded that CBT provided 
effective skills to self-manage their symptoms/problems at the end of the psychotherapy, while only 
about 35% responded as much or completely. In addition, only 50% stated that the therapeutic goals 
were achieved at the end of the CBT course, while another 50% responded that they were reached a 
little or at some degree.  
Thus, data on satisfaction indicated that the CBT modular protocol was perceived by participants as 
a useful goal-oriented, problem-focused path able to increase their awareness of their 
symptoms/problems, to improve their strengths and personal resources and provide effective skills to 
manage symptoms. However, responses from a relevant part of the group highlighted that there is 
room for further improvement of the intervention. For example, additional strategies could be 
introduced to further perceived well-being but also self-management skills to be used when the 
psychotherapy course has finished; adding more booster sessions could improve this satisfaction 
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outcome. Moreover, further strategies targeting relapse prevention could be integrated. In effect, in 
the current protocol only a final session was dedicated to relapse prevention.  
 
 
5.4.3. Limitations and future directions 
Some important limitations should be noted. A potential bias in the recruitment strategies was the 
lack of a broad screening procedure, used for all the population of help-seeking individuals. Thus, 
this limitation could have influenced the identification of cases since hep-seeking individuals were 
only identified and recruited by referrals. Future research in Italy should use a wide screening strategy 
in order to optimize recruitment of suspected cases. In addition, the small number of recruited 
participants require additional studies with larger samples in Italy.  
Another important limitation concerned the time window considered for follow-up assessments, 
which could be viewed as relatively short. Future research should use longer follow-up assessments 
with several years (2 years or longer), given that longer time windows are associated with increased 
risk of developing a fist episode of psychosis moving from a transition risk 21.7 to 35.8 (Fusar-Poli 
et al., 2012). 
Another aspect that needs for further improvement regarded the use of a functioning measure. Some 
research has indicated differences between the functioning construct and quality of life dimensions 
(Muldoon et al., 1998). Thus, further research should use quality of life measures to assess the effects 
of CBT for UHR people. An additional outcome which should be investigate is subjective well-being. 
Another limitation regarded the use of a monocentre design, which could prevent generalization to 
other mental health sites. In addition, the recruited individuals were from mental health centres; future 
studies in Italy should introduce recruitment strategies also from primary care settings in order to 
improve early detection.  
The CBT protocol appeared to be more effective on reducing subclinical psychotic symptoms than 
the control condition. However, as participants assigned to control did not receive all the other 
therapeutic components included in CBT, this effect cannot be attributed to the module targeting 
distress related to psychotic experiences. Future process research should investigate which 
component could be associated to a better outcome on ARMS status.  
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5.5. Conclusions 
In conclusion, the current study seemed to expand evidence on early detection and intervention on 
psychosis, highlighting also directions of future research. The present data provided further 
knowledge on the efficacy and feasibility of CBT for UHR groups, as in the current literature there is 
a small number of studies on this topic. CBT appeared to be a useful strategy to prevent or delay first 
episode of psychosis and also to produce remission on ARMS status. However, present data showed 
that transition conversion was reduced only at a trend level as compared with supportive therapy as 
control condition (treatment as usual). Current study considered a broad set of clinical and functional 
outcomes, that were not sufficiently assessed in the literature, including anxiety, depression, worry 
and global functioning. However, from the current analyses CBT did not seem to sufficiently improve 
functioning and worry. One of the future challenges in UHR research is the development of effective 
strategies to target worry and improve functioning in this population of young people.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
108 
 
Acknowledgements 
 
 
 
I wish to gratefully thank the following colleagues for their kind participation in this study: 
 
 
Prof. Davide Dèttore, PsyD, University of Florence 
Dr. Sandro Domenichetti, MD, Azienda USL Toscana Centro 
Dr. Andrea Cicogni, MD Azienda USL Toscana Centro 
Dr. Nicoletta Giaquinta, PsyD Centre for Cognitive and Behavioural Therapy (CTTC) 
Dr. Elisabetta Ruggieri, PsyD Azienda USL Toscana Centro 
Dr. Andrea Bencini, MD Azienda USL Toscana Centro 
Dr. Cinzia Di Matteo, MD Azienda USL Toscana Centro 
Dr. Andrea Tanini, MD Azienda USL Toscana Centro 
Dr. Stefano Calamandrei, MD Azienda USL Toscana Centro 
Dr. Stefano Berrettini, MD Azienda USL Toscana Centro 
Dr. Stefania Bianchini, nurse manager Azienda USL Toscana Centro 
Dr. Riccardo Lo Parrino, MD Azienda USL Toscana Centro 
Dr. Vanna Vocino, PsyD Azienda USL Toscana Centro 
Dr. Daniela Falchini, PsyD Azienda USL Toscana Centro 
Dr. Alberto Santelli, PsyD Cooperativa di Vittorio 
 
 
 
Finally, I warmly, kindly thank all the participants of the study. 
 
 
 
 
 
109 
 
Ringraziamenti 
 
 
 
 
 
 
 
 
 
Ringrazio il Professor Davide Dèttore, in tutti questi anni mio supervisore tanto nella pratica clinica 
quanto nell’attività scientifica universitaria, per avermi trasmesso la passione per questo delicato e 
avvincente lavoro, per tutti gli incoraggiamenti che mi ha dato, per avermi trasmesso l’attenzione al 
rigore metodologico, a essere consapevole dei miei obiettivi, alla ricerca delle fonti di ciò che citiamo 
ed al tempo stesso della semplicità in quello che facciamo. 
Ringrazio il Dott. Sandro Domenichetti per avermi trasmesso quanto a volte sia importante nel nostro 
lavoro avere un atteggiamento di leggerezza, di ironia ma soprattutto di autoironia, per avermi 
insegnato che “l’ansia può essere la porta di accesso di qualcosa di più grande”. 
Ringrazio la Dott.ssa Anna Meneghelli, perché durante questo cammino, in momenti di fervore del 
lavoro, mi ha offerto l’opportunità di osservarmi dall’esterno in quello che stavo facendo, per 
l’entusiasmo che mi ha infuso, per l’interesse “ai casi clinici poco chiari”. 
Ringrazio tutti i membri della mia famiglia per avermi permesso di portare avanti questo percorso, 
per aver ascoltato i miei bisogni, per il loro affetto costante, per tutte le volte in cui si sono presi cura 
di me nei momenti difficili. 
Ringrazio la mia compagna, Nicoletta, per tutte le volte in cui mi ha fatto sentire capito ed accettato 
nelle mie fragilità e per la forza che mi ha dato e mi dà ogni giorno nel fare certe scelte. 
Ringrazio i miei amici, Alessandro, Giovanni e Gabriele, per tutti i sorrisi che ci siamo scambiati in 
questi anni. 
Ringrazio infine, tutte le persone che in questi anni hanno deciso di partecipare a questo studio, per 
le fortissime emozioni che mi hanno permesso di condividere con loro.  
. 
 
 
 
 
110 
 
References 
 
Abel, K. M., Drake, R., & Goldstein, J. M. (2010). Sex differences in schizophrenia. International 
Review of Psychiatry, 22(5), 417-428. 
Addington, J., Cadenhead, K. S., Cannon, T. D., Cornblatt, B., McGlashan, T. H., Perkins, D. O., ... 
& Heinssen, R. (2007). North American Prodrome Longitudinal Study: a collaborative multisite 
approach to prodromal schizophrenia research. Schizophrenia Bulletin, 33(3), 665-672. 
Addington, J., Case, N., Saleem, M. M., Auther, A. M., Cornblatt, B. A., & Cadenhead, K. S. (2014). 
Substance use in clinical high risk for psychosis: a review of the literature. Early Intervention in 
Psychiatry, 8(2), 104-112.  
Addington, J., Case, N., Saleem, M. M., Auther, A. M., Cornblatt, B. A., & Cadenhead, K. S. (2014). 
Substance use in clinical high risk for psychosis: a review of the literature. Early Intervention in 
Psychiatry, 8(2), 104-112. 
Addington, J., Cornblatt, B. A., Cadenhead, K. S., Cannon, T. D., McGlashan, T. H., Perkins, D. O., 
... & Heinssen, R. (2011). At clinical high risk for psychosis: outcome for nonconverters. American 
Journal of Psychiatry, 168(8), 800-805. 
Addington, J., Epstein, I., Liu, L., French, P., Boydell, K. M., & Zipursky, R. B. (2011). A randomized 
controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. 
Schizophrenia Research, 125(1), 54-61. 
Addington, J., Heinssen, R. K., Robinson, D. G., Schooler, N. R., Marcy, P., Brunette, M. F., ... & 
Robinson, J. A. (2015). Duration of untreated psychosis in community treatment settings in the United 
States. Psychiatric Services, 66(7), 753–756. 
Addington, J., Penn, D., Woods, S. W., Addington, D., & Perkins, D. O. (2008). Social functioning 
in individuals at clinical high risk for psychosis. Schizophrenia Research, 99(1), 119-124. 
Allen, P., Aleman, A., & Mcguire, P. K. (2007). Inner speech models of auditory verbal 
hallucinations: evidence from behavioural and neuroimaging studies. International Review of 
Psychiatry, 19(4), 407-415.  
Allen, P., Chaddock, C. A., Howes, O. D., Egerton, A., Seal, M. L., Fusar-Poli, P., ... & McGuire, P. 
K. (2012). Abnormal relationship between medial temporal lobe and subcortical dopamine function 
in people with an ultra-high risk for psychosis. Schizophrenia Bulletin, 38(5), 1040-1049. 
111 
 
Álvarez-Jiménez, M., Parker, A. G., Hetrick, S. E., McGorry, P. D., & Gleeson, J. F. (2011). 
Preventing the second episode: a systematic review and meta-analysis of psychosocial and 
pharmacological trials in first-episode psychosis. Schizophrenia Bulletin, 37(3), 619-630.  
American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders 
(3rd ed. Revised). Washington, DC: American Psychiatric Association Publishing. 
American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders (4th 
ed.). Washington, DC: American Psychiatric Association Publishing. 
American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders 
(DSM5), 5th ed. Washington, DC: American Psychiatric Association Publishing. 
Amminger, G. P., Berger, G. E., Schäfer, M. R., Klier, C., Friedrich, M. H., & Feucht, M. (2007). 
Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-
controlled pilot study. Biological Psychiatry, 61(4), 551-553. 
Amminger, G. P., Leicester, S., Yung, A. R., Phillips, L. J., Berger, G. E., Francey, S. M., ... & 
McGorry, P. D. (2006). Early-onset of symptoms predicts conversion to non-affective psychosis in 
ultra-high risk individuals. Schizophrenia Research, 84(1), 67-76. 
Amminger, G. P., & McGorry, P. D., (2012). Update on omega-3 polyunsaturated fatty acids in early-
stage psychotic disorders. Neuropsychopharmacology, 37(1) 309-310. 
Amminger, G. P., Schäfer, M. R., Klier, C. M., Schlögelhofer, M., Mossaheb, N., Thompson, A., ... 
& Nelson, B. (2012). Facial and vocal affect perception in people at ultra‐high risk of psychosis, first‐
episode schizophrenia and healthy controls. Early Intervention in Psychiatry, 6(4), 450-454. 
Amminger,G. P., Schafer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., 
Mackinnon, A., McGorry, P. D., Berger, G. E., (2010). Long-chain omega-3 fatty acids for indicated 
prevention of psychotic disorders: a randomized, placebo-controlled trial. Archives of General 
Psychiatry, 67(2), 146–154. 
Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Schlögelhofer, M., Mossaheb, N., 
... & McGorry, P. D. (2012). Emotion recognition in individuals at clinical high-risk for 
schizophrenia. Schizophrenia Bulletin, 38(5), 1030-1039.  
An, S. K., Kang, J. I., Park, J. Y., Kim, K. R., Lee, S. Y., & Lee, E. (2010). Attribution bias in ultra-
high risk for psychosis and first-episode schizophrenia. Schizophrenia Research, 118(1), 54-61. 
112 
 
Auther, A. M., McLaughlin, D., Carrión, R. E., Nagachandran, P., Correll, C. U., & Cornblatt, B. A. 
(2012). Prospective study of cannabis use in adolescents at clinical high risk for psychosis: impact on 
conversion to psychosis and functional outcome. Psychological Medicine, 42(12), 2485-2497. 
Barajas, A., Ochoa, S., Obiols, J. E., & Lalucat-Jo, L. (2015). Gender differences in individuals at 
high-risk of psychosis: a comprehensive literature review. The Scientific World Journal, 1(1), 1-13. 
Barbato, M., Liu, L., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., McGlashan, T. H., ... & 
Woods, S. W. (2015). Theory of mind, emotion recognition and social perception in individuals at 
clinical high risk for psychosis: Findings from the NAPLS-2 cohort. Schizophrenia Research, 2(3), 
133-139. 
Bechdolf, A., Wagner, M., Ruhrmann, S., Harrigan, S., Putzfeld, V., Pukrop, R., ... & Bottlender, R. 
(2012). Preventing progression to first-episode psychosis in early initial prodromal states. The British 
Journal of Psychiatry, 200(1), 22-29.  
Beck, A. T. (1976) Cognitive Therapy and the Emotional Disorders. New York, NY: International 
Universities Press. 
Beck, A. T. (1979) Cognitive Therapy of Depression. New York, NY: Guilford Press. 
Beck, A. T., & Steer, R. A. (1990). Beck anxiety inventory: BAI. Manual. San Antonio, TX: The 
Psychological Corporation Harcourt Brace & Company. 
Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Beck Depression Inventory-Second Edition Manual. 
San Antonio, TX: The Psychological Corporation Harcourt Brace & Company. 
Bell, V., Halligan, P. W., & Ellis, H. D. (2006). Explaining delusions: a cognitive perspective. Trends 
in Cognitive Sciences, 10(5), 219-226. 
Berger, G., Dell’Olio, M., Amminger, P., Cornblatt, B., Phillips, L., Yung, A., ... & McGorry, P. 
(2007). Neuroprotection in emerging psychotic disorders. Early Intervention in Psychiatry, 1(2), 114-
127. 
Bernstein, D. P., Stein, J. A., Newcomb, M. D., Walker, E., Pogge, D., Ahluvalia, T., ... & Zule, W. 
(2003). Development and validation of a brief screening version of the Childhood Trauma 
Questionnaire. Child Abuse & Neglect, 27(2), 169-190. 
Blazer, D. G., Kessler, R. C., & McGonagle, K. A. (1994). The prevalence and distribution of major 
depression in a national community sample: the National Comorbidity Survey. Age (years), 15(24), 
24-7.  
113 
 
Blechert, J., & Meyer, T. D. (2005). Are measures of hypomanic personality, impulsive 
nonconformity and rigidity predictors of bipolar symptoms? British Journal of Clinical Psychology, 
44(1), 15-27.  
Bleuler, E. (1950). Dementia Praecox or the group of Schizophrenias. Oxford, UK: International 
Universities Press.  
Bodatsch, M., Ruhrmann, S., Wagner, M., Müller, R., Schultze-Lutter, F., Frommann, I., ... & 
Brockhaus-Dumke, A. (2011). Prediction of psychosis by mismatch negativity. Biological 
Psychiatry, 69(10), 959-966.  
Boonstra, N., Klaassen, R., Sytema, S., Marshall, M., De Haan, L., Wunderink, L., & Wiersma, D. 
(2012). Duration of untreated psychosis and negative symptoms—a systematic review and meta-
analysis of individual patient data. Schizophrenia Research, 142(1), 12-19. 
Boonstra, N., Sterk, B., Wunderink, L., Sytema, S., De Haan, L., & Wiersma, D. (2012). Association 
of treatment delay, migration and urbanicity in psychosis. European Psychiatry, 27(7), 500-505. 
Borkovec, T. D., & Roemer, L. (1995). Perceived functions of worry among generalized anxiety 
disorder subjects: distraction from more emotionally distressing topics? Journal of Behavior Therapy 
and Experimental Psychiatry, 26(1), 25-30. 
Broome, M. R., Johns, L. C., Valli, I., Woolley, J. B., Tabraham, P., Brett, C., ... & McGuire, P. K. 
(2007). Delusion formation and reasoning biases in those at clinical high risk for psychosis. The 
British Journal of Psychiatry, 191(51), 38-42. 
Broussard, B., Kelley, M. E., Wan, C. R., Cristofaro, S. L., Crisafio, A., Haggard, P. J., ... & Compton, 
M. T. (2013). Demographic, socio-environmental, and substance-related predictors of duration of 
untreated psychosis (DUP). Schizophrenia Research, 148(1), 93-98. 
Brüne, M. (2005). Emotion recognition, “theory of mind”, and social behavior in 
schizophrenia. Psychiatry Research, 133(2), 135-147. 
Brüne, M., Özgürdal, S., Ansorge, N., von Reventlow, H. G., Peters, S., Nicolas, V., ... & Lissek, S. 
(2011). An fMRI study of “theory of mind” in at-risk states of psychosis: comparison with manifest 
schizophrenia and healthy controls. Neuroimage, 55(1), 329-337.  
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., ... & Keller, 
W. (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and 
summary statements. Schizophrenia Bulletin, 36(1), 71-93.  
114 
 
Buchy, L., Perkins, D., Woods, S. W., Liu, L., & Addington, J. (2014). Impact of substance use on 
conversion to psychosis in youth at clinical high risk of psychosis. Schizophrenia Research, 156(2), 
277-280. 
Buckley, P. F., Miller, B. J., Lehrer, D. S., & Castle, D. J. (2009). Psychiatric comorbidities and 
schizophrenia. Schizophrenia bulletin, 35(2), 383-402. 
Burns, K. J. (2012). Cannabis use and duration of untreated psychosis: a systematic review and meta-
analysis. Current Pharmaceutical Design, 18(32), 5093-5104. 
Carpenter, W. T., & van Os, J. (2011). Should attenuated psychosis syndrome be a DSM-5 diagnosis? 
American Journal of Psychiatry, 168(5), 460-463.  
Carter, J. W., Parnas, J., Cannon, T. D., Schulsinger, F., & Mednick, S. A. (1999). MMPI variables 
predictive of schizophrenia in the Copenhagen High‐Risk Project: a 25‐year follow‐up. Acta 
Psychiatrica Scandinavica, 99(6), 432-440. 
Chan, A. W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., & Moher, 
D. (2013). SPIRIT 2013 statement: defining standard protocol items for clinical trials. Annals of 
Internal Medicine, 158(3), 200-207. 
Chapman, L. J., & Chapman, J. P. (1980). Scales for rating psychotic and psychotic-like experiences 
as continua. Schizophrenia Bulletin, 6(3), 476. 
Clark, D. M., & Wells, A. (1995). A cognitive model of social phobia. Social phobia: Diagnosis, 
assessment, and treatment, 41(68), 22-23.  
Cocchi, A., Lora, A., Meneghelli, A., La Greca, E., Pisano, A., Cascio, M. T., & Preti, A. (2014). Sex 
differences in first-episode psychosis and in people at ultra-high risk. Psychiatry Research, 215(2), 
314-322. 
Cohen, J. (1977). Statistical power analysis for the behavioral sciences. Hillsdale, NJ, England: 
Lawrence Erlbaum Associates. 
Comparelli, A., Corigliano, V., De Carolis, A., Mancinelli, I., Trovini, G., Ottavi, G., ... & Girardi, 
P. (2013). Emotion recognition impairment is present early and is stable throughout the course of 
schizophrenia. Schizophrenia Research, 143(1), 65-69. 
Compton, M. T., & Broussard, B. (2011). Conceptualizing the multifaceted determinants of the 
duration of untreated psychosis. Current Psychiatry Reviews, 7(1), 1-11.  
115 
 
Compton, M. T., Chien, V. H., Leiner, A. S., Goulding, S. M., & Weiss, P. S. (2008). Mode of onset 
of psychosis and family involvement in help-seeking as determinants of duration of untreated 
psychosis. Social Psychiatry and Psychiatric Epidemiology, 43(12), 975-982.  
Compton, M. T., Gordon, T. L., Goulding, S. M., Esterberg, M. L., Carter, T., Leiner, A. S., ... & 
Kaslow, N. J. (2011). Patient-Level Predictors and Clinical Correlates of Duration of Untreated 
Psychosis Among Hospitalized First-Episode Patients [CME]. The Journal of Clinical 
Psychiatry, 72(2), 225-232. 
Corcoran, C. M., Kimhy, D., Stanford, A., Khan, S., Walsh, J., Thompson, J., ... & Cressman, V. 
(2008). Temporal association of cannabis use with symptoms in individuals at clinical high risk for 
psychosis. Schizophrenia Research, 106(2), 286-293. 
Cornblatt, B. A., Carrión, R. E., Addington, J., Seidman, L., Walker, E. F., Cannon, T. D., ... & 
Woods, S. W. (2011). Risk factors for psychosis: impaired social and role functioning. Schizophrenia 
Bulletin, 38(6), 1247-1257. 
Cornblatt, B. A., Carrión, R. E., Auther, A., McLaughlin, D., Olsen, R. H., John, M., & Correll, C. 
U. (2015). Psychosis prevention: a modified clinical high risk perspective from the Recognition and 
Prevention (RAP) Program. American Journal of Psychiatry, 172(10), 986-994.  
Cotton, S. M., Lambert, M., Schimmelmann, B. G., Foley, D. L., Morley, K. I., McGorry, P. D., & 
Conus, P. (2009). Gender differences in premorbid, entry, treatment, and outcome characteristics in 
a treated epidemiological sample of 661 patients with first episode psychosis. Schizophrenia 
Research, 114(1), 17-24. 
Couture, S. M., Penn, D. L., Addington, J., Woods, S. W., & Perkins, D. O. (2008). Assessment of 
social judgments and complex mental states in the early phases of psychosis. Schizophrenia 
Research, 100(1), 237-241. 
Crow, T. J. (1980). Molecular pathology of schizophrenia: more than one disease process? British 
Medical Journal, 280(6207) 66-68. 
Crum, W. R., Griffin, L. D., Hill, D. L., & Hawkes, D. J. (2003). Zen and the art of medical image 
registration: Correspondence, homology, and quality. Neuroimage, 20(3), 1425–1437 
Debbané, M., & Barrantes-Vidal, N. (2015). Schizotypy from a developmental perspective. 
Schizophrenia Bulletin, 41(Suppl. 2), S386-S395. 
DeVylder, J. E., Ben‐David, S., Kimhy, D., & Corcoran, C. M. (2013). Attributional style among 
youth at clinical risk for psychosis. Early Intervention in Psychiatry, 7(1), 84-88.  
116 
 
DeVylder, J. E., Muchomba, F. M., Gill, K. E., Ben-David, S., Walder, D. J., Malaspina, D., & 
Corcoran, C. M. (2014). Symptom trajectories and psychosis onset in a clinical high-risk cohort: the 
relevance of subthreshold thought disorder. Schizophrenia Research, 159(2), 278-283. 
Dickinson, D., Ramsey, M. E., & Gold, J. M. (2007). Overlooking the obvious: a meta-analytic 
comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Archives of 
General Psychiatry, 64(5), 532-542. 
Dragt, S., Nieman, D. H., Becker, H. E., van de Fliert, R., Dingemans, P. M., de Haan, L., ... & 
Linszen, D. H. (2010). Age of onset of cannabis use is associated with age of onset of high-risk 
symptoms for psychosis. The Canadian Journal of Psychiatry, 55(3), 165-171.  
Dragt, S., Nieman, D. H., Schultze‐Lutter, F., Van Der Meer, F., Becker, H., De Haan, L., ... & 
Heinimaa, M. (2012). Cannabis use and age at onset of symptoms in subjects at clinical high risk for 
psychosis. Acta Psychiatrica Scandinavica, 125(1), 45-53. 
Drury, V., Birchwood, M., Cochrane, R., & MacMillan, F. (1996). Cognitive therapy and recovery 
from acute psychosis: a controlled trial. I. Impact on psychotic symptoms. The British Journal of 
Psychiatry, 169(5), 593-601.  
Eisenberg, D., Downs, M. F., Golberstein, E., & Zivin, K. (2009). Stigma and help seeking for mental 
health among college students. Medical Care Research and Review, 66(5), 522-541. 
Erlenmeyer-Kimling, L., Cornblatt, B. A., Rock, D., Roberts, S., Bell, M., & West, A. (1993). The 
New York High-Risk Project: anhedonia, attentional deviance, and psychopathology. Schizophrenia 
Bulletin, 19(1), 141-153. 
Farrer, C., & Franck, N. (2007). Self-monitoring in schizophrenia. Current Psychiatry Reviews, 3(4), 
243-251.  
Fine, C., Gardner, M., Craigie, J., & Gold, I. (2007). Hopping, skipping or jumping to conclusions? 
Clarifying the role of the JTC bias in delusions. Cognitive Neuropsychiatry, 12(1), 46-77.  
Fisher, H. L., Major, B., Chisholm, B., Rahaman, N., Joyce, J., Woolley, J., ... & Johnson, S. (2013). 
Duration of untreated psychosis in adolescents: Ethnic differences and clinical 
profiles. Schizophrenia Research, 150(2), 526-532.  
Freeman, D., Garety, P., Kuipers, E., Colbert, S., Jolley, S., Fowler, D., ... & Bebbington, P. (2006). 
Delusions and decision-making style: use of the Need for Closure Scale. Behaviour Research and 
Therapy, 44(8), 1147-1158. 
117 
 
French, P., & Morrison, A. P. (2004). Early detection and cognitive therapy for people at high risk 
of developing psychosis: A treatment approach. New York, NY: John Wiley & Sons.  
Fusar-Poli, P. (2012). Voxel-wise meta-analysis of fMRI studies in patients at clinical high risk for 
psychosis. Journal of Psychiatry and Neuroscience, 37(2), 106-112. 
Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., Schultze-Lutter, F., 
... & Valmaggia, L. (2013). The psychosis high-risk state: a comprehensive state-of-the-art 
review. JAMA Psychiatry, 70(1), 107-120.  
Fusar-Poli, P., Broome, M. R., Matthiasson, P., Woolley, J. B., Mechelli, A., Johns, L. C., ... & 
McGuire, P. (2011). Prefrontal function at presentation directly related to clinical outcome in people 
at ultrahigh risk of psychosis. Schizophrenia Bulletin, 37(1), 189-198.  
Fusar‐Poli, P., Cappucciati, M., Rutigliano, G., Schultze‐Lutter, F., Bonoldi, I., Borgwardt, S., ... & 
McGlashan, T. H. (2015). At risk or not at risk? A meta‐analysis of the prognostic accuracy of 
psychometric interviews for psychosis prediction. World Psychiatry, 14(3), 322-332.  
Fusar-Poli, P., Carpenter, W. T., Woods, S. W., & McGlashan, T. H. (2014). Attenuated psychosis 
syndrome: ready for DSM-5.1? Annual Review of Clinical Psychology, 10(1), 155-192. 
Fusar-Poli, P., Nelson, B., Valmaggia, L., Yung, A. R., & McGuire, P. K. (2014). Comorbid 
depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on 
psychopathology and transition to psychosis. Schizophrenia Bulletin, 40(1), 120-131.  
Fusar-Poli, P., Perez, J., Broome, M., Borgwardt, S., Placentino, A., Caverzasi, E., ... & McGuire, P. 
(2007). Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-
analysis. Neuroscience & Biobehavioral Reviews, 31(4), 465-484. 
Fusar-Poli, P., Radua, J., McGuire, P., & Borgwardt, S. (2011). Neuroanatomical maps of psychosis 
onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies. Schizophrenia Bulletin, 38(6), 
1297-1307.  
Galdas, P. M., Cheater, F., & Marshall, P. (2005). Men and health help‐seeking behaviour: literature 
review. Journal of Advanced Nursing, 49(6), 616-623.  
Garety, P. A., Bebbington, P., Fowler, D., Freeman, D., & Kuipers, E. (2007). Implications for 
neurobiological research of cognitive models of psychosis: a theoretical paper. Psychological 
Medicine, 37(10), 1377-1391. 
118 
 
Garner, B., Pariante, C. M., Wood, S. J., Velakoulis, D., Phillips, L., Soulsby, B., ... & Yung, A. R. 
(2005). Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of 
developing psychosis. Biological Psychiatry, 58(5), 417-423. 
Garner, B., Phassouliotis, C., Phillips, L. J., Markulev, C., Butselaar, F., Bendall, S., ... & McGorry, 
P. D. (2011). Cortisol and dehydroepiandrosterone-sulphate levels correlate with symptom severity 
in first-episode psychosis. Journal of Psychiatric Research, 45(2), 249-255. 
Gee, D. G., Karlsgodt, K. H., van Erp, T. G., Bearden, C. E., Lieberman, M. D., Belger, A., ... & 
Woods, S. W. (2012). Altered age-related trajectories of amygdala-prefrontal circuitry in adolescents 
at clinical high risk for psychosis: a preliminary study. Schizophrenia Research, 134(1), 1-9. 
Gerstenberg, M., Theodoridou, A., Traber-Walker, N., Franscini, M., Wotruba, D., Metzler, S., ... & 
Rössler, W. (2016). Adolescents and adults at clinical high-risk for psychosis: age-related differences 
in attenuated positive symptoms syndrome prevalence and entanglement with basic 
symptoms. Psychological Medicine, 46(5), 1069-1078.  
Goldberg, D. P., & Hillier, V. F. (1979). A scaled version of the General Health 
Questionnaire. Psychological Medicine, 9(1), 139-145. 
Goldstein, J. M., Cherkerzian, S., Seidman, L. J., Petryshen, T. L., Fitzmaurice, G., Tsuang, M. T., & 
Buka, S. L. (2011). Sex-specific rates of transmission of psychosis in the New England high-risk 
family study. Schizophrenia Research, 128(1), 150-155. 
Grant, P. M., & Beck, A. T. (2009). Defeatist beliefs as a mediator of cognitive impairment, negative 
symptoms, and functioning in schizophrenia. Schizophrenia Bulletin, 35(4), 798-806.  
Grant Steen, R., Mull, C., McCure, R., Hamer, R. M., & Lieberman, J. A. (2006). Brain volume in 
first-episode schizophrenia: Systematic review and meta-analysis of magnetic resonance imaging 
studies. British Journal of Psychiatry, 188(6), 510-518. 
Green, M. F., Bearden, C. E., Cannon, T. D., Fiske, A. P., Hellemann, G. S., Horan, W. P., ... & 
Subotnik, K. L. (2011). Social cognition in schizophrenia, part 1: performance across phase of 
illness. Schizophrenia Bulletin, 38(4), 854-864.  
Green, C. E. L., McGuire, P. K., Ashworth, M., & Valmaggia, L. R. (2011). Outreach and Support in 
South London (OASIS). Outcomes of non-attenders to a service for people at high risk of psychosis: 
the case for a more assertive approach to assessment. Psychological Medicine, 41(2), 243-250. 
Gross, G. (1987). The Bonn Scale for the Assessment of Basic Symptoms (BSABS). International 
Journal of Neuroscience, 32(1-2), 739-740.  
119 
 
Gross, G. (1989). The" basic" symptoms of schizophrenia. The British Journal of Psychiatry, 155(7), 
21-25.  
Gumley, A., O' Grady, M., McNay, L., Reilly, J., Power, K., & Norrie, J. (2003). Early intervention 
for relapse in schizophrenia: results of a 12-month randomized controlled trial of cognitive 
behavioural therapy. Psychological Medicine, 33(3), 419-431.  
Haahr, U. H., Larsen, T. K., Simonsen, E., Rund, B. R., Joa, I., Rossberg, J. I., ... & Vaglum, P. 
(2016). Relation between premorbid adjustment, duration of untreated psychosis and close 
interpersonal trauma in first‐episode psychosis. Early Intervention in Psychiatry, 12(1), 1-9. 
Häfner, H., Maurer, K., Löffler, W., an der Heiden, W., Hambrecht, M., & Schultze-Lutter, F. (2003). 
Modeling the early course of schizophrenia. Schizophrenia Bulletin, 29(2), 325-340.  
Hanssen, M., Bak, M., Bijl, R., Vollebergh, W., & van Os, J. (2005). The incidence and outcome of 
subclinical psychotic experiences in the general population. British Journal of Clinical 
Psychology, 44(2), 181-191.  
Haroun, N., Dunn, L., Haroun, A., & Cadenhead, K. S. (2006). Risk and protection in prodromal 
schizophrenia: ethical implications for clinical practice and future research. Schizophrenia 
Bulletin, 32(1), 166-178. 
Harrison, G., Hopper, K. I. M., Craig, T., Laska, E., Siegel, C., Wanderling, J., ... & Holmberg, S. K. 
(2001). Recovery from psychotic illness: a 15-and 25-year international follow-up study. The British 
Journal of Psychiatry, 178(6), 506-517.  
Hasselbalch, H. C. (1993). Idiopathic myelofibrosis—an update with particular reference to clinical 
aspects and prognosis. International Journal of Clinical and Laboratory Research, 23(1-4), 124-138. 
Healey, K. M., Penn, D. L., Perkins, D., Woods, S. W., & Addington, J. (2013). Theory of mind and 
social judgments in people at clinical high risk of psychosis. Schizophrenia Research, 150(2), 498-
504. 
Heckers, S. (2001). Neuroimaging studies of the hippocampus in 
Schizophrenia. Hippocampus, 11(5), 520-528. 
Heinimaa, M., Salokangas, R. K. R., Ristkari, T., Plathin, M., Huttunen, J., Ilonen, T., ... & 
McGlashan, T. H. (2003). PROD‐screen – a screen for prodromal symptoms of 
psychosis. International Journal of Methods in Psychiatric Research, 12(2), 92-104. 
120 
 
Hooker, C. I., Carol, E. E., Eisenstein, T. J., Yin, H., Lincoln, S. H., Tully, L. M., ... & Seidman, L. 
J. (2014). A pilot study of cognitive training in clinical high risk for psychosis: initial evidence of 
cognitive benefit. Schizophrenia Research, 157(1), 314-316.  
Howes, O. D., & Kapur, S. (2009). The dopamine hypothesis of schizophrenia: version III — the 
final common pathway. Schizophrenia Bulletin, 35(3), 549-562. 
Huber, G., & Gross, G. (1989). The concept of basic symptoms in schizophrenic and schizoaffective 
psychoses. Recenti Progressi in Medicina, 80(12), 646-652. 
Hui, C., Morcillo, C., Russo, D. A., Stochl, J., Shelley, G. F., Painter, M., ... & Perez, J. (2013). 
Psychiatric morbidity, functioning and quality of life in young people at clinical high risk for 
psychosis. Schizophrenia Research, 148(1), 175-180. 
Hur, J. W., Byun, M. S., Shin, N. Y., Shin, Y. S., Kim, S. N., Jang, J. H., & Kwon, J. S. (2013). 
General intellectual functioning as a buffer against theory-of-mind deficits in individuals at ultra-high 
risk for psychosis. Schizophrenia Research, 149(1), 83-87. 
Ising, H. K., Veling, W., Loewy, R. L., Rietveld, M. W., Rietdijk, J., Dragt, S., ... & van der Gaag, 
M. (2012). The validity of the 16-item version of the Prodromal Questionnaire (PQ-16) to screen for 
ultra-high risk of developing psychosis in the general help-seeking population. Schizophrenia 
Bulletin, 38(6), 1288-1296.  
Job, D. E., Whalley, H. C., Johnstone, E. C., & Lawrie, S. M. (2005). Grey matter changes over time 
in high risk subjects developing schizophrenia. Neuroimage, 25(4), 1023-1030.  
Johns, L. C., Allen, P., Valli, I., Winton-Brown, T., Broome, M., Woolley, J., ... & McGuire, P. 
(2010). Impaired verbal self-monitoring in individuals at high risk of psychosis. Psychological 
Medicine, 40(9), 1433-1442. 
Johns, L. C., Gregg, L., Allen, P., & McGuire, P. K. (2006). Impaired verbal self-monitoring in 
psychosis: effects of state, trait and diagnosis. Psychological Medicine, 36(4), 465-474.  
Johns, L. C., & McGuire, P. K. (1999). Verbal self-monitoring and auditory hallucinations in 
schizophrenia. The Lancet, 353(9151), 469-470.  
Johnstone, E. C., Ebmeier, K. P., Miller, P., Owens, D. G., & Lawrie, S. M. (2005). Predicting 
schizophrenia: findings from the Edinburgh high-risk study. The British Journal of 
Psychiatry, 186(1), 18-25. 
121 
 
Kapur, S. (2003). Psychosis as a state of aberrant salience: a framework linking biology, 
phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry, 160(1), 13-
23. 
Katsura, M., Ohmuro, N., Obara, C., Kikuchi, T., Ito, F., Miyakoshi, T., ... & Matsumoto, K. (2014). 
A naturalistic longitudinal study of at-risk mental state with a 2.4 year follow-up at a specialized 
clinic setting in Japan. Schizophrenia Research, 158(1), 32-38.  
Kaymaz, N., van Os, J., de Graaf, R., ten Have, M., Nolen, W., & Krabbendam, L. (2007). The impact 
of subclinical psychosis on the transition from subclinicial mania to bipolar disorder. Journal of 
Affective Disorders, 98(1), 55-64. 
Keefe, R. S., Arnold, M. C., Bayen, U. J., & Harvey, P. D. (1999). Source monitoring deficits in 
patients with schizophrenia; a multinomial modelling analysis. Psychological Medicine, 29(4), 903-
914. 
Kelleher, I., & Cannon, M. (2011). Psychotic-like experiences in the general population: 
characterizing a high-risk group for psychosis. Psychological Medicine, 41(1), 1-6. 
Kempton, M. J., Bonoldi, I., Valmaggia, L., McGuire, P., & Fusar-Poli, P. (2015). Speed of psychosis 
progression in people at ultra-high clinical risk: a complementary meta-analysis. JAMA 
Psychiatry, 72(6), 622-623. 
Kendler, K. S., Gallagher, T. J., Abelson, J. M., & Kessler, R. C. (1996). Lifetime prevalence, 
demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US 
community sample: the National Comorbidity Survey. Archives of General Psychiatry, 53(11), 1022-
1031. 
Kirkbride, J. B., Errazuriz, A., Croudace, T. J., Morgan, C., Jackson, D., Boydell, J., ... & Jones, P. 
B. (2012). Incidence of schizophrenia and other psychoses in England, 1950–2009: a systematic 
review and meta-analyses. PloS One, 7(3), e31660. 
Kirkbride, J. B., Fearon, P., Morgan, C., Dazzan, P., Morgan, K., Tarrant, J., ... & Mallett, R. M. 
(2006). Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings 
from the 3-center AeSOP study. Archives of general psychiatry, 63(3), 250-258.  
Kline, E., & Schiffman, J. (2014). Psychosis risk screening: a systematic review. Schizophrenia 
Research, 158(1), 11-18. 
122 
 
Kline, E., Wilson, C., Ereshefsky, S., Denenny, D., Thompson, E., Pitts, S. C., ... & Schiffman, J. 
(2012). Psychosis risk screening in youth: a validation study of three self-report measures of 
attenuated psychosis symptoms. Schizophrenia Research, 141(1), 72-77. 
Klosterkötter, J., Hellmich, M., Steinmeyer, E. M., & Schultze-Lutter, F. (2001). Diagnosing 
schizophrenia in the initial prodromal phase. Archives of General Psychiatry, 58(2), 158-164. 
Kobayashi, H., Nemoto, T., Koshikawa, H., Osono, Y., Yamazawa, R., Murakami, M., ... & Mizuno, 
M. (2008). A self-reported instrument for prodromal symptoms of psychosis: testing the clinical 
validity of the PRIME Screen—Revised (PS-R) in a Japanese population. Schizophrenia 
Research, 106(2), 356-362. 
Kohler, C. G., Richard, J. A., Brensinger, C. M., Borgmann-Winter, K. E., Conroy, C. G., Moberg, 
P. J., ... & Calkins, M. E. (2014). Facial emotion perception differs in young persons at genetic and 
clinical high-risk for psychosis. Psychiatry Research, 216(2), 206-212. 
Konings, M., Bak, M., Hanssen, M., Van Os, J., & Krabbendam, L. (2006). Validity and reliability 
of the CAPE: a self‐report instrument for the measurement of psychotic experiences in the general 
population. Acta Psychiatrica Scandinavica, 114(1), 55-61. 
Korver, N., Nieman, D. H., Becker, H. E., van de Fliert, J. R., Dingemans, P. H., de Haan, L., ... & 
Linszen, D. H. (2010). Symptomatology and neuropsychological functioning in cannabis using 
subjects at ultra-high risk for developing psychosis and healthy controls. Australian and New Zealand 
Journal of Psychiatry, 44(3), 230-236. 
Koutsouleris, N., Riecher-Rössler, A., Meisenzahl, E. M., Smieskova, R., Studerus, E., Kambeitz-
Ilankovic, L., ... & Borgwardt, S. (2014). Detecting the psychosis prodrome across high-risk 
populations using neuroanatomical biomarkers. Schizophrenia Bulletin, 41(2), 471-482. 
Køster, A., Lajer, M., Lindhardt, A., & Rosenbaum, B. (2008). Gender differences in first episode 
psychosis. Social Psychiatry and Psychiatric Epidemiology, 43(12), 940-946. 
Kraan, T., Velthorst, E., Koenders, L., Zwaart, K., Ising, H. K., van den Berg, D., ... & van der Gaag, 
M. (2016). Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-
analysis. Psychological Medicine, 46(4), 673-681. 
Kraan, T., Velthorst, E., Smit, F., de Haan, L., & van der Gaag, M. (2015). Trauma and recent life 
events in individuals at ultra high risk for psychosis: review and meta-analysis. Schizophrenia 
Research, 161(2), 143-149.  
123 
 
Kuepper, R., van Os, J., Lieb, R., Wittchen, H. U., Höfler, M., & Henquet, C. (2011). Continued 
cannabis use and risk of incidence and persistence of psychotic symptoms: 10-year follow-up cohort 
study. British Medical Journal, 342(1), 731-738. 
Kwapil, T. R., Miller, M. B., Zinser, M. C., Chapman, L. J., Chapman, J., & Eckblad, M. (2000). A 
longitudinal study of high scorers on the hypomanic personality scale. Journal of Abnormal 
Psychology, 109(2), 222. 
Kwon, J. S., Byun, M. S., Lee, T. Y., & An, S. K. (2012). Early intervention in psychosis: insights 
from Korea. Asian Journal of Psychiatry, 5(1), 98-105. 
Lam, M. M., Hung, S. F., & Chen, E. Y. (2006). Transition to psychosis: 6-month follow-up of a 
Chinese high-risk group in Hong Kong. Australian and New Zealand Journal of Psychiatry, 40(5), 
414-420. 
Landa, Y., Mueser, K., Wyka, K., Shreck, E., Jespersen, R., Jacobs, M., ... & Silbersweig, D. (2015). 
Development of a group and family-based cognitive behavioral therapy program for youth at risk for 
psychosis. Early Intervention in Psychiatry, 10(6) 511-521. 
Larsson, S., Andreassen, O. A., Aas, M., Røssberg, J. I., Mork, E., Steen, N. E., ... & Melle, I. (2013). 
High prevalence of childhood trauma in patients with schizophrenia spectrum and affective 
disorder. Comprehensive Psychiatry, 54(2), 123-127.  
Laruelle, M., Kegeles, L. S., & Abi‐Dargham, A. (2003). Glutamate, dopamine, and 
schizophrenia. Annals of the New York Academy of Sciences, 1003(1), 138-158. 
Lemos-Giráldez, S., Vallina-Fernández, O., Fernández-Iglesias, P., Vallejo-Seco, G., Fonseca-
Pedrero, E., Paíno-Piñeiro, M., ... & Gutiérrez-Pérez, A. (2009). Symptomatic and functional outcome 
in youth at ultra-high risk for psychosis: a longitudinal study. Schizophrenia Research, 115(2), 121-
129. 
Lencz, T., Smith, C. W., Auther, A. M., Correll, C. U., & Cornblatt, B. A. (2003). The assessment 
of" prodromal schizophrenia": unresolved issues and future directions. Schizophrenia Bulletin, 29(4), 
717. 
Lieberman, J. A., Tollefson, G. D., Charles, C., Zipursky, R., Sharma, T., Kahn, R. S., ... & Perkins, 
D. (2005). Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of 
General Psychiatry, 62(4), 361-370. 
124 
 
Lin, A., Wigman, J. T. W., Nelson, B., Vollebergh, W. A. M., Van Os, J., Baksheev, G., ... & Yung, 
A. R. (2011). The relationship between coping and subclinical psychotic experiences in adolescents 
from the general population–a longitudinal study. Psychological Medicine, 41(12), 2535-2546.  
Lin, A., Wood, S. J., Nelson, B., Beavan, A., McGorry, P., & Yung, A. R. (2015). Outcomes of 
nontransitioned cases in a sample at ultra-high risk for psychosis. American Journal of 
Psychiatry, 172(3), 249-258. 
Loewy, R. L., Bearden, C. E., Johnson, J. K., Raine, A., & Cannon, T. D. (2005). The prodromal 
questionnaire (PQ): preliminary validation of a self-report screening measure for prodromal and 
psychotic syndromes. Schizophrenia Research, 79(1), 117-125. 
Loewy, R. L., Therman, S., Manninen, M., Huttunen, M. O., & Cannon, T. D. (2012). Prodromal 
psychosis screening in adolescent psychiatry clinics. Early intervention in psychiatry, 6(1), 69-75.  
Luzón, O., Harrop, C., & Nolan, F. (2009). Cognitive Processes during Acute Psychosis: The Role 
of Heightened Responsibility and Catastrophic Misinterpretations. Behavioural and Cognitive 
Psychotherapy, 37(4), 357-371. 
Maric, N., Krabbendam, L., Vollebergh, W., de Graaf, R., & van Os, J. (2003). Sex differences in 
symptoms of psychosis in a non-selected, general population sample. Schizophrenia Research, 63(1), 
89-95. 
Marshall, M., Lewis, S., Lockwood, A., Drake, R., Jones, P., & Croudace, T. (2005). Association 
between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic 
review. Archives of General Psychiatry, 62(9), 975-983. 
Marshall, M., & Rathbone, J. (2011). Early intervention for psychosis. Schizophrenia Bulletin, 37(6), 
1111-1114.  
Mason, O., Startup, M., Halpin, S., Schall, U., Conrad, A., & Carr, V. (2004). Risk factors for 
transition to first episode psychosis among individuals with ‘at-risk mental states’. Schizophrenia 
Research, 71(2), 227-237.  
Maurer, K., Hörrmann, F., Trendler, G., Schmidt, M., & Häfner, H. (2006). Früherkennung des 
Psychoserisikos mit dem Early Recognition Inventory (ERIraos) Beschreibung des Verfahrens und 
erste Ergebnisse zur Reliabilität und Validität der Checkliste. Nervenheilkunde, 25(1), 11-16. 
Mayer, J. D. (2002). Mayer-Salovey-Caruso emotional intelligence test. Toronto: Multi-Health 
Systems. 
125 
 
Mayer, J. D., Caruso, D. R., & Salovey, P. (1999). Emotional intelligence meets traditional standards 
for an intelligence. Intelligence, 27(4), 267-298.  
McGlashan, T. H. (1984). The Chestnut Lodge follow-up study: I. Follow-up methodology and study 
sample. Archives of General Psychiatry, 41(6), 573-585. 
McGlashan, T.H., Miller, T. J., Woods, S. W., Hofman, R. E., & Davidson, R. (2001). A scale for the 
assessment of prodromal symptoms and states. In T. J. Miller, S. A. Mednick, T. H. McGlashan, J. 
Libeger & J. O. Johannessen (Eds.), Early Intervention in Psychotic Disorders (pp. 135-149). 
Dordrecht: Kluwer Academic Publisher. 
McGlashan, T., Walsh, B., & Woods, S. (2010). The psychosis-risk syndrome: handbook for 
diagnosis and follow-up. Oxford, UK: Oxford University Press. 
McGlashan, T. H., Zipursky, R. B., Perkins, D., Addington, J., Miller, T., Woods, S. W., ... & 
Addington, D. (2006). Randomized, double-blind trial of olanzapine versus placebo in patients 
prodromally symptomatic for psychosis. American Journal of Psychiatry, 163(5), 790-799. 
McGorry, P. D., Hickie, I. B., Yung, A. R., Pantelis, C., & Jackson, H. J. (2006). Clinical staging of 
psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective 
interventions. Australian and New Zealand Journal of Psychiatry, 40(8), 616-622. 
McGorry, P. D., Killackey, E., & Yung, A. (2008). Early intervention in psychosis: concepts, 
evidence and future directions. World Psychiatry, 7(3), 148-156. 
McGorry, P. D., Nelson, B., Amminger, G. P., Bechdolf, A., Francey, S. M., Berger, G., ... & 
Schultze-Lutter, F. (2009). Intervention in individuals at ultra-high risk for psychosis: a review and 
future directions. The Journal of Clinical Psychiatry, 70(9), 1206-1212.  
McGorry, P. D., Nelson, B., Phillips, L. J., Yuen, H. P., Francey, S. M., Thampi, A., ... & Dip, G. 
(2013). Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: 
twelve-month outcome. The Journal of Clinical Psychiatry, 74(4), 349-356. 
McGorry, P. D., Purcell, R., Hickie, I. B., Yung, A. R., Pantelis, C., & Jackson, H. J. (2007). Clinical 
staging: a heuristic model for psychiatry and youth mental health. Medical Journal of 
Australia, 187(Suppl.7), S40-S42. 
McGorry, P. D., Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S., Cosgrave, E. M., ... & Adlard, 
S. (2002). Randomized controlled trial of interventions designed to reduce the risk of progression to 
first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General 
Psychiatry, 59(10), 921-928. 
126 
 
Meehl, P. E. (1962). Schizotaxia, schizotypy, schizophrenia. American Psychologist, 17(12), 827-
838. 
Meneghelli, A., Meliante, M., Amato, L., Pozza, A., & Dettore, D. (2016). "I fear going crazy"... 
could Cognitive Concerns be early warning signs of Psychosis? Evidence from the Anxiety 
Sensitivity in the first stages of Psychosis study (ASP study). Early intervention in psychiatry, 
10(Suppl. 1), 229-229.  
Meyer, T. J., Miller, M. L., Metzger, R. L., & Borkovec, T. D. (1990). Development and validation 
of the penn state worry questionnaire. Behaviour Research and Therapy, 28(6), 487-495. 
Miklowitz, D. J., O’Brien, M. P., Schlosser, D. A., Addington, J., Candan, K. A., Marshall, C., ... & 
Friedman-Yakoobian, M. (2014). Family-focused treatment for adolescents and young adults at high 
risk for psychosis: results of a randomized trial. Journal of the American Academy of Child & 
Adolescent Psychiatry, 53(8), 848-858. 
Miller, T. J., Cicchetti, D., Markovich, P. J., McGlashan, T. H., & Woods, S. W. (2004). The SIPS 
screen: a brief self-report screen to detect the schizophrenia prodrome. Schizophrenia Research, 70 
(1), 78-78.  
Miller, T. J., McGlashan, T. H., Rosen, J. L., Somjee, L., Markovich, P. J., Stein, K., & Woods, S. 
W. (2002). Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured 
Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive 
validity. American Journal of Psychiatry, 159(5), 863-865. 
Mittal, V. A., Dean, D. J., Mittal, J., & Saks, E. R. (2015). Ethical, Legal, and Clinical Considerations 
when Disclosing a High‐Risk Syndrome for Psychosis. Bioethics, 29(8), 543-556. 
Mizrahi, R., Addington, J., Rusjan, P. M., Suridjan, I., Ng, A., Boileau, I., ... & Wilson, A. A. (2012). 
Increased stress-induced dopamine release in psychosis. Biological Psychiatry, 71(6), 561-567.  
Mondelli, V., Dazzan, P., Hepgul, N., Di Forti, M., Aas, M., D'Albenzio, A., ... & Morgan, C. (2010). 
Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: 
the role of stress and of antipsychotic treatment. Schizophrenia Research, 116(2), 234-242. 
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. 
(2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic 
review. The Lancet, 370(9584), 319-328. 
127 
 
Morani, S., Pricci, D., & Sanavio, E. (1999). Penn State Worry Questionnaire e Worry Domains 
Questionnaire. Presentazione delle versioni italiane ed analisi della fedeltà. Psicoterapia Cognitiva e 
Comportamentale, 5(3), 13-34. 
Morgan, V. A., Castle, D. J., & Jablensky, A. V. (2008). Do women express and experience psychosis 
differently from men? Epidemiological evidence from the Australian National Study of Low 
Prevalence (Psychotic) Disorders. Australian and New Zealand Journal of Psychiatry, 42(1), 74-82. 
Moritz, S., & Woodward, T. S. (2005). Jumping to conclusions in delusional and non‐delusional 
schizophrenic patients. British Journal of Clinical Psychology, 44(2), 193-207. 
Moritz, S., & Woodward, T. S. (2007). Metacognitive training in schizophrenia: from basic research 
to knowledge translation and intervention. Current Opinion in Psychiatry, 20(6), 619-625. 
Morosini, P. L., Magliano, L., Brambilla, L., Ugolini, S., & Pioli, R. (2000). Development, reliability 
and acceptability of a new version of the DSM‐IV Social and Occupational Functioning Assessment 
Scale (SOFAS) to assess routine social funtioning. Acta Psychiatrica Scandinavica, 101(4), 323-329. 
Morrison, A. P. (2001). The interpretation of intrusions in psychosis: an integrative cognitive 
approach to hallucinations and delusions. Behavioural and Cognitive Psychotherapy, 29(3), 257-276.  
Morrison, A. P., Bentall, R. P., French, P., Walford, L., Kilcommons, A., Knight, A., ... & Lewis, S. 
W. (2002). Randomised controlled trial of early detection and cognitive therapy for preventing 
transition to psychosis in high-risk individuals. The British Journal of Psychiatry, 181(43), s78-s84. 
Morrison, A. P., French, P., Stewart, S. L., Birchwood, M., Fowler, D., Gumley, A. I., ... & Patterson, 
P. (2012). Early detection and intervention evaluation for people at risk of psychosis: multisite 
randomised controlled trial. British Medical Journal, 344, 2233. 
Morrison, A. P., French, P., & Wells, A. (2007). Metacognitive beliefs across the continuum of 
psychosis: Comparisons between patients with psychotic disorders, patients at ultra-high risk and 
non-patients. Behaviour Research and Therapy, 45(9), 2241-2246. 
Mossaheb, N., Becker, J., Schaefer, M. R., Klier, C. M., Schloegelhofer, M., Papageorgiou, K., & 
Amminger, G. P. (2012). The Community Assessment of Psychic Experience (CAPE) questionnaire 
as a screening-instrument in the detection of individuals at ultra-high risk for 
psychosis. Schizophrenia Research, 141(2), 210-214. 
Nelson, M. T., Seal, M. L., Pantelis, C., & Phillips, L. J. (2013). Evidence of a dimensional 
relationship between schizotypy and schizophrenia: a systematic review. Neuroscience & 
Biobehavioral Reviews, 37(3), 317-327. 
128 
 
Nelson, B., Thompson, A., & Yung, A. R. (2012). Basic self-disturbance predicts psychosis onset in 
the ultra high risk for psychosis “prodromal” population. Schizophrenia Bulletin, 38(6), 1277-1287. 
Nelson, B., Yuen, H. P., Wood, S. J., Lin, A., Spiliotacopoulos, D., Bruxner, A., ... & Francey, S. M. 
(2013). Long-term follow-up of a group at ultra high risk (“prodromal”) for psychosis: the PACE 400 
study. JAMA Psychiatry, 70(8), 793-802.  
Nelson, B., & Yung, A. R. (2009). Psychotic-like experiences as overdetermined phenomena: when 
do they increase risk for psychotic disorder? Schizophrenia Research, 108(1), 303-304. 
Newell, D. J. (1992). Intention-to-treat analysis: implications for quantitative and qualitative research. 
International Journal of Epidemiology, 21, 837-841. 
Nieman, D. H., Rike, W. H., Becker, H. E., Dingemans, P. M., van Amelsvoort, T. A., de Haan, L., 
... & Linszen, D. H. (2009). Prescription of antipsychotic medication to patients at ultra high risk of 
developing psychosis. International Clinical Psychopharmacology, 24(4), 223-228. 
Nordentoft, M., Thorup, A., Petersen, L., Øhlenschlæger, J., Melau, M., Christensen, T. Ø., ... & 
Jeppesen, P. (2006). Transition rates from schizotypal disorder to psychotic disorder for first-contact 
patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard 
treatment. Schizophrenia Research, 83(1), 29-40. 
Norman, R. M., & Malla, A. K. (2001). Duration of untreated psychosis: a critical examination of the 
concept and its importance. Psychological Medicine, 31(3), 381-400. 
O’ Brien, M. P., Miklowitz, D. J., Candan, K. A., Marshall, C., Domingues, I., Walsh, B. C., ... & 
Cannon, T. D. (2014). A randomized trial of family focused therapy with populations at clinical high 
risk for psychosis: Effects on interactional behavior. Journal of Consulting and Clinical 
Psychology, 82(1), 90. 
O' Brien, M. P., Zinberg, J. L., Bearden, C. E., Daley, M., Niendam, T. A., Kopelowicz, A., & 
Cannon, T. D. (2007). Psychoeducational multi‐family group treatment with adolescents at high risk 
for developing psychosis. Early Intervention in Psychiatry, 1(4), 325-332. 
O' Donoghue, B., Lyne, J. P., Renwick, L., Lane, A., Madigan, K., Staines, A., ... & Clarke, M. 
(2016). Neighbourhood characteristics and the incidence of first-episode psychosis and duration of 
untreated psychosis. Psychological Medicine, 46(7), 1367-1378. 
Ohayon, M. M. (2000). Prevalence of hallucinations and their pathological associations in the general 
population. Psychiatry Research, 97(2), 153-164. 
129 
 
Olesen, J., Gustavsson, A., Svensson, M., Wittchen, H. U., & Jönsson, B. (2012). The economic cost 
of brain disorders in Europe. European Journal of Neurology, 19(1), 155-162. 
Overall, J. E., & Gorham, D. R. (1962). The brief psychiatric rating scale. Psychological Reports, 
10(3), 799–812. 
Palaniyappan, L., Mallikarjun, P., Joseph, V., White, T. P., & Liddle, P. F. (2011). Reality distortion 
is related to the structure of the salience network in schizophrenia. Psychological Medicine, 41(8), 
1701-1708. 
Palaniyappan, L., Simmonite, M., White, T. P., Liddle, E. B., & Liddle, P. F. (2013). Neural primacy 
of the salience processing system in schizophrenia. Neuron, 79(4), 814-828. 
Palmier‐Claus, J. E., Dunn, G., Taylor, H., Morrison, A. P., & Lewis, S. W. (2013). Cognitive‐self-
consciousness and metacognitive beliefs: Stress sensitization in individuals at ultra‐high risk of 
developing psychosis. British Journal of Clinical Psychology, 52(1), 26-41. 
Pantelis, C., Velakoulis, D., McGorry, P. D., Wood, S. J., Suckling, J., Phillips, L. J., ... & Desmond, 
P. (2003). Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and 
longitudinal MRI comparison. The Lancet, 361(9354), 281-288. 
Pantelis, C., Yücel, M., Wood, S. J., Velakoulis, D., Sun, D., Berger, G., ... & McGorry, P. D. (2005). 
Structural brain imaging evidence for multiple pathological processes at different stages of brain 
development in schizophrenia. Schizophrenia Bulletin, 31(3), 672-696. 
Parnas, J., Handest, P., Jansson, L., & Sæbye, D. (2005). Anomalous subjective experience among 
first-admitted schizophrenia spectrum patients: empirical investigation. Psychopathology, 38(5), 
259-267. 
Penttilä, M., Jääskeläinen, E., Hirvonen, N., Isohanni, M., & Miettunen, J. (2014). Duration of 
untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-
analysis. The British Journal of Psychiatry, 205(2), 88-94. 
Perivoliotis, D., Morrison, A. P., Grant, P. M., French, P., & Beck, A. T. (2009). Negative 
performance beliefs and negative symptoms in individuals at ultra-high risk of psychosis: a 
preliminary study. Psychopathology, 42(6), 375-379. 
Perkins, D. O., Gu, H., Boteva, K., & Lieberman, J. A. (2005). Relationship between duration of 
untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-
analysis. American Journal of Psychiatry, 162(10), 1785-1804. 
130 
 
Phillips, J. (2013). Conceptual issues in the classification of psychosis. Current Opinion in 
Psychiatry, 26(2), 214-218. 
Phillips, L. J., Curry, C., Yung, A. R., Pan Yuen, H., Adlard, S., & Mcgorry, P. D. (2002). Cannabis 
use is not associated with the development of psychosis in an ultra high-risk group. Australian and 
New Zealand Journal of Psychiatry, 36(6), 800-806. 
Phillips, L. J., Nelson, B., Yuen, H. P., Francey, S. M., Simmons, M., Stanford, C., ... & Amminger, 
P. (2009). Randomized controlled trial of interventions for young people at ultra-high risk of 
psychosis: study design and baseline characteristics. Australian and New Zealand Journal of 
Psychiatry, 43(9), 818-829. 
Phillips, L. J., Velakoulis, D., Pantelis, C., Wood, S., Yuen, H. P., Yung, A. R., ... & McGorry, P. D. 
(2002). Non-reduction in hippocampal volume is associated with higher risk of 
psychosis. Schizophrenia Research, 58(2), 145-158. 
Preti, A., & Cella, M. (2010). Randomized-controlled trials in people at ultra high risk of psychosis: 
a review of treatment effectiveness. Schizophrenia Research, 123(1), 30-36. 
Raine, A., & Benishay, D. (1995). The SPQ-B: A brief screening instrument for schizotypal 
personality disorder. Journal of Personality Disorders, 9(4), 346-355. 
Raine, A., Lencz, T., & Mednick, S. A. (1995). Schizotypal personality. Cambridge: Cambridge 
University Press. 
Regier, D. A., Kuhl, E. A., Kupfer, D. J., & McNulty, J. P. (2010). Patient involvement in the 
development of DSM-V. Psychiatry, 73(4), 308-310.  
Riecher-Rössler, A., Aston, J., Ventura, J., Merlo, M., Borgwardt, S., Gschwandtner, U., & Stieglitz, 
R. D. (2008). [The Basel Screening Instrument for Psychosis (BSIP): development, structure, 
reliability and validity]. Fortschritte der Neurologie-Psychiatrie, 76(4), 207-216. 
Riecher‐Rössler, A., Gschwandtner, U., Aston, J., Borgwardt, S., Drewe, M., Fuhr, P., ... & Stieglitz, 
R. D. (2007). The Basel early‐detection‐of‐psychosis (FEPSY)‐study–design and preliminary 
results. Acta Psychiatrica Scandinavica, 115(2), 114-125. 
Riecher-Rössler, A., Pflueger, M. O., Aston, J., Borgwardt, S. J., Brewer, W. J., Gschwandtner, U., 
& Stieglitz, R. D. (2009). Efficacy of using cognitive status in predicting psychosis: a 7-year follow-
up. Biological Psychiatry, 66(11), 1023-1030. 
Rietdijk, J., Dragt, S., Klaassen, R., Ising, H., Nieman, D., Wunderink, L., ... & van der Gaag, M. 
(2010). A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking 
131 
 
population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention 
Evaluation (EDIE-NL) trial. Trials, 11(1), 1-9. 
Rietdijk, J., Fokkema, M., Stahl, D., Valmaggia, L., Ising, H. K., Dragt, S., ... & Delespaul, P. (2014). 
The distribution of self-reported psychotic-like experiences in non-psychotic help-seeking mental 
health patients in the general population; a factor mixture analysis. Social Psychiatry and Psychiatric 
Epidemiology, 49(3), 349-358.  
Rietdijk, J., Hogerzeil, S. J., van Hemert, A. M., Cuijpers, P., Linszen, D. H., & van der Gaag, M. 
(2011). Pathways to psychosis: help-seeking behavior in the prodromal phase. Schizophrenia 
Research, 132(2), 213-219.  
Rubio, J. M., Sanjuán, J., Flórez-Salamanca, L., & Cuesta, M. J. (2012). Examining the course of 
hallucinatory experiences in children and adolescents: a systematic review. Schizophrenia 
Research, 138(2), 248-254. 
Ruhrmann, S., Bechdolf, A., KÜHN, K. U., Wagner, M., Schultze-Lutter, F., Janssen, B., ... & Maier, 
W. (2007). Acute effects of treatment for prodromal symptoms for people putatively in a late initial 
prodromal state of psychosis. The British Journal of Psychiatry, 191(51), s88-s95. 
Ruhrmann, S., Schultze-Lutter, F., & Klosterkötter, J. (2003). Early detection and intervention in the 
initial prodromal phase of schizophrenia. Pharmacopsychiatry, 36(3), 162-167. 
Ruhrmann, S., Schultze-Lutter, F., Salokangas, R. K., Heinimaa, M., Linszen, D., Dingemans, P., ... 
& Morrison, A. (2010). Prediction of psychosis in adolescents and young adults at high risk: results 
from the prospective European prediction of psychosis study. Archives of General Psychiatry, 67(3), 
241-251. 
Russo, D. A., Stochl, J., Painter, M., Dobler, V., Jackson, E., Jones, P. B., & Perez, J. (2014). Trauma 
history characteristics associated with mental states at clinical high risk for psychosis. Psychiatry 
Research, 220(1), 237-244. 
Sadler, J. Z. (2013). Making the DSM-5. New York, NY: Springer.  
Şahin, S., Yüksel, Ç., Güler, J., Karadayı, G., Akturan, E., Göde, E., ... & Üçok, A. (2013). The 
history of childhood trauma among individuals with ultra high risk for psychosis is as common as 
among patients with first‐episode schizophrenia. Early Intervention in Psychiatry, 7(4), 414-420. 
Saleem, M. M., Stowkowy, J., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., McGlashan, T. H., 
... & Woods, S. W. (2014). Perceived discrimination in those at clinical high risk for psychosis. Early 
Intervention in Psychiatry, 8(1), 77-81. 
132 
 
Salokangas, R. K. R., Dingemans, P., Heinimaa, M., Svirskis, T., Luutonen, S., Hietala, J., ... & 
Birchwood, M. (2013). Prediction of psychosis in clinical high-risk patients by the Schizotypal 
Personality Questionnaire. Results of the EPOS project. European Psychiatry, 28(8), 469-475. 
Salokangas, R. K., Ruhrmann, S., von Reventlow, H. G., Heinimaa, M., Svirskis, T., From, T., ... & 
Birchwood, M. (2012). Axis I diagnoses and transition to psychosis in clinical high-risk patients 
EPOS project: prospective follow-up of 245 clinical high-risk outpatients in four 
countries. Schizophrenia Research, 138(2), 192-197.  
Schlosser, D. A., Zinberg, J. L., Loewy, R. L., Casey-Cannon, S., O' Brien, M. P., Bearden, C. E., ... 
& Cannon, T. D. (2010). Predicting the longitudinal effects of the family environment on prodromal 
symptoms and functioning in patients at-risk for psychosis. Schizophrenia Research, 118(1), 69-75. 
Schmidt, A., Smieskova, R., Aston, J., Simon, A., Allen, P., Fusar-Poli, P., ... & Borgwardt, S. (2013). 
Brain connectivity abnormalities predating the onset of psychosis: correlation with the effect of 
medication. JAMA Psychiatry, 70(9), 903-912. 
Schmidt, S. J., Schultze-Lutter, F., Schimmelmann, B. G., Maric, N. P., Salokangas, R. K. R., 
Riecher-Rössler, A., ... & Morrison, A. (2015). EPA guidance on the early intervention in clinical 
high risk states of psychoses. European Psychiatry, 30(3), 388-404.  
Schultze-Lutter, F. (2009). Subjective symptoms of schizophrenia in research and the clinic: the basic 
symptom concept. Schizophrenia Bulletin, 35(1), 5-8. 
Schultze-Lutter, F., & Klosterkötter, J. (2002). Bonn Scale for the Assessment of Basic Symptoms-
Prediction list (BSABS-P). Cologne: University of Cologne. 
Schultze-Lutter, F., Ruhrmann, S., Berning, J., Maier, W., & Klosterkötter, J. (2010). Basic symptoms 
and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophrenia 
Bulletin, 36(1), 182-191.  
Schwartz, R. C. (2007). Concurrent validity of the Global Assessment of Functioning Scale for clients 
with schizophrenia. Psychological Reports, 100(2), 571-574.  
Seeber, K., & Cadenhead, K. S. (2005). How does studying schizotypal personality disorder inform 
us about the prodrome of schizophrenia? Current Psychiatry Reports, 7(1), 41-50. 
Seidman, L. J., & Nordentoft, M. (2015). New targets for prevention of schizophrenia: is it time for 
interventions in the premorbid phase? Schizophrenia Bulletin, 41(4), 795-800. 
133 
 
Seiferth, N. Y., Pauly, K., Habel, U., Kellermann, T., Shah, N. J., Ruhrmann, S., ... & Kircher, T. 
(2008). Increased neural response related to neutral faces in individuals at risk for 
psychosis. Neuroimage, 40(1), 289-297. 
Sensky, T., Turkington, D., Kingdon, D., Scott, J. L., Scott, J., Siddle, R., ... & Barnes, T. R. (2000). 
A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in 
schizophrenia resistant to medication. Archives of General Psychiatry, 57(2), 165-172.  
Shah, J., Eack, S. M., Montrose, D. M., Tandon, N., Miewald, J. M., Prasad, K. M., & Keshavan, M. 
S. (2012). Multivariate prediction of emerging psychosis in adolescents at high risk for 
schizophrenia. Schizophrenia Research, 141(2), 189-196. 
Sica, C., Ghisi, M., & Lange, M. A. (2007). Leading-edge psychological tests and testing research. 
New York, NY: Nova Publisher.  
Simon, A. E., & Umbricht, D. (2010). High remission rates from an initial ultra-high risk state for 
psychosis. Schizophrenia Research, 116(2), 168-172. 
Smieskova, R., Fusar-Poli, P., Allen, P., Bendfeldt, K., Stieglitz, R. D., Drewe, J., ... & Borgwardt, 
S. J. (2010). Neuroimaging predictors of transition to psychosis—a systematic review and meta-
analysis. Neuroscience & Biobehavioral Reviews, 34(8), 1207-1222.  
Smith, S. (2010). Gender differences in antipsychotic prescribing. International Review of 
Psychiatry, 22(5), 472-484.  
Spauwen, J., Krabbendam, L., Lieb, R., Wittchen, H. U., & van Os, J. (2003). Sex differences in 
psychosis: normal or pathological? Schizophrenia Research, 62(1), 45-49.  
Stain, H. J., Bucci, S., Baker, A. L., Carr, V., Emsley, R., Halpin, S., ... & Startup, M. (2016). A 
randomised controlled trial of cognitive behaviour therapy versus non-directive reflective listening 
for young people at ultra high risk of developing psychosis: The detection and evaluation of 
psychological therapy (DEPTh) trial. Schizophrenia Research, 176(2), 212-219. 
Stanford, A. D., Messinger, J., Malaspina, D., & Corcoran, C. M. (2011). Theory of Mind in patients 
at clinical high risk for psychosis. Schizophrenia Research, 131(1), 11-17. 
Startup, H., Freeman, D., & Garety, P. A. (2007). Persecutory delusions and catastrophic worry in 
psychosis. Developing the understanding of delusion distress and persistence. Behaviour Research 
and Therapy, 45(3), 523-537. 
Startup, M., Jackson, M. C., & Bendix, S. (2002). The concurrent validity of the Global Assessment 
of Functioning (GAF). British Journal of Clinical Psychology, 41(4), 417-422. 
134 
 
Steen, N. E., Tesli, M., Kähler, A. K., Methlie, P., Hope, S., Barrett, E. A., ... & Agartz, I. (2010). 
SRD5A2 is associated with increased cortisol metabolism in schizophrenia spectrum 
disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34(8), 1500-1506.  
Tarrier, N., Kinney, C., McCarthy, E., Humphreys, L., Wittkowski, A., & Morris, J. (2000). Two–
year follow–up of cognitive–behavioral therapy and supportive counseling in the treatment of 
persistent symptoms in chronic schizophrenia. Journal of Consulting and Clinical Psychology, 68(5), 
917-922. 
Tarrier, N., Yusupoff, L., Kinney, C., McCarthy, E., Gledhill, A., Haddock, G., & Morris, J. (1998). 
Randomised controlled trial of intensive cognitive behaviour therapy for patients with chronic 
schizophrenia. British Medical Journal, 317(7154), 303-307.  
Thomas, S. P., & Nandhra, H. S. (2009). Early intervention in psychosis: a retrospective analysis of 
clinical and social factors influencing duration of untreated psychosis. Primary care companion to 
the Journal of clinical psychiatry, 11(5), 212-214.  
Thompson, K. N., Berger, G., Phillips, L. J., Komesaroff, P., Purcell, R., & McGorry, P. D. (2007). 
HPA axis functioning associated with transition to psychosis: combined DEX/CRH test. Journal of 
Psychiatric Research, 41(5), 446-450.  
Thompson, A., Papas, A., Bartholomeusz, C., Allott, K., Amminger, G. P., Nelson, B., ... & Yung, 
A. (2012). Social cognition in clinical “at risk” for psychosis and first episode psychosis 
populations. Schizophrenia Research, 141(2), 204-209. 
Thompson, A., Papas, A., Bartholomeusz, C., Nelson, B., & Yung, A. (2013). Externalized 
attributional bias in the Ultra High Risk (UHR) for psychosis population. Psychiatry 
Research, 206(2), 200-205.  
Thompson, K. N., Phillips, L. J., Komesaroff, P., Yuen, H. P., Wood, S. J., Pantelis, C., ... & McGorry, 
P. D. (2007). Stress and HPA-axis functioning in young people at ultra high risk for 
psychosis. Journal of Psychiatric Research, 41(7), 561-569. 
Thorup, A., Petersen, L., Jeppesen, P., Ohlenschlæger, J., Christensen, T., Krarup, G., ... & 
Nordentoft, M. (2007). Gender differences in young adults with first-episode schizophrenia spectrum 
disorders at baseline in the Danish OPUS study. The Journal of Nervous and Mental Disease, 195(5), 
396-405. 
135 
 
Tikka, M., Luutonen, S., Ilonen, T., Tuominen, L., Kotimäki, M., Hankala, J., & Salokangas, R. K. 
(2013). Childhood trauma and premorbid adjustment among individuals at clinical high risk for 
psychosis and normal control subjects. Early Intervention in Psychiatry, 7(1), 51-57. 
Tsujino, N., Nemoto, T., Morita, K., Katagiri, N., Ito, S., & Mizuno, M. (2013). Long-term efficacy 
and tolerability of perospirone for young help-seeking people at clinical high risk: a preliminary open 
trial. Clinical Psychopharmacology and Neuroscience, 11(3), 132-136. 
Usall, J., Ochoa, S., Araya, S., & Marquez, M. (2003). Gender differences and outcome in 
schizophrenia: a 2-year follow-up study in a large community sample. European Psychiatry, 18(6), 
282-284.  
Van Dael, F., Versmissen, D., Janssen, I., Myin-Germeys, I., Van Os, J., & Krabbendam, L. (2006). 
Data gathering: biased in psychosis? Schizophrenia Bulletin, 32(2), 341-351. 
van der Gaag, M. (2006). A neuropsychiatric model of biological and psychological processes in the 
remission of delusions and auditory hallucinations. Schizophrenia Bulletin, 32(Suppl 1), S113-S122. 
van der Gaag, M., Nieman, D. H., Rietdijk, J., Dragt, S., Ising, H. K., Klaassen, R. M., ... & Linszen, 
D. H. (2012). Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a 
randomized controlled clinical trial. Schizophrenia Bulletin, 38(6) 1180-1188. 
Van der Gaag, M., Nieman, D., & Van den Berg, D. (2013). CBT for Those at Risk of a First Episode 
Psychosis: Evidence-based Psychotherapy for People with an “at Risk Mental State”. New York, 
NY: Routledge. 
van der Gaag, M., Smit, F., Bechdolf, A., French, P., Linszen, D. H., Yung, A. R., ... & Cuijpers, P. 
(2013). Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention 
trials of 12month and longer-term follow-ups. Schizophrenia Research, 149(1), 56-62. 
van Os, J., Hanssen, M., Bijl, R. V., & Vollebergh, W. (2001). Prevalence of psychotic disorder and 
community level of psychotic symptoms: an urban-rural comparison. Archives of General 
Psychiatry, 58(7), 663-668.  
van Os, J., & Linscott, R. J. (2012). Introduction: the extended psychosis phenotype—relationship 
with schizophrenia and with ultrahigh risk status for psychosis. Schizophrenia Bulletin, 38(2), 227-
230. 
Van Os, J., Linscott, R. J., Myin-Germeys, I., Delespaul, P., & Krabbendam, L. (2009). A systematic 
review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness–
persistence–impairment model of psychotic disorder. Psychological Medicine, 39(2), 179-195. 
136 
 
van Rijn, S., Schothorst, P., van't Wout, M., Sprong, M., Ziermans, T., van Engeland, H., ... & Swaab, 
H. (2011). Affective dysfunctions in adolescents at risk for psychosis: emotion awareness and social 
functioning. Psychiatry Research, 187(1), 100-105.  
Velakoulis, D., Wood, S. J., Smith, D. J., Soulsby, B., Brewer, W., Leeton, L., ... & Pantelis, C. 
(2002). Increased duration of illness is associated with reduced volume in right medial 
temporal/anterior cingulate grey matter in patients with chronic schizophrenia. Schizophrenia 
Research, 57(1), 43-49. 
Velakoulis, D., Wood, S. J., Wong, M. T., McGorry, P. D., Yung, A., Phillips, L., ... & Pantelis, C. 
(2006). Hippocampal and amygdala volumes according to psychosis stage and diagnosis: A magnetic 
resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra–high-risk 
individuals. Archives of General Psychiatry, 63(2), 139-149. 
Velthorst, E., Nelson, B., O’Connor, K., Mossaheb, N., de Haan, L., Bruxner, A., ... & Thompson, A. 
(2013). History of trauma and the association with baseline symptoms in an ultra-high risk for 
psychosis cohort. Psychiatry Research, 210(1), 75-81. 
Velthorst, E., Nieman, D. H., Becker, H. E., van de Fliert, R., Dingemans, P. M., Klaassen, R., ... & 
Linszen, D. H. (2009). Baseline differences in clinical symptomatology between ultra high risk 
subjects with and without a transition to psychosis. Schizophrenia Research, 109(1), 60-65.  
Velthorst, E., Nieman, D. H., Klaassen, R. M. C., Becker, H. E., Dingemans, P. M., Linszen, D. H., 
& De Haan, L. (2011). Three‐year course of clinical symptomatology in young people at ultra high 
risk for transition to psychosis. Acta Psychiatrica Scandinavica, 123(1), 36-42. 
Versmissen, D., Janssen, I., Johns, L., McGUIRE, P. H. I. L. I. P., Drukker, M., Campo, J. A., ... & 
Krabbendam, L. (2007). Verbal self-monitoring in psychosis: a non-replication. Psychological 
Medicine, 37(04), 569-576.  
Versmissen, D., Myin-Germeys, I., Janssen, I., Franck, N., Georgieff, N., Campo, J., ... & 
Krabbendam, L. (2007). Impairment of self-monitoring: part of the endophenotypic risk for 
psychosis. The British Journal of Psychiatry, 191(51), s58-s62. 
Walder, D. J., Holtzman, C. W., Addington, J., Cadenhead, K., Tsuang, M., Cornblatt, B., ... & 
Seidman, L. J. (2013). Sexual dimorphisms and prediction of conversion in the NAPLS psychosis 
prodrome. Schizophrenia Research, 144(1), 43-50.  
137 
 
Walker, E. F., Brennan, P. A., Esterberg, M., Brasfield, J., Pearce, B., & Compton, M. T. (2010). 
Longitudinal changes in cortisol secretion and conversion to psychosis in at-risk youth. Journal of 
Abnormal Psychology, 119(2), 401.  
Weinberger, D. R., & Marenco, S. (2003). Schizophrenia as a neurodevelomental disorder. In S. R. 
Hirsch & D. R. Weinberger (Eds.), Schizophrenia. Oxford, UK: Blackwell Science Ltd. 
Weinstein, D. D., Diforio, D., Schiffman, J., Walker, E., & Bonsall, R. (1999). Minor physical 
anomalies, dermatoglyphic asymmetries, and cortisol levels in adolescents with schizotypal 
personality disorder. American Journal of Psychiatry, 156(4), 617–623. 
Wells, A. (1995). Meta-cognition and worry: A cognitive model of generalized anxiety 
disorder. Behavioural and Cognitive Psychotherapy, 23(3), 301-320.  
Wells, A., & Cartwright-Hatton, S. (2004). A short form of the metacognitions questionnaire: 
properties of the MCQ-30. Behaviour Research and Therapy, 42(4), 385-396. 
Welsh, P., & Tiffin, P. A. (2014). The “at-risk mental state” for psychosis in adolescents: clinical 
presentation, transition and remission. Child Psychiatry & Human Development, 45(1), 90-98.  
Wigman, J. T. W., Lin, A., Vollebergh, W. A. M., van Os, J., Raaijmakers, Q. A. W., Nelson, B., ... 
& Yung, A. R. (2011). Subclinical psychosis and depression: co-occurring phenomena that do not 
predict each other over time. Schizophrenia Research, 130(1), 277-281. 
Wigman, J. T., van Nierop, M., Vollebergh, W. A., Lieb, R., Beesdo-Baum, K., Wittchen, H. U., & 
van Os, J. (2012). Evidence that psychotic symptoms are prevalent in disorders of anxiety and 
depression, impacting on illness onset, risk, and severity—implications for diagnosis and ultra–high 
risk research. Schizophrenia Bulletin, 38(2)247-257. 
Willhite, R. K., Niendam, T. A., Bearden, C. E., Zinberg, J., O'Brien, M. P., & Cannon, T. D. (2008). 
Gender differences in symptoms, functioning and social support in patients at ultra-high risk for 
developing a psychotic disorder. Schizophrenia Research, 104(1), 237-245. 
Wilson, J. M. G., & Jungner, G. (1968). Principles and practice of screening for disease. World Health 
Organization. Public Health Paper, 34(1) 1-163.  
Wiltink, S., Velthorst, E., Nelson, B., McGorry, P. M., & Yung, A. R. (2015). Declining transition 
rates to psychosis: the contribution of potential changes in referral pathways to an ultra–high‐risk 
service. Early Intervention in Psychiatry, 9(3), 200-206. 
138 
 
Winton-Brown, T. T., Broome, M. R., Allen, P., Valli, I., Howes, O., Garety, P. A., ... & McGuire, 
P. (2015). Misattributing speech and jumping to conclusions: a longitudinal study in people at high 
risk of psychosis. European Psychiatry, 30(1), 32-37. 
Wolff, S., Townshend, R., McGuire, R. J., & Weeks, D. J. (1991). “Schizoid” personality in childhood 
and adult life. II: Adult adjustment and the continuity with schizotypal personality disorder. The 
British Journal of Psychiatry, 159(5), 620-629. 
Wölwer, W., Brinkmeyer, J., Stroth, S., Streit, M., Bechdolf, A., Ruhrmann, S., ... & Gaebel, W. 
(2012). Neurophysiological correlates of impaired facial affect recognition in individuals at risk for 
schizophrenia. Schizophrenia Bulletin, 38(5), 1021-1029. 
Woods, S. W., Addington, J., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Heinssen, R., ... & 
McGlashan, T. H. (2009). Validity of the prodromal risk syndrome for first psychosis: findings from 
the North American Prodrome Longitudinal Study. Schizophrenia Bulletin, 35(5), 894-908.  
Wood, S. J., Berger, G., Velakoulis, D., Phillips, L. J., McGorry, P. D., Yung, A. R., ... & Pantelis, 
C. (2003). Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk 
individuals. Schizophrenia Bulletin, 29(4), 831.  
Woods, S. W., Tully, E. M., Walsh, B. C., Hawkins, K. A., Callahan, J. L., Cohen, S. J., ... & 
McGlashan, T. H. (2007). Aripiprazole in the treatment of the psychosis prodrome. The British 
Journal of Psychiatry, 191(51), 96-101.  
World Health Organization. (1994). The ICD-10 classification of mental and behavioural disorders: 
diagnostic criteria for research. Geneva, Switzerland: The World Health Organization. 
Yıldırım, O., Dogan, O., Semiz, M., & Kilicli, F. (2011). Serum cortisol and dehydroepiandrosterone‐
sulfate levels in schizophrenic patients and their first‐degree relatives. Psychiatry and Clinical 
Neurosciences, 65(6), 584-591.  
Yung, A. R., Cotter, J., Wood, S. J., McGorry, P., Thompson, A. D., Nelson, B., & Lin, A. (2015). 
Childhood maltreatment and transition to psychotic disorder independently predict long-term 
functioning in young people at ultra-high risk for psychosis. Psychological Medicine, 45(16), 3453-
3465. 
Yung, A. R. (2003). Commentary: The schizophrenia prodrome: a high-risk concept. Schizophrenia 
Bulletin, 29(4) 859-865. 
Yung, A. R., & McGorry, P. D. (1996). The initial prodrome in psychosis: descriptive and qualitative 
aspects. Australian and New Zealand Journal of Psychiatry, 30(5), 587-599. 
139 
 
Yung, A. R., McGorry, P. D., McFarlane, C. A., Jackson, H. J., Patton, G. C., & Rakkar, A. (2004). 
Monitoring and care of young people at incipient risk of psychosis. Focus, 2(1) 158-174. 
Yung, A. R., & Nelson, B. (2011). Young people at ultra high risk for psychosis: a research 
update. Early Intervention in Psychiatry, 5(1)52-57.  
Yung, A. R., Nelson, B., Baker, K., Buckby, J. A., Baksheev, G., & Cosgrave, E. M. (2009). 
Psychotic-like experiences in a community sample of adolescents: implications for the continuum 
model of psychosis and prediction of schizophrenia. Australian and New Zealand Journal of 
Psychiatry, 43(2), 118-128.  
Yung, A. R., Nelson, B., Thompson, A. D., & Wood, S. J. (2010). Should a “Risk Syndrome for 
Psychosis” be included in the DSMV? Schizophrenia Research, 120(1), 7-15. 
Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S. M., McFarlane, C. A., Hallgren, M., & McGorry, 
P. D. (2003). Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) 
group. Schizophrenia Research, 60(1), 21-32.  
Yung, A. R., Woods, S. W., Ruhrmann, S., Addington, J., Schultze-Lutter, F., Cornblatt, B. A., ... & 
Cannon, T. D. (2012). Whither the attenuated psychosis syndrome? Schizophrenia Bulletin, 38(6), 
1130-1134. 
Yung, A. R., Yuen, H. P., Berger, G., Francey, S., Hung, T. C., Nelson, B., ... & McGorry, P. (2007). 
Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of 
risk? Schizophrenia Bulletin, 33(3), 673-681.  
Ziermans, T. B., Schothorst, P. F., Sprong, M., & van Engeland, H. (2011). Transition and remission 
in adolescents at ultra-high risk for psychosis. Schizophrenia Research, 126(1), 58-64. 
Zimmermann, G., Favrod, J., Trieu, V. H., & Pomini, V. (2005). The effect of cognitive behavioral 
treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-
analysis. Schizophrenia Research, 77(1), 1-9. 
 
 
  
140 
 
 
 
 
 
 
 
 
APPENDIX  
COGNITIVE BEHAVIOURAL THERAPY MANUAL  
AND 
THERAPEUTIC MATERIALS AND WORKSHEETS 
  
141 
 
 
 
 
 
 
 
 
 
 
MANUALE DI TERAPIA COGNITIVO  
COMPORTAMENTALE  
E  
MATERIALI TERAPEUTICI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
142 
 
 
 
 
 
 
 
 
 
 
 
MODULO “INTRODUZIONE” 
SEDUTE 1-4 
INTRODUZIONE DEL PERCORSO 
ASSESSMENT 
DEFINIZIONE DEGLI OBIETTIVI TERAPEUTICI 
INGAGGIO 
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SCHEDA. INTRODUZIONE DEL PERCORSO 
 
 
 
 Discussione dei risultati alle interviste e scale di valutazione 
 
 
 Descrizione dei problemi/sintomi emersi dalle scale 
 
 
 Presentazione generale del percorso 
144 
 
SCHEDA: OBIETTIVI DEL PERCORSO PSICOTERAPEUTICO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lista dei problemi attuali 
 
 
 
1) ……………………………………………………………………
……………………………………………………………………
……………………………………………………………………
…………………………………………………………………… 
2) ……………………………………………………………………
……………………………………………………………………
……………………………………………………………………
……………………………….................................................... 
3) ……………………………………………………………………
……………………………………………………………………
……………………………………………………………………
…………………………………………………………………… 
4) ……………………………………………………………………
……………………………………………………………………
……………………………………………………………………
…………………………………………………………………… 
5) ……………………………………………………………………
……………………………………………………………………
……………………………………………………………………
…………………………………………………………………… 
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Obiettivi a medio-breve termine 
 
 
1) …………………………………………………………………………………………………
…………………………………………………………………………………………………
……………………………………………………………………………………………….... 
2) …………………………………………………………………………………………………
…………………………………………………………………………………………………
………………………………………………………………………………………………… 
3) …………………………………………………………………………………………………
…………………………………………………………………………………………………
………………………………………………………………………………………………… 
 
 
 
 
 
 
Obiettivi a lungo termine 
1) …………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………. 
2) …………………………………………………………………………………………………
…………………………………………………………………………………………………
…………………………………………………………………………………………………. 
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SCHEDA: PENSIERI, EMOZIONI, COMPORTAMENTI SONO COLLEGATI TRA LORO… 
IL MODELLO ABC 
                                                                                                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Secondo il modello ABC e emozioni e i comportamenti delle persone sono influenzati dalla 
loro percezione ed interpretazione degli eventi. Non è la situazione di per sé a determinare 
ciò che le persone sentono, ma è piuttosto il modo in cui queste interpretano tale situazione 
(Beck, 1964; Ellis, 1962). Immagina, per esempio, una situazione nella quale un gruppo 
di studenti sta leggendo in classe lo stesso libro di narrativa. Ciascuno di loro ha risposte 
emotive a questa situazione piuttosto differenti, a seconda di quello che sta passando loro 
nella sua mente mentre legge. 
 Maria pensa: “Quello che sto leggendo è davvero affascinante, questo racconto è 
avvincente”, e si sente eccitata. 
 Riccardo, invece, pensa: “Questa roba è inutile, una perdita di tempo, vorrei fare altro”, 
e si sente scontento.  
 Silvia ha i seguenti pensieri: “Questo libro non è quello che mi aspettavo. Che spreco di 
soldi”, e si sente delusa, frustrata. 
 Roberto pensa: “È troppo difficile…. e se all’interrogazione non ricordassi quello che ho 
letto?”, e si sente ansioso. 
Così, il modo in cui le persone si sentono è associato al modo in cui interpretano e quello 
che passa per la loro mente in una situazione. La situazione in sé stessa non determina 
direttamente il modo in cui si sentono: il modo in cui ci sentiamo dipende dalla percezione 
della situazione.  
 
 
MESSAGGI PUBBLICITARI CHE ARRIVANO ALLA NOSTRA MENTE…. 
I PENSIERI AUTOMATICI 
Mentre leggi questo testo potresti notare vari pensieri che ti passano per la mente. Ci sono 
diversi livelli di nel tuo pensiero. Parte della mente è focalizzata sulle informazioni 
contenute nel testo: ciò significa che stai cercando di capire e integrare alcune 
informazioni. Ad un altro livello, tuttavia, potresti avere alcuni pensieri veloci, di tipo 
valutativo. Questi ultimi sono chiamati pensieri automatici e non sono il risultato della 
riflessione o del ragionamento. Piuttosto, questi pensieri sembrano comparire 
improvvisamente e sono spesso piuttosto veloci e concisi. Potresti esserne appena 
consapevole, ma, più probabilmente, sei consapevole delle emozioni che ad essi seguono. 
Come risultato, con più probabilità accetti acriticamente come veri i tuoi pensieri 
automatici. Tuttavia, è possibile imparare ad identificare i propri pensieri automatici 
prestando attenzione ai cambiamenti dell’umore. Avendo identificato i tuoi pensieri 
automatici, puoi valutarne la validità, e probabilmente in qualche misura lo fai già. Se ti 
accorgi che la tua interpretazione è erronea e la correggi, probabilmente scoprirai che il 
tuo umore migliora. In termini cognitivi, quando i pensieri disfunzionali sono soggetti 
alla riflessione razionale, le emozioni generalmente cambiano. 
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SITUAZIONE 
Leggo un libro 
PENSIERI AUTOMATICI 
È troppo difficile…non lo capirò 
 
Emozioni 
Frustrazione 
Comportamenti 
Chiudo il libro 
Segnali corporei 
Pesantezza al petto 
RISPOSTE 
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SCHEDA DI AUTO-OSSERVAZIONE ABC: “PENSIERI, EMOZIONI E COMPORTAMENTI” 
Data 
Situazioni stimolo 
(Dove ero, quando è successo, cosa facevo) 
Pensieri automatici 
(Cosa mi passa per la mente?) 
Emozioni  
(Intensità  
0-100) 
Segnali 
corporei 
Comportamenti  
(Cosa faccio in risposta a pensieri  
e emozioni?) 
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SCHEDA: TERMOMETRO DELL’INTENSITÀ DELLE EMOZIONI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANSIA 
 
/_______/_______/_______/_______/_______/_______/_______/_______/_______/______/ 
    0         10             20            30             40           50           60           70           80         90         100 
 
Per niente ansioso            Un po’ ansioso                          Moderatamente ansioso                   Molto ansioso              Estremamente ansioso 
 
Le emozioni non sono un’esperienza tutto o nulla. Esiste una varietà di sfumature di 
intensità che noi sentiamo. Ciascuno di noi possiede un personale termometro delle 
emozioni che prova, ovvero la nostra percezione di quanto intense le avvertiamo nel 
nostro corpo, siano esse emozioni positive o negative. 
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SCHEDA: AVVIO DELLA SEDUTA 
EVENTI ATTIVANTI    
ESPERIENZE STRARDINARIE 
EVENTI DI VITA 
 
   CREDENZE DI BASE 
   CREDENZE INTERMEDIE 
   PENSIERI AUTOMATICI 
   CONSEQUENZE 
RISPOSTE 
COMPORTAMENT
ALI RISPOSTE 
FISIOLOGICHE 
RISPOSTE 
EMOZIONALI 
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SCHEDA: SINTESI DELLA SEDUTA E HOMEWORK PER LA SETTIMANA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DATA: ____________________ 
 
 
MESSAGGI CHIAVE DA PORTARE CON ME A CASA: 
_____________________________________________________________________________________________
_____________________________________________________________________________________________
_____________________________________________________________________________________________
_____________________________________________________________________________________________
_____________________________________________________________________________________________
_____________________________________________________________________________________________
_____________________________________________________________________________________________
_____________________________________________________________________________________________
_____________________________________________________________________________________________
_____________________________________________________________________________________________
_____________________________________________________________________________________________
_____________________________________________________________________________________________
_____________________________________________________________________________________________ 
 
 
IMPEGNI ED ESERCIZI DA SVOLGERE DURANTE LA SETTIMANA: 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
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SCHEDA: AVVIO DELLA SEDUTA 
 
Introdurre la seduta terapeutica riprendendo la seduta precedente: 
 
 
 
 Ricordi i punti/gli argomenti che abbiamo affrontato la scorsa seduta? 
 Hai delle domande? 
 Hai dei dubbi che sono emersi durante la settimana e vorresti chiarire? 
 Hai trovato qualcosa di spiacevole o poco chiaro tra i temi che abbiamo 
affrontato? 
 Quali problemi/eventi/aspetti della tua quotidianità vorresti che 
affrontassimo oggi? 
 Quali sono le cose per te essenziali/importanti che vorresti affrontare oggi? 
 Cosa ti piacerebbe cambiare per prima? 
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SCHEDA: CONCETTUALIZZAZIONE DEL PROBLEMA 
 
 
 
 
Riassumi con parole tue lo schema di concettualizzazione del 
problema: …………………………………………………………………………………………………
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
…………………………………………………………………………… 
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
……………………………………………………………… 
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
……………………………………………………………………………… 
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MODULO “ESPERIENZE 
STRAORDINARIE” 
SEDUTE 5-7 
PSICOEDUCAZIONE E  
NORMALIZZAZIONE  
DELLE ESPERIENZE PSICOTICHE 
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Le esperienze straordinarie e l’ipersensibilità della dopamina 
 
Periodi di stress prolungato possono favorire uno squilibrio di alcune sostanze normalmente 
presenti nel nostro cervello, i cosiddetti neurotrasmettitori. Nel caso della depressione lo 
squilibrio riguarda il livello di serotonina. Se invece ad alterarsi è il livello di dopamina, 
un’altra sostanza simile alla serotonina, questo può favorire le esperienze straordinarie, come 
sentire delle voci o avvertire la sensazione che qualcosa di importante stia per accadere oppure 
avere certi pensieri strani che invece sembrano appartenere a altre persone. Inoltre, alcuni 
dettagli specifici dell’ambiente che ci circonda possono diventare il fuoco su cui concentriamo 
tutta la nostra attenzione e darci la sensazione che abbiano un significato o un messaggio per 
noi molto importante. Tutto questo, accompagnato talvolta da sensazioni di eccitamento o di 
forte ansia, può darci la sensazione terrificante che qualcosa di molto brutto stia per accaderci.  
La dopamina regola anche il nostro livello di motivazione, le nostre iniziative e la nostra 
capacità di iniziare le attività quotidiane. Un’alterazione dei suoi normali livelli di 
concentrazione può portarci anche a perdere i nostri abituali interessi per le attività piacevoli, 
per i nostri hobby, sport, relazioni sociali e per la sessualità.  
Abitualmente, la dopamina viene rilasciata nel nostro cervello appena facciamo esperienza di 
una nuova situazione nel nostro campo di attenzione. Ad esempio, se per strada mi succede di 
incontrare l’auto della polizia che le sirene spiegate, le terminazioni nervose nel mio cervello 
potranno rilasciare dopamina nello spazio sinaptico tra una fibra nervosa e l’altra. Di 
conseguenza, la mia esperienza potrà essere più o meno la seguente:  
 Smetto di fare ciò che stavo facendo per un attimo 
 Focalizzo la mia attenzione sulle sirene e sull’auto 
 Provo a capire quello che sta accadendo 
 Mi preparo a scappare (nel caso in cui io abbia la “coscienza sporca” oppure dopo 
poco riprendo a fare ciò che stavo facendo 
Non appena hai capito quello che puoi fare in questa situazione, i livelli di dopamina 
tenderanno a calare e conseguentemente tornerai a fare le tue cose.  
Gli studiosi del comportamento umano ritengono che nelle persone che hanno esperienze 
straordinarie, la dopamina sia rilasciata nel cervello senza un vero e proprio motivo. Dato che 
il rilascio di questa sostanza avviene di solito quando facciamo esperienza di eventi nuovi e 
che per noi sono importanti, queste persone possono avere reazioni simili anche in situazioni 
più neutre o casuali. Se per esempio stai guardando il telegiornale, ed il tuo cervello 
improvvisamente inizia a rilasciare dopamina, potrai avere la sensazione che quello che stai 
dicendo il cronista abbia un significato di vitale importanza per te, sia un messaggio 
personalmente diretto a te. Dal momento che la sensazione in quel preciso momento è 
estremamente forte e reale, la maggior parte delle persone che fanno questa esperienza non 
avrà dei dubbi sul fatto che sia solo un’interpretazione. Ad esempio, se il cronista parla del 
fatto che ci sono stati dei brogli elettorali alle ultime elezioni, potrai pensare che ti stia dando 
avvertendo del fatto che c’è qualcuno che ti sta ingannando.  
 
Il rilascio di dopamina può portarci ad interpretazioni distorte degli eventi… 
 
Situazioni inaspettate possono capitare e potrai avere la sensazione che qualcosa o qualcuno 
abbia preso il controllo dei tuoi pensieri e delle tue emozioni.  
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Cosa favorisce l’ipersensibilità della dopamina 
Una specifica popolazione di persone può avere una vulnerabilità in parte ereditaria sulla 
disfunzione del sistema che regola nel cervello la dopamina. In questo gruppo di persone, 
durante periodi di stress prolungati le persone possono non riuscire ad abituarsi. Questo 
significa che i problemi quotidiani possono diventare fonte di forte disagio.  
La dopamina è anche responsabile del nostro livello di motivazione nelle attività, come si è 
detto. Questo significa che è possibile che tu abbia delle difficoltà negli impegni scolastici o 
a lavoro.  
La maggior parte delle persone che hanno esperienze straordinarie semplicemente ne fanno 
esperienza di volta in volta che esse si presentano – così queste esperienze spesso vanno e 
vengono oppure “rimangono sullo sfondo”, non prendono grande importanza per la persona, 
quindi non hanno grande influenza sul loro comportamento nella vita quotidiana.  
Tuttavia, un sottogruppo di persone, una proporzione molto piccola, può sviluppare una 
particolare ipersensibilità della dopamina che viene chiamata psicosi. Alcune di queste 
persone possono avvertire uno stato di forte malessere a causa delle esperienze straordinarie 
e quindi passare da una normale sospettosità a pensieri di tipo paranoico che via via vengono 
confermati da piccoli eventi quotidiani. 
La cannabis influenza il sistema della dopamina ed aumenta la probabilità che si sviluppi 
l’ipersensibilità della dopamina. Questo può accadere anche con altre droghe come la 
cocaina, le amfetamine. Allo stesso modo, fare esperienza di un trauma come un abuso fisico 
o sessuale oppure l’esperienza di essere bullizzato o discriminato possono aumentare la 
probabilità di ipersensibilità della dopamina.  
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Le esperienze straordinarie sono normali 
Ti sarà qualche volta accaduto di sentirti chiamare mentre sei solo nella tua stanza e questo ti 
può preoccupare. Esperienze strane, insolite, inspiegabili sono relativamente frequenti nella 
popolazione generale e il più delle volte innocue. Da varie ricerche che gli studiosi hanno fatto su 
grandi campioni di persone sappiamo oggi che circa metà della popolazione generale tende a 
credere in un certo modo alla telepatia e che molti effettivamente ne hanno fatto esperienza. Ad 
esempio, quando ti capita di pensare a qualcosa, può succedere in quel momento che squilli il 
telefono e per l’appunto è proprio la persona a cui stavi pensando. Oppure pensi al nome di 
qualcuno e proprio in quel momento lo senti pronunciare alla radio. Queste esperienze ci 
accadono certe volte durante la settimana e questo non che sembrare altro che una mera 
coincidenza. 
La maggior parte della gente tende ad essere sospettosa verso gli altri e questo non è 
necessariamente una cosa negativa…le persone che sono troppo inclini alla fiducia 
incondizionata possono subire prevaricazioni… 
Una sana sospettosità ci protegge dai pericoli quotidiani 
Nei gruppi è molto comune che ci sia qualcuno che ha il ruolo della cosiddetta “pecora nera” – 
esperienze di bullismo e prevaricazione sono purtroppo comuni a scuola o sul lavoro. 
Sentire, vedere, avvertire suoni, cose, odori che gli altri non notano, e senza che vi sia una fonte 
ben precisa nell’ambiente circostante, sono sensazioni che vengono chiamata “esperienze 
straordinarie” – allucinazione e talvolta, visioni.   
Circa una persona su sei nel corso della propria vita può attraversare un periodo in cui tende 
a avvertire voci o suoni che non sono presenti in quel momento attorno 
Da diverse ricerche sappiamo che circa il due per cento del nostro Paese nelle ultime due settimane 
ha avvertito voci o suoni non presenti nell’ambiente. È un’esperienza molto comune, sono 
sensazioni familiari a molti di noi e che spesso tendono a scomparire spontaneamente con il 
passare dei giorni.  
Tuttavia, un piccolo gruppo di persone può iniziare ad attribuire estrema importanza a questi 
fenomeni che avverte, sentirsi preoccupato da queste percezioni – queste esperienze possono 
iniziare a interferire con il funzionamento quotidiano. Qualcuno può iniziare a sviluppare 
sospettosità sempre più forte da chiudersi in casa gran parte del giorno. Altri possono iniziare a 
portare l’attenzione continuamente sulle voci che sentono ed iniziare a credere che abbia dei poteri 
soprannaturali o provengano da creature molto potenti, quindi sentirsi intimoriti da queste 
esperienze e talvolta obbedire ciò che chiedono loro di fare. Altri possono iniziare a ritirarsi dalla 
vita sociale quotidiana, ogni piccola cosa costa un enorme fatica, troppa energie e provocare 
sensazioni molto negative di ansia. Altri ancora possono iniziare a trascorrere molto tempo a 
riflette sulle proprie esperienze straordinarie, immergersi in un vero e proprio rimuginio mentale 
e preoccuparsene.  
 
Diverse ricerche hanno mostrato come la possibilità che normali esperienze straordinarie 
diventino fonte di forte disagio e si sviluppino in un vero e proprio disturbo psicologico dipende, 
almeno in parte, dal modo in cui inizialmente interpretiamo e ci spieghiamo queste stesse 
esperienze. 
158 
 
 
Vari tipi di esperienze straordinarie 
 
Esperienze alienanti 
 L’ambiente circostante mi appare strano, come se fosse nuovo o non familiare 
 Il tempo sembra passare più velocemente, in altri momenti poi più lentamente 
 Ti sembra di perdere il contatto con te stesso, come se non fossi nella realtà 
Esperienze legate al sentirsi influenzati 
 Emozioni e pensieri non sembrano sotto il controllo della tua volontà 
 Emozioni e pensieri sembrano come se fossero inseriti dall’esterno o sottratti alla mia mente  
 Il pensiero che ti vengano inviati dei messaggi speciali con un significato personale diretto a te, 
inviato da altre persone tramite radio, internet, TV, giornali 
Esperienze di danno personale 
 La sensazione che gli altri si riferiscano a te 
 La sensazione che gli altri stiano cospirando contro di te 
Esperienze percettive che solo te avverti 
 L’esperienza di suoni, voci, bisbigli, dentro o fuori la tua testa 
 L’esperienza di sentire i tuoi pensieri pronunciati da altri 
 Visioni strane 
 Sensazioni corporee insolite, inspiegabili, senza un motivo ben definito 
Sensazioni di confusione e difficoltà di concentrazione 
 Avvertire la difficoltà a organizzare i pensieri e scegliere le parole giuste 
 Sentire che gli altri fanno spesso fatica a comprender quello che vogliamo dire 
Cambiamenti nelle esperienze a contatto con le persone 
 Avvertire spesso poco interesse o piacere a stare in compagnia degli altri 
 Avvertire un senso di nervosismo a stare a contatto con le persone, in luoghi affollati 
 Gli altri tendono spesso a dirti che hai delle abitudini, dei modi di fare strani o che non esprimi 
abbastanza le tue emozioni 
 Gli impegni, i cambiamenti stressanti della vita quotidiana diventano spesso difficili, pesanti 
da sostenere 
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Esperienze dispercettive straordinarie: le voci 
 
Le voci sono produzioni linguistiche che provengono da aree della nostra mente di cui 
siamo in genere poco consapevoli. Dato che esse si presentano con le caratteristiche vocali 
della voce di qualcun altro e dato che il messaggio che portano è un tema ricorrente, 
l’impressione che possono dare è che siano create da qualcun altro diverso da noi stessi. 
Talvolta le voci possono suggerirci di sapere delle cose che noi non conosciamo, tuttavia, 
se proviamo a metterle alla prova scopriremo in realtà che non è mai così… .ad esempio, 
prova chiedere alle voci se conoscono i titoli del giornale di domani senza che tu li sappia. 
Non sapranno risponderti. In realtà, le voci sanno solo quello che tu già sai.  
Quando noi facciamo una scansione del cervello con i macchinari computerizzati di cui 
oggi disponiamo, quello che possiamo vedere è che si attivano le stesse identiche aree che 
si attivano quando pensiamo e parliamo.  
 
I discorsi che sentiamo nell’ambiente esterno arrivano all’orecchio da cui si dirigono 
all’area di Wernicke, l’area della comprensione del linguaggio, che si trova proprio dietro 
l’orecchio. Se percepiamo i nostri pensieri come un nostro dialogo interno, questi dall’area 
della corteccia prefrontale dall’area di produzione del linguaggio (area di Broca) 
successivamente si dirigono all’area di Wernicke.  
La corteccia cingolata anteriore ha il compito di avvertirci se il discorso che stiamo 
avvertendo in quel momento è un dialogo interno nostro oppure un suono proveniente 
dall’esterno. Quindi la corteccia cingolata anteriore ha il compito di monitor in grado di 
etichettare i pensieri come prodotti nostri oppure come rumori esterni. Durante le 
esperienze dispercettive, questa corteccia tende a essere meno attiva, quindi questo può 
far sì che pensieri che provengono dalla nostra mente vengano da noi erroneamente 
etichettati come rumori esterni, appunto le voci. 
Quando udiamo le voci, qualsiasi cosa esse stiano dicendo in quel momento, noi non 
siamo responsabili del loro contenuto 
Quello che le voci dicono in quel momento non fa parte della nostra personalità. Quello 
che le crea quindi è solo un meccanismo temporaneamente bloccato nella nostra mente. 
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Esperienze straordinarie percettive…come funzionano 
 
Il nostro cervello è una macchina molto complessa. Negli ultimi anni abbiamo imparato 
molto sul suo funzionamento, ma rimangono ancora diverse cose da conoscere meglio. 
Alcune teorie che spiegano il modo in cui si sviluppano le dispercezioni e diventano poi 
allucinazioni assumono che alcune nostre informazioni personali, come pensieri, ricordi, 
immagini mentali - provenienti dalla nostra memoria o dalle parti di noi di cui siamo 
meno consapevoli - vengono da noi etichettate sul momento come informazioni 
provenienti dall’esterno, appunto voci o rumori presenti nell’ambiente ma che in realtà 
sono da attribuire alla nostra mente. 
Quando ci troviamo in certe particolari condizioni, tutti noi tendiamo a avere 
allucinazioni 
 Quando siamo stanchi 
 Quando assumiamo certe sostanze 
 Quando stiamo a lungo deprivati da un punto di vista sensoriale 
 Mentre stiamo per addormentarci o subito dopo il risveglio 
 
In mancanza di input sensoriali il nostro cervello può crearne di propri per tenersi 
stimolato. Ad esempio, si è visto che alcuni detenuti in carcere per anni spesso tendono a 
riferire esperienze sensoriali come le voci. Analogamente, gli scalatori delle montagne che 
trascorrono lunghi periodi in isolamento e in deprivazione di ossigeno possono sviluppare 
queste esperienze. 
Tecniche moderne di visualizzazione del cervello in funzione hanno mostrato come le voci 
sono prodotte dal cervello stesso. Si è notato un aumento del livello di attività nelle aree 
cerebrali deputate alla produzione del linguaggio quando la persona avverte in quel 
momento le allucinazioni verbali. Allo stesso modo, si è visto che la tensione delle corde 
vocali tende ad aumentare quando la persona avverte le voci, in modo simile a quando 
pensiamo ad alta voce. 
 
 
Le allucinazioni sono quindi innocui, normali fenomeni interni prodotti dal nostro 
cervello che vengono percepiti come provenienti dall’esterno 
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SCHEDA. QUANDO MI SENTO FUORI DI ME… 
LA DEPERSONALIZZAZIONE 
 
È la sensazione di perdere il contatto con noi stessi. Spesso si presenta 
associata alla derealizzazione – la sensazione che il mondo che mi circonda 
non sia reale. È come sentirmi in un sogno e guardare la realtà da dietro 
un vetro. 
Questo tipo di esperienze è di per sé innocuo e comune tra le persone – 
circa il 50% della popolazione generale ne ha sperimentate in qualche 
momento nel corso della sua vita.  
Spesso tende a presentarsi in persone che sono state traumatizzate nel 
corso dell’infanzia o che hanno un disturbo di ansia o depressivo. Anche 
stati prolungati di stress, abuso di alcol o droghe possono ricreare questa 
esperienza.  
Se attribuiamo queste esperienze alle circostanze e le tolleriamo come una 
sensazione passeggera, in genere il problema tende a scomparire in modo 
naturale e avere un effetto limitato sulla nostra vita.  
Se però interpretiamo queste sensazioni in modo catastrofico, può essere 
più problematico – ad esempio come segno di stare per perdere il controllo, 
di poter impazzire, di poter avere una malattia neurologica o mentale, di 
poter divenire invisibili. In casi come questi la nostra reazione può essere 
di ansia, di paura. 
Può sembrare strano ma le ricerche hanno mostrato che in realtà durante 
la depersonalizzazione non c’è un aumento dell’attività del sistema nervoso 
autonomo – ovvero quel sistema che regola la frequenza cardiaca, la 
pressione arteriosa, la sudorazione, la respirazione, l’afflusso di sangue ai 
tessuti. Al contrario, avviene una diminuzione dell’attività autonoma e 
questo è responsabile della sensazione di non essere coinvolti nelle ose che 
ci circondano. 
Evitando certe situazioni che possono ricreare la depersonalizzazione (le 
lezioni a scuola, il lavoro, le uscite con gli amici, i viaggi in treno/bus) 
manteniamo il nostro stato di preoccupazione che possa riverificarsi 
questa sensazione. A lungo termine, l’ansia tende a aumentare. Allo stesso 
tempo la trappola dell’attenzione selettiva ci porta a monitorare 
continuamente il più piccolo segnale di depersonalizzazione durante il 
giorno ma portare l’attenzione su noi stesso così intensamente aumenta 
l’ansia di fronte a ogni cambiamento, ansia che a volte diventa panico e 
quindi paradossalmente fa scattare un nuovo episodio di 
depersonalizzazione.  
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Sensazioni di depersonalizzazione  
e derealizzazione 
 
Riduzione dei sintomi  
in altri contesti 
Interpretazioni catastrofiche 
 
“Potrei perdere il controllo” 
“Potrei impazzire” 
“E se avessi una seria malattia al cervello?” 
 
Attribuzione alle 
circostanze 
 
Aumento dell’ansia 
 
Rafforzano il circolo vizioso 
 
Evitamento 
Attenzione selettiva ai sintomi 
Rimuginio  
 
 
Stress, affaticamento, uso di 
alcol/sostanze, traumi passati 
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FLASHCARD. ACCOGLI LA DEPERSONALIZZAZIONE 
 
 
 Quando noti le sensazioni di depersonalizzazione o derealizzazione, è 
importante che tu rimanga calmo fino a quando non calano da sole 
 
 Sono esperienza comuni a molti di noi, innocue, possono essere un modo con 
cui la nostra mente ci avverte che siamo stressati, stanchi 
 
 Interpretarle in modo catastrofico – segnali di una malattia al cervello – può 
solo aumentare la tua apprensione e così facendo amplifica la 
depersonalizzazione stessa 
 
 Focalizzare la tua attenzione sul tuo corpo aumenta l’ansia che la 
depersonalizzazione possa peggiorare 
 
 Porta la tua attenzione su quello che avverti con i 5 sensi nell’ambiente che ti 
circonda, tocca qualcosa e nota le sensazioni tattili, ascolta qualcosa e nota i 
suoni… 
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AFFRONTARE LE ESPERIENZE STRAORDINARIE 
 
 
 
 
Francesco 
Occasionalmente sente il proprio nome pronunciato mentre è per strada, anche 
se nota che nessuno lo avverte. A volte sente che i propri pensieri sono ripetuti 
da una voce – altre volte una voce nella sua testa gli sussurra cosa deve fare: 
“non fidarti dei vicini”.  
Una persona su 50 può sentire una voce mentre nessuno in realtà sta parlando. 
Il modo migliore più efficace per affrontare questa esperienza è non prendere 
questa voce sul serio e cercare di continuare a fare ciò che stiamo facendo. A 
volte la mente gioca degli scherzi, soprattutto prima di andare a letto.  
In alternativa, Francesco potrebbe iniziare a interpretare la voce come un suono 
che proviene da qualcuno molto potente, come i servizi segreti, una setta 
satanica, il diavolo o altro. Se Francesco interpreta quella voce in questo modo, 
allora è più probabile che poi si senta ansioso, spaventato o anche sopraffatto 
ed umiliato, senta che non c’è via di fuga da questa voce. Di conseguenza, inizia 
a dormire male la notte, a rimuginare spesso durante la giornata, evita le uscite, 
progressivamente si ritira in casa – può cercare di tenere la voce segreta, 
cercare di resistere alle sue pressioni o anche accondiscendere.  
 
 
 
 
Non è l’esperienza straordinaria di per sé...  
è la nostra interpretazione 
 
L’interpretazione che noi tendiamo a dare alle nostre esperienze straordinarie è di 
grande importanza e può determinare il fatto che noi riusciamo a conviverci oppure 
iniziamo a soffrirne in modo intenso. Un’esperienza straordinaria può diventare 
nociva per noi il nostro tempo inizia a essere troppo occupato da essa e ci impedisce 
dal partecipare alle attività per noi significative e dallo stare in contatto con gli 
altri. La maggior parte delle esperienze straordinarie sono innocue, normali per 
molti di noi. È importante non prestare più di tanto ascolto ed attenzione. È molto 
utile imparare a prendere in considerazione spiegazioni alternative alle 
interpretazioni che ci verrebbero immediatamente di un fatto 
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MODULO “CREDENZE 
DISFUNZIONALI” 
SEDUTE 8-15 
RISTRUTTURAZIONE COGNITIVA 
INTERVENTO METACOGNITIVO 
ESPERIMENTI COMPORTAMENTALI 
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SCHEDA DIARIO ABC DELLE ESPERIENZE STRAORDINARIE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Esperienza straordinaria Interpretazione Risposta emotiva 
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QUANDO LA SOLUZIONE È IL PROBLEMA: LA TRAPPOLA DELL’EVITAMENTO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Il meccanismo che può favorire la sospettosità è proprio l’evitamento. 
Chiunque abbia vissuto un incidente in auto, è molto probabile che 
sperimenti disagio e tensione appena riprende a guidare. Chi si propone di 
riprendere l’auto nonostante questo, riesce più facilmente a superare questa 
paura. Chi invece decide di smettere di guidare appena avverte la paura 
impara a evitare le auto e i loro rischi però con il risultato che ogni volta 
prova a salirvi sentirà il cuore che batte forte e gli altri segnali della 
tensione. È come quando si sviluppa la paura per i cani dopo che si è stati 
morsi. L’evitamento crea un circolo vizioso che mantiene la paura. Nello 
stesso modo funziona anche la sospettosità. La paranoia aumenta dopo 
l’evitamento ripetuto di una data situazione. Il modo migliore per ridurre la 
sospettosità e l’ansia che crea è esporsi alle situazioni, affrontarle per 
permetterci di metter in discussione in pensieri automatici e le 
interpretazioni che abbiamo. 
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                            SCHEDA: LE DISTORSIONI COGNITIVE 
 
 
Tutti noi tendiamo a fare continui errori di pensiero. Quando abbiamo un pensiero automatico, 
possiamo provare ad identificare mentalmente, verbalmente o per iscritto il tipo di errore che 
stiamo facendo. Gli errori di pensiero più comuni sono riportati di seguito. 
 
 
 
 
PENSIERO "TUTTO O NULLA" (chiamato anche pensiero in bianco/nero o dicotomico) 
Vediamo una situazione in soli due modi contrapposti, in due categorie, invece che in un 
continuum. Gli eventi vengono visti come tutti bianchi o tutti neri, buoni o cattivi. Si ha 
un’insistenza su scelte e valutazioni estreme. Ci possiamo sentire perfetti o completamente 
imperfetti. Non esiste una via di mezzo. Quando usiamo il pensiero "tutto o nulla" seguiamo 
binari prestabiliti e rigidi. Siamo nella logica del "o...o". 
Esempi: 
a. “O fai quello che dico, o non ci vedremo mai più” 
b. “Se non mi realizzo nel lavoro, la mia vita sarà un completo fallimento” 
c. “Siete con me o contro di me?” 
d. …………………………………………………………………………… 
 
 
PENSIERO CATASTROFICO (chiamato anche predizione del futuro) 
Prediciamo il futuro in maniera negativa senza considerare altri possibili esiti o sviluppi. Ci 
si aspetta in continuazione che avvenga un disastro. Siamo sempre all'erta perché ci 
aspettiamo che arrivi da un momento all'altro la temuta tragedia. "Che ne sarà di noi?". 
Pensando in questo modo al futuro, si creano intense reazioni di ansia. 
Esempi: 
a. “Ho un neo, si trasformerà sicuramente in un tumore...” 
b. “Se all’ora di pranzo non è tornata a casa è perché sicuramente ha avuto un 
incidente” 
c. “Sarò così agitato che non sarò in grado di agire adeguatamente” 
d.……………………………………………………………………………… 
 
 
LETTURA DEL PENSIERO 
Crediamo di sapere quello che gli altri pensano e provano, o il motivo per cui agiscono in un 
certo modo evitando di considerare, più probabili, possibilità. In particolare diventiamo abili 
a prevedere quello che una persona pensa di noi (effetto “palla di vetro”).  
Esempi: 
a. “Anche se lei mi sorride, io so che non le piaccio” 
b. “Non mi ha salutato perché non mi ritiene un suo amico” 
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FILTRO MENTALE (chiamato anche astrazione selettiva) 
Prestiamo un'attenzione ingiustificata ad un unico dettaglio negativo invece di considerare e 
valutare appropriatamente tutto l'insieme. 
Esempi: 
a. “Ho un solo voto basso nella mia valutazione (in cui ci sono però numerosi voti alti), divento 
triste perché penso di aver fatto un pessimo lavoro” 
b. “Tutti mi hanno fatto i complimenti per le scarpe nuove, ma a Marta non sono piaciute. 
Quel solo giudizio negativo cancella tutti gli altri, rendendomi insoddisfatta” 
c.……………………………………………………………………………… 
 
 
PERSONALIZZAZIONE 
Crediamo che gli altri si comportino negativamente a causa nostra, senza prendere in 
considerazione spiegazioni più plausibili per il loro comportamento. 
Esempi: 
a. “Il tecnico riparatore è stato sgarbato con me perché ho fatto qualcosa di sbagliato” 
b. “Papà beve perché sono cattivo” 
c. “Mi tratta male perché non valgo nulla” 
d.……………………………………………………………………………… 
 
 
IPERGENERALIZZAZIONE 
Tendiamo ad arrivare a conclusioni di carattere generale in maniera affrettata, 
allontanandoci dalla situazione concreta e attuale. 
Esempi: 
a. “Siccome non mi sono sentito a mio agio al party penso: Non ho ciò che ci 
vuole per fare amicizia” 
b. “Mi tratta sempre male” 
c. “Non mi ascolta mai” 
d.……………………………………………………………………………… 
 
 
RAGIONAMENTO EMOTIVO 
Pensiamo che qualcosa sia vera solo per il fatto che "sentiamo" (in realtà crediamo) fortemente 
che è così, ignorando, svalutando o minimizzando tutto ciò che prova il contrario. 
Esempi: 
a. “Mi sento stupido e insignificante”. Il fatto di sentire "qualcosa" non significa affatto che 
sia vero. 
b. “Lo sentivo che alla fine mi avrebbe abbandonato” 
c. “So di far bene molte cose al lavoro ma mi 'sento' lo stesso un fallimento” 
d.……………………………………………………………………………… 
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VISIONE TUNNEL  
Vediamo solo gli aspetti negativi di una situazione. Ad esempio, le persone con visione tunnel 
vedono soltanto ciò che collima con il loro atteggiamento o stato mentale. Altri aspetti 
importanti sono cancellati, censurati o minimizzati. 
Esempio: 
a. “Non abbiamo fatto altro che litigare per tutto il viaggio” (in realtà quando valutiamo 
obiettivamente il tempo del litigio ci rendiamo conto che era durato non più di 5 minuti). 
b. “Nessuno mi ha mai amato” 
c.……………………………………………………………………………… 
 
 
AFFERMAZIONI "DOVREI" E "DEVO" (chiamate anche Doverizzazioni) 
Abbiamo un’idea fissa, precisa, rigida di come noi o gli altri dovremmo comportarci e diamo 
una valutazione eccessivamente negativa alle possibilità che queste aspettative non vengano 
soddisfatte. L'errore sta nel considerare un'esigenza assoluta ciò che nella maggior parte dei 
casi sarebbe obiettivamente solo preferibile. Chi infrange tali regole provoca in noi una collera 
intollerabile; se siamo noi stessi a farlo, ci colpevolizziamo. 
Esempi: 
a. “È terribile che io abbia fatto un errore. Devo sempre essere irreprensibile” 
b. “Non devi mai fare domande personali alla gente” 
c.……………………………………………………………………………… 
 
 
ETICHETTAMENTO 
Tendiamo ad attribuire a noi stessi e agli altri etichette globali, rigide senza considerare che 
l’evidenza potrebbe condurre più ragionevolmente a conclusioni meno drastiche o disastrose. 
Diamo, infatti, giudizi definitivi ad un evento o a una persona basandoci su una o poche 
caratteristiche che li riguardano. 
Esempi: 
a. “Paola è stata una perdente dal primo giorno che l’ho conosciuta” 
b. “Io sono un buono a nulla” 
c.……………………………………………………………………………… 
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SQUALIFICARE O SVALUTARE IL POSITIVO 
Irragionevolmente ci diciamo che le nostre esperienze, azioni o qualità positive non contano, 
non hanno valore o, nello stesso modo rifiutiamo o svalutiamo il nostro fisico o parti di esso, 
non attribuendogli alcun valore. 
Esempi: 
a. “Ho realizzato bene quel progetto, ma questo non vuol dire che sono competente; ho 
semplicemente fortuna” 
b. “Ho eseguito bene questo compito, ma tutti ne sarebbero capaci” 
c. “Tutti mi dicono che ho dei begli occhi ma per me non è così” 
d.……………………………………………………………………………… 
 
 
 
ESAGERAZIONE / MINIMIZZAZIONE 
Quando valutiamo noi stessi, un’altra persona o una situazione, esageriamo 
irragionevolmente il negativo e/o minimizziamo il positivo. 
Esempi: 
a. “Se ottengo una valutazione mediocre, questo prova quanto io sia 
inadeguato” 
b. “Se ottengo un voto alto, non significa che sono brillante” 
c.……………………………………………………………………………… 
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SCHEDA: LA TRAPPOLA DELL’ATTENZIONE SELETTIVA 
 
Se provi a prestare tutta la attenzione a una situazione, a un dettaglio dell’ambiente 
che apparentemente non porta con sé pericolo o aspetti negativi, è molto probabile che 
poi tenderai a notare pericoli, minacce o aspetti negativi in molte altre situazioni.  
Facciamo un esercizio che può aiutarci a capire come funziona la trappola 
dell’attenzione selettiva.  
 
La prossima settimana dovrai prestare tutta la tua attenzione possibile a un elemento 
specifico ogni giorno: 
1. Il primo giorno devi appuntarti quante macchine blu hai visto, le scriverai nella 
nostra scheda di appunti. Ogni ora della giornata devi segnare quante 
macchine blu vedi, mentre sei a casa, mentre fuori per strada, mentre sei in 
bus o in treno, mentre sei a scuola, a lavoro o all’università. Poi devi sommare 
quante macchine blu hai visto quel giorno; oltre a questo devi annotare le 
sensazioni che provavi in quel momento mentre facevi l’esercizio. 
2. Il secondo giorno devi annotare tutti i rumori, i suoni che puoi percepire mentre 
sei in una stanza e che provengono da fuori quella stanza, quando sei in camera 
tua, in altre camere di casa, in aula a scuola, in stanza a lavoro etc. devi poi 
somare i rumori che hai notato e appuntare anche le tue sensazioni mentre 
facevi l’esercizio. 
3. Il terzo giorno appunta tutte le persone che vedi che portano gli occhiali, poi 
sommale e annota anche le tue sensazioni durante l’esercizio. 
4. Il quarto giorno è di riposo. Dopo cena, prediti del tempo per annotare le 
sensazioni che hai avuto oggi e confrontale con quelle dei tre giorni precedenti. 
5. Il quinto giorno presta la tua attenzione e segna tutte le persone che durante 
la giornata ti creano sensazioni spiacevoli (ansia, rabbia, tristezza etc). 
Potranno essere persone che hai avuto la sensazione ti abbiano guardato in un 
modo strano, che si vestono in un modo completamente diverso da te, che sono 
più alti di te, che sembrano criminali, che sembrano atteggiarsi con supponenza 
etc. metti insieme tutte queste situazioni annotate e riporta le sensazioni che 
hai provato durante l’esercizio. 
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SCHEDA: L’ESERCIZIO DELL’ATTENZIONE SELETTIVA 
 
 
Tempo 
Giorno 1 
Macchine 
blu 
Giorno 2 
Rumori/suoni 
fuori la stanza 
Giorno 3 
Persone con 
occhiali 
Giorno 4 
Riposo 
Giorno 5 
Persone 
spiacevoli 
8.00      
9.00      
10.00      
11.00      
12.00      
13.00      
14.00      
15.00      
16.00      
17.00      
18.00      
19.00      
20.00      
21.00      
22.00      
 
 
Giorno 1    Sensazioni provate e considerazioni:  
 
 
Giorno 2 Sensazioni provate e considerazioni: 
 
 
Giorno 3 Sensazioni provate e considerazioni: 
 
 
Giorno 4 Sensazioni provate e considerazioni: 
 
 
Giorno 5 Sensazioni provate e considerazioni: 
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SCHEDA 
LE VOCI - NOSTRI PENSIERI AUTOMATICI CHE ATTRIBUIAMO AD ALTRI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
La distorsione “Attribuzione di pensieri a altri” 
 
È un tipo di distorsione che più frequentemente accade a chi ha una tendenza a 
sperimentare voci. È molto importante essere consapevoli se stiamo seguendo questa 
distorsione. 
Il nostro cervello è in grado di etichettare il contenuto della memoria in modo tale da 
aiutarci a capire se un certo evento è avvenuto dentro di noi (es un pensiero) oppure 
fuori (un rumore esterno). Talvolta per alcuni è possibile che questo processo non 
funzioni correttamente in dei momenti, quindi un evento interno può essere etichettato 
come esterno erroneamente. Questo meccanismo di etichettamento scorretto è quello che 
accade durante le allucinazioni, quando pensieri interni vengono percepiti e considerati 
esterni. La voce appare come una cosa diversa da te e sembra dire qualcosa che qualcun 
altro potrebbe dire.  
Esistono varie sfumature di esperienze. Alcune persone possono sentire i propri pensieri 
detti ad alta voce. In tal caso sono pensieri ma si differenziano dai normali pensieri per 
il fatto che li sente all’esterno. Altri tipi di esperienze sono pensieri ripetitivi che 
improvvisamente diventano udibili, come una voce.  
I pensieri ossessivi sono pensieri percepiti come involontari ed automatici, spesso 
arrivano veloci alla mente, sono percepiti come indesiderabili perché spesso hanno un 
contenuto aggressivo o sessuale, morale. Da questo punto di vista, pensieri ossessivi e 
voci sono simili. Entrambi sono intrusivi, la persona cerca di controllarli ma con scarso 
successo. Ciò che li differenzia i primi sono pensieri riconosciuti dal soggetto come 
pensieri mentre le seconde sono gli stessi pensieri prodotti dalla nostra mente senza che 
però sembrino pensieri, piuttosto frasi pronunciate all’esterno da altri.  
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FLASHCARD. MESSAGGI DA PORTARE CON TE 
 
 
 
 Le esperienze straordinarie sono normali, sono reali 
esperienze  
 
 Sono favorite da lievi squilibri in alcune sostanze 
nel tuo cervello, la conseguenza del rilascio di 
dopamina in situazioni improvvise 
 
 Con il tempo, in alcune persone possono scomparire 
da sole, in altre rimanere ma non in modo invadente 
 
 Le distorsioni cognitive e l’evitamento mantengono 
le emozioni di ansia che possono provocarti 
 
 Il problema è se pensi che dipendano da qualcun 
altro fuori di te 
 
 Abbiamo poco controllo su queste esperienze, quindi 
la prima spiegazione logica che uno potrebbe avere 
è che sia coinvolto qualcun altro….ma non è così 
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SCHEDA. CERCARE UNA SPIEGAZIONE ALLE COINCIDENZE 
 
 
 
 
Può succedere che le coincidenze non ci sembrino coincidenze. Ti concentri a lungo guardando il 
dado e ti ripeti a bassa voce: “Un sei, un sei, un sei”. Lanci il dado ed esce un sei. Allora lo puoi 
fare! 
Nel Medioevo alcune popolazioni iniziarono a pensare che la peste fosse provocata da dai gas 
pericolosi nelle città. Allora alcuni gruppi si ritirarono a vivere nelle montagne. Nessuno si 
ammalò nelle montagne: l’aria era salutare – il collegamento fu ovvio…. 
Successivamente, si scoprì che la qualità dell’aria non aveva niente a che vedere con la peste, 
che invece si capì era provocata da batteri trasferiti all’uomo dai ratti.  
 
 
 
 
 
 
Una coincidenza a volte non sembra una coincidenza 
 
 
 
 
 
Se lanci un dado sei volte di fila, la serie 6-6-6-6-6-6 è tanto probabile quanto la serie 3-4-2-1-5-
3. Eppure la prima serie può sembrarci una coincidenza ma lo di fatto lo è….a ogni lancio la 
probabilità di avere un 6, un 3, un 2 o un 5 è sempre 1 su 6! 
Non sempre teniamo sufficientemente a mente l’effetto del caso...spesso confondiamo la 
sincronicità con la causa. 
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FLASHCARD. MESSAGGI DA PORTARE CON TE 
 
 
Se due eventi ci capitano contemporaneamente, potrebbe esserci 
un legame di causa ed effetto 
 
 
…. ma in genere è solo una coincidenza 
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SCHEDA 
LA DISTORSIONE DELLE ASPETTATIVI PESSIMISTICHE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dopo alcuni insuccessi può succedere di iniziare a pensare che non dobbiamo aspettarci 
niente di positivo dalle situazioni. Possiamo iniziare ad avere una visione pessimista del 
futuro: niente di positivo ci aspetta, qualsiasi sforzo per raggiungere determinati obiettivi 
non servirà. L’estremo pessimismo può talvolta essere una “profezia che si auto-avvera”: 
se non mi aspetto niente di buono, evito di impegnarmi in comportamenti positivi e quindi 
sarà più probabile che non raggiunga nessuno dei miei obiettivi.  
Sappiamo che le interpretazioni che diamo delle cose influenzano il nostro modo di sentire 
le emozioni e comportarci. Le interpretazioni vanno oltre i fatti. I fatti sono eventi distinti, 
registrabili, misurabili. Il nostro linguaggio influenza molto le nostre interpretazioni. 
Pensiamo adesso a un uomo che sta sotto la pioggia con un lungo cappotto. Il linguaggio 
potrebbe affermare questo evento così: “Quell’uomo sta sotto la pioggia con un lungo 
cappotto”. Però, potrebbe anche portare ad un’interpretazione: “Quell’uomo sotto la 
pioggia è stato appena lasciato dalla sua ragazza” oppure un’altra interpretazione 
potrebbe essere “Quell’uomo sotto la pioggia con un lungo cappotto è in attesa della sua 
ragazza”. Ma potrebbe essere anche essere che gli piace la pioggia ed è sceso per una 
passeggiata. C’è quindi una differenza tra un fatto ed un’interpretazione. La prima 
interpretazione che abbiamo dato è un’interpretazione pessimistica. 
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SCHEDA 
DIARIO DELLE INTERPRETAZIONI PESSIMISTICHE 
 
 
Prova a notare la settimana che segue le situazioni nelle quali tendi a dare un’interpretazione 
pessimistica. In fondo alla giornata, prova a riesaminare quello che è successo e ad appuntare gli 
eventi in cui hai dato un’interpretazione pessimistica del risultato e come quest’ultima ha influenzato 
il tuo comportamento, il tuo modo di sentire. È molto importante provare a tenere a mente possibili 
interpretazioni alternative. 
  
Situazioni della 
giornata 
Interpretazione pessimistica e 
conseguenze sul mio modo di sentire 
e comportarmi 
Interpretazione 
alternativa 
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SCHEDA 
COME AIUTARMI A METTERE IN DISCUSSIONE I MIEI PENSIERI AUTOMATICI 
 
 
 
Quando sei troppo lontano da ciò che puoi percepire con i tuoi cinque sensi, è facile entrare nel mondo della fantasia e 
dell’irrazionale. Quando ti aggrappi a ciò che percepisci con i 5 sensi sei di solito su un terreno più sicuro. Questa lista di domande 
può aiutarti a creare pensieri alternativi e comportamenti più assertivi. Provando a considerare domande come queste puoi 
aiutarti a mettere in discussione i pensieri automatici che talvolta creano emozioni troppo intense, come rabbia o ansia:   
 
 
1. Da cosa lo vedo che le cose stanno come dice questo pensiero automatico? 
2. C’è una spiegazione alternativa? Quali sono le prove contro questa idea? 
3. Qual è la cosa peggiore che potrebbe accadere?  
4. Qual è la cosa migliore che potrebbe accadere? 
5. Cosa può succedere a me se credo a questo pensiero automatico? 
6. Quale potrebbe essere l’effetto del cambiare il mio pensiero? 
7. Che cosa direi a un amico se lui si trovasse nella stessa situazione? 
8. Questo mio pensiero è basato su fatti reali? 
9. Posso provare in base alle distorsioni cognitive che conosco che la mia convinzione è falsa? 
10. Mantenendo questo pensiero potrò raggiungere dei buoni risultati? 
11. Le mie interpretazioni delle situazioni sono troppo lontano dalla realtà per essere vere? 
12. Sto confondendo la mia versione dei fatti? 
13. Sto pensando in termini di tutto o niente? 
14. Sto usando parole o frasi che sono estreme o esagerate? (Parole come sempre, mai, devo, non posso, ogni volta, raramente   
                  corrispondono alla realtà) 
15. Sto portando esempi scelti al di fuori dal contesto? 
16. È attendibile la mia fonte di informazione? 
17. Sto pensando in termini di certezza invece che di probabilità? 
18. Sto confondendo una bassa probabilità con un’alta probabilità? 
19. I miei giudizi sono basati su sensazioni piuttosto che su fatti o eventi? 
20. Mi sto concentrando su fattori irrilevanti? 
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COSTRUIRE UNA GERARCHIA DI SITUAZIONI ATTIVANTI 
 
 
SITUAZIONI 
TERMOMETRO INTENSITÀ 
EMOZIONI NEGATIVE  
(0-100%) 
 
10 
 
20 
 
30 
 
40 
 
50 
 
60 
 
70 
 
80 
 
90 
 
100 
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ESPERIMENTO COMPORTAMENTALE 
Data ______________ 
 
 
Descrizione esercizio 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
 
Cosa prevedo che accadrà? Quali conseguenze su di me/sugli altri? 
_____________________________________________________________________________________________________
_____________________________________________________________________________________________________ 
 
 
Quanto disagio/ansia/tensione prevedo di provare? (valuta 0-100%)____________ 
 
 
Cosa è realmente successo? 
_____________________________________________________________________________________________________
____________________________________________________________________________________________________ 
 
Quanto disagio ho provato? (0-100%)   _______________ 
 
  
                                                                          100% 
                                                        
                                                                            80% 
 
                                                             Disagio   50% 
                                                        
                                                                             30%                 Tempo di svolgimento esercizio                                         
                                                                                          
Cosa ho imparato? 
_____________________________________________________________________________________________________
_____________________________________________________________________________________________________ 
 
 
Grado di successo dell’esercizio (0-100%) ___________________ 
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SCHEDA: METTERE IN DISCUSSIONE I PENSIERI AUTOMATICI 
 
 
 
Pensiero Automatico _________________________________________________________________ 
 
 
 
Prove a favore Prove contrarie 
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        SCHEDA: VALUTA L’UTILITÀ DEI PENSIERI AUTOMATICI 
 
 
 
Pensiero Automatico _________________________________________________________________ 
 
 
 
Vantaggi nel seguire/credere quel 
pensiero (a breve e lungo termine) 
Svantaggi nel seguire/credere quel 
pensiero (a breve e lungo termine) 
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SCHEDA: CREA PENSIERI ALTERNATIVI 
 
 
 
                                                                                    
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
La prima interpretazione che abbiamo di un evento potrebbe non essere la migliore. 
Impulsivamente possiamo intuire il significato di una data situazione e aderire a 
questa iniziale interpretazione, pensando che debba essere corretta. I giudizi 
successivi, spesso più razionali, solo raramente sembrano confermarsi così solidi 
come quelli iniziali. Di conseguenza, alcune persone continuano a pensare che, ad 
esempio, una tensione ai muscoli pettorali possa indicare un attacco cardiaco, 
semplicemente perché questo è stato il pensiero iniziale oppure si convincono di 
essere antipatici a qualcuno, solo perché quella persona non li ha salutati in 
un’occasione. 
  
1. Pensa alle emozioni spiacevoli che hai sperimentato durante la settimana (come 
rabbia, tristezza, paura, etc.) e annotale sul diario dei pensieri automatici. 
2. Scrivi l’evento (situazione) legato all’emozione che hai provato e la tua prima 
interpretazione di questo evento/pensiero. 
3. Rileggi la tua prima interpretazione e valuta, in base a ciò che hai appreso, se è 
corretta. Se ti accorgi che non lo è, trova almeno altre quattro interpretazioni 
alternative. 
 
Prendi l’abitudine di discutere e sostituire i tuoi pensieri irrazionali in questo 
modo, per più tempo possibile. Ricordati che ci sono voluti anni ad apprendere ad 
essere come sei, ci vorrà molta forza ed energia per poter cambiare il tuo modo di 
pensare. È molto importante che le interpretazioni alternative che provi a creare 
siano realistiche; non è utile sostituire un pensiero automatico negativo con una 
falsa credenza positiva. 
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SCHEDA:  
STILE DI VITA E STRATEGIE PER METTERE IN DISCUSSIONE I PENSIERI 
AUTOMATICI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Concediti di discutere alcune delle esperienze straordinarie che ti accadono 
con persone che conosci: scegli uno o più amici o parenti con i quali parlarne 
e di cui hai fiducia, che sai essere persone comprensive. È molto utile. Può 
aiutarti a comprendere anche che spesso i pensieri automatici che arrivano 
alla nostra mente sono realistici in un certo modo. 
 
 Porta la tua attenzione sull’effetto che credere a un certo pensiero automatici 
ha sulle tue sensazioni corporee, sulle emozioni che provi e sul tuo 
comportamento. Prima di agire prova a notare l’effetto che avrebbe credere a 
quel pensiero automatico, prova a notare cosa stai pensando in quel momento 
particolare. 
 
 Considera che anche le esperienze sensoriali straordinarie sono 
semplicemente esperienze, in genere favorite un meccanismo 
temporaneamente alterato nei neurotrasmettitori. Questo passeggero 
cambiamento nella nostra mente può risolversi da solo e scomparire in modo 
naturale dopo un po’ con il passare del tempo. 
 
 Cerca di impegnarti in attività sociali, come incontrare amici, frequentare la 
scuola/università o lavoro. 
 
 Riduci il tempo durante la giornata che dedichi ad attività di pensiero su 
questioni esistenziali e prova ad individuare piccoli obiettivi giornalieri da 
programmare e poi svolgere, come passeggiate, attività sportive e sociali, la 
cura del tuo corpo, la cura della tua casa e della tua camera. 
 
 Fissa degli obiettivi:  
 Specifici: definire esattamente cosa si vuole 
 Misurabili: quali saranno i criteri per valutare il successo 
 Appropriati: assicurati che siano appropriati per te 
 Realistici e realizzabili 
 Limitati: al momento in cui li stai attuando 
 
 Impegnati a trattenerti dal fare uso di sostanze e cannabis, soprattutto 
quando noti che amplificano le esperienze straordinarie. 
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SCHEDA TRAINING ATTENTIVO 
 
Adesso che ti sei esercitato con il training attentivo insieme al tuo terapeuta, è molto importante che tu 
possa fare pratica anche a casa. Affinché sia efficace, deve essere un vero e proprio allenamento per 
l’attenzione. Questa scheda è pensata per aiutarti a tener traccia degli esercizi. 
1. Individua un posto dove esercitarti, in cui potrai introdurre – o identificare – diversi suoni (almeno 
tre, ma più sono meglio è). È utile che i suoni provengano da punti diversi dell’ambiente che ti circonda. 
Ad esempio, la radio nella stanza accanto (cucina), la TV in salotto, i rumori che vengono dalla finestra 
aperta sulla strada, il ticchettio dell’orologio nella tua camera Alcuni possono essere anche soltanto punti 
dello spazio verso cui dirigere la tua attenzione al di là che vi siano effettivamente rumori nelle vicinanze 
I suoni che potrei introdurre sono: 
a………………………………………….. 
b…………………………………………... 
c. suoni che posso udire nelle vicinanze 
d. suoni che posso udire in lontananza 
e. suoni che possono provenire da destra 
f. suoni che possono provenire da sinistra 
2. Esercitati per circa 10-15 minuti, dividendo il tempo come segue: approssimativamente 5 minuti in 
cui focalizzi la tua attenzione su singoli suoni differenti; 5 minuti in cui la sposti rapidamente tra i vari 
suoni; 2 minuti di attenzione divisa. 
3. Annota i giorni in cui ti sei esercitato contrassegnando una X nelle caselle sottostanti 
 
Lunedì Martedì  Mercoledì  Giovedì  Venerdì  Sabato  Domenica  
       
 
 
 
 
       -6      -5        -4     -3       -2        -1      0        +1     +2      +3      +4     +5      +6 
         /_____/_____/_____/_____/_____/_____/_____/_____/_____/_____/_____/____/ 
 
Attenzione                                       Attenzione                                  Attenzione 
completamente                               equamente                            completamente 
sui pensieri                                         divisa                                   sull’ambiente 
automatici                                                                                                    esterno 
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MODULO “EMOZIONI” 
SEDUTE 16-17 
CONSAPEVOLEZZA E  
STRUMENTI DI GESTIONE DELLE EMOZIONI 
PSICOEDUCAZIONE SULLE EMOZIONI 
TECNICHE DI RILASSAMENTO 
 
 
 
 
 
 
 
 
 
 
 
 
189 
 
SCHEDA: DIARIO DEI SEGNALI CORPOREI 
 
Giorni e 
orario 
Segnali 
corporei 
(0-100) 
Disagio 
(0-100) 
Pensieri 
automatici 
(quanto sono 
convinto da 
questi 
pensieri? 
0-100) 
Quanto sento la 
necessità di 
controllare? 
(0-100) 
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SCHEDA: GESTIONE DELL’ANSIA E METODI DI RILASSAMENTO  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AUDIO SU ESERCIZIO DI RESPIRAZIONE DIAFRAMMATICA 
15 MINUTI DI ASCOLTO 
AUDIO SU RILASSAMENTO MUSCOLARE PROGRESSIVO 
15 MINUTI DI ASCOLTO 
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SCHEDA: DAI UN NOME ALLE TUE EMOZIONI 
Emozioni Parole che esprimono l’emozione 
Alcuni segnali corporei che le 
accompagnano 
Rabbia 
Pazzo, inquietato, adirato, risentito, irritato, 
esasperato, arrabbiato, furioso, turbato, 
incazzato, alterato 
Testa 
Calda, pesante, mi scoppia, come se salisse il 
sangue al cervello, tesa 
Viso 
Rosso, pesante, brucia, teso, contratto 
Gambe 
Rigide, tese, irrequiete, muscoli tesi 
Ansia 
Preoccupato, timoroso, terrorizzato, preso dal 
panico, pauroso, spaventato, nervoso, 
apprensivo, inquietato, agitato, sopraffatto, 
sotto pressione, teso, soffocato 
Respiro 
corto, veloce, affannoso, superficiale, pesante, 
interrotto 
Testa 
leggera, confusa, vuota, come se non 
funzionasse 
Petto  
pesante, rigido, come se ci fosse un macigno o 
un peso che lo porta giù 
Addome 
peso, fastidio 
Gola 
sensazione che si stringa, che ci sia un nodo, 
sensazione amara 
Gambe 
Rigide, tese, irrequiete, muscoli tesi 
Cuore 
Batte più forte, veloce 
Imbarazzo Stupido, impacciato, confuso, inadeguato 
Viso 
Caldo, rosso 
Mani, gambe 
Vacillanti, mi mancano le forze, tremanti 
Senso di 
colpa 
Pieno di vergogna, sentirsi in colpa, cattivo 
Petto  
pesante, rigido, come se ci fosse un macigno o 
un peso che lo porta giù 
Gola 
si stringe, manca l’aria 
Senza 
speranza 
Senza speranza Scoraggiato, pessimista, 
disperato, impotente, sfiduciato 
Petto  
pesante, rigido, come se ci fosse un macigno o 
un peso che lo porta giù 
Gola 
si stringe, manca l’aria 
Tristezza 
Dispiaciuto, giù, infelice, triste, melanconico, 
ferito, deluso, depresso, Abbandonato, solo, 
isolato, rifiutato, indesiderato, respinto 
Petto  
pesante, rigido, come se ci fosse un macigno o 
un peso che lo porta giù 
Gola 
si stringe, manca l’aria 
Testa 
leggera, confusa, vuota, come se non 
funzionasse 
Petto  
pesante, rigido, come se ci fosse un macigno o 
un peso che lo porta giù 
Addome 
peso, fastidio 
Gola 
sensazione che si stringa, che ci sia un nodo, 
sensazione amara 
Gambe:  
Rigide, tese, irrequiete, muscoli tesi 
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SCHEDA: L’IPERVENTILAZIONE E LA RESPIRAZIONE DIAFRAMMATICA  
 
 
 
 
Per imparare a gestire l’ansia può essere utile conoscere il particolare fenomeno 
dell’iperventilazione. Il corpo ha bisogno di ossigeno per sopravvivere: quando inspiriamo, 
l’ossigeno viene trasportato ai polmoni è raccolto dall’emoglobina che lo trasporta alle cellule 
che poi lo utilizzano per produrre energia necessaria tutte le nostre funzioni. Come sotto 
prodotto si forma l’anidride carbonica che attraverso la circolazione viene trasportata ai 
polmoni per essere espirata. L’efficienza delle nostre funzioni dipende dall’equilibrio tra 
consumo di ossigeno e produzione di anidride carbonica dipende: questo equilibrio è garantito 
da una adeguata frequenza e profondità respiratoria. L’iperventilazione, che può essere 
definita come l’aumento della frequenza e profondità respiratoria proporzionata alle esigenze 
energetiche delle nostre cellule, può provocare una riduzione dei livelli di anidride carbonica; 
l’ipoventilazione ha invece, l’effetto opposto.  
Naturalmente, se la richiesta di ossigeno e la produzione di anidride carbonica aumentano 
entrambi (come durante l’attività fisica), anche la frequenza e la profondità respiratoria 
devono aumentare in funzione delle maggiori richieste energetiche. Al contrario, se come 
durante il rilassamento il bisogno di ossigeno e la produzione di anidride carbonica 
diminuiscono, la frequenza e la profondità del respiro devono diminuire. 
La funzione respiratoria è regolata da sistemi chimici e fisici “automatici” ma anche sotto il 
controllo della nostra volontà. Infatti è abbastanza facile trattenere il respiro (es. nuotare 
sott’acqua), oppure soffiare (ad es. per gonfiare un palloncino); perciò numerosi meccanismi 
volontari e tra questi anche l’emozione, lo stress o l’abitudine possono indurre 
l’iperventilazione. Questi meccanismi possono essere particolarmente importanti per le persone 
che soffrono di ansia. L’iperventilazione è responsabile della vasocostrizione e ciò riduce 
l’apporto di sangue ai vari organi. Quindi si verifica che meno sangue raggiunge i vari tessuti 
ma anche meno ossigeno viene rilasciato alle cellule. Paradossalmente mentre, con 
l’iperventilazione catturiamo più ossigeno, in pratica meno ossigeno raggiunge le zone 
periferiche del nostro corpo. Queste conseguenze dell’iperventilazione spiegano i sintomi che 
possiamo avvertire durante gli attacchi di panico: vertigini, capogiri, visione confusa, 
confusione mentale e sensazioni di irrealtà, palpitazione, dispnea, tensione muscolare, 
estremità fredde, sudate ed intorbidite sono dovute al ridotto apporto di ossigeno agli organi 
dell’organismo. Spasmi e crampi muscolare possono essere causati dal protrarsi 
dell’iperventilazione. Importante sottolineare, però che il diminuito apporto di ossigeno alla 
periferia è trascurabile e del tutto innocuo. Inoltre l’iperventilazione è responsabile 
dell’aumento del lavoro fisico: l’aumento della frequenza della profondità respiratoria per 
periodi prolungati di tempo causano stanchezza ed esaurimento, il soggetto si sente accaldato, 
arrossato e sudato e può avvertire dolore o costrizione toracica. Quando iperventiliamo, 
tendiamo a respirare con il torace, piuttosto che con il diaframma, il muscolo che separa i 
polmoni dall’addome. Esistono due tipi respirazione:  
 toracica (di petto) 
 diaframmatica.  
La respirazione toracica comprende i muscoli intercostali esterni, che alza la gabbia toracica 
in alto ed in fuori ad ogni inspirazione, mentre quella diaframmatica coinvolge l’uso del 
diaframma ed è caratterizzata dal movimento dello stomaco verso l’interno e l’esterno durante 
la stessa. La maggior parte delle persone utilizza la respirazione addominale, infatti utilizza 
di più l’uso del diaframma piuttosto che quella toracica.  
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Riconoscere e controllare l’iperventilazione 
Il primo passo per evitare e/o controllare l’iperventilazione è riconoscerla. Provate a fare un 
monitoraggio della vostra frequenza respiratoria.  
Respirate molto velocemente? 
In media necessitiamo solo di 10-12 respiri al minuto quando siamo a riposo. Se la vostra 
frequenza respiratoria è maggiore, è utile ridurla.  
Respirate troppo profondamente? Qualche volta il vostro petto vi sembra sovraespanso? 
È utile respirare con il diaframma e attraverso il naso.  
Respirate dall’addome? 
Sedetevi con le braccia incrociate leggermente sulla pancia, e mentre respirate naturalmente, 
osservate le braccia, il petto e le spalle. Mentre si muovono tutti e tre, il movimento principale 
dovrebbe essere quello della pancia, se respirate correttamente dal diaframma. 
Ansimate o inspirate fortemente quando qualcuno nomina quello che temete? 
Fare un respiro profondo può fare scattare un ciclo di iperventilazione in molte persone. 
Respirate attraverso la bocca? 
È più probabile che iperventiliate se respirate attraverso la bocca, tutte le volte che vi accorgete 
di questo, dovreste ritornare consciamente a respirare attraverso il naso. La respirazione 
cadenzata a bocca chiusa può essere sufficiente, se effettuata prima di un vero forte attacco. 
Cosa fare se siete in iperventilazione? 
Tecnica del respiro lento 
Questa tecnica va utilizzare ai primi segnali di ansia o quando si riconoscono i primi segnali 
di iperventilazione: 
 interrompere quello che si sta facendo 
 trattenere il fiato (senza prima fare un respiro profondo) e contare fino a 10  
 quando si arriva a 10 si lascia uscire fuori l’aria e si pensa “mi rilasso” in modo calmo e 
tranquillo 
 inspirare ed espirare lentamente in cicli di 6 secondi: inspirare per tre secondi ed espirare 
per tre secondi. In questo modo si fanno circa 10 respiri completi al minuto, si pensa “mi 
rilasso” ogni volta che si espira 
 Ogni minuto (dopo una serie di 10 respiri) si trattiene di nuovo il fiato per 10 secondi, poi 
si riprende a respirare in cicli di 6 secondi. 
 Si continua così fino alla scomparsa di tutti i sintomi dell’iperventilazione 
Per quanto riguarda gli attacchi di panico, se invece siete già in iperventilazione non dovete 
usate la tecnica del respiro lento, ma i vostri sintomi cesseranno respirando una miscela di 
ossigeno CO2 al 30% o più semplicemente aria arricchita di CO2 per esempio riciclando l’aria 
espirando e respirando con un sacchetto di plastica sulla bocca. 
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MODULO “SINTOMI DEPRESSIVI” 
SEDUTE 18-21 
GRAFICO DELL’UMORE 
DISTORSIONI COGNITIVE CHE MANTENGONO LA DEPRESSIONE 
RISTRUTTURAZIONE COGNITIVA 
ESPERIMENTI COMPORTAMENTALI 
PROGRAMMAZIONE DI ATTIVITÀ 
GESTIRE LA TENDENZA A PROCRASTINARE 
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     SCHEDA: PROGRAMMAZIONE DELLE ATTIVITÀ GIORNALIERE 
 
Orario Lunedì Martedì Mercoledì Giovedì Venerdì Sabato Domenica 
8-10        
10-12        
12-14        
14-16        
16-18        
18-20        
20-22        
22-24        
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                SCHEDA: TERMOMETRO DELL'UMORE 
 
  GIORNI _____-______ 
 
                          0______10_______20______30______40______50_______60_____70_______80_____90______100 
 
 
 
SEGNALI DEPRESSIONE DISTIMIA EUTIMIA IPOMANIA MANIA 
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                      SCHEDA: DIARIO DELLE EMOZIONI POSITIVE 
 
 
 
ATTIVITA' 
PIACEVOLE 
Cosa stavo facendo?  
Dove ero? Con chi? 
EMOZIONI 
Come mi sentivo in quel 
momento? 
Quali sensazioni positive 
avevo? 
SENSAZIONI 
CORPOREE 
Quali sensazioni nel corpo 
sentivo associate a quelle 
emozioni? 
 
PENSIERI 
Cosa mi passava per la 
mente di positivo che mi 
faceva sentire quelle 
emozioni? 
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                                              Le attività piacevoli 
 
 
Questo elenco è un insieme di attività costruttive e di rinforzo che possono esserti utili a regolare il tuo 
umore e contrastare uno stato depressivo. Ognuno di noi può individuare quali di queste possono, nel 
proprio caso, risultare piacevoli, dare distrazione, dare degli scopi giornalieri. Questa lista può 
stimolarti a riflettere sulle attività quotidiane da inserire nel tuo programma giornaliero. 
 
 
 
 
1. Fare una gita in campagna 
2. Indossare abiti costosi o esclusivi 
3. Offrire un contributo per una giusta causa 
4. Conversare di sport 
5. Fare una nuova conoscenza (stesso sesso) 
6. Sostenere un esame ben preparati 
7. Andare a un concerto pop 
8. Giocare a pallone 
9. Programmare escursioni o vacanze 
10. Fare degli acquisti per se stessi 
11. Stare sulla spiaggia 
12. Fare attività creative (pittura, scultura,  
               disegno, cinema,) 
13. Fare alpinismo 
14. Leggere la Bibbia o altri testi religiosi 
15. Giocare a golf o a minigolf 
16. Modificare la disposizione dei mobili della 
               casa o della stanza 
17. Correre in giro nudi 
18. Andare a vedere un avvenimento sportivo 
19. Andare alle corse (cavalli, automobili,  
               barche) 
20. Leggere consigli per la propria situazione 
21. Leggere romanzi, racconti, pezzi teatrali,  
               poesie 
22. Andare in un locale 
23. Andare a una conferenza 
24. Guidare l’automobile 
25. Scrivere una canzone o comporre un pezzo  
               musicale 
26. Giocare col computer 
27. Esprimere un’opinione apertamente 
28. Andare in barca a vela o in canoa 
29. Fare una cosa gradita ai genitori 
30. Restaurare pezzi antichi (mobili, ecc.) 
31. Guardare la televisione 
32. Parlare da solo 
33. Andare in campeggio 
34. Fare attività politica 
35. Dedicarsi a semplici lavori di manutenzione  
              (automobile, moto, bicicletta, elettrodomestici) 
36. Fare progetti per il futuro 
37. Giocare a carte 
38. Svolgere bene un impegno difficile 
39. Ridere 
40. Fare parole crociate, puzzle, ecc. 
41. Partecipare a matrimoni, battesimi, lauree, 
42. Criticare qualcuno 
43. Mangiare insieme a parenti o amici 
44. Partecipare a corsi culturali 
45. Giocare a tennis 
46. Fare una doccia 
47. Guidare per un lungo tratto 
48. Fare lavori di intaglio o carpenteria 
49. Scrivere romanzi, racconti, pezzi teatrali,  
                poesie 
50. Occuparsi di animali 
51. Andare in aereo 
52. Fare giri esplorativi (deviare dalle strade  
              consuete, esplorare zone non conosciute,) 
53. Intrattenere un discorso leale e aperto 
54. Cantare in un coro 
55. Riflettere su se stessi o sui propri problemi 
56. Attivarsi professionalmente 
57. Andare a un party 
58. Parlare una lingua straniera 
59. Andare a manifestazioni religiose (raccolte  
               benefiche, conferenze) 
60. Andare a riunioni di associazioni 
               socialmente utili 
61. Andare a un’inaugurazione 
62. Guidare una macchina sportiva o di lusso 
63. Suonare uno strumento musicale 
64. Sciare 
65. Ricevere aiuto 
66. Essere vestiti leggeri 
67. Pettinarsi o spazzolarsi i capelli 
68. Fare attività di recitazione 
69. Fare un pisolino 
70. Stare insieme agli amici 
71. Preparare alimenti, conservarli, congelarli 
72. Guidare veloce 
73. Risolvere un problema personale 
74. Fare un bagno 
75. Canticchiare 
76. Giocare a biliardo 
77. Stare insieme ai nipotini 
78. Giocare a scacchi o a dama 
79. Impegnarsi in lavori creativi (lavorare con  
               creta, gioielli, pelle, perle, uncinetto, ecc.) 
80. Andare allo zoo o al circo 
81. Grattarsi 
82. Truccarsi, pettinarsi, ecc. 
83. Creare o disegnare qualcosa 
84. Andare a trovare persone malate o in  
               difficoltà 
85. Essere contenti, trasmettere buonumore 
86. Giocare a bowling 
87. Osservare gli animali 
88. Avere un’idea originale 
89. Fare giardinaggio o lavori di campagna 
90. Fare un buon affare 
91. Leggere testi e manuali professionali specifici 
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92. Indossare degli abiti nuovi 
93. Ballare 
94. Stare seduti al sole 
95. Andare in motocicletta 
96. Starsene seduti a riflettere 
97. Bere un bicchierino in compagnia 
98. Partecipare a un avvenimento positivo per la  
                famiglia o per un amico 
99. Visitare un parco di divertimenti 
100. Discutere di argomenti religiosi o filosofici 
101. Giocare d’azzardo 
102. Progettare o organizzare qualcosa 
103. Andare al cimitero 
104. Bere qualcosa da soli 
105. Ascoltare i rumori della natura 
106. Prendere appuntamento per amoreggiare con  
               qualcuno dell’altro sesso 
107.  Sostenere un’accesa discussione  
108. Fare gare di corsa 
109. Ascoltare la radio 
110. Ricevere la visita di amici 
111. Partecipare a una gara sportiva 
112. Presentare l’un l’altro delle persone che si  
               presume possano intendersi bene 
113. Fare regali 
114. Assistere alle udienze 
115. Essere massaggiati 
116. Ricevere lettere 
117. Osservare il cielo, le nuvole o una tempesta 
118. Intrattenersi all’aperto (in un parco o in un  
               giardino per un pic-nic, una grigliata, ecc.) 
119. Giocare a pallacanestro o a pallavolo 
120. Comprare qualcosa per la famiglia 
121. Fotografare 
122. Tenere un discorso o una conferenza 
123. Studiare carte geografiche 
124. Collezionare oggetti della natura (bacche  
               selvatiche, pietre, ecc.) 
125. Badare alle proprie faccende 
126. Indossare abiti puliti 
127. Fare un acquisto o un investimento  
               (automobile, oggetti per la casa) 
128. Aiutare qualcuno 
129. Concorrere per un nuovo lavoro 
130. Ascoltare barzellette 
131. Vincere una scommessa 
132. Parlare dei propri figli o nipoti 
133. Fare una nuova conoscenza dell’altro sesso 
134. Parlare della propria salute 
135. Mangiare bene 
136. Fare qualcosa per la salute (far mettere a  
               posto i denti, comprare gli occhiali nuovi,   
               cambiare alimentazione) 
137. Farsi un giro per la città 
138. Praticare lotta o boxe 
139. Dedicarsi al tiro con la pistola 
140. Suonare in una banda 
141. Fare escursionismo 
142. Visitare un museo o una esposizione 
143. Tenere un diario 
144. Svolgere bene un compito 
145. Avere tempo libero 
146. Andare a pescare 
147. Prestare qualcosa 
148. Essere notato come sessualmente attraente 
149. Fare contento il datore di lavoro, l’insegnante 
150. Consigliare qualcuno 
151. Andare in una palestra o in una sauna 
152. Imparare qualcosa di nuovo 
153. Fare complimenti a qualcuno o lodarlo 
154. Pensare a persone care 
155. Vendicarsi di qualcuno 
156. Stare insieme ai propri genitori 
157. Cavalcare 
158. Fare conversazioni telefoniche 
159. Sognare a occhi aperti 
160. Giocare con foglie, sabbia, pietrisco, ecc 
161. Giocare a bocce 
162. Andare a raduni di vecchi compagni di  
               scuola 
163. Vedere gente famosa 
164. Andare al cinema 
165. Baciarsi 
166. Stare da soli 
167. Cucinare 
168. Riuscire a mettere nel sacco una persona  
               ritenuta molto furba 
169. Fare in casa dei lavori occasionali 
170. Piangere 
171. Sentirsi dire che si è utili 
172. Partecipare a una festa o a un incontro con  
               familiari 
173. Organizzare un party o un incontro piacevole 
174. Lavarsi i capelli 
175. Dare disposizioni a qualcuno 
176. Guardare o odorare un fiore o una pianta 
177. Essere invitati a uscire 
178. Mettersi un profumo o dell’acqua di colonia 
179. Essere d’accordo con qualcuno 
180. Rivivere ricordi, parlare di tempi passati 
181. Alzarsi al mattino presto 
182. Trovare pace 
183. Fare esperimenti o ricerche scientifiche 
184. Andare a trovare degli amici 
185. Farsi consigliare, ricevere un consiglio 
186. Pregare 
187. Massaggiare qualcuno 
188. Viaggiare in autostop 
189. Praticare meditazione o yoga 
190. Assistere a un combattimento 
191. Parlare con i compagni di classe o di lavoro 
192. Rilassarsi 
193. Essere pregati per concedere un consiglio o  
               un aiuto 
194. Riflettere sui problemi di altre persone 
195. Giocare a giochi di società 
196. Dormire profondamente di notte 
197. Fare lavori pesanti all’aperto (tagliare la           
               legna, fare giardinaggio) 
198. Leggere il giornale 
199. Partecipare a gruppi di autoesperienza 
200. Giocare a tennis da tavolo 
201. Lavarsi i denti 
202. Nuotare 
203. Correre, fare jogging, ginnastica o altre  
               attività all’aperto 
204. Correre scalzi 
205. Giocare ad acchiapparello o simili 
206. Fare il bucato o le pulizie 
207. Ascoltare musica 
208. Avere piacere sessuale 
209. Lavorare a maglia, uncinetto, cucire in  
               maniera creativa 
210. Flirtare 
211. Fare divertire delle persone 
212. Parlare di problemi sessuali 
213. Andare dal parrucchiere o dall’estetista 
214. Avere ospiti a casa 
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215. Stare insieme a qualcuno cui si vuol bene 
216. Leggere delle riviste 
217. Dormire fino a sentirsi completamente  
               riposati 
218. Iniziare una nuova attività 
219. Essere ostinati 
220. Discutere 
221. Avere rapporti sessuali 
222. Andare in biblioteca 
223. Giocare a pallavolo 
224. Preparare una pietanza nuova o speciale 
225. Osservare gli uccelli 
226. Uscire per compere 
227. Osservare la gente 
228. Accendere o osservare un fuoco 
229. Superare con successo un confronto 
230. Vendere o contrattare qualcosa 
231. Portare a termine un impegno 
232. Confessare o farsi perdonare 
233. Acquistare degli oggetti 
234. Andare in bicicletta 
235. Dire alla gente cosa deve fare 
236. Stare in compagnia di persone 
237. Partecipare a giochi durante una festa 
238. Scrivere lettere o cartoline 
239. Parlare di politica o di questioni sociali 
240. Chiedere aiuto o consigli 
241. Parlare dei propri hobby o interessi specifici 
242. Guardare uomini o donne 
243. Sorridere alle persone 
244. Giocare sulla sabbia, sull’erba, presso il  
               fiume 
245. Parlare di altre persone 
246. Stare insieme al coniuge 
247. Ricevere attenzione per le proprie opinioni da          
              parte di altre persone 
 
248. Fumare tabacco 
249. Occuparsi delle piante di casa 
250. Bere un caffè o un tè con gli amici 
251. Fare una passeggiata 
252. Collezionare diverse cose 
253. Cucire 
254. Ricordarsi di un amico morto 
255. Fare qualcosa insieme a dei bambini 
256. Ricevere complimenti o gratificazioni per  
               qualcosa che si è compiuto 
257. Sentirsi dire di essere amati 
258. Fare uno spuntino 
259. Rimanere alzati fino a tardi 
260. Stare insieme ai figli 
261. Andare a un’asta 
262. Riflettere su una domanda interessante 
263. Fare volontariato o partecipare a progetti  
               sociali 
264. Praticare sci d’acqua, surf, attività  
               subacquea 
265. Difendere o proteggere qualcuno; intervenire  
               contro una truffa o un abuso 
266. Dare un passaggio a un autostoppista 
267. Vincere una lotteria 
268. Parlare del lavoro o della scuola 
269. Leggere giornali a fumetti 
270. Farsi prestare qualcosa 
271. Partecipare a un viaggio di gruppo 
 
 
 SCHEDA: RINVIA LA TENDENZA A PROCRASTINARE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Sei costantemente in ritardo? Hai la sensazione di non aver raccolto molto alla 
fine della tua giornata? La lista delle “cose da fare” continua a crescere? Oppure ti succede di 
trascorrere molto tempo senza fare niente o sapere come gestirlo? Se la risposta a una o più di 
queste domande è sì, allora potresti avere alcuni problemi nella gestione del tempo. Alcune di 
queste strategie potrebbero esserti di aiuto per gestire in modo migliore il tuo tempo: 
 
 
Fai una lista degli obiettivi.  
Scrivi i lavori o i compiti che vuoi portare a termine nella settimana. Crea una lista delle “cose 
da fare”.  Questo aiuta e incoraggia a pianificare in anticipo. 
Fissa le priorità.   
Valuta le priorità di ogni compito: alto, medio o basso. Per quanto? Valuta la quantità di tempo 
necessaria per svolgere ogni compito 
Fai un programma.   
Utilizza un’agenda per programmare quando farai ogni cosa. Assegna scadenze realistiche 
Accorda le cose da fare con il tuo livello di energia.  
Per esempio, “sei una persona mattiniera?”  se sì, allora programma i compiti più impegnativi 
al mattino. Non aspettare il pomeriggio o la sera quando potresti essere troppo stanco. 
 
 
Hai troppe cose da fare?  
 Delega: assegna alcune delle tue cose ad altre persone 
 Snellisci: c’è un modo per fare le cose in modo più efficiente? Le cose raramente 
devono essere perfette 
 Scarta: alcune cose possono essere omesse 
 Riduci le fonti di disturbo per migliorare la tua efficienza. Se hai bisogno di un 
certo periodo di tempo per portare a termine un compito importante, per esempio, 
chiudi la porta dell’ufficio e inoltra le tue telefonate 
 
 
Rimandare è un problema?  
 Esamina i tuoi pensieri. Stai dicendo a te stesso che il compito da affrontare è troppo 
difficile? Che deve essere perfetto? Che non sei abbastanza bravo per affrontarlo? 
Questi pensieri sono realistici? Le persone spesso rimandano perché sovrastimano 
la difficoltà di un compito e sottovalutano le proprie capacità 
 Motivati. Pensa in modo da auto-motivarti come “Consideralo già fatto”, “Fallo e 
basta!”. Poi premiati per aver portato a termine ciò che avevi da fare. 
 Appuntamento con il destino. Usando la tua agenda giornaliera metti da parte il 
giusto tempo per svolgere ciò che devi fare 
 La regola dei 5 minuti.  Dì a te stesso che lavorerai su di una cosa difficile per 5 
minuti, dopodiché vedrai se avrai voglia di continuare.  È probabile che una volta 
che hai iniziato, vorrai proseguire. 
 
  
 
 
 
 
 
 
 
 
MODULO “RIMUGINIO” 
SEDUTE 22-25 
GRAFICO DELL’UMORE 
DISTORSIONI COGNITIVE CHE MANTENGONO LA DEPRESSIONE 
RISTRUTTURAZIONE COGNITIVA 
ESPERIMENTI COMPORTAMENTALI 
PROGRAMMAZIONE DI ATTIVITÀ 
GESTIRE LA TENDENZA A PROCRASTINARE 
 
 
 
 
 
 
 
 
 
 
 
 
 SCHEDA: UN FALSO COMPAGNO DI VIAGGIO: IL RIMUGINIO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Cosa è il rimuginio? 
 Riguarda prevalentemente situazioni che devono accadere 
 È fatto di pensieri automatici del tipo “E se…?” 
 Porta con sé la distorsione della catastrofizzazione 
 Vantaggi a breve termine: ci fa sentire più preparati ad affrontare le situazioni, 
ci fa sentire che possiamo controllare i problemi se dovessero presentarsi 
 Svantaggi a lungo termine: mantiene la preoccupazione per gli eventi futuri, 
predita di tempo, predita di concentrazione ed energie, svaluto il presente 
 Non è problem solving 
 Sembra incontrollabile - se porti la tua attenzione, noterai che ci sono momenti 
della giornata non cui lo sospendi volontariamente (mentre rispondi al telefono, 
quando fai esercizi di rilassamento, quando programmi attività giornaliere…) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCHEDA. PRENDI UN APPUNTAMENTO CON IL RIMUGINIO 
 
 
 Fissa un appuntamento con il rimuginio nella tua giornata ad un orario prestabilito 
 L’orario dovrà essere il più possibile sempre lo stesso 
 L’appuntamento potrà durare un massimo di 20 minuti 
 Nei 20 minuti potrai preoccuparti dei pensieri automatici della giornata 
 Al di fuori di questo orario programma nella tua giornata attività piacevoli, 
interessanti, coinvolgenti, che attirino la tua attenzione e ti impegnino con obiettivi 
a breve termine nella quotidianità 
 Mentre svolgi le attività presta la tua attenzione con i 5 sensi a quello che senti, 
odori, vedi, noti… 
 Programma attività che ti impegnino dal rimuginio 
 
 SCHEDA: DIARIO DELLE PREOCCUPAZIONI  
 
DATA 
ORA 
PREOCCUPAZIONE 
Di cosa mi sono preoccupato? 
Che cosa mi ha dato apprensione? 
INTENSITA’ 
ANSIA 
Da 0=molto bassa 
a 100=molto alta 
REAZIONE 
Cosa ho fatto per calmarmi? Cosa 
hanno fatto gli altri? 
Cosa mi sono detto? Cosa hanno 
detto gli altri? 
   
 
 
 
 
 
   
 
 
 
 
 
   
 
 
 
 
 
   
 
 
 
 
 
   
 
 
 
 
 
 
 
 SCHEDA: TORTA DELLE PROBABILITÀ 
 
Pensiero automatico: ___________________________________________________________________________ 
Probabilità prima dell’evento che ciò che viene predetto da quel pensiero si realizzi? ________% 
Possibili esiti/conseguenze alternative: 
________________________________________________________________________________________________
________________________________________________________________________________________________ 
Probabilità di quelle conseguenze? _________% 
 
 
 
 
 
 
 
 
 
 
 
Nuova probabilità dopo l’evento che ciò che viene predetto da quel pensiero si realizzi? ________% 
Nuova probabilità delle conseguenze alternative? _________% 
Nuove conseguenze? _____________ 
Pensieri alternativi più realistici: _________________________________________________________________ 
 
 
 
 
 
 
 
 SCHEDA: 
LA BILANCIA DELL’EVITAMENTO DI SITUAZIONI FONTE DI ANSIA PER ME 
 
 
VANTAGGI DELL’EVITAMENTO SVANTAGGI DELL’EVITAMENTO 
  
  
  
  
  
  
  
SVANTAGGI DI AFFRONTARLE VANTAGGI DI AFFRONTARLE 
  
  
  
  
  
  
  
 
 
 
 
 SCHEDA: LA CURVA DEL’ANSIA 
 
 
 
 
           100 
 
 
 
 
                      SITUAZIONE ATTIVANTE 
LIVELLO  
DI  
ANSIA 
 
 
 
 
 
 
 
 
               0 
         INIZIO DELL’ESPOSIZIONE                                                                                                                          FINE DELL’ESPOSIZIONE 
                      TEMPO 
 
 
 
Se non ti sforzi di evitarla, l’ansia è come un’onda del mare quando ti passa addosso… 
…cala da sola 
 
 
 
 SCHEDA: PASSI DEL PROBLEM SOLVING  
 
 
 
Identifica la situazione 
Individua il problema 
Quali sono i tuoi scopi/obiettivi/bisogni in questa situazione? 
 
Quali comportamenti hai adottato finora in risposta ai pensieri automatici?  
 
Quali sono i vantaggi di questi comportamenti? Quali gli svantaggi? 
Brainstorming: Quali potrebbero essere comportamenti assertivi o alternativi? 
Prova a scrivere di getto una lista di possibili comportamenti senza valutarli 
rispetto alla funzionalità 
Quali sono i comportamenti maggiormente funzionali ed utili a perseguire i tuoi 
scopi/obiettivi/bisogni? Confronta vantaggi e svantaggi di ciascuno 
 
Pesa ogni vantaggio/svantaggio 
Confronta i vari comportamenti individuati 
Scegli il/i comportamenti/i con maggiori vantaggi e minori svantaggi 
[Dopo aver eseguito l’esercizio sull’assertività] Hai raggiunto i tuoi scopi? 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
MODULO “ANSIA SOCIALE” 
SEDUTE 26-29 
ASSERTIVITÀ E ABILITÀ SOCIALI 
ROLE PLAYING 
ESPOSIZIONI A SITUAZIONI SOCIALI 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I COMPORTAMENTI ASSERTIVI 
 
 
 
 
 
 
 
 
 
 
 
 
 
Il comportamento passivo 
 Restio ad esprimere le proprie opinioni e, 
in particolare, i propri sentimenti 
 Spesso si sente usato dagli altri 
 Non si ribella quando gli altri 
approfittano di lui 
 Si trattiene dal lamentarsi quando i 
servizi o i prodotti non sono adeguati 
allo standard 
 Trova difficoltà nel rifiutare le richieste 
altrui 
 Dimostra acquiescenza verso le opinioni 
ed i desideri della maggioranza anche se 
essi sono in conflitto con le inclinazioni 
personali 
 Giunge spesso a dei compromessi per 
mantenere l'armonia 
 È riluttante a disturbare le persone per i 
propri bisogni 
 Si sottomette in presenza di un 
comportamento aggressivo 
 Preferisce mantenere privati i propri 
punti di vista 
 Antepone i bisogni altrui ai propri 
 
Il comportamento assertivo 
Quando si è assertivi, si bilanciano i bisogni degli altri coi propri. Si trattano gli altri come si 
desidererebbe essere trattati. Quando è necessario si può scegliere se dare la priorità alle necessità 
altrui o se considerare maggiormente le proprie necessità. 
 
 È capace ad esprimere agli altri desideri e sentimenti  
 È capace a conversare e lavorare bene con gli altri a tutti i livelli 
 È capace ad apprezzare i punti di vista degli altri e ad accettarli se appaiono più ragionevoli dei 
propri 
 È anche capace di mostrarsi in disaccordo con gli altri pur mantenendo la loro amicizia ed il loro 
rispetto 
 Si preoccupa dei desideri e bisogni altrui 
 È in grado di fare concessioni agli altri senza sentimenti d’inadeguatezza 
 È capace ad esprimere una preoccupazione o un bisogno col minimo imbarazzo per entrambe le 
parti 
 È capace a controllare i sentimenti e le emozioni anche nelle situazioni difficoltose o emotivamente 
forti 
 È capace a rifiutare una richiesta senza sentirsi colpevole o obbligato 
 È capace a chiedere qualcosa che desidera e può insistere su ciò che gli compete di diritto senza 
emozionarsi  
 
Il comportamento aggressivo 
 Discute frequentemente con gli altri 
 Si arrabbia frequentemente e pensa che gli 
altri abbiano bisogno di essere messi al loro 
posto 
 Non ha difficoltà a protestare quando riceve 
prodotti o servizi di scarsa qualità 
 Di solito agisce di testa sua 
 Si aspetta che gli altri si adattino ai suoi 
tempi 
 Ha delle forti convinzioni su molti 
argomenti e non ha difficoltà ad esprimerle 
 Facilmente e frequentemente trova difetti 
negli altri 
 Lavora in continuazione secondo il proprio 
ordine del giorno a spese degli altri 
 Si preoccupa raramente dei bisogni o 
sentimenti altrui 
 È in competizione con gli altri e si arrabbia 
se non ottiene successo 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VANTAGGI DELL’ASSERTIVITÀ 
 
 
 Essere più in contatto con i nostri bisogni 
 Far valere i nostri diritti e raggiungere più efficacemente i nostri obiettivi nel 
rispetto altrui 
 Si può porre un limite al proprio ed all’altrui comportamento 
 Si può avere una visione realistica di cosa è nelle proprie possibilità e cosa 
non lo è 
 Non si è influenzati negativamente da chi è sgarbato o scortese 
 Si è capaci di rallegrarsi dei propri successi e di accettare i propri fallimenti 
 Si può mantenere sempre il controllo del proprio comportamento, e non farsi 
istigare all’ira o forzare alla sottomissione 
 Sentirsi capiti dagli altri 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HOMEWORK: FARE COMPLIMENTI 
 
Individua cinque amici o colleghi; per ognuno elenca tre o quattro qualità positive che ti 
piacciono di loro e pensa a degli esempi di quando loro dimostrano queste qualità o 
comportamenti, soprattutto nei tuoi confronti. 
 
 Scrivi cosa dirai loro la prossima volta che si comporteranno così; usa l'affermazione 
in prima persona ("Io penso/sento/vorrei che tu sapessi" invece di "Sei così bravo 
a…"), sii specifico, menzionando nel tuo apprezzamento il comportamento che stanno 
mettendo in atto. 
 Stai a vedere come reagiscono e osserva se aumentano o meno quella caratteristica del 
loro comportamento in tua presenza. 
 Per una settimana prendi la decisione di complimentarti con almeno tre persone per 
il loro lavoro, comportamento o aiuto che ti danno; annotati sul diario gli specifici 
"apprezzamenti" per ricordarti di averli effettivamente fatti 
 
 SCHEDA: RINFORZA L’AUTOSTIMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assertività ed autostima sono collegate tra loro. Si può migliorare 
significativamente la propria autostima psicologica occupandoci di noi stessi. 
Alcune strategie per farlo possono includere:  
 
 
1. Fai regolarmente esercizio fisico per tenerti in forma.  
2. Pianifica il “tempo dedicato a me", in modo da ricavarti dei momenti in ogni 
settimana per avere tempo per te stesso.  
3. Rimpiazza la televisione con un interesse che impegni in qualche modo 
(fisicamente, socialmente, intellettualmente o emotivamente).  
4. Pianifica momenti di qualità con la famiglia e con chi è sentimentalmente 
importante per te  
5. Premiati per i tuoi successi, con piccoli premi per le piccole cose e significative 
ricompense per i traguardi maggiori.  
 
 Flashcards 1. Saper dire di no 
“Sono costretto a 
rifiutare, ma grazie 
di aver pensato a 
me” 
“Stavolta non posso 
proprio” 
“In questo momento non 
ho proprio tempo per 
fare quello che mi 
chiedi” 
“Sono molto 
impegnato in questo 
periodo” 
“So troppo 
indaffarato per fare 
questa cosa” 
“Non mi sento di 
fare questa cosa” 
“In questo momento 
non posso, magari 
più avanti” 
“Sembra interessante ma 
non ho tempo di farla” 
“No, non posso 
aiutarti” 
“Vorrei poterti 
aiutare ma non ho 
tempo” 
Flashcards 2. Affermare il mio punto di vista 
“Non sono d’accordo 
con questo” 
“Io invece 
penso/credo che….” 
“Le cose stanno così, però 
stanno anche in questo 
modo…” 
“Ci sono rimasto 
male del fatto che 
tu…” 
“Sono rimasto 
stupito da te che…” 
“Non lo condivido” 
“Capisco il tuo punto 
di vista ma io 
penso…” 
“Quello che dici è vero, 
ma è anche vero che …” 
“Non mi aspettavo 
che tu…” 
“Le cose non stanno 
proprio come dici te” 
Flashcards 3. Motivare me stesso 
“Posso farcela” “Continua così!” “Non arrenderti!” 
“Mi sto 
impegnando!” 
“Altre volte ce l’ho 
fatta!” 
“Ce la puoi fare!” “Non mollare!” “Posso cambiare!” 
“In altre situazioni 
ci sono riuscito!” 
“E’ meglio fare 
qualcosa, anche 
piccola, che non fare 
niente” 
Flashcards 4. Essere più in contatto con i miei bisogni 
“Qual è il mio 
obiettivo in questa 
situazione?” 
“Quali sono i miei 
bisogni in questa 
situazione?” 
“Cosa vorrei ottenere con 
il mio comportamento?” 
“E’ davvero 
fondamentale che io 
raggiunga il mio 
obiettivo alla 
perfezione?” 
“Come mi sento in 
questa situazione? 
Quale emozione sto 
provando?” 
“Se penso così, riesco 
a raggiungere 
veramente i miei 
obiettivi?” 
“Quali sono le 
conseguenze su me 
stesso se credo a 
questo pensiero? 
“Quali sono le 
conseguenze su me stesso 
se non do importanza a 
questo pensiero?” 
“Ci sono delle cose 
positive che ho fatto 
in questa situazione? 
Posso provare a 
vedere le cose 
positive che ho 
fatto?” 
“In quali altri 
contesti ho avuto 
questo pensiero?” 
 
 SCHEDA: ESPERIMENTI ED ESPOSIZIONI A SITUAZIONI SOCIALI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Provare prima con role playing in studio o con il terapeuta. Prima di iniziare prova ad 
appuntare i pensieri automatici negativi che arrivano alla mente sulla situazione da 
affrontare, individua la probabilità con cui stai temendo certe possibili conseguenze 
negative. Dopo l’esperimento rivaluta la probabilità, formula pensieri alternativi. 
 
1. Per strada impegnati a guardare le persone fisso negli occhi e prova a non smettere finché 
loro distolgono lo sguardo, poi fai un leggero sorriso in modo tranquillo ed amichevole 
dicendo “Buongiorno" 
2. Recati ad una bancarella e mercanteggia sul prezzo: a. Facendo delle offerte, b. Chiedendo 
se si può abbassarlo 
3. Entra dal parrucchiere, chiedi un appuntamento, prenota, dopo 15 minuti, torna, disdici 
ed esci salutando cordialmente  
4. In un bar chiede acqua del rubinetto, bevi ed esci senza pagare 
5. Inizia una conversazione sul tempo, sui mezzi pubblici etc con persone alla fermata del 
bus 
6. Chiedi informazioni stradali in un negozio 
7. Entra in un negozio, chiedi alla commessa di farti mostrare varie tipologie di capi, chiedile 
dei consigli, prezzo, caratteristiche, provali, poi esci senza acquistare niente. 
8. Paga un caffè con una banconota da 50 euro 
  
 
 
 
 
 
 
 
MODULO “PREVENZIONE  
DELLE RICADUTE” 
SEDUTA 30 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
SCHEDA: I SEGNALI DI ALLARME 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Come possiamo sapere se sta per venire un temporale? Forse 
possiamo metterci in ascolto dei tuoni, rimanere ad osservare per un po’ il 
cielo, notare se è scuro o ci sono nuvole grigie. Se non vogliamo farci cogliere 
impreparati da un temporale, allora possiamo decidere di rientrare a casa, 
chiudere le finestre, mettere al riparo i panni… 
In un modo molto simile, se acquisisco più consapevolezza dei primi segnali di 
allarme, posso prevenire momenti di più forte ansia, stress, depressione e 
quindi evitare ricadute. Ciascuno di noi ha i propri segnali specifici, anche se 
alcuni posso risultare comuni a molti. Una volta che sono diventato più 
consapevole dei miei segnali di allarme, il secondo passo e controllarli 
regolarmente. Non è molto utile che tu sia consapevole dei segnali ma non li 
monitori con regolarità e continui a vivere le giornate senza prestarvi 
attenzione. 
 
 SCHEDA: RICONOSCI I SEGNALI DI ALLARME 
 
  
 
 
 
 
 
 
 
 
 
Compila un elenco dei segnali di allarme che più ti riguardano e porta questa 
scheda con te. Controlla questo elenco ogni cinque giorni durante la settimana. Chiedi alle 
persone che vivono con te e in cui ha fiducia di informarti quando notano nei tuoi 
comportamenti dei possibili segnali di allarme. 
 
I MIEI COMPORTAMENTI DI ALLARME,
COSA FACCIO, COME AGISCO 
 
 
 
 
 
 
 
 
 
 
 
 
 
I PENSIERI CHE MI PASSANO PER LA 
MENTE 
LE EMOZIONI CHE PROVO, COME MI 
SENTO 
 
 
 
 
 
 
 
 
 
 
 
 
 
COME AGISCO, MI COMPORTO CON 
LE ALTRE PERSONE 
COSA POSSONO NOTARE LE PERSONE 
CHE MI STANNO VICINO (PARENTI, 
AMICI) 
 
 
 
 
 
 
 
 
 
 
 
SITUAZIONI CHE FANNO SCATTARE 
IN ME EMOZIONI NEGATIVE E 
STRESS 
 
